<SEC-DOCUMENT>0001628280-22-012629.txt : 20220506
<SEC-HEADER>0001628280-22-012629.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505160557
ACCESSION NUMBER:		0001628280-22-012629
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		22896157

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgmo-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:3c33364c-6fd7-4e66-b5dc-1ec40b4f7ba5,g:db557487-1255-4119-bfcf-47c79d663408,d:4456822efa7a4e3293b4821bff1ee4c1--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20220331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV8yLTEtMS0xLTM3MjYx_efa43bc6-03b0-4210-90bd-3ffd5276ac94">false</ix:nonNumeric><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV8zLTEtMS0xLTM3MjYx_1fe3a6c5-c10b-4d17-b583-81db4ba05eb9">2022</ix:nonNumeric><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV80LTEtMS0xLTM3MjYx_afb639ee-afaf-4320-af5e-13b01ea6b673">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV81LTEtMS0xLTM3MjYx_50d8143e-7e38-4cf7-b94c-7dc728f2956d">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV82LTEtMS0xLTM3MjYx_33b575bc-fec0-47fd-b002-68d63dff11e2">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie82ebd2afdea4a1990f6789118d0eb42_I20220502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i49808b7d5a184b629b594c228b0d228f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i98eb94bb16d64b339437154eeb6a8c7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41b9a853412a4de5bbfc5086f43609a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f8868245aa4443834ca54fd2f6d165_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia25b49838a1e4216a648cda338998cd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16363a48a1db4200a557e20f74a6663e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0831195cbcb42c78e3d9a80acb8bd55_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i415e7d08c2134893996d32a46190bba6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bdbe1eebb07447cadf7cd259b6f2ca8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e2ecbeebddf486b8f3eeebae6987fca_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i662af85bbcb24003939aa4e3f3b753ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83b558b1d1b24287b972767cc449ee9c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd50e43eaec244a6a48c48e150d26257_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1dcfc8af9f54d79891a8e4f97258d64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb68b7a02dc941ddb5eaea5f9e94cea0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i147ac2e91ee24c898b9135e2412019b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7736e400eca2413e926ef07b420d3523_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79928d1c5b534f9297876cf1cd9f42a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if027201194ec44b2a8a8aaa563d56062_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133d4b1be36148219d4c9ca2c70121af_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a5d019cb57482287e3752a44cd9473_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7621415fb2b84296bc6b90e3b825982c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib41c6577ca4a47df91565832e4f8c52f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ac3d6b9a014f3fb9c09c50fb836aa1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1696ceaafa594b6e8a7aa213973bb86f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i179494c7d70e4d1980c455d43a0ccccd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ac39ac4cc046d3891f2f198d2f40a6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c1c94341c8140bb850188c07c23add8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b727537ef44d20a3118a3b2f4aae71_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c52382b7dc4becb1cb30fb680833c0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ce04a30e5b4a2f9c36548cda5a8458_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44f00bdda5c4a5e8fdf09b0b409881d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0fd799de345849b7bde24906fccf9e47_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb254f83fdd54a5394d3789ac0432acd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb3e3c9e9fc34bada2506884b81bcc4a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib77a01f4821e403fbaed538181093649_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399ab68bf5a34a708f1ac215d91b5ef3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf49db6b57ed4468b600943a63027618_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e569774fd874df0b2278b667d3537b1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ec91078cbd4fef9b2ff9b118a62896_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e8560aa3fb044e2afe37becdf007481_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2e671b261e4b9a9510eea1dd524ffe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143dc860af4e41ca8ad56c89389f8c0e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ff2db9628f4469aa4b0d9190c623367_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16bb308b033f4cfd8478d6ed83ab7469_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09f7155daf244fe2847f5df4bca90b38_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50c2af11dc0945a1a2b563bdd67a34e9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708b092c6ed84bd1bbf020943bc286ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id893d7bf0fe340b493ce98b8ad036faa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie45eb48d4aac42dcb834ce4d4238cbc5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b546e6ad858449f9375bab65733a9ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30b4f1bdb97d4271beba4b63564701b1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied809edebcb648f59c57c3137795b9c2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1456174ba11d44a79cda4fef54a9527a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i304cf3079db74ee581bad5edc8ea8eb6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic21a61daf2da4126898da412720ef0c1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic156a4b9bcd648ffabb65ad460686df9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb75b0131d244f9b44926706c6e6e1a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08f31b20a2b442a592d8b411d50e9a36_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c76a773d414d409fa20c7e798a1ead_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6006abfadc42c5890e9f29785dbba5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b0b1b7628b74a32bf1f89c76bd39253_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9f93a4e5c614d898f2dba36b145b91a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d2ad076baf46aa95e6b9a86a08f8fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021e4eb600444817b880d3c34fb52136_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id96bcec60508420a9f72a54a34521d52_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i906b3eb7e3734168ba335e172b1fa959_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5adf2fec9bea4ba899e404e902cb35bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05b14fccaf44e1180d2ef8bbe382fec_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c37e7249d9345dc9330907394eb067f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i412513ce57b94ec0bf641412ee64ef34_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a823a89d644a15b67b9a1a84a15ea6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d1cbbf6bfc4b6fae628fbceab20e0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e70945d068e421d8e7e13119a342d96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c70fd8f212a44f0b0fd39c5da686631_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d5062dc4f6c4aea9b5af1b8206788f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8460203d45415f877cfffa51733070_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e5e6402ec45427eae4f571d473ddedf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752f160556a747deb9e6619b306a9579_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba495162727d4dc1ad3ca1981bbe7c17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa05cd9050654d27a2da2817cacdacc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib156eb5be64c4a22a4011ee880db1829_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1034cd2a6148f9a0d34eccdef2cb56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c0f076cbacf47db8a333a0ba2a9744c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15c97739d5bf4f7aaf30ff5711b7b551_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id90c35cf8bca444c9fe316fa99c0ccc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8eb71551dfe411696e39c0e4a98ac05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f2894d23e54b5c8bc3535256e6f430_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia241ff32633d44d0995fa41d3b30c749_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i652c08590692478dbad26f055bd24b22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1900186abb04fcd8679b20fe15aa9eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94522ff63b14c7c8f42c47bc206bcf9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a079914a6f4629944a16c5c8f8c67f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b82c587da8e49dba0a77764e4e9678f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89392c2987434d09bae08df932002bb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadab9f649ee64aa18743fe966255becd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd13862a3fc0418f8cf10ae64ad1ac6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0369288ea6d34134bdc95a49a5e089a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c2de2dac42941aea08c2173d245c90d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667d8119170448249bd6a172234e2142_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b3b84611284755a34ba8152a2646d0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75f59c89b2b44fd2919394b10858dd42_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e69bac7be71489fac652fab2215a8a9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib47a4b1baad248318523c5fba0c2d164_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9333aab4cdd548f1818b9a801558d624_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i417758d232ed45199817bccf384dfcad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7428cfc7656446308caa6ab7f38e8fc4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d0041f6579043f2bee5ca967b1a19d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4cc59f044c84fa483597e518c67dd8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149b1f00b3f944a699030236b1718bb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708da3120a854222abfec0d32c8d9c70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a473804e0f74354bf949e0a954fac9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e67faf817f4852b243d3c63990d266_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56fb168b92b405fb217588fffb34483_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6efcae223674852a4973214fc153fa8_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37db8a6698834ba296ee551626e923fb_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c1aa614e1a4775b6bbd58069fa1667_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b7eb1bd518d40e1b0ab1d54a66550cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01e697d1114342af9aab4ece3ebe09d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900d4a285bf74e898040e450e39bae33_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517982897103458981bfa35ceae5ab4c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib06b72ef26254e088a29f9eb02ae084f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be9da6c94aa4aeda66aa0067113c02e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib750ba895b6945248f5dd3b66450ec06_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55716db833614f819cf9af228e7bacc0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab11137987e8447bb24585d1df56594e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa9d46b5b32044e89d50e8f389f7bdd3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766f4d877bf6408b9503aa5663f38abe_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15891adf431c452c86cb7e1beafbb9f8_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib839a8edfdf240f293867c6246e5a8fa_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e6b8fbf7904621a6d9173012bb2011_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e1ede754aa400bb099f3f7aed0dfb1_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6738521b264171b6251397feadfc36_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product_target"><xbrli:measure>sgmo:product_target</xbrli:measure></xbrli:unit><xbrli:context id="i39ca1d92750e4fc887cd62b4bb56da6e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ca29e9a3803412cb13b7748ae0de063_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2957eaa5fb949ba9103ee631650c838_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i041acd4815694161b1e7542a2e160c9c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3e9b2076b04da29cf24d841569c73f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a105ad9f2c44de8af6b7d8886dbfe92_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0037c3659814babb6528aeace32f367_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41afe851c52346368324b29729905d65_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ae54d9711045f5b069428dadfcf2ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b2dfb4d52545a4945d9acab347bcee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idadbcdba5852493e8a7279c2071547c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e8a0ae4fe34fcbbda1cb1a13234369_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4be5c493833416e94842f25e42f4ed2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5797d08acc004769826046653f737b78_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc36d4cf8fee4657a85ef91caf216030_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>sgmo:milestone</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>sgmo:option</xbrli:measure></xbrli:unit><xbrli:context id="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c4d875d4a2406e8c1ed49500a382d3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63eac9ce149544bc82e859b7f3bbb3b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib70ee13d8d7a427da05f3f516bfa3b24_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2986c1f9c44f4c47b92d4e4fe0632ce1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07682bb1e1c4e59a83b477d9c74c798_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11fedbfa9d70466daba921e2e917b72b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba81ecb70cf48beb5b5bc44b8920a30_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7245852459b450a993c961a809e0dfa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa617603ebd4abeb4444421df29e6bc_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>sgmo:program</xbrli:measure></xbrli:unit><xbrli:context id="iadba8aa480b646cfbd9364a355e68cbe_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58d8c1b745014cc8b8f4a724f1510553_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i415e26556db342079b36c2d48875c6cd_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e4a1930763f4519a9e4c291ee43d2e0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i220eb5b01a5049368db95372ebd0fd9b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc0ab2db92b44c1bdba051d96895b2a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>sgmo:product</xbrli:measure></xbrli:unit><xbrli:context id="i93cdf026a37d429da9fbaf18e0a75afd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66d1819ab0a41bcae82ab0a30c2b5a0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b1460fe9b3430aaad2d02372d4e0fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7009d476b5214df7b02507f512948107_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7850a3329dd84fb9bb08174c06ab99e3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4014aec3ed654925849776520902d5b7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5055577b77d947f4bef796328015008c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1fe22c826474fe69f5ed5ada7ece18f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792a74f3766e43feb0c12d95327cbf47_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5834c04299d4d58ac0d606a80ed8b5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i195087e919f9493f90985edbce9e5c13_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d053e63e174530b26c614c63fbadbd_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ece67192c1d42a59cc7910bf5faa61c_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42824e5c4da04a68abc1181162bd12fa_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e709748299454d8a4c0545d5caa0c0_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i775b57c0965745638063300c10bf719b_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b464e1bc69c4b89951ddb6d3fee56d9_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c9910cf6b742cf89b4a8a7d9606e71_D20171201-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="royalty_fee"><xbrli:measure>sgmo:royalty_fee</xbrli:measure></xbrli:unit><xbrli:context id="ia8bed9085c38465985a0d366ec10dc28_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf2d29f1912433caabee4d25f53741b_D20170501-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f51b07af0864153afac3abe30c851e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b3dd93e1a194866bed6cbf58dde6ab6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51e7fa3e99494ccabbb4f5480eae52b8_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f57259deda46369255333e92bf2fe1_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644151b6138447f397ecbd47582bdb71_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b439ab1a3340e7a1a2684ce3f73c38_D20171201-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia544d315ec7d4af5a972efb96f552dba_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib257bf5eb1c3440fb565b1bc921fddb1_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2de27440831843859499b5316c0123fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13d3e19bc1f941bfada2a1d34fbabcd0_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ad9356ed1a4e1e8a0ce2245ba0883a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f348bc656a048d89a2becabe2d582e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed88b3f0256493eb611d1c6df10aa32_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d78a85fa8bf4c2088761487072d070b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ccfc5457b247c9a4372c7a7b6fd8b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ae6a236ee94776b86d549585e14bb1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03631c915ffa4c589e31bd1ac9a7dfc1_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645065c4f11143f6a0bcdbb35e8a38f5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75cd2dd96b0241acae7b413f811622f1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_1"></div><div style="min-height:36pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY4_a8343189-65c4-44f1-a9e3-2885df01bfb7">10-Q</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NjEwYzY5MGNhZjVlNDVjZGExMTI3MzBjNzE5NTFlZmQvdGFibGVyYW5nZTo2MTBjNjkwY2FmNWU0NWNkYTExMjczMGM3MTk1MWVmZF8wLTAtMS0xLTM3MjYx_ac94c31a-f399-4594-a348-5ef99e9af2b6">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMzE_867713f8-2ddd-4a74-8a7a-a19bc0399a6e">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6YTU2NTNjMDQyYmExNDc5NjhlNmZjOTAwMDYzMTlkOTgvdGFibGVyYW5nZTphNTY1M2MwNDJiYTE0Nzk2OGU2ZmM5MDAwNjMxOWQ5OF8wLTAtMS0xLTM3MjYx_99e86113-d0ac-448f-ba75-3bbc5d9cfa1b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY5_a804ffe5-80b2-4f26-a921-5b41e5d888f7">000-30171</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY0_33fb75d7-0a0a-4af6-9f6d-3ce1598aa056">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:30.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8wLTAtMS0xLTM3MjYx_a5c4cc38-aa91-4e2c-a25e-837c2560bbbb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8wLTQtMS0xLTM3MjYx_b3c3abcf-aa1c-40ca-b3d2-fe4b11a3a1f7">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8zLTAtMS0xLTM3MjYxL3RleHRyZWdpb246YjM2ZmM1YWYzNjQ3NDhkNGJkNmZjZjZjNzc1YmMwY2JfNA_d1d8dc27-af8e-4458-b2bb-002839079637">7000 Marina Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8zLTAtMS0xLTM3MjYxL3RleHRyZWdpb246YjM2ZmM1YWYzNjQ3NDhkNGJkNmZjZjZjNzc1YmMwY2JfOA_6b0ff650-b44e-4908-b8cc-5ec5c9eec605">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8zLTAtMS0xLTM3MjYxL3RleHRyZWdpb246YjM2ZmM1YWYzNjQ3NDhkNGJkNmZjZjZjNzc1YmMwY2JfMTI_0065adf8-c3de-49de-9d19-2080c099d563">California</ix:nonNumeric>, <ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8zLTAtMS0xLTM3MjYxL3RleHRyZWdpb246YjM2ZmM1YWYzNjQ3NDhkNGJkNmZjZjZjNzc1YmMwY2JfMTY_f04ac794-f8b4-4c4a-bebd-c463d6f500af">94005</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY1_27789246-c651-439f-ad33-98d6d72a32ba">510</ix:nonNumeric>) <ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY2_e86c4bda-00bb-4eb5-9882-52724003777e">970-6000</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:38.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NzA0YTQwZWMwYmVkNDQ4MzgyOTIwOGZkOWY1ZjAyMmMvdGFibGVyYW5nZTo3MDRhNDBlYzBiZWQ0NDgzODI5MjA4ZmQ5ZjVmMDIyY18xLTAtMS0xLTM3MjYx_49d00c1f-161f-4694-9559-91687c636c71">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NzA0YTQwZWMwYmVkNDQ4MzgyOTIwOGZkOWY1ZjAyMmMvdGFibGVyYW5nZTo3MDRhNDBlYzBiZWQ0NDgzODI5MjA4ZmQ5ZjVmMDIyY18xLTItMS0xLTM3MjYx_762b2a61-606f-49cc-95c3-2a660a426ef3">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NzA0YTQwZWMwYmVkNDQ4MzgyOTIwOGZkOWY1ZjAyMmMvdGFibGVyYW5nZTo3MDRhNDBlYzBiZWQ0NDgzODI5MjA4ZmQ5ZjVmMDIyY18xLTQtMS0xLTM3MjYx_8ead68f6-04d4-4a84-948d-4dae4bd9a505">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY3_95ff7a2d-4c36-4307-bbb7-4cb7025f6327">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjcw_bee2058c-5972-44c6-a766-930037e5376d">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:2pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:21.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NDg4ZWE4YjZjMWYyNDk2YTkwZGJhZmY3ZDAzOGQwY2EvdGFibGVyYW5nZTo0ODhlYThiNmMxZjI0OTZhOTBkYmFmZjdkMDM4ZDBjYV8wLTAtMS0xLTM3MjYx_004cda35-e409-46f3-8e52-8c5f79922323">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NDg4ZWE4YjZjMWYyNDk2YTkwZGJhZmY3ZDAzOGQwY2EvdGFibGVyYW5nZTo0ODhlYThiNmMxZjI0OTZhOTBkYmFmZjdkMDM4ZDBjYV8xLTQtMS0xLTM3MjYx_0a4be115-89a9-423a-b931-fe5d3ad868b7">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NDg4ZWE4YjZjMWYyNDk2YTkwZGJhZmY3ZDAzOGQwY2EvdGFibGVyYW5nZTo0ODhlYThiNmMxZjI0OTZhOTBkYmFmZjdkMDM4ZDBjYV8yLTQtMS0xLTM3MjYx_e07bda8c-5969-451d-8ff9-35ad8b21ba2d">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;&#160; <ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM180OTQ3ODAyMzI3MjY3_d2d06523-8717-49ff-8247-f4df1cc682fc">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of May&#160;2, 2022, <ix:nonFraction unitRef="shares" contextRef="ie82ebd2afdea4a1990f6789118d0eb42_I20220502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMTc4_21705de0-e9a0-465a-87fb-de7f5728adf5">146,687,251</ix:nonFraction> shares of the issuer&#8217;s common stock, par value $0.01 per share, were outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i4456822efa7a4e3293b4821bff1ee4c1_16">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_19">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_19">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">Condensed Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">2 and Decem</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">ber 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_25">Condensed Consolidated Statements of Operations for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_25">Months </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_25">Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">2 and 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_25">(unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_28">Condensed Consolidated Statements of Comprehensive Loss for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_28">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">2 and 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_28"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_31">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">2 and 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_31"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_34">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_34">Th</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_34">ree</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_34"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_34"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_34">and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_34">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_34"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_37">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_76">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_76">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_94">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_94">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_94">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_97">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_97">31</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i4456822efa7a4e3293b4821bff1ee4c1_100">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_103">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_103">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_106">Item&#160;1A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_106">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_106">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_109">Item</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_109">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_109">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_109">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_109">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_112">Item</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_112">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_112">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_112">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_112">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_115">Item</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_115">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_115">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_115">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_115">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_118">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_118">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_118">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_121">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_121">36</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i4456822efa7a4e3293b4821bff1ee4c1_124">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_124">37</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to &#8220;Sangamo,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S. and Sangamo Therapeutics UK Ltd.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some statements contained in this report are &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to our future events, including our anticipated operations, research, development, manufacturing and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated research and development of product candidates and potential commercialization of any resulting approved products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of our product candidates, including the durability of therapeutic effects;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of technologies used by us in our product candidates, including our gene therapy and cell therapy technologies, zinc finger protein technology platform, zinc finger nucleases and zinc finger protein transcription factors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements, including our ability to find a potential new collaboration partner for the SAR445136 program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated revenues from existing and new collaborations and the timing thereof;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the impact of the evolving COVID-19 pandemic on our business and operations and the business and operations of our collaborators, including clinical trials and manufacturing, and our ability to manage such impacts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development and other expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers or from our own in-house manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of Sangamo and our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates, including the ability to proceed with clinical trials following the imposition of regulatory holds on our clinical trials, and the timing and costs associated with obtaining regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain and maintain rights to the technologies required to develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments, including the impact on our competitive position of rival products and product candidates and our ability to meet competition from rival products and product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the growth of our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected operating and financial performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operational and legal risks; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by use of future dates or by terms such as: &#8220;aim,&#8221; &#8220;anticipates,&#8221; &#8220;assume,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;guidance,&#8221; &#8220;intends,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plans,&#8221; &#8220;project,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with no approved products or product revenues. Our success depends substantially on clinical trial results demonstrating safety and efficacy of our product candidates to the satisfaction of regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Many of our product candidates are based on novel zinc finger protein technologies that have yet to yield any approved commercially viable therapeutic products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We have incurred significant operating losses since inception and anticipate continued losses for the foreseeable future. We may never become profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We require significant additional capital to fund our operations and continue operating as a viable business. This additional capital may not be available to us on favorable terms or at all.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We rely heavily on collaborations with larger biopharmaceutical companies to generate revenues and develop, obtain regulatory approvals for and commercialize many of our product candidates. If conflicts arise with our collaborators or if the collaborations terminate for any reason, our revenues and product development efforts would be negatively impacted.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Biotechnology and genomic medicine are highly competitive businesses. Our competitors may develop rival technologies and products that are superior to or are commercialized more quickly than our technologies and product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Manufacturing genomic medicines is complex, expensive, highly regulated and risky. We currently rely heavily on third&#8209;party manufacturers and have limited experience manufacturing products ourselves. Manufacturing challenges may result in unexpected costs, supply interruptions and harm and delay to our product development efforts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Even if we obtain regulatory approvals for our product candidates, our approved products may not gain market acceptance among physicians and patients and adequate coverage and reimbursement from third-party payors and may not demonstrate commercial viability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We may not be able to obtain, maintain and enforce necessary and desirable intellectual property protections for our technologies and product candidates in all desired jurisdictions, which could adversely affect the value of our technologies and our product development efforts and could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Third parties, who may or may not be competitors, may allege that we are infringing, misappropriating, or otherwise practicing in an unauthorized manner their patents or other proprietary rights. Such allegations may result in infringement actions, other misappropriation actions or threats of such actions, all of which could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Our success depends on hiring, integrating and retaining additional highly qualified skilled employees and retaining current key executives and employees, which may be challenging given that competition for these individuals is intense and increases in employee attrition across the United States resulting from the &#8220;great resignation&#8221;.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The ongoing and evolving COVID-19 pandemic could continue to adversely impact our business and operations and the business and operations of our collaborators, manufacturers and other business partners. If such impacts become material, our revenues and product development efforts could be negatively impacted.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of any investment in our common stock. We are a clinical-stage biotechnology company with no approved products or product revenues. Our success depends substantially on clinical trial results demonstrating safety and efficacy of our product candidates and durability of therapeutic effects to the satisfaction of regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may be subject to significant delays or never occur for any product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional discussion of the risks, uncertainties and other factors described above, as well as other risks and uncertainties material to our business, can be found under &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on February&#160;24, 2022, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q, and we encourage you to refer to that additional discussion. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. You should read this report completely and with the understanding that our actual future results and the timing of events may be materially different from what we expect, and we cannot otherwise guarantee that any forward-looking statement will be realized. We hereby qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You are advised, however, to consult any further disclosures we make on related subjects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes discussion of certain clinical studies and trials relating to various product candidates. These studies typically are part of a larger body of clinical data relating to such product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical data are subject to differing interpretations, and even if we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_19"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_22"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:74.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMy0xLTEtMS0zNzI2MQ_8c74a9b2-78dc-4e1a-bbcc-91925c5f2452">120,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMy0zLTEtMS0zNzI2MQ_5d9acc56-81a5-48f6-ae76-6af08e2b2a6a">178,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNC0xLTEtMS0zNzI2MQ_a0fdd490-4f35-4db8-8b58-ddab459d97e5">197,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNC0zLTEtMS0zNzI2MQ_2afae9da-bd0f-4f98-b988-89df0f103f86">197,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNS0xLTEtMS0zNzI2MQ_9247ee91-4c06-4dc0-ad87-1601c9d76bc9">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNS0zLTEtMS0zNzI2MQ_ecbca8cb-32e4-41e9-83f8-fbb4320b5d46">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNi0xLTEtMS0zNzI2MQ_27464fc8-e89e-4f6b-8c11-089dda7d036d">6,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNi0zLTEtMS0zNzI2MQ_2cd8cb19-f935-4ffc-aabd-9f2b337267a8">6,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNy0xLTEtMS0zNzI2MQ_fc5c94de-2533-45d2-ad7a-80a089be8ecc">14,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNy0zLTEtMS0zNzI2MQ_0f5a86d2-4fdb-469d-86dc-3d18c1700846">15,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfOC0xLTEtMS0zNzI2MQ_b7435950-7f82-4f2d-b569-3b57f569e864">340,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfOC0zLTEtMS0zNzI2MQ_48089063-e854-4d22-a9d4-46f0610e74f8">398,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfOS0xLTEtMS0zNzI2MQ_ca4aa176-7b3a-4c41-aff8-ea1bb6014d32">82,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfOS0zLTEtMS0zNzI2MQ_01fdab55-0d7e-4e09-aacc-fad533bfff91">88,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTAtMS0xLTEtMzcyNjE_c82e382b-5a96-4b00-ba48-7265ac49c1ba">51,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTAtMy0xLTEtMzcyNjE_f4640b6a-8f50-451c-98be-a6d5d6f6075b">51,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTEtMS0xLTEtMzcyNjE_8b0c24c2-0007-4a41-a87d-07e90157a338">52,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTEtMy0xLTEtMzcyNjE_548bef7c-2f61-413a-bb6a-6edf55c1d5e6">53,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTItMS0xLTEtMzcyNjE_71f927e4-a1ca-4092-ad0a-112710dbd404">38,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTItMy0xLTEtMzcyNjE_741bdc2e-8794-43a8-8c95-41866cab4340">39,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTMtMS0xLTEtMzcyNjE_633a5fdc-0a6a-497e-a1bb-19601d730185">70,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTMtMy0xLTEtMzcyNjE_68afe8ec-bae5-43d8-ba0a-19fbc60dd2e2">73,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTQtMS0xLTEtMzcyNjE_7370835e-3e1b-4505-a45d-1247db9e8a65">16,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTQtMy0xLTEtMzcyNjE_b9d4cfbf-3f63-4a7a-a129-2edb2d25fc02">15,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTUtMS0xLTEtMzcyNjE_919b1ace-d311-4b2f-8524-934b60d4ddbe">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTUtMy0xLTEtMzcyNjE_c92b5a5c-6e0f-4a7e-8994-f808d318cbba">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTYtMS0xLTEtMzcyNjE_32e4c863-21bc-43b7-b6bf-ba4e34fa1fa5">654,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTYtMy0xLTEtMzcyNjE_5b626a14-3aa7-4ff8-bcbc-49bd4be8a739">721,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTktMS0xLTEtMzcyNjE_9e85f3a1-8404-48b7-bf31-a070df4f71d9">11,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTktMy0xLTEtMzcyNjE_1253165d-672d-446f-a281-ce5968d8ede5">9,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjAtMS0xLTEtMzcyNjE_9031e37d-31ef-4624-a8a5-a0978c39cab1">12,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjAtMy0xLTEtMzcyNjE_95ded760-a412-4142-a4af-dee59db039fd">20,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjEtMS0xLTEtMzcyNjE_c1c986de-2b53-4985-adc2-12c1a3a85867">14,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjEtMy0xLTEtMzcyNjE_485b9406-7022-4c85-9070-715bde091ba1">11,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjItMS0xLTEtMzcyNjE_dc736d55-ed62-46cb-a6d7-4dad856a1012">80,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjItMy0xLTEtMzcyNjE_2132b9a3-b96e-4d30-8185-80fd95cb939d">85,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjMtMS0xLTEtMzcyNjE_84341239-1100-4b8e-b773-984ab7f903eb">118,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjMtMy0xLTEtMzcyNjE_e8fee5f1-f8ac-4215-ac47-0705b31769a0">127,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjQtMS0xLTEtMzcyNjE_5e9fbeb5-e594-4706-8981-4fda19a36878">150,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjQtMy0xLTEtMzcyNjE_7f9382e8-f0b9-4777-9025-69cfd1100211">166,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjUtMS0xLTEtMzcyNjE_a95cb08c-5d59-4ba9-9e9f-d89802e121e2">42,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjUtMy0xLTEtMzcyNjE_05142c6a-5814-407a-ac36-253d4e20a34e">44,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjYtMS0xLTEtMzcyNjE_7becb873-7ba7-4377-9a29-11fb9a5ba4bd">6,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjYtMy0xLTEtMzcyNjE_daf4fcd2-1650-4858-9362-faa7668910ff">6,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjctMS0xLTEtMzcyNjE_45ebd16b-6bc0-4137-b9b9-f2f7703c4c90">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjctMy0xLTEtMzcyNjE_0c964875-c741-42f2-bd65-ffee72f4392e">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjgtMS0xLTEtMzcyNjE_fd717b45-e0bd-4d48-b80a-37f8b4823fab">319,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjgtMy0xLTEtMzcyNjE_4555bf16-a948-4bc7-b817-bf66aee3480b">346,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjktMS0xLTEtMzcyNjE_fc22d66f-deb2-48a1-abd4-5f32228a2cee"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjktMy0xLTEtMzcyNjE_e6e16a0c-0ad5-4b7f-b6c3-8ba7efa60de6"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzEtMS0xLTEtMzcyNjE_8ff10722-cd60-4dd7-9c99-a8542a786d2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzEtMy0xLTEtMzcyNjE_f102a538-17c6-4127-a53b-2d448451e5ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzItMS0xLTEtMzcyNjE_650d2b67-4fc8-4322-914b-145a35683a89">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzItMy0xLTEtMzcyNjE_98f8c3bb-34ef-4803-80c2-f1866f4f955e">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzMtMS0xLTEtMzcyNjE_3d80108f-c36d-41d8-a29b-af105f5ef162">1,340,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzMtMy0xLTEtMzcyNjE_63be9b6a-62a0-491e-9154-8f80bb732a27">1,334,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzQtMS0xLTEtMzcyNjE_0ec447ba-119e-4b19-8abe-09ab99705c78">1,000,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzQtMy0xLTEtMzcyNjE_0a4b7bd3-2ef6-4ca8-a8a2-fa68582caf90">956,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzUtMS0xLTEtMzcyNjE_48a41542-8680-4e72-8c1b-21716823ebbd">6,955</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzUtMy0xLTEtMzcyNjE_bfada623-003b-44fc-acc3-b31947dfb29b">3,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzYtMS0xLTEtMzcyNjE_b44417fb-06cf-4ab3-954f-edba30050b06">334,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzYtMy0xLTEtMzcyNjE_7e9a4129-8dbf-4781-bcb4-56196e55680b">375,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzktMS0xLTEtMzcyNjE_30720e01-370e-40c0-a62a-2cef64fd5e57">654,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzktMy0xLTEtMzcyNjE_26e4053f-069f-4d64-a272-4c970eca56a4">721,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except per share amounts)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:74.368%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMi01LTEtMS0zNzI2MQ_4f614625-9e10-4345-8894-945a2e46ce5a">28,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMi03LTEtMS0zNzI2MQ_820211dd-844e-4907-8a0e-8fdef991d854">26,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNC01LTEtMS0zNzI2MQ_3e04c410-341e-4d2d-97b7-f8e85d15aad5">58,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNC03LTEtMS0zNzI2MQ_62e80a45-768a-4611-9309-0444f18388f9">56,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNS01LTEtMS0zNzI2MQ_05ae905c-1014-4dfb-a68a-99fdcd3142e2">14,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNS03LTEtMS0zNzI2MQ_3962a64b-ab3b-4c84-a708-b407e0650948">16,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNi01LTEtMS0zNzI2MQ_eca27375-7f1c-401c-849b-94ceb460b15d">73,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNi03LTEtMS0zNzI2MQ_ad12beef-571e-4c0f-a6e5-8de570968d10">72,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNy01LTEtMS0zNzI2MQ_744eb115-5425-40c5-a4cb-20e5445f32de">45,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNy03LTEtMS0zNzI2MQ_a63156fc-8396-4fa7-975e-fceeb9bb6a55">46,302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfOC01LTEtMS0zNzI2MQ_11fe4196-8df6-4dae-ab56-412be6ed6c1b">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfOC03LTEtMS0zNzI2MQ_5be27725-bd6e-49b7-9d59-4450f49308ae">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfOS01LTEtMS0zNzI2MQ_e613e4e5-419a-41e8-9f17-7ea9eca0cecf">43,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfOS03LTEtMS0zNzI2MQ_abc990bb-2f4e-4b50-bba4-e3bd4d39ade2">45,677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTAtNS0xLTEtMzcyNjE_54f51ca9-732d-42a8-917d-463e0058a6f7">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTAtNy0xLTEtMzcyNjE_a0ae4b9b-6794-4793-9411-cadf2dadab4c">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTEtNS0xLTEtMzcyNjE_354755a7-2dc2-4e19-9e48-c6775ba09476">43,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTEtNy0xLTEtMzcyNjE_1d04e98b-cfca-4779-a1e3-45852a4567b5">45,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTItNS0xLTEtMzcyNjE_2d222e79-0e48-44b8-8a94-4bba6ef7a9d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTItNy0xLTEtMzcyNjE_d98559a6-c421-4588-9087-22130b5816e2">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTMtNS0xLTEtMzcyNjE_980a897c-aade-4b1e-bd20-13b6f7af81b2">43,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTMtNy0xLTEtMzcyNjE_0868a8d2-3d3c-409d-9a43-8b032a3bbc0b">45,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTQtNS0xLTEtMzcyNjE_06821f7b-40af-44cc-8f42-49e2aaefbf38"><ix:nonFraction unitRef="usdPerShare" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTQtNS0xLTEtMzcyNjE_9259763c-1885-4a9e-acd7-30edce5f47d8">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTQtNy0xLTEtMzcyNjE_0f3634d7-e333-41eb-ae55-27daab1d4d5f"><ix:nonFraction unitRef="usdPerShare" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTQtNy0xLTEtMzcyNjE_b12e84bf-8516-4051-8ab0-4399213c6636">0.32</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTUtNS0xLTEtMzcyNjE_9175871d-89fb-4670-9e72-2c3730edfabe"><ix:nonFraction unitRef="shares" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTUtNS0xLTEtMzcyNjE_b0d62144-7d6e-4b26-8e71-ce7e177c67d5">146,218</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTUtNy0xLTEtMzcyNjE_69551e6b-f443-4baa-b7e5-8e9005761063"><ix:nonFraction unitRef="shares" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTUtNy0xLTEtMzcyNjE_dbdd9c66-20f6-45db-bf9c-49adff5ee410">143,112</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.474%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfMi01LTEtMS0zNzI2MQ_354755a7-2dc2-4e19-9e48-c6775ba09476">43,977</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfMi03LTEtMS0zNzI2MQ_a2005f4e-c850-4298-b819-1faa5407388b">45,939</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfMy01LTEtMS0zNzI2MQ_bc49de8b-ea20-442c-ad2b-0bc3c0ea33ab">1,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfMy03LTEtMS0zNzI2MQ_ce912ed9-90da-4e81-b670-77a56050e802">4,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension gains</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNC01LTEtMS00MTEwOQ_058b0604-f501-4e10-b3e0-7c76fe6793b6">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNC03LTEtMS00MTEwOQ_d00dd45e-dd98-4409-aa9e-b7a5d4fd35a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNC01LTEtMS0zNzI2MQ_9c4ffe27-a9c1-484e-9fed-6b006eb0dc46">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNC03LTEtMS0zNzI2MQ_e4bf596d-6704-48b7-ad52-f02ced15f8a3">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNi01LTEtMS0zNzI2MQ_b5f110ce-6877-401e-8adf-cdb3f3a1d333">46,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNi03LTEtMS0zNzI2MQ_2fb24634-ac94-4c25-9271-5f079e4422fd">50,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to non-controlling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNy01LTEtMS0zNzI2MQ_c1bdb4ea-bf33-4bd7-9963-80e21f80fef0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNy03LTEtMS0zNzI2MQ_4e36d8a3-b3c1-42c7-bb05-346e1af47f11">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfOC01LTEtMS0zNzI2MQ_b75cdd17-5801-4d4d-8d7b-e5475b7bf6fc">46,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfOC03LTEtMS0zNzI2MQ_8a1bd8cb-74fb-4d19-8466-e18c22d0cb1e">50,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.229%"><tr><td style="width:1.0%"></td><td style="width:28.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98eb94bb16d64b339437154eeb6a8c7e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy0xLTEtMS0zNzI2MQ_230a636b-efbd-4560-98ab-1fd633027047">145,921,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98eb94bb16d64b339437154eeb6a8c7e_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy0zLTEtMS0zNzI2MQ_63ca0f9c-7dc6-468b-bcbb-e39fd1aea707">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b9a853412a4de5bbfc5086f43609a9_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy01LTEtMS0zNzI2MQ_2cda2669-7b35-45ac-94d5-ab37172a6b0e">1,334,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37f8868245aa4443834ca54fd2f6d165_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy03LTEtMS0zNzI2MQ_fc9443c3-b051-4450-bd3d-ad0aa290e5a9">956,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia25b49838a1e4216a648cda338998cd0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy05LTEtMS0zNzI2MQ_1230ff74-4546-4a88-9ec5-c9013417b550">3,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy0xMy0xLTEtMzcyNjE_6dba0860-94ea-43fe-935f-191586605ab0">375,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16363a48a1db4200a557e20f74a6663e_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNS0xLTEtMS0zNzI2MQ_283efac5-ed7a-4e10-9206-269d65c7e061">743,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16363a48a1db4200a557e20f74a6663e_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNS0zLTEtMS0zNzI2MQ_3d91dbf1-073d-4ca8-90e8-a41b8495f034">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0831195cbcb42c78e3d9a80acb8bd55_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNS01LTEtMS0zNzI2MQ_399b359e-426c-418e-b4a3-5ad1cf3f8a6c">1,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNS0xMy0xLTEtMzcyNjE_78f87618-e4f2-47b8-871e-5049e477a849">1,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0831195cbcb42c78e3d9a80acb8bd55_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNy01LTEtMS0zNzI2MQ_ed26ca96-f068-4d39-8599-17328e43a930">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNy0xMy0xLTEtMzcyNjE_1b91f7ba-475b-45f1-929b-6bdf6089b42a">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i415e7d08c2134893996d32a46190bba6_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfOS05LTEtMS0zNzI2MQ_acc2c0da-0a66-4c79-bf11-426f7550c829">1,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfOS0xMy0xLTEtMzcyNjE_db1d999e-9607-40ae-9400-c3735866e290">1,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net pension gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i415e7d08c2134893996d32a46190bba6_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTEtOS0xLTEtNDExMTU_fa5d9615-434e-44c2-a4f9-d5f85b6efe6f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTEtMTMtMS0xLTQxMTE1_32a8e175-726b-426e-806e-9b9aaa344c26">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i415e7d08c2134893996d32a46190bba6_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTEtOS0xLTEtMzcyNjE_368d1645-9b47-44d6-bb59-1551a518f3af">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTEtMTMtMS0xLTM3MjYx_e90afeb9-9122-41fd-86e5-37af04be31de">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bdbe1eebb07447cadf7cd259b6f2ca8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTMtNy0xLTEtMzcyNjE_4738c110-5381-4571-95b8-036ec5e1c7da">43,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTMtMTMtMS0xLTM3MjYx_e18b38ec-ebea-41b4-9af5-5a53ffaa54be">43,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e2ecbeebddf486b8f3eeebae6987fca_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtMS0xLTEtMzcyNjE_d7665df9-8bd0-4165-b2c5-d7554d13eab5">146,664,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2ecbeebddf486b8f3eeebae6987fca_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtMy0xLTEtMzcyNjE_2bb8e5d3-531e-49ce-9263-3d0cf38f4119">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i662af85bbcb24003939aa4e3f3b753ea_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtNS0xLTEtMzcyNjE_38e293f5-0ba0-4f1f-af70-15d96ea766bc">1,340,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83b558b1d1b24287b972767cc449ee9c_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtNy0xLTEtMzcyNjE_23c7b0b5-05db-4ebd-9189-ed1874ab2e46">1,000,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd50e43eaec244a6a48c48e150d26257_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtOS0xLTEtMzcyNjE_f9b1af05-5544-452f-b8ff-550208574905">6,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtMTMtMS0xLTM3MjYx_c32247e9-e842-4203-a61d-b40c77c98214">334,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:26.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1dcfc8af9f54d79891a8e4f97258d64_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy0xLTEtMS0zNzI2MQ_a7d0e97a-dbc4-4101-9d2e-e8e6f111be9e">142,063,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1dcfc8af9f54d79891a8e4f97258d64_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy0zLTEtMS0zNzI2MQ_f5725e1f-2a32-4844-96df-ac4620f0360e">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb68b7a02dc941ddb5eaea5f9e94cea0_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy01LTEtMS0zNzI2MQ_80e329ea-7397-4636-a100-77ffc3ddaa0e">1,269,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i147ac2e91ee24c898b9135e2412019b8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy03LTEtMS0zNzI2MQ_ed69a0f4-58db-45ab-89ef-2c87c0b18d74">777,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7736e400eca2413e926ef07b420d3523_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy05LTEtMS0zNzI2MQ_00617d20-738b-480b-82be-f3b27c0b9fbe">5,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79928d1c5b534f9297876cf1cd9f42a0_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy0xMS0xLTEtMzcyNjE_f700986b-4792-4f66-b483-0c1dcde9f5d6">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy0xMy0xLTEtMzcyNjE_dc3dc409-417b-4cfd-8e49-aade84250d24">497,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNC0xLTEtMS0zNzI2MQ_6283eb53-5048-4ab4-9975-c92d9e83f630">1,034,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNC0zLTEtMS0zNzI2MQ_cc1729af-bd07-418c-858a-cd70db43a038">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133d4b1be36148219d4c9ca2c70121af_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNC01LTEtMS0zNzI2MQ_95c687ee-7383-4e0b-976c-25e8ba7e4d15">15,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNC0xMy0xLTEtMzcyNjE_ece5de92-1bf9-43b9-ac9b-0acaf0b5791d">15,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNS0xLTEtMS0zNzI2MQ_b1bfa446-5443-4fba-8fcc-7d90af3d57bd">615,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNS0zLTEtMS0zNzI2MQ_05478e3d-ce23-4ffa-86be-e4a56ed5dd1b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i133d4b1be36148219d4c9ca2c70121af_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNS01LTEtMS0zNzI2MQ_eef61f6c-3a5e-44b6-8080-9fae8672bbbb">422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNS0xMy0xLTEtMzcyNjE_375bb2ca-21d9-4caa-ae8b-d6931c07ddf3">416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133d4b1be36148219d4c9ca2c70121af_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNy01LTEtMS0zNzI2MQ_4b179124-e132-4b78-bf77-a546aac76ba9">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNy0xMy0xLTEtMzcyNjE_87676362-1751-4dc6-a7a8-b74e17cd5d23">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of additional shares of Sangamo France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0a5d019cb57482287e3752a44cd9473_D20210101-20210331" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfOC0xMS0xLTEtMzcyNjE_0282e4a8-4a8f-41d3-aa62-640b06afb232">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfOC0xMy0xLTEtMzcyNjE_85962e6f-7137-4e22-8c10-28af1e479568">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7621415fb2b84296bc6b90e3b825982c_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfOS05LTEtMS0zNzI2MQ_014553de-e541-45d6-96ff-60756a7659d4">4,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfOS0xMy0xLTEtMzcyNjE_4a90525b-6f79-4241-85a7-afd198f2e52d">4,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7621415fb2b84296bc6b90e3b825982c_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTEtOS0xLTEtMzcyNjE_7c1b72e8-96cf-40fc-b615-cc724da19838">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTEtMTMtMS0xLTM3MjYx_2555f561-a8a4-44ba-9b54-b6c98ebe9e8d">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib41c6577ca4a47df91565832e4f8c52f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTItNy0xLTEtMzcyNjE_e05bf1cf-5b12-445a-9be0-83906c5f4407">45,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0a5d019cb57482287e3752a44cd9473_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTItMTEtMS0xLTM3MjYx_97d90a81-84f2-4ef5-bdf4-5ec42fe78638">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTItMTMtMS0xLTM3MjYx_afb1ae16-9ff3-4332-9cb7-5aec6b0222d0">45,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0ac3d6b9a014f3fb9c09c50fb836aa1_I20210331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtMS0xLTEtMzcyNjE_35a94522-28c1-44b3-bbf9-7a4b9d9d537b">143,713,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ac3d6b9a014f3fb9c09c50fb836aa1_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtMy0xLTEtMzcyNjE_931180e3-2ec7-4c2d-8c97-d579cca9b415">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1696ceaafa594b6e8a7aa213973bb86f_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtNS0xLTEtMzcyNjE_5026d36a-59c1-4580-86c7-a9c45e651e52">1,292,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179494c7d70e4d1980c455d43a0ccccd_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtNy0xLTEtMzcyNjE_93133610-2824-4513-843e-a668d1e5b5f2">823,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76ac39ac4cc046d3891f2f198d2f40a6_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtOS0xLTEtMzcyNjE_5a8fb4af-ec64-453b-8201-d954a6384160">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c1c94341c8140bb850188c07c23add8_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtMTEtMS0xLTM3MjYx_651ba6e1-bab4-4186-a186-d397d4653e24">938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtMTMtMS0xLTM3MjYx_5ed3e85c-ac6d-4ef6-805d-aaa4d5ac28e1">469,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:74.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMy0xLTEtMS0zNzI2MQ_0236cdf8-0565-402a-b7db-20b437e53cb5">43,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMy0zLTEtMS0zNzI2MQ_975aed2e-f851-4790-a076-c4feac7e8ac4">45,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNS0xLTEtMS0zNzI2MQ_3b576969-5aa6-45d2-84b0-749ae2da0cd5">2,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNS0zLTEtMS0zNzI2MQ_183bfe04-dad8-441c-8a92-e0fc1d8f8905">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNi0xLTEtMS0zNzI2MQ_2a76b4e6-8915-4dd5-b3fe-bd42cbd2e909">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNi0zLTEtMS0zNzI2MQ_c90f5a69-025a-47e6-b8ff-7f748c2314df">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and other changes in operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNy0xLTEtMS0zNzI2MQ_639e2b8a-30cf-446b-8e45-a29970876537">2,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNy0zLTEtMS0zNzI2MQ_b2e0b62b-2a3a-467d-8495-41f2d7204119">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on free shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="sgmo:GainLossOnFreeShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfOC0xLTEtMS0zNzI2MQ_0753fd33-010a-47b8-b190-27a422649871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="sgmo:GainLossOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfOC0zLTEtMS0zNzI2MQ_be93fc8e-aae9-4d5f-9ef4-da406e2143ef">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfOS0xLTEtMS0zNzI2MQ_4ad75651-b388-4e8e-a8d7-0bb2880e7af3">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfOS0zLTEtMS0zNzI2MQ_b61ab17b-49b0-4b9c-83ca-c34c723a8ef3">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTMtMS0xLTEtMzcyNjE_973c7143-ba40-405c-84fe-03a5709161ab">925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTMtMy0xLTEtMzcyNjE_b3a4d002-e24e-4d1a-9c9a-9b76c9f12f22">1,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTQtMS0xLTEtMzcyNjE_5f690995-9941-41e0-9054-e5ebe91d7720">248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTQtMy0xLTEtMzcyNjE_511cc0cb-ff3a-4162-bb51-a80319b12bbc">1,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTUtMS0xLTEtMzcyNjE_bced7a70-db9b-4039-85fc-f067ea441535">3,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTUtMy0xLTEtMzcyNjE_5d614db2-f39d-419c-9cf3-17ddfb03ca6e">3,829</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTctMS0xLTEtMzcyNjE_eeeea7a0-0961-4832-9954-7f24a51f631b">8,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTctMy0xLTEtMzcyNjE_ccea1a23-9dc7-4947-98df-f760a7c983a7">7,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTktMS0xLTEtMzcyNjE_579d508e-a790-44db-8e28-7701f5e3d7ca">21,004</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTktMy0xLTEtMzcyNjE_6ec69f46-68c0-48c9-94d0-1e8bf2308f04">20,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjAtMS0xLTEtMzcyNjE_78887217-bb13-49ae-93e7-9b3aa415a6aa">972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjAtMy0xLTEtMzcyNjE_17e520e5-55b7-4e75-aa35-12b22fca89c7">1,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjEtMS0xLTEtMzcyNjE_c6033073-33fd-4151-a33a-fc14f64b5dc9">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjEtMy0xLTEtMzcyNjE_3b2f7a06-ce47-4ddd-bc21-ada5e98a6467">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjItMS0xLTEtMzcyNjE_7f2d3c3e-0a7b-4bcf-ac82-0925076ce814">58,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjItMy0xLTEtMzcyNjE_699ba0bf-3873-4c7e-9c18-6697f52b1897">68,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjQtMS0xLTEtMzcyNjE_e8792ed8-94de-4433-8d9f-687ac31f7757">65,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjQtMy0xLTEtMzcyNjE_8e083949-0abb-4f4b-b375-ad350f6ac7cf">97,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjUtMS0xLTEtMzcyNjE_2c163c73-211c-4cf8-812e-f295281e3ba9">70,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjUtMy0xLTEtMzcyNjE_e54a5698-4ecb-4ea9-b3e4-ba72da402246">144,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjYtMS0xLTEtMzcyNjE_ff078586-b7ea-4fad-a569-39b979183eae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjYtMy0xLTEtMzcyNjE_e7e1a424-5022-4a5e-82ff-76132e3409c9">6,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjctMS0xLTEtMzcyNjE_eefc263f-3876-48de-bee1-3ce658d75e9a">2,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjctMy0xLTEtMzcyNjE_8d1a2a71-526f-46dc-9a32-497ef744e2f9">7,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of additional Sangamo France shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjgtMS0xLTEtMzcyNjE_5a3e5fd3-1ebe-486a-a2b6-a57b4acd8f45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjgtMy0xLTEtMzcyNjE_d811de30-f2a6-477d-851e-1dc641c946ee">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzAtMS0xLTEtMzcyNjE_27d619a3-915e-4b38-ae02-3910e971b0ef">1,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzAtMy0xLTEtMzcyNjE_b0ce95af-3a86-48d5-8f0f-3055c07be3a3">45,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c52382b7dc4becb1cb30fb680833c0_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzItMS0xLTEtMzcyNjE_1ef186b1-9747-4d2d-95b6-92c5d1bc41b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ce04a30e5b4a2f9c36548cda5a8458_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzItMy0xLTEtMzcyNjE_7c775072-8e43-49b6-9bcb-34eeb532329d">15,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzQtMS0xLTEtMzcyNjE_ceb5b51c-3321-4f8b-ab4b-a7c9da413a61">1,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzQtMy0xLTEtMzcyNjE_b7e39acc-e274-45b3-85eb-fd71c76c9c06">2,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzUtMS0xLTEtMzcyNjE_fea53eba-b5f3-4342-b2c9-f1e653c9f71f">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzUtMy0xLTEtMzcyNjE_abde58f7-2201-4395-9163-f1dab67af98e">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzctMS0xLTEtMzcyNjE_269aed37-1a6b-4787-862e-e311ac0eff73">1,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzctMy0xLTEtMzcyNjE_93a0640e-d249-42ba-926d-7b3df74f89f9">15,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzgtMS0xLTEtMzcyNjE_1c10484c-66d2-4393-88de-c91b04155de6">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzgtMy0xLTEtMzcyNjE_abdf7fce-d609-43c8-8354-457bba37a8e8">328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzktMS0xLTEtMzcyNjE_6a137384-a035-41cc-8f24-5584e64f4604">58,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzktMy0xLTEtMzcyNjE_78afd387-7e98-402f-97b5-fbf34e5dcf4b">8,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDAtMS0xLTEtMzcyNjE_6109f509-a431-47ed-92d5-f7a73b9ce429">180,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDAtMy0xLTEtMzcyNjE_a8206b34-3d88-4b63-b307-749fdb459ef8">132,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDEtMS0xLTEtMzcyNjE_f46c7150-823f-4364-a045-9bf27e24f583">121,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDEtMy0xLTEtMzcyNjE_2fa3db48-64b8-4665-a8a5-61bef2327e45">124,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in unpaid liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDMtMS0xLTEtMzcyNjE_9942c92e-35a8-4d0b-be68-a77f6c3e0394">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDMtMy0xLTEtMzcyNjE_8ccc3cbe-8984-48cf-9e64-d3466b7ffc1f">2,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDQtMS0xLTEtMzcyNjE_1bb16565-bdfe-4c76-b818-17433db215ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDQtMy0xLTEtMzcyNjE_9c77e6c0-b874-4984-8860-8458c3b4d1b7">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_40"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1&#8212;<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxNDQ_f46328af-44c9-4c9b-9352-f80676a3ecd4" continuedAt="i198f0445bfa64c03bd0b8dbaade70f89" escape="true">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i198f0445bfa64c03bd0b8dbaade70f89" continuedAt="idd6ca578b13149c4bd1a10b9f86b46ce"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.</span></div><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxNDE_9e1fab9d-6dcf-4e58-9392-523e4df3b758" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The Condensed Consolidated Balance Sheet data at December&#160;31, 2021 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;2021 Annual Report&#8221;) as filed with the SEC on February&#160;24,&#160;2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2021, included in the 2021 Annual Report.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents, and marketable securities as of March&#160;31, 2022, and expected future milestones and research services revenue from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12&#160;months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, if at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxNDA_4b3afd73-dd0d-4d33-a4a3-04f084341351" continuedAt="ia746512196ef47319505e18185494dfa" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="idd6ca578b13149c4bd1a10b9f86b46ce" continuedAt="i64b7c3a02b154596a6f427fce2fd659f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia746512196ef47319505e18185494dfa">making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</ix:continuation> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in estimates during the three months ended March&#160;31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMTY_23ac2b21-bd1f-49a0-9ddb-b2469d099317" continuedAt="i084caf50788e45549e16a1df9d561b64" escape="true"><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC&#160;Topic&#160;606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="i64b7c3a02b154596a6f427fce2fd659f"><ix:continuation id="i084caf50788e45549e16a1df9d561b64"><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMTk_390f50c2-e966-4389-ab3e-4c60264a83c3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:74.368%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib44f00bdda5c4a5e8fdf09b0b409881d_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfMi01LTEtMS0zODA4Mw_350887df-af12-48b3-a09a-4be898a02901">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0fd799de345849b7bde24906fccf9e47_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfMi03LTEtMS0zODA4Mw_ee183212-038d-4c48-bd0a-116071eea9fd">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb254f83fdd54a5394d3789ac0432acd_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfMi01LTEtMS0zNzI2MQ_fba78b03-0314-4390-ba55-49d1b56133b1">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3e3c9e9fc34bada2506884b81bcc4a_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfMi03LTEtMS0zNzI2MQ_df764cc1-4692-4d75-af19-bfdd8f73d84a">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib77a01f4821e403fbaed538181093649_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfNC01LTEtMS0zNzI2MQ_0070df7e-fc35-434f-9319-ed94dc0137db">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i399ab68bf5a34a708f1ac215d91b5ef3_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfNC03LTEtMS0zNzI2MQ_b35097b2-4683-482f-91f7-8a3ea7506715">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi S.A.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf49db6b57ed4468b600943a63027618_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfNS01LTEtMS0zNzI2MQ_ad4adb06-a283-4cc6-bb2b-d0aaa4876e31">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e569774fd874df0b2278b667d3537b1_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfNS03LTEtMS0zNzI2MQ_bc422348-48dc-46d9-b297-c405f143e901">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div></ix:continuation><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMzY_6235aae3-2edd-4077-8028-e2c5d8268b15" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMTcwMTg_9b3f73bc-fa28-4936-be1d-de138b281ade">1.5</ix:nonFraction>&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMzI_641230c5-da3b-436f-99c3-c82c5ac894e7" escape="true"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMzI_c3a01cc3-6efc-4056-aebf-8b200f611614" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMS0xLTEtMS0zNzI2MQ_f4806808-4444-4a8c-93bf-bbb3af7188c0">120,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMS0zLTEtMS0zNzI2MQ_c5aaa511-fa6e-4abb-99b5-437bd8a18dbe">178,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMS01LTEtMS0zNzI2MQ_eacb1f04-ec2d-46ab-af89-d047028187b8">122,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMS03LTEtMS0zNzI2MQ_d028c43d-b3ff-4af8-940a-f5ef9dc35e26">131,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMi0xLTEtMS0zNzI2MQ_37ebee5c-5460-4baa-b2a3-9cd0243891c3">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMi0zLTEtMS0zNzI2MQ_8caf13fd-822a-4cc5-8881-94c137dec393">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMi01LTEtMS0zNzI2MQ_2852136d-2c21-47cc-a709-1aeb65fbc96f">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMi03LTEtMS0zNzI2MQ_4c92eb8d-f433-4e53-bde7-b946cc6a019e">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMy0xLTEtMS0zNzI2MQ_3685c2e0-a800-47f1-aac7-fc04f1da8429">121,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMy0zLTEtMS0zNzI2MQ_85ff7109-12cb-4c83-b072-67313130b959">180,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMy01LTEtMS0zNzI2MQ_44d55f7f-baea-40cd-8771-fcc7a8b30e9c">124,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMy03LTEtMS0zNzI2MQ_20a27cb3-400c-4233-b789-cf91793f9062">132,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMjQ_6a3de123-b8b2-42fa-91e9-236e077b7487" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric></ix:continuation><div id="i4456822efa7a4e3293b4821bff1ee4c1_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2&#8212;<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RleHRyZWdpb246ZWJjZmNmNDFhYTg4NDRmYTllZWVmMDVjNGEyZDQxMGJfMzEwMg_8027386e-8028-4cd7-85e0-e6c73bf15586" continuedAt="iff6db31b798d4f328324c2ec792495dd" escape="true"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RleHRyZWdpb246ZWJjZmNmNDFhYTg4NDRmYTllZWVmMDVjNGEyZDQxMGJfNDk0NzgwMjMzMTQwNQ_1d40cc43-a262-4689-86d2-b0ec095c450e" continuedAt="ic7beb40337fa4c62a6235327fd59fca1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="iff6db31b798d4f328324c2ec792495dd" continuedAt="i4f2b3e979e1b47b18d833c2ecf3f6cf2"><ix:continuation id="ic7beb40337fa4c62a6235327fd59fca1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities, and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="i4f2b3e979e1b47b18d833c2ecf3f6cf2"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RleHRyZWdpb246ZWJjZmNmNDFhYTg4NDRmYTllZWVmMDVjNGEyZDQxMGJfMzA5OQ_5fb54e9d-4e63-4753-9630-bafa49c7ce4a" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ec91078cbd4fef9b2ff9b118a62896_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNS0xLTEtMS0zNzI2MQ_3d4a9677-a3a3-4ad2-8f9b-f08aa70fed15">49,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e8560aa3fb044e2afe37becdf007481_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNS0zLTEtMS0zNzI2MQ_f14ecd78-1621-442d-81cc-c5d27ed558ca">49,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2e671b261e4b9a9510eea1dd524ffe_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNS01LTEtMS0zNzI2MQ_b3a6ad29-3c12-46dc-a186-9e2a04569072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143dc860af4e41ca8ad56c89389f8c0e_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNS03LTEtMS0zNzI2MQ_c7f77870-f475-44f2-aa4b-3cb969a4d006">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff2db9628f4469aa4b0d9190c623367_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy0xLTEtMS00MTEyNA_a5d7db16-ce9e-4a09-afc8-8416257bb11d">15,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb308b033f4cfd8478d6ed83ab7469_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy0zLTEtMS00MTEyNA_95817a1a-a42e-48eb-b240-f5633e13d9a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09f7155daf244fe2847f5df4bca90b38_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy01LTEtMS00MTEyNA_f4646ab4-7752-4541-9f53-bdc438bb86d7">15,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c2af11dc0945a1a2b563bdd67a34e9_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy03LTEtMS00MTEyNA_0023cc47-95a6-4de7-b3e1-bd16f3334876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708b092c6ed84bd1bbf020943bc286ea_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy0xLTEtMS0zNzI2MQ_82a6ba2f-399f-4f95-9417-7a50bc1aa13f">64,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id893d7bf0fe340b493ce98b8ad036faa_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy0zLTEtMS0zNzI2MQ_77f644fd-490c-4d51-a643-9f97cb897f49">49,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45eb48d4aac42dcb834ce4d4238cbc5_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy01LTEtMS0zNzI2MQ_dcd8a784-a8a6-44f8-824d-8c4d0b05f22f">15,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b546e6ad858449f9375bab65733a9ff_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy03LTEtMS0zNzI2MQ_c9fd5aa4-130e-4a19-9c0c-57bfb76cd429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff2db9628f4469aa4b0d9190c623367_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfOS0xLTEtMS0zNzI2MQ_85e6ade4-9b3a-4bc2-be11-bb99fda381ee">24,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb308b033f4cfd8478d6ed83ab7469_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfOS0zLTEtMS0zNzI2MQ_6f57e131-a801-454e-8394-a32b34eef9eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09f7155daf244fe2847f5df4bca90b38_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfOS01LTEtMS0zNzI2MQ_db89d589-c846-4e63-abd0-578a6afcf069">24,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c2af11dc0945a1a2b563bdd67a34e9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfOS03LTEtMS0zNzI2MQ_1b41eec9-3cee-48fe-86ac-5557b5360f4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b4f1bdb97d4271beba4b63564701b1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTAtMS0xLTEtMzcyNjE_0f870a18-0ea2-4d08-a1b6-3529d576166b">117,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied809edebcb648f59c57c3137795b9c2_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTAtMy0xLTEtMzcyNjE_c80b0a21-7a6e-4355-9f52-8e3cab8456ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1456174ba11d44a79cda4fef54a9527a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTAtNS0xLTEtMzcyNjE_2a2adaed-6341-4fa4-9dbe-f26b41bc3238">117,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i304cf3079db74ee581bad5edc8ea8eb6_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTAtNy0xLTEtMzcyNjE_fd40a67d-3b72-4dd5-92ff-dfbb38702187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21a61daf2da4126898da412720ef0c1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTEtMS0xLTEtMzcyNjE_c2416d2d-1a1e-494c-9ee3-522c2adc4399">17,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic156a4b9bcd648ffabb65ad460686df9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTEtMy0xLTEtMzcyNjE_3ff963bb-0445-4564-9bd1-8a290bed2899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb75b0131d244f9b44926706c6e6e1a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTEtNS0xLTEtMzcyNjE_34287f44-460c-4830-b8b5-9e0a1043dff9">17,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08f31b20a2b442a592d8b411d50e9a36_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTEtNy0xLTEtMzcyNjE_93a4a90a-ff50-442f-8860-9e8f21e2fcaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c76a773d414d409fa20c7e798a1ead_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTItMS0xLTEtMzcyNjE_3dd4456e-f7c4-4dde-9681-cb7e9cc94ec4">67,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6006abfadc42c5890e9f29785dbba5_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTItMy0xLTEtMzcyNjE_4062c700-b107-4cf7-a924-a461bb19d186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0b1b7628b74a32bf1f89c76bd39253_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTItNS0xLTEtMzcyNjE_2c480cc3-5ad3-430d-9b15-10d837b64959">67,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f93a4e5c614d898f2dba36b145b91a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTItNy0xLTEtMzcyNjE_24002e97-5db5-470d-9985-9ec472ac4c9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d2ad076baf46aa95e6b9a86a08f8fc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtMS0xLTEtNDA4MDI_52e4ecf6-5474-4aa3-a881-153be7c897cf">2,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021e4eb600444817b880d3c34fb52136_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtMy0xLTEtNDA4MDg_ea4571f3-16b4-4b68-bd45-563292bfc6b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96bcec60508420a9f72a54a34521d52_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtNS0xLTEtNDA4MTQ_9a2ab5b8-a186-477b-90f0-3f1abc4eb6f0">2,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906b3eb7e3734168ba335e172b1fa959_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtNy0xLTEtNDA3OTU_ba79abc5-4309-493e-8eef-b1e2b144e55f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adf2fec9bea4ba899e404e902cb35bd_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTMtMS0xLTEtMzcyNjE_7a563f65-3c10-43df-9be9-4fa4fb321667">50,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05b14fccaf44e1180d2ef8bbe382fec_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTMtMy0xLTEtMzcyNjE_f3351156-4915-44fd-a814-3355eee7a296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c37e7249d9345dc9330907394eb067f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTMtNS0xLTEtMzcyNjE_d92fd2f3-2866-4ecf-b90f-d54ba00ec99b">50,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412513ce57b94ec0bf641412ee64ef34_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTMtNy0xLTEtMzcyNjE_933989a7-ed01-4d59-bda2-0a8adf992eae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708b092c6ed84bd1bbf020943bc286ea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtMS0xLTEtMzcyNjE_756f9d87-bc7e-4531-a9da-1a2a4ba130c0">280,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id893d7bf0fe340b493ce98b8ad036faa_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtMy0xLTEtMzcyNjE_df4f8940-8df5-43b0-975c-8e8002cf7589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45eb48d4aac42dcb834ce4d4238cbc5_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtNS0xLTEtMzcyNjE_d4f61623-56d3-4f9b-ad0b-29e61ddd6a63">280,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b546e6ad858449f9375bab65733a9ff_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtNy0xLTEtMzcyNjE_053799a3-6a4f-40c0-877b-e1c4e097d690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708b092c6ed84bd1bbf020943bc286ea_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTUtMS0xLTEtMzcyNjE_c15b3116-e0af-40b9-bacf-cd86ee933a24">344,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id893d7bf0fe340b493ce98b8ad036faa_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTUtMy0xLTEtMzcyNjE_07bca680-1879-4542-b5e3-6afceff76c8e">49,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45eb48d4aac42dcb834ce4d4238cbc5_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTUtNS0xLTEtMzcyNjE_6ed3c5b8-25f3-4c40-a94d-c05e7677c6b7">295,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b546e6ad858449f9375bab65733a9ff_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTUtNy0xLTEtMzcyNjE_e71ee58c-feb5-4e6d-bc20-b223ed99ee7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a823a89d644a15b67b9a1a84a15ea6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNS0xLTEtMS0zNzI2MQ_32b456cf-eb4b-4c4d-878e-d21023655199">119,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1cbbf6bfc4b6fae628fbceab20e0c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNS0zLTEtMS0zNzI2MQ_a27435fc-3b85-4499-9554-a6781b03da9f">119,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e70945d068e421d8e7e13119a342d96_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNS01LTEtMS0zNzI2MQ_e71add87-2668-4433-903b-91973e66d7ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c70fd8f212a44f0b0fd39c5da686631_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNS03LTEtMS0zNzI2MQ_0491a4c0-f750-417a-9914-1c951affa9d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5062dc4f6c4aea9b5af1b8206788f4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNi0xLTEtMS0zNzI2MQ_a3f6993c-d832-401f-9a54-6dd77ebeb38b">119,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8460203d45415f877cfffa51733070_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNi0zLTEtMS0zNzI2MQ_25f4a02b-55c3-45de-aa61-12a81d19137b">119,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5e6402ec45427eae4f571d473ddedf_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNi01LTEtMS0zNzI2MQ_2fd71643-4bc3-4a9a-9df4-010b437600d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752f160556a747deb9e6619b306a9579_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNi03LTEtMS0zNzI2MQ_89a17100-78c2-4549-876c-c3bf6d3caf35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba495162727d4dc1ad3ca1981bbe7c17_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOC0xLTEtMS0zNzI2MQ_eb6c3ed2-d3a4-43d4-8cee-30f74438e429">30,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa05cd9050654d27a2da2817cacdacc0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOC0zLTEtMS0zNzI2MQ_e3501c03-5654-481a-98fb-d36e603b3632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib156eb5be64c4a22a4011ee880db1829_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOC01LTEtMS0zNzI2MQ_c55581d9-3707-45ad-9744-06fc6ec9ed37">30,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1034cd2a6148f9a0d34eccdef2cb56_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOC03LTEtMS0zNzI2MQ_1156a518-d5d9-4f6b-8980-550e797c5c23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c0f076cbacf47db8a333a0ba2a9744c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOS0xLTEtMS0zNzI2MQ_5459a75f-207c-49db-b0c9-086279138ce7">105,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c97739d5bf4f7aaf30ff5711b7b551_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOS0zLTEtMS0zNzI2MQ_5248c359-3c0c-4851-aab9-9bb31690f8e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90c35cf8bca444c9fe316fa99c0ccc9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOS01LTEtMS0zNzI2MQ_9ade1487-4510-4a22-9a75-0fae9ed48abf">105,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8eb71551dfe411696e39c0e4a98ac05_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOS03LTEtMS0zNzI2MQ_e2ec1a1a-f57a-466a-9a31-a8248dcc314f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85f2894d23e54b5c8bc3535256e6f430_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTAtMS0xLTEtMzcyNjE_2d2fab5a-dd22-4381-ae47-5bad814feef9">33,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia241ff32633d44d0995fa41d3b30c749_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTAtMy0xLTEtMzcyNjE_2b1eaf33-1597-4283-8036-298cd4828efa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652c08590692478dbad26f055bd24b22_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTAtNS0xLTEtMzcyNjE_06d265a5-45df-4961-982d-141c4606c3e6">33,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1900186abb04fcd8679b20fe15aa9eb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTAtNy0xLTEtMzcyNjE_b2766a39-a467-467c-aa0f-71c75d23c10b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94522ff63b14c7c8f42c47bc206bcf9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTEtMS0xLTEtMzcyNjE_4a44f5ef-4522-4cb7-a71f-1eb8b6269502">70,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a079914a6f4629944a16c5c8f8c67f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTEtMy0xLTEtMzcyNjE_6d31df1d-4e03-49dc-b870-2861f697f341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b82c587da8e49dba0a77764e4e9678f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTEtNS0xLTEtMzcyNjE_fe0324dd-0cc0-430e-a9fe-5599f7c34495">70,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89392c2987434d09bae08df932002bb7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTEtNy0xLTEtMzcyNjE_1dc93482-7671-45ea-82ab-c54775e4ff32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadab9f649ee64aa18743fe966255becd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTItMS0xLTEtMzcyNjE_72993cf2-f814-47b2-8615-1c8d84a47dc1">45,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd13862a3fc0418f8cf10ae64ad1ac6a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTItMy0xLTEtMzcyNjE_1c9cfdc1-8c4b-45d1-8ab7-d98806586b2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0369288ea6d34134bdc95a49a5e089a2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTItNS0xLTEtMzcyNjE_8d47918b-c161-491c-8f1d-c29801dc7f5a">45,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2de2dac42941aea08c2173d245c90d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTItNy0xLTEtMzcyNjE_bbccf775-751c-4054-8285-dd9d437aba6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5062dc4f6c4aea9b5af1b8206788f4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTMtMS0xLTEtMzcyNjE_f19cc2b7-3f3a-4f2a-b472-df0c7274b675">285,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8460203d45415f877cfffa51733070_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTMtMy0xLTEtMzcyNjE_5e5603e2-2266-42ea-ad0b-6d27e3796007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5e6402ec45427eae4f571d473ddedf_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTMtNS0xLTEtMzcyNjE_fdb941a4-397d-4014-9ad0-864bb94cf834">285,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752f160556a747deb9e6619b306a9579_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTMtNy0xLTEtMzcyNjE_35b65ea1-50bb-4521-bfe7-4ad3aef4f1ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5062dc4f6c4aea9b5af1b8206788f4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTQtMS0xLTEtMzcyNjE_caaf1572-28f9-478d-b3ba-6565b81cd0f1">405,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8460203d45415f877cfffa51733070_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTQtMy0xLTEtMzcyNjE_7ffcf665-3431-4c93-9f88-6b828f205cfe">119,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5e6402ec45427eae4f571d473ddedf_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTQtNS0xLTEtMzcyNjE_600c432e-900c-405b-b2d2-7ff017e9a249">285,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752f160556a747deb9e6619b306a9579_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTQtNy0xLTEtMzcyNjE_f3f1d43a-a499-492b-9b99-5a550dc78b97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3&#8212;<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfMTk3NA_8b18112b-cf21-4b04-bfa3-21d5a9f6a167" continuedAt="i483ec983c178440fb8939be937a28ca2" escape="true">CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i483ec983c178440fb8939be937a28ca2" continuedAt="i816f5731c0174e01ad8c926014cb9088"><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfMTk3Nw_8432189d-28cb-456d-a812-946f20968a5d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667d8119170448249bd6a172234e2142_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNC0xLTEtMS0zNzI2MQ_e25f0e4d-c8c4-4ddd-a02c-a3cce2dce186">49,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667d8119170448249bd6a172234e2142_I20220331" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNC0zLTEtMS0zNzI2MQ_b2e18f02-aba1-48f7-9f55-0e1bf778164c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667d8119170448249bd6a172234e2142_I20220331" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNC01LTEtMS0zNzI2MQ_77bb2e7a-020d-481e-afbf-c3f422c28f6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667d8119170448249bd6a172234e2142_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNC03LTEtMS0zNzI2MQ_e54703b8-b34d-490c-9895-8475fb7cdde4">49,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi0xLTEtMS00MTEzNA_cf736197-e45c-4cbc-a134-42958fbe471c">15,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331" xsi:nil="true" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi0zLTEtMS00MTEzNA_de575253-f338-4347-ab12-6640701cba51"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi01LTEtMS00MTEzNA_729f48d3-6152-41ca-854a-f54474d617f1">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi03LTEtMS00MTEzNA_995a4268-d373-4d58-8c3b-1451506ca172">15,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f59c89b2b44fd2919394b10858dd42_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi0xLTEtMS0zNzI2MQ_a9bb99e9-b4a0-4cf9-8c8d-2a074803aede">64,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f59c89b2b44fd2919394b10858dd42_I20220331" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi0zLTEtMS0zNzI2MQ_b72e8de1-38e8-4a1c-bd17-214e33340367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75f59c89b2b44fd2919394b10858dd42_I20220331" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi01LTEtMS0zNzI2MQ_949dda22-762d-43fd-870b-a71a45869737">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f59c89b2b44fd2919394b10858dd42_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi03LTEtMS0zNzI2MQ_9c2b229d-2e0f-4b8c-b8e3-30c76f3af61c">64,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOC0xLTEtMS0zNzI2MQ_665a07b3-10ce-4e43-9ce7-0cee58ffb458">24,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOC0zLTEtMS0zNzI2MQ_d5282940-df6a-4aa7-bd02-dd325694efb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOC01LTEtMS0zNzI2MQ_e24ef164-a197-4546-95bd-a6607b48b6d1">347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOC03LTEtMS0zNzI2MQ_42c813ed-01aa-4c6f-bbf5-63e8be6b0ae3">24,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e69bac7be71489fac652fab2215a8a9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOS0xLTEtMS0zNzI2MQ_b74e2375-e2bf-4952-8ae5-337f73c459ed">117,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e69bac7be71489fac652fab2215a8a9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOS0zLTEtMS0zNzI2MQ_f286ee50-17b9-470b-9579-1905b6d9165e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e69bac7be71489fac652fab2215a8a9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOS01LTEtMS0zNzI2MQ_9b43b549-b628-4168-9b11-1ad8afc7cd6e">384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e69bac7be71489fac652fab2215a8a9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOS03LTEtMS0zNzI2MQ_4e85b927-5c4f-48fd-b567-dae4dacf6e40">117,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47a4b1baad248318523c5fba0c2d164_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTAtMS0xLTEtMzcyNjE_e5e4b05e-965f-4876-a2a9-95cc3ed52deb">17,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47a4b1baad248318523c5fba0c2d164_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTAtMy0xLTEtMzcyNjE_9698e798-ab5b-4a48-b506-cf5282510f0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib47a4b1baad248318523c5fba0c2d164_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTAtNS0xLTEtMzcyNjE_69267f82-492c-4947-be3c-23ff306da096">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47a4b1baad248318523c5fba0c2d164_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTAtNy0xLTEtMzcyNjE_aa850ff2-faa6-407c-a9b7-9f582ce948c9">17,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9333aab4cdd548f1818b9a801558d624_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTEtMS0xLTEtMzcyNjE_3ed26c79-b3ff-4780-83ed-f7a923f90ef8">67,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9333aab4cdd548f1818b9a801558d624_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTEtMy0xLTEtMzcyNjE_feff1e44-cfa2-4df1-bc39-7ad07068ce11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9333aab4cdd548f1818b9a801558d624_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTEtNS0xLTEtMzcyNjE_feba99eb-3069-4087-9c4c-99e89319c98d">375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9333aab4cdd548f1818b9a801558d624_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTEtNy0xLTEtMzcyNjE_6be52715-d304-4a2e-a588-97eaa900dbb4">67,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417758d232ed45199817bccf384dfcad_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtMS0xLTEtNDA4MjE_1550673a-a6f9-444d-9432-d68dea4104ae">2,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417758d232ed45199817bccf384dfcad_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtMy0xLTEtNDA4Mjg_2da4acf5-a1df-4a11-9cce-6ae8c0a4dcfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417758d232ed45199817bccf384dfcad_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtNS0xLTEtNDA4MzQ_0377c39c-4388-4893-be9c-15b2282631eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417758d232ed45199817bccf384dfcad_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtNy0xLTEtNDA4NDA_4d497afc-7a85-48d0-b362-594f23f6d2a0">2,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTItMS0xLTEtMzcyNjE_ca0a4576-f40f-4f60-beff-b3b5c769695b">50,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTItMy0xLTEtMzcyNjE_e873fddd-ae49-4157-a6e4-441c79bcd0b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTItNS0xLTEtMzcyNjE_27172d07-d795-4a32-b807-afbf83683d28">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTItNy0xLTEtMzcyNjE_b0260e53-aae2-4bb6-bd58-7f709310302c">50,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtMS0xLTEtMzcyNjE_10c7a430-5b68-425f-b51a-d5d809046f39">281,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtMy0xLTEtMzcyNjE_293f5cd7-22a2-465d-99a0-8c41a81047fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtNS0xLTEtMzcyNjE_014787e8-de75-4c2e-a1ea-b236167cdfa3">1,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtNy0xLTEtMzcyNjE_48609bdb-6e40-404e-8e2e-c3b8cf256116">280,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTQtMS0xLTEtMzcyNjE_80f6626b-5555-4bb8-a4e8-05fdf5abf208">346,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTQtMy0xLTEtMzcyNjE_dcf314a2-55fd-422f-81e8-9605189be476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTQtNS0xLTEtMzcyNjE_7c1115b7-2963-46c7-8f57-e2249f985205">1,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTQtNy0xLTEtMzcyNjE_ab582546-6c07-4fd5-a7a9-b120bc978f37">344,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7428cfc7656446308caa6ab7f38e8fc4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTktMS0xLTEtMzcyNjE_aaf426b7-6fa4-4297-bb43-034ed7eecc11">119,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7428cfc7656446308caa6ab7f38e8fc4_I20211231" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTktMy0xLTEtMzcyNjE_f460a828-8e3f-4089-91ab-01ef0695d664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7428cfc7656446308caa6ab7f38e8fc4_I20211231" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTktNS0xLTEtMzcyNjE_0d643ce2-0392-432c-b4ab-cb9ade4b68fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7428cfc7656446308caa6ab7f38e8fc4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTktNy0xLTEtMzcyNjE_c7dde923-e4c6-46be-9ab1-66345bc870e5">119,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0041f6579043f2bee5ca967b1a19d4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjAtMS0xLTEtMzcyNjE_c85cfa00-3ee7-4be1-90e2-1fd2b1aa8ea8">119,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0041f6579043f2bee5ca967b1a19d4_I20211231" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjAtMy0xLTEtMzcyNjE_727b647c-6e0d-492a-80fa-81ca752d7dfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0041f6579043f2bee5ca967b1a19d4_I20211231" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjAtNS0xLTEtMzcyNjE_c9bce10d-16f7-4d5e-8e4f-4d59c1793aca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0041f6579043f2bee5ca967b1a19d4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjAtNy0xLTEtMzcyNjE_97933616-269a-4722-a2b1-edf6b54be5e0">119,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4cc59f044c84fa483597e518c67dd8d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjItMS0xLTEtMzcyNjE_03612a24-275b-4482-b702-090764d014c0">30,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4cc59f044c84fa483597e518c67dd8d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjItMy0xLTEtMzcyNjE_1a1979d5-383d-4bf7-bd38-ee31474ecdee">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4cc59f044c84fa483597e518c67dd8d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjItNS0xLTEtMzcyNjE_feb80f9b-5e82-44fe-b35f-e186c1f7235e">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4cc59f044c84fa483597e518c67dd8d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjItNy0xLTEtMzcyNjE_e4ab28a1-9c05-491d-91a1-ee158bf423df">30,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149b1f00b3f944a699030236b1718bb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjMtMS0xLTEtMzcyNjE_f99c1cb3-c85c-477b-83ba-3572e6417af0">105,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149b1f00b3f944a699030236b1718bb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjMtMy0xLTEtMzcyNjE_32abd707-a805-4487-b97e-f5e789959d4c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i149b1f00b3f944a699030236b1718bb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjMtNS0xLTEtMzcyNjE_3e66dc6b-2172-47a4-af53-24e706e85437">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149b1f00b3f944a699030236b1718bb0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjMtNy0xLTEtMzcyNjE_f842b726-455b-45d3-b89b-b157531aeed7">105,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708da3120a854222abfec0d32c8d9c70_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjQtMS0xLTEtMzcyNjE_1aead7c5-f5d9-450a-8654-af608c539875">33,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708da3120a854222abfec0d32c8d9c70_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjQtMy0xLTEtMzcyNjE_a00ee437-12ea-4eed-94b2-c01d6abb9ef6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i708da3120a854222abfec0d32c8d9c70_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjQtNS0xLTEtMzcyNjE_2c8eeef7-5ad2-4393-b6b3-6785551b8ef0">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708da3120a854222abfec0d32c8d9c70_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjQtNy0xLTEtMzcyNjE_8cfd10fb-1c72-4a91-a1e4-f4b57b5d9d91">33,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjUtMS0xLTEtMzcyNjE_9b07d1b4-e890-460c-a720-ea8a92bd9adf">70,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjUtMy0xLTEtMzcyNjE_0f75cb11-c9bf-44ff-b514-504678c8468d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjUtNS0xLTEtMzcyNjE_261d5e41-94e3-43ef-b9db-8cc5a93724a9">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjUtNy0xLTEtMzcyNjE_3978c04e-f7c1-4176-862b-f002bdcaa56a">70,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a473804e0f74354bf949e0a954fac9f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjYtMS0xLTEtMzcyNjE_1863048f-6efa-469d-87e4-2996b8145955">45,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a473804e0f74354bf949e0a954fac9f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjYtMy0xLTEtMzcyNjE_7a8a9d77-42c7-4276-994c-9551b02e8f5b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a473804e0f74354bf949e0a954fac9f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjYtNS0xLTEtMzcyNjE_39024394-504e-40ab-ae52-b8c332359c74">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a473804e0f74354bf949e0a954fac9f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjYtNy0xLTEtMzcyNjE_60f75ba9-f09e-47e4-bdea-a0d0a3571a6f">45,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjctMS0xLTEtMzcyNjE_6e57a888-4712-44ed-874c-8c702a74e88a">286,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjctMy0xLTEtMzcyNjE_d82c6da8-0cb1-4ad8-8d8a-bdf6e5d3c5c5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjctNS0xLTEtMzcyNjE_87cabf13-f79d-46d5-b062-3a8c77648fb6">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjctNy0xLTEtMzcyNjE_0b59e92b-4ddf-4f5a-98d8-451231c4a675">285,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjgtMS0xLTEtMzcyNjE_212a0967-7d3a-4617-a35f-43075d1d8ce6">406,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjgtMy0xLTEtMzcyNjE_c0ac127c-14f5-49ff-83f9-b1f271478e17">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjgtNS0xLTEtMzcyNjE_007e452b-9679-46be-9c08-63a392966ec8">304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjgtNy0xLTEtMzcyNjE_a07fb606-eb64-4433-9e48-c67c433c7289">405,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:36pt"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfMTk3NQ_593582fe-0472-4179-8547-e932dfff56d2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:74.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMS0xLTEtMS0zNzI2MQ_cc3960bf-0d02-4f0f-9cc9-d35e68eec92f">212,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMS0zLTEtMS0zNzI2MQ_cd3f0c94-9bd1-457f-871f-b299b80f0838">197,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMi0xLTEtMS0zNzI2MQ_ffd62557-7ba2-445f-ba2a-b1c4386b94c0">82,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMi0zLTEtMS0zNzI2MQ_247787de-ae8c-46f2-96ac-c3ebccf6a101">88,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="-3" name="sgmo:DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMy0xLTEtMS0zNzI2MQ_065def59-5426-4573-ab79-3f5acfeb606d">295,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="-3" name="sgmo:DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMy0zLTEtMS0zNzI2MQ_4c09d37d-94b4-4403-80b9-59fc1e14b7b0">285,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did <ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNTA1_330257f4-dd1b-48b3-9066-76579268ad2b"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNTA1_3a54404a-175d-45a3-bb1c-3911c4cfed59"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNTA1_b84296ba-bc87-4703-93e3-b1202100f7a0"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNTA1_d924fbad-5c4e-4f46-8f12-ccfcaef85067">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2022 and 2021. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that are in a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i816f5731c0174e01ad8c926014cb9088">continuous unrealized loss position for greater than 12 months as of March&#160;31, 2022 and December&#160;31, 2021. Based on the scheduled maturities of its investments, the Company determined that it was more likely than not that it will hold these investments for a period of time sufficient for a recovery of its cost basis. Total unrealized gains for securities with net gains in accumulated other comprehensive income were not material for the three months ended March&#160;31, 2022. The unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, the Company determined that <ix:nonFraction unitRef="usd" contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNDk0NzgwMjMyODY0MA_17c8f157-c5ab-42e1-89b8-f18a71b04e3d"><ix:nonFraction unitRef="usd" contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNDk0NzgwMjMyODY0MA_98a7ba60-d17e-4c88-8a03-3183077353a1">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to its marketable securities was required at either March&#160;31, 2022 or December&#160;31, 2021.</ix:continuation></span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4&#8212;<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81Mi9mcmFnOjM5ODllNThiYjE1YzRhMWVhNGIyYjc2NzI0YTkyNjcwL3RleHRyZWdpb246Mzk4OWU1OGJiMTVjNGExZWE0YjJiNzY3MjRhOTI2NzBfMTA3NA_6ea55a1a-e71c-4c4d-9546-1c6eb1c0c4f9" continuedAt="iea72b271b6634d1aa8a1a2abfe76475b" escape="true">BASIC AND DILUTED NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="iea72b271b6634d1aa8a1a2abfe76475b"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of March&#160;31, 2022 and 2021 totaled <ix:nonFraction unitRef="shares" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81Mi9mcmFnOjM5ODllNThiYjE1YzRhMWVhNGIyYjc2NzI0YTkyNjcwL3RleHRyZWdpb246Mzk4OWU1OGJiMTVjNGExZWE0YjJiNzY3MjRhOTI2NzBfMTA1MA_4f4daf13-1461-49c7-8e07-bbb2070e8492">19,128,238</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81Mi9mcmFnOjM5ODllNThiYjE1YzRhMWVhNGIyYjc2NzI0YTkyNjcwL3RleHRyZWdpb246Mzk4OWU1OGJiMTVjNGExZWE0YjJiNzY3MjRhOTI2NzBfMTA1Nw_30758bb7-be6e-48c2-8a0b-4ff3e6906ca1">17,614,376</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="i4456822efa7a4e3293b4821bff1ee4c1_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5&#8212;<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NDU_28ce9d00-4105-4dd1-8023-d57e1a6b71f9" continuedAt="i2796d312349740e59ec0e175bc984195" escape="true">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="i2796d312349740e59ec0e175bc984195" continuedAt="ibefe8ba710e84d84831deaa20ff60f55"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#8220;ZFP&#8221;) transcription factors (&#8220;ZFP-TFs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company is performing early research activities over the collaboration period for each gene target and manufacture the ZFP-TFs required for such research, costs of which is funded by Novartis. Novartis is responsible for additional research activities, studies enabling investigational new drug applications (&#8220;INDs&#8221;), clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Novartis paid the Company a $<ix:nonFraction unitRef="usd" contextRef="ie4e67faf817f4852b243d3c63990d266_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTc4Nw_ca8dee78-9ea4-41e0-aa0f-1b82cb811df2">75.0</ix:nonFraction>&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $<ix:nonFraction unitRef="usd" contextRef="ib56fb168b92b405fb217588fffb34483_D20200727-20200727" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk2MQ_1aa51626-3061-4953-915c-36a2d4c61edd">420.0</ix:nonFraction>&#160;million in development milestones and up to $<ix:nonFraction unitRef="usd" contextRef="id6efcae223674852a4973214fc153fa8_D20200727-20200727" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjAwMA_5a607a9b-3fae-489c-b60f-0bf14ae69c95">300.0</ix:nonFraction>&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement, when earned, are non-refundable and non-creditable. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i37db8a6698834ba296ee551626e923fb_D20200727-20200727" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjk0NA_b7aa3e0d-1ffd-4c54-9488-536c44354d25">95.1</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i37db8a6698834ba296ee551626e923fb_D20200727-20200727" decimals="-5" name="sgmo:CollaborativeArrangementLicenseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjk4Mw_2064ec32-137d-4d6b-a03c-5270b1a65c83">75.0</ix:nonFraction>&#160;million and estimated research costs of $<ix:nonFraction unitRef="usd" contextRef="i37db8a6698834ba296ee551626e923fb_D20200727-20200727" decimals="-5" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzAxOA_a7339245-da40-4d89-84ae-b5c6ef054bd1">20.1</ix:nonFraction>&#160;million to be provided over the estimated research period. All clinical or regulatory milestone amounts were considered fully constrained at inception of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="ibefe8ba710e84d84831deaa20ff60f55" continuedAt="i0ff7290a2d684a0281981939f1374593"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the agreement. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic&#160;606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $<ix:nonFraction unitRef="usd" contextRef="id8c1aa614e1a4775b6bbd58069fa1667_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MjQyMw_6f7c0237-abca-46c2-bbd5-c52c083bd973"><ix:nonFraction unitRef="usd" contextRef="i4b7eb1bd518d40e1b0ab1d54a66550cc_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MjQyMw_ec041743-932d-4996-a825-b0053122df8a">1.9</ix:nonFraction></ix:nonFraction>&#160;million for both periods and deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="id8c1aa614e1a4775b6bbd58069fa1667_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDYzOA_ceb9e579-9ab2-4f34-aae6-ec96fe47e997">33.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4b7eb1bd518d40e1b0ab1d54a66550cc_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDY0NQ_8d6115f8-e4c1-4ffd-9152-e8fd5edaa720">40.9</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i01e697d1114342af9aab4ece3ebe09d4_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NDQ_6e8cf805-04ef-4a08-af10-ee9d59eb67fa" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:74.226%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900d4a285bf74e898040e450e39bae33_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfMy01LTEtMS0zNzI2MQ_85339b20-947a-42cd-9228-c938c91b011c">7,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517982897103458981bfa35ceae5ab4c_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfMy03LTEtMS0zNzI2MQ_3c028f9a-0f2e-4729-9e1b-b2c33c96ae1b">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib06b72ef26254e088a29f9eb02ae084f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfNC01LTEtMS0zNzI2MQ_269dd09e-1413-4b40-b50b-b5d3c8a8dfb7">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be9da6c94aa4aeda66aa0067113c02e_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfNC03LTEtMS0zNzI2MQ_fb4f0686-dcd7-436a-951a-4d0569a85048">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e697d1114342af9aab4ece3ebe09d4_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfNS01LTEtMS0zNzI2MQ_11eefdf9-ccfa-4c00-a307-e4cd8622b6b1">8,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib750ba895b6945248f5dd3b66450ec06_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfNS03LTEtMS0zNzI2MQ_6bb7f2a4-1f89-4f1d-8d6e-fabe67b7105d">7,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="i55716db833614f819cf9af228e7bacc0_D20200101-20201231" decimals="-5" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDc4MA_0916bb9d-38f9-4328-8ad9-df676ee4faca">1.5</ix:nonFraction>&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="i55716db833614f819cf9af228e7bacc0_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDg2MQ_8913cebe-6460-4972-bf04-b13b60c06fb0">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="ie4e67faf817f4852b243d3c63990d266_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDg2Nw_15134c8f-fcc9-4195-b2e0-c8f966d77669">75.0</ix:nonFraction>&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i55716db833614f819cf9af228e7bacc0_D20200101-20201231" decimals="-5" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk5Ng_0916bb9d-38f9-4328-8ad9-df676ee4faca">1.5</ix:nonFraction>&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic&#160;340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC Topic&#160;340&#8221;). The Company amortized $<ix:nonFraction unitRef="usd" contextRef="iab11137987e8447bb24585d1df56594e_D20210101-20210331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNTM0OQ_18e8f146-5c3f-405d-ad34-c063d80ed6ad"><ix:nonFraction unitRef="usd" contextRef="iaa9d46b5b32044e89d50e8f389f7bdd3_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNTM0OQ_cbcd6e84-9b9e-45e0-9560-169d9330e440">0.1</ix:nonFraction></ix:nonFraction>&#160;million during each of the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase <ix:nonFraction unitRef="shares" contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjExNA_394e45bd-6f0f-4c2c-ab0d-bac2e436f2be">24,420,157</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i766f4d877bf6408b9503aa5663f38abe_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjIwMQ_67d9a2c1-632a-481c-b18e-bbfd9ab38073">9.2137</ix:nonFraction>, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjI1NA_2f5601ec-6f02-4148-b35b-f5fff2c1c2b8">225.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $<ix:nonFraction unitRef="usd" contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjUyMg_31b59cc5-2bc5-481e-9800-a8c254a20ca4">225.0</ix:nonFraction>&#160;million for the purchase of the Biogen Shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i15891adf431c452c86cb7e1beafbb9f8_D20200501-20200531" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjY0OQ_f66b2909-739f-4265-bf8e-500a20da7319">125.0</ix:nonFraction>&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="ib839a8edfdf240f293867c6246e5a8fa_I20200430" decimals="-8" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjgxMA_68cfe1f6-ad94-46be-a079-1fc41a076407">2.4</ix:nonFraction>&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $<ix:nonFraction unitRef="usd" contextRef="ib0e6b8fbf7904621a6d9173012bb2011_I20200430" decimals="-5" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjk3Mw_115711ad-d592-4d4d-a14c-2ecc43c2fd0c">925.0</ix:nonFraction>&#160;million in pre-approval milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="i92e1ede754aa400bb099f3f7aed0dfb1_I20200430" decimals="-8" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNzAyMQ_5ef56b87-486a-42b8-8fe1-e34bea33a487">1.5</ix:nonFraction>&#160;billion in first commercial sale and other sales-based milestone payments. In addition, the Company is eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to <ix:nonFraction unitRef="product_target" contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfProductTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNzcyNw_90e2f463-43a7-4245-a4e2-e114feffec15">twelve</ix:nonFraction>&#160;neurological disease gene targets selected by Biogen. Biogen has already selected four of these: ST-501 to treat tauopathies, ST-502 to treat synucleinopathies including Parkinson&#8217;s disease, a third product candidate targeting DM1, a neuromuscular disease, and a fourth undisclosed neurological disease gene target. Biogen has exclusive rights to nominate up to <ix:nonFraction unitRef="product_target" contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" decimals="INF" name="sgmo:CollaborationAgreementNumberOfAdditionalProductTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfODA2NQ_42a2ee95-dd47-4811-b13d-63acf486d946">eight</ix:nonFraction> additional targets over a target selection period of <ix:nonNumeric contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" name="sgmo:CollaborationAgreementTargetSelectionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfODEyMQ_4bf5edea-1de8-45b3-a15b-90fb1b407af9">five years</ix:nonNumeric>. For each gene target selected by Biogen, the Company </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="i0ff7290a2d684a0281981939f1374593" continuedAt="i1a9410df95ef4f8b9c1fc3f08e366106"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performs early research activities, costs of which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first <ix:nonFraction unitRef="product_target" contextRef="ib839a8edfdf240f293867c6246e5a8fa_I20200430" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfODcwNg_de12d110-6372-490d-a1b2-b37441804c39">three</ix:nonFraction> products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first <ix:nonFraction unitRef="product_target" contextRef="ib839a8edfdf240f293867c6246e5a8fa_I20200430" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfODk1Nw_f68c71f0-c56f-445a-b654-fc5dc7cd9a86">three</ix:nonFraction> products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed <ix:nonNumeric contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" name="sgmo:CollaborationArrangementResearchPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfOTA2OA_37ff9e4d-e02f-4689-8910-df94fb0c7617">seven years</ix:nonNumeric> from the effective date of the agreement (i.e., through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to <ix:nonFraction unitRef="product_target" contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" decimals="INF" name="sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfOTcwMA_49fef229-adf9-48b4-9b70-47eba023045d">ten</ix:nonFraction> targets. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the <ix:nonNumeric contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" name="sgmo:CollaborativeArrangementStandstillRestrictionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NTY_b4927462-ccb4-4a24-8ed4-e2c9c7e0956d">three-year</ix:nonNumeric> anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="i766f4d877bf6408b9503aa5663f38abe_I20200430" decimals="INF" name="sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA2NjQ_d678b78b-2f60-4fef-bff0-b07b87f597a4">5</ix:nonFraction>% of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTIyMDA_bd9bd3a1-8edf-4957-b487-249e4da2472d">204.6</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTIyMzk_cc790db3-ad52-428c-bd4b-422308b90ae5">125.0</ix:nonFraction>&#160;million and the excess consideration from the stock purchase of $<ix:nonFraction unitRef="usd" contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" decimals="-5" name="sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTIyOTg_89918971-bc2e-43ac-a125-f9031aa1f8ea">79.6</ix:nonFraction>&#160;million, which represents the difference between the $<ix:nonFraction unitRef="usd" contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTIzNDY_37bff2e9-be43-4446-abaa-045cf2653b20">225.0</ix:nonFraction>&#160;million received for the purchase of the Biogen Shares and the $<ix:nonFraction unitRef="usd" contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" decimals="-5" name="sgmo:CollaborationAgreementEquityIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTI0MDQ_4bae553a-bc9d-4ab9-b13c-af02843116e6">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $<ix:nonFraction unitRef="usd" contextRef="i39ca1d92750e4fc887cd62b4bb56da6e_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MjgxMQ_20a5c712-17b2-4604-beba-1d5cdc5826cf">3.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8ca29e9a3803412cb13b7748ae0de063_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MjgwNA_7e63696b-2dcb-4add-af10-9ca4ca080faf">2.8</ix:nonFraction>&#160;million, respectively, and deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i39ca1d92750e4fc887cd62b4bb56da6e_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ0MjQ_830810fe-e479-4cf0-a47b-a38e3df93196">146.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8ca29e9a3803412cb13b7748ae0de063_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ0MzE_39766b6b-900c-4f90-97db-5e138afdaf2d">154.0</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><ix:nonNumeric contextRef="ic2957eaa5fb949ba9103ee631650c838_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NDg_e485816f-6d20-4b15-8f14-afe603faacaf" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:74.404%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041acd4815694161b1e7542a2e160c9c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfMy01LTEtMS0zNzI2MQ_dd7df132-43af-4ab1-b690-e6428ec303f4">7,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3e9b2076b04da29cf24d841569c73f_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfMy03LTEtMS0zNzI2MQ_8174d6de-694c-4a3f-ad55-82820733392d">7,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a105ad9f2c44de8af6b7d8886dbfe92_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfNC01LTEtMS0zNzI2MQ_7b3a8948-c742-487e-8c35-128771a058d6">3,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0037c3659814babb6528aeace32f367_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfNC03LTEtMS0zNzI2MQ_4528955c-5c63-4d2d-8641-dfa75fbf339d">3,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2957eaa5fb949ba9103ee631650c838_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfNS01LTEtMS0zNzI2MQ_f2a1cb75-2d99-4931-aafc-908ceaad76c1">11,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41afe851c52346368324b29729905d65_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfNS03LTEtMS0zNzI2MQ_4c8f42e0-c539-4b7d-aab1-ee6b7ba1ee86">10,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="if6ae54d9711045f5b069428dadfcf2ac_D20200101-20201231" decimals="-5" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ1Njg_c76ed2f9-6b57-44b6-8f4f-56397ac35c64">7.0</ix:nonFraction>&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="if6ae54d9711045f5b069428dadfcf2ac_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ2NDk_986d271f-33a2-4e3c-bcbc-6a00ab513b67">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ2NTU_37bff2e9-be43-4446-abaa-045cf2653b20">225.0</ix:nonFraction>&#160;million received for the sale of shares and <ix:nonFraction unitRef="number" contextRef="if6ae54d9711045f5b069428dadfcf2ac_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ2OTQ_df0e00ba-ba38-4da6-9545-200195dcb5f8">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ3MDA_cc790db3-ad52-428c-bd4b-422308b90ae5">125.0</ix:nonFraction>&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and the stock purchase agreement for the sale of shares. The Company believes that </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="i1a9410df95ef4f8b9c1fc3f08e366106" continuedAt="i58dcf8320dd244faacfadacd1149c178"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ic0b2dfb4d52545a4945d9acab347bcee_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUwMTI_55c53c0c-1ae1-47da-9df7-25541e72d439">4.1</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUwMzM_a44e05e6-b026-4607-8d9f-124df911dc85">2</ix:nonFraction>% of the transaction price of $<ix:nonFraction unitRef="usd" contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUwNjQ_aa6718ca-d871-469f-bd1e-c39acc6f6278">204.6</ix:nonFraction>&#160;million, as a contract asset. This balance is amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340. The Company amortized $<ix:nonFraction unitRef="usd" contextRef="idadbcdba5852493e8a7279c2071547c9_D20210101-20210331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUzMDA_22f2b299-53ea-4957-8e8c-a9f063006ff4"><ix:nonFraction unitRef="usd" contextRef="i01e8a0ae4fe34fcbbda1cb1a13234369_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUzMDA_49b71b70-9e45-4eb3-af0a-0c229cf44fc6">0.1</ix:nonFraction></ix:nonFraction>&#160;million during each of the three months ended March&#160;31, 2022 and 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="id4be5c493833416e94842f25e42f4ed2_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTU0NzU_435048d9-cd68-4c60-9fee-17974d5c7663">2.9</ix:nonFraction>&#160;million, which represented <ix:nonFraction unitRef="number" contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTU0OTc_f93a6968-1557-4f4e-8452-3427c54279b0">2</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430" decimals="-5" name="sgmo:CollaborationAgreementEquityIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTU1MDc_4bae553a-bc9d-4ab9-b13c-af02843116e6">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in net proceeds.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), a Gilead Sciences, Inc. subsidiary, which became effective in April 2018, and was amended and restated in September 2019, for the research, development, and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex&#160;vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions, except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the effective date, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTc4NTI_d1d425a1-83f9-44c6-a6fd-1703b0822071">150.0</ix:nonFraction>&#160;million upfront payment from Kite. In addition, Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $<ix:nonFraction unitRef="usd" contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430" decimals="-8" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTgwODI_a6f507a0-1ba3-4450-aaef-62ddce7da8b4">3.0</ix:nonFraction>&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $<ix:nonFraction unitRef="usd" contextRef="i5797d08acc004769826046653f737b78_D20180401-20180430" decimals="-8" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTgxOTI_719eb908-225e-4507-809d-f0aad409f6ad">1.3</ix:nonFraction>&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $<ix:nonFraction unitRef="usd" contextRef="idc36d4cf8fee4657a85ef91caf216030_D20180401-20180430" decimals="-8" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTgzMzQ_7afa7e7e-2737-49a0-86dc-adfaba8a56fc">1.8</ix:nonFraction>&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product and, (ii)&#160;only for the first <ix:nonFraction unitRef="milestone" contextRef="idc36d4cf8fee4657a85ef91caf216030_D20180401-20180430" decimals="INF" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTg3MTQ_f048b51a-8f57-4ea3-bcd6-40fe9f647625">10</ix:nonFraction> times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term in the agreement is <ix:nonNumeric contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430" name="sgmo:InitialResearchTermOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTkyODc_43ae6fae-8b85-482e-a28a-b07a548fe4ea">six years</ix:nonNumeric>. Kite has an option to extend the research term for up to <ix:nonFraction unitRef="option" contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430" decimals="INF" name="sgmo:NumberOfOptionsToExtendInitialResearchTerm" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTkzNjU_bde2d989-c760-4944-8bfe-1384a5d44e08">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430" name="sgmo:ExtendedResearchTermOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NTA_75737a09-e994-4526-9734-8ab12772aa66">one-year</ix:nonNumeric> periods for a separate upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430" decimals="-5" name="sgmo:SeparateUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk0MjU_12f656aa-c402-4091-8787-0ed31b80a0c5">10.0</ix:nonFraction>&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930" decimals="-5" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk3Mzg_85aea225-40d2-4905-9f3c-862e37c6007e">3.4</ix:nonFraction>&#160;million, which is included in the total transaction price. The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk4ODU_f87e2422-5610-4b93-afe4-85f268089aae">189.3</ix:nonFraction>&#160;million and includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk5Mjg_e3fa2945-609c-4ce2-aba5-61e229b752b3">150.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930" decimals="-5" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk5MzU_b60fa3eb-77a7-4251-be14-27c4935887e4">39.3</ix:nonFraction>&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic&#160;606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="i58dcf8320dd244faacfadacd1149c178" continuedAt="id96570e89eba4aa28ca771b2bfa7884c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the primary performance obligations within the Kite agreement as: (1)&#160;a license to the technology along with the stand-ready obligation to perform research services, and (2)&#160;the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through April 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $<ix:nonFraction unitRef="usd" contextRef="i98c4d875d4a2406e8c1ed49500a382d3_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MzI2OQ_f863e97a-ed70-4dd4-b9c9-2cf7b03b199a">0.1</ix:nonFraction>&#160;million for both periods, and deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i98c4d875d4a2406e8c1ed49500a382d3_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjI0MzI_d3fa168c-da72-461f-9083-17e26bda902f">50.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i63eac9ce149544bc82e859b7f3bbb3b2_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjI0Mzk_6bcff910-0221-4372-b406-f44565f3338c">56.5</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ib70ee13d8d7a427da05f3f516bfa3b24_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NTM_a99b9f28-793f-4be4-a7f9-e51032a6cc71" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:74.439%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2986c1f9c44f4c47b92d4e4fe0632ce1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfMy01LTEtMS0zNzI2MQ_03d01c25-937f-4e34-8b32-fb8ee3cd26da">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07682bb1e1c4e59a83b477d9c74c798_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfMy03LTEtMS0zNzI2MQ_4ed1204b-a7fa-49b2-bd8c-2fca08580cec">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fedbfa9d70466daba921e2e917b72b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfNC01LTEtMS0zNzI2MQ_935c3d6b-4d9d-4d51-95be-aae611becb7e">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba81ecb70cf48beb5b5bc44b8920a30_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfNC03LTEtMS0zNzI2MQ_4ce69fff-25d9-4662-a56f-39dbfd0bde5e">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib70ee13d8d7a427da05f3f516bfa3b24_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfNS01LTEtMS0zNzI2MQ_4cc6b360-3872-4ca2-9d81-e284da6537d3">6,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7245852459b450a993c961a809e0dfa_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfNS03LTEtMS0zNzI2MQ_21ccb7ce-9a99-4f2c-bce9-1f431e296e95">6,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi S.A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company was originally jointly conducting <ix:nonFraction unitRef="program" contextRef="i1aa617603ebd4abeb4444421df29e6bc_D20140101-20140131" decimals="INF" name="sgmo:NumberOfResearchProgram" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzYyMDA_1cec18ac-4807-448b-9c43-3596fbc3e9d5">two</ix:nonFraction> research programs: a beta thalassemia program, which was discontinued in the third quarter of 2021, and the SCD program, which resulted in the development of SAR445136, a ZF nuclease, gene-edited cell therapy product candidate for the treatment of SCD, which remains active.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the SCD program, the Company and Sanofi were jointly responsible for research and development activities prior to filing of an IND, but Sanofi is now responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. Subject to the terms of the agreement, the Company had granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company had also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company received an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i1aa617603ebd4abeb4444421df29e6bc_D20140101-20140131" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzg1NDE_bdfb0388-aa51-4a2c-890e-cc905517bc6a">20.0</ix:nonFraction>&#160;million and was eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="iadba8aa480b646cfbd9364a355e68cbe_D20140101-20140131" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzg1Nzc_6779f528-a044-4581-b2bc-dd59dfbd8a81">115.8</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $<ix:nonFraction unitRef="usd" contextRef="i58d8c1b745014cc8b8f4a724f1510553_D20140101-20140131" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzg2OTE_0dff6aa9-34a0-45e2-9468-97df9c73961e">160.5</ix:nonFraction>&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, was up to $<ix:nonFraction unitRef="usd" contextRef="i415e26556db342079b36c2d48875c6cd_D20140101-20140131" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzg5MzE_ac8b1059-d39e-4d77-9e7c-03d3c0df72a3">276.3</ix:nonFraction>&#160;million. In addition, the Company was to receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi was to reimburse Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $<ix:nonFraction unitRef="usd" contextRef="i8e4a1930763f4519a9e4c291ee43d2e0_I20220331" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzkyNDA_c8e17db8-8616-4d22-b5d0-1bb61bf31864">6.0</ix:nonFraction>&#160;million milestone has been achieved related to ST&#8209;400 for beta thalassemia and another $<ix:nonFraction unitRef="usd" contextRef="i220eb5b01a5049368db95372ebd0fd9b_I20220331" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzkzMjI_9eb5f182-b048-49a5-863e-77a6fd0ceead">7.5</ix:nonFraction>&#160;million milestone has been achieved related to SCD, however <ix:nonFraction unitRef="product" contextRef="i8dc0ab2db92b44c1bdba051d96895b2a_D20220101-20220331" decimals="INF" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzkzNzc_bb034ec7-7ba9-41f2-9c49-4071a43d7941">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i93cdf026a37d429da9fbaf18e0a75afd_D20220101-20220331" decimals="INF" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk0MjI_66f2a211-9936-4016-b3ac-a84b090cb7f6">no</ix:nonFraction> royalty fees have been earned under the Sanofi agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Sanofi notified the Company of its termination for convenience, effective June 28, 2022 (the &#8220;Termination Date&#8221;), of the collaboration agreement. In its notice to the Company, Sanofi indicated that its termination relates to Sanofi&#8217;s change in strategic direction to focus on allogeneic universal genomic medicine approaches rather than autologous personalized cell therapies. As of the Termination Date, the collaboration agreement will be terminated in its entirety and following the Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Sanofi. As of the Termination Date, Sanofi will have no further obligations to develop or to fund the development of any collaboration research programs under the collaboration agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="id96570e89eba4aa28ca771b2bfa7884c" continuedAt="i9f12e431c5bd4296a666df9f70311954"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All contingent payments under the agreement, when earned, were non-refundable and non-creditable. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i415e26556db342079b36c2d48875c6cd_D20140101-20140131" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk2MDk_96771980-8556-4c31-9f12-56b8a33abbd5">96.3</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i415e26556db342079b36c2d48875c6cd_D20140101-20140131" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk2NDg_aec71afd-debd-47e6-9c2d-69c8a721f8d0">20.0</ix:nonFraction>&#160;million, two unconstrained milestones in the amount of $<ix:nonFraction unitRef="usd" contextRef="if66d1819ab0a41bcae82ab0a30c2b5a0_I20220331" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk2OTg_3883b1dd-a430-4cb2-9a74-6095a4518f11">13.5</ix:nonFraction>&#160;million and estimated research costs of $<ix:nonFraction unitRef="usd" contextRef="i415e26556db342079b36c2d48875c6cd_D20140101-20140131" decimals="-5" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk3MzM_b77b9efe-88a7-4d79-b053-6121240b0137">62.8</ix:nonFraction>&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Sanofi in accordance with ASC Topic&#160;606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through June 28, 2022, the estimated period the Company will perform research services pursuant to the agreement. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $<ix:nonFraction unitRef="usd" contextRef="i46b1460fe9b3430aaad2d02372d4e0fa_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY5NDM5OQ_12674531-a04b-497d-99f3-60a01e44f274">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7009d476b5214df7b02507f512948107_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY5NDM5Mw_145afb76-89ba-402a-b3f9-9f6bef18614e">0.6</ix:nonFraction>&#160;million, respectively, and deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i46b1460fe9b3430aaad2d02372d4e0fa_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDE1NjU_f5b774f2-06c7-4d3e-8ee9-e37b4d2999ab">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7009d476b5214df7b02507f512948107_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDE1NzI_711ac23d-1fa7-4639-807e-8526536495ee">1.1</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i8dc0ab2db92b44c1bdba051d96895b2a_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NDY_533c4692-646f-40a3-80f2-d1b43a4827a7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:74.368%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7850a3329dd84fb9bb08174c06ab99e3_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfMy01LTEtMS0zNzI2MQ_cbb89e08-37b2-40fc-962c-0e83f0603934">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4014aec3ed654925849776520902d5b7_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfMy03LTEtMS0zNzI2MQ_c51b88d6-f3ee-41ac-bef7-f3a10079ace0">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5055577b77d947f4bef796328015008c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNC01LTEtMS0zNzI2MQ_55713665-4779-4062-9ec8-2a6eaaf6deb7">978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fe22c826474fe69f5ed5ada7ece18f_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNC03LTEtMS0zNzI2MQ_36b61530-a10e-444c-bb0e-b1d892f0a3ca">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a74f3766e43feb0c12d95327cbf47_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNS01LTEtMS0zNzI2MQ_b5d767a2-f134-4304-aea6-2853cc7c9ed3">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5834c04299d4d58ac0d606a80ed8b5f_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNS03LTEtMS0zNzI2MQ_5561e27c-1fd1-4700-850b-128f7c33011e">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc0ab2db92b44c1bdba051d96895b2a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNi01LTEtMS0zNzI2MQ_565d00e2-1a20-4992-8ab7-02a816bda07f">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195087e919f9493f90985edbce9e5c13_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNi03LTEtMS0zNzI2MQ_86df0177-3e22-4f87-8115-5082b40520fb">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) <ix:nonNumeric contextRef="id6d053e63e174530b26c614c63fbadbd_D20170501-20170531" name="sgmo:AgreementTerminationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODA1NA_a8e2e0ac-e15f-4b29-a6af-c8e0add5fc0b">fifteen years</ix:nonNumeric> after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i9ece67192c1d42a59cc7910bf5faa61c_D20170501-20170531" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODA3NA_7d42e386-498a-4e7f-9095-37acd57b7ddb">70.0</ix:nonFraction>&#160;million and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i42824e5c4da04a68abc1181162bd12fa_D20170501-20170531" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODA4OQ_e5db206d-8a9e-475f-b228-37a9e1c436a3">208.5</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i9ece67192c1d42a59cc7910bf5faa61c_D20170501-20170531" decimals="-5" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODEwNQ_cfb079d2-6cfb-4276-963d-7373c15705ba">266.5</ix:nonFraction>&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="i9f12e431c5bd4296a666df9f70311954" continuedAt="ia59bb6f89c554f29ac625660ecd430e0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="i35e709748299454d8a4c0545d5caa0c0_D20170501-20170531" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODEyMQ_203e0b6d-f4b9-465e-848c-e2f7a9b80a97">475.0</ix:nonFraction>&#160;million, which includes up to $<ix:nonFraction unitRef="usd" contextRef="i775b57c0965745638063300c10bf719b_I20170531" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODEzNw_fdce0d20-ac6e-4df1-83b9-1c64cd26dd9b">300.0</ix:nonFraction>&#160;million for giroctocogene fitelparvovec and up to $<ix:nonFraction unitRef="usd" contextRef="i2b464e1bc69c4b89951ddb6d3fee56d9_I20170531" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODE1Mw_a347813b-caba-41e5-992b-a6cd485b3d30">175.0</ix:nonFraction>&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, <ix:nonFraction unitRef="milestone" contextRef="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331" decimals="0" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM4Mw_ff238df5-3a9b-4b66-b79a-d6de5d5a1990">two</ix:nonFraction> milestones of $<ix:nonFraction unitRef="usd" contextRef="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODE2OQ_e87868f5-b617-4609-b27e-32dd84a0476e">55.0</ix:nonFraction>&#160;million in aggregate have been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331" decimals="0" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODQxNQ_2e3778e2-b28e-4a96-a5a0-01c1e3a7507a">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="royalty_fee" contextRef="ia4c9910cf6b742cf89b4a8a7d9606e71_D20171201-20220331" decimals="0" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODQyMw_6dbe723e-775a-47c7-b2ee-f4273c330c23">no</ix:nonFraction> royalty fees have been earned under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="ia8bed9085c38465985a0d366ec10dc28_D20170501-20170531" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODE4NA_362c1e08-5d06-47b2-8802-2ab56c874e94">134.0</ix:nonFraction>&#160;million, which represents the upfront fee and research services fees of $<ix:nonFraction unitRef="usd" contextRef="ia8bed9085c38465985a0d366ec10dc28_D20170501-20170531" decimals="-5" name="sgmo:CollaborativeArrangementResearchServiceFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODIwMA_5e9c136b-5db1-4198-b7f6-4eac36ae3b8c">79.0</ix:nonFraction>&#160;million and fees related to <ix:nonFraction unitRef="milestone" contextRef="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331" decimals="0" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM5MQ_5a833c12-f40a-41c3-aa70-f47c9d8bb5d4">two</ix:nonFraction> achieved milestones in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="iccf2d29f1912433caabee4d25f53741b_D20170501-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODIxNQ_0ca1528f-70e5-4778-a2fa-aae09537db58">55.0</ix:nonFraction>&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and <ix:nonFraction unitRef="usd" contextRef="i0f51b07af0864153afac3abe30c851e0_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODIzMQ_8042a3c4-25b3-464c-93cd-429744d06aae"><ix:nonFraction unitRef="usd" contextRef="i3b3dd93e1a194866bed6cbf58dde6ab6_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODIzMQ_b1f03acf-c1df-49c9-a156-ef92b65fe847">no</ix:nonFraction></ix:nonFraction> revenues have been recognized during the three months ended March 31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) <ix:nonNumeric contextRef="i51e7fa3e99494ccabbb4f5480eae52b8_D20171201-20171231" name="sgmo:AgreementTerminationTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODI0Mg_498cbe6a-e62c-48db-abdd-600d6a6d5b0a">15</ix:nonNumeric> years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><ix:continuation id="ia59bb6f89c554f29ac625660ecd430e0" continuedAt="i654eb8c969e144a4999554c6d23ef287"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $<ix:nonFraction unitRef="usd" contextRef="i51e7fa3e99494ccabbb4f5480eae52b8_D20171201-20171231" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODI1Nw_e4d3dd91-a1f8-4db3-b3f8-946a992a05f9">12.0</ix:nonFraction>&#160;million upfront payment from Pfizer and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ib9f57259deda46369255333e92bf2fe1_D20171201-20171231" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODI3Mg_d344ee34-f221-4877-9935-ef9061828b47">60.0</ix:nonFraction>&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i644151b6138447f397ecbd47582bdb71_D20171201-20171231" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODI4Nw_08eb6166-0204-4aee-b2aa-210ebeb4f010">90.0</ix:nonFraction>&#160;million in commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $<ix:nonFraction unitRef="usd" contextRef="ie5b439ab1a3340e7a1a2684ce3f73c38_D20171201-20220331" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODMwMg_a15a25bd-af1f-44a4-be5c-92f5dd827938">5.0</ix:nonFraction>&#160;million has been achieved and paid, however <ix:nonFraction unitRef="milestone" contextRef="ie5b439ab1a3340e7a1a2684ce3f73c38_D20171201-20220331" decimals="0" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM5OQ_e559718e-4974-42ff-838b-a2318e8411f7">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="ie5b439ab1a3340e7a1a2684ce3f73c38_D20171201-20220331" decimals="0" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODQwNw_054964a1-2eab-422b-bcb1-4936cfad3343">no</ix:nonFraction> royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="ia544d315ec7d4af5a972efb96f552dba_D20171201-20171231" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODMxNg_5cc7de6c-374b-4385-bd76-56075d0a12d8">17.0</ix:nonFraction>&#160;million, which represents the upfront fees of $<ix:nonFraction unitRef="usd" contextRef="ib257bf5eb1c3440fb565b1bc921fddb1_D20171201-20171231" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODMzMQ_709ebe63-f2e9-4ad8-b750-5776826fc590">12.0</ix:nonFraction>&#160;million and fees related to achievement of one milestone in the amount of $<ix:nonFraction unitRef="usd" contextRef="ia544d315ec7d4af5a972efb96f552dba_D20171201-20171231" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM0Ng_5b846498-3f81-46e8-ad98-016394d3882a">5.0</ix:nonFraction>&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services.  </span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i654eb8c969e144a4999554c6d23ef287">The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $<ix:nonFraction unitRef="usd" contextRef="i2de27440831843859499b5316c0123fa_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM2MA_0d10c079-d3af-42e8-810a-3c4dea7aca9a"><ix:nonFraction unitRef="usd" contextRef="i13d3e19bc1f941bfada2a1d34fbabcd0_D20200901-20200930" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM2MA_b3ae6905-9baa-480d-826f-6fefab639f7f">5.0</ix:nonFraction></ix:nonFraction>&#160;million milestone, which the Company recognized on a cumulative basis during the year ended December 31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and <ix:nonFraction unitRef="usd" contextRef="id4ad9356ed1a4e1e8a0ce2245ba0883a_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM3NQ_bbdf453f-cc0f-4fcb-97f2-1e82afb9d515"><ix:nonFraction unitRef="usd" contextRef="i4f348bc656a048d89a2becabe2d582e0_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM3NQ_f32f1197-856a-48d9-925e-4d8fda926733">no</ix:nonFraction></ix:nonFraction> revenues have been recognized during the three months ended March 31, 2022 and 2021.</ix:continuation> </span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6&#8212;<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RleHRyZWdpb246YzMyOTQzMjExYmRhNDc5OWJiODk2MzhhYjk2Mjc3ODhfMTgy_2a07cedc-4f24-4962-80a8-45382acec8ea" continuedAt="i915c3c16a86c4bf8bb84f12edc678779" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i915c3c16a86c4bf8bb84f12edc678779"><ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RleHRyZWdpb246YzMyOTQzMjExYmRhNDc5OWJiODk2MzhhYjk2Mjc3ODhfMTgz_9be2dcea-d6a8-4b79-a7f0-94c828d5452c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:74.439%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed88b3f0256493eb611d1c6df10aa32_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfMi01LTEtMS0zNzI2MQ_63053030-68ef-47a6-a958-1a0d00039831">4,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d78a85fa8bf4c2088761487072d070b_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfMi03LTEtMS0zNzI2MQ_34466369-7563-4e4d-91a7-b6288a9276b0">4,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ccfc5457b247c9a4372c7a7b6fd8b6_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfMy01LTEtMS0zNzI2MQ_a3b0fe01-99ce-4618-905a-312bdd0558d9">3,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ae6a236ee94776b86d549585e14bb1_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfMy03LTEtMS0zNzI2MQ_ae81e1b7-2c22-43e5-b4fd-6bbd0798caae">3,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfNC01LTEtMS0zNzI2MQ_9b07e758-7894-4225-9eef-4645e111d8a9">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfNC03LTEtMS0zNzI2MQ_26ddfe16-d7be-450b-8845-006c11aa9e39">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7&#8212;<ix:nonNumeric contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfNjc5_92c35977-c00a-453b-8e68-b6c8b2a6dcc0" continuedAt="i7318060069394c33a2808c79e2fe1507" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i7318060069394c33a2808c79e2fe1507"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i03631c915ffa4c589e31bd1ac9a7dfc1_D20200801-20200831" decimals="-5" name="sgmo:StockOfferingProgramMaximumValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfMzg4_d5431719-6bc6-4724-a5c7-ba55ce3bd939">150.0</ix:nonFraction>&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. During the three months ended March&#160;31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i645065c4f11143f6a0bcdbb35e8a38f5_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfMTA5OTUxMTYyODQ5Mg_95898900-7675-4b13-bdbd-fbd1bf6aea21">1,034,762</ix:nonFraction> shares of its common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i645065c4f11143f6a0bcdbb35e8a38f5_D20210101-20210331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfMTA5OTUxMTYyODQ4OQ_c6c6a4d7-db6e-44d0-8fdc-ef12d40f1ba2">15.7</ix:nonFraction>&#160;million. <ix:nonFraction unitRef="shares" contextRef="i75cd2dd96b0241acae7b413f811622f1_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfNDk0NzgwMjMyNTg5OQ_99e36160-7560-4b6c-ac26-5975cecb00f5">No</ix:nonFraction> shares were sold during the three months ended March&#160;31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. These forward-looking statements include, without limitation, statements containing the words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited to, the &#8220;Risk Factors&#8221; described in Part I, Item 1A our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2021 as filed with the Securities and Exchange Commission on February&#160;24,&#160;2022, or the 2021 Annual Report, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. You should also read the following discussion and analysis in conjunction with our Condensed Consolidated Financial Statements and accompanying notes included in this report and the Consolidated Financial Statements and accompanying notes thereto included in our 2021 Annual Report.</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_79"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious diseases. We plan to deliver on this mission through development of our clinical and preclinical product candidates leveraging&#160;our novel science and our in-house manufacturing capabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical-stage product candidates are:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Isaralgagene civaparvovec, also known as ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, is currently being evaluated in our Phase 1/2 STAAR clinical study, and we have initiated plans for a Phase 3 clinical trial;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;SAR445136, our zinc finger nuclease, or ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease, or SCD, is currently being evaluated in our Phase 1/2 PRECIZN-1 clinical study. We are developing SAR445136 with our collaborator Sanofi S.A., or Sanofi, through June 28, 2022, at which time SAR445136 will become a product candidate wholly-owned by Sangamo;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;TX200, our wholly-owned Chimeric Antigen Receptor, or CAR, engineered regulatory T cell, or CAR-Treg, cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation, is currently being evaluated in our Phase 1/2 STEADFAST clinical study; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A and is the subject of the registrational Phase 3 AFFINE clinical trial. We are developing giroctocogene fitelparvovec with our collaborator Pfizer Inc., or Pfizer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preclinical development is focused in two innovative priority areas: (i) CAR-Treg cell therapies for autoimmune disorders and (ii) genome engineering for neurological diseases. Indications for our preclinical programs include neurodevelopmental disorders, cancer, inflammatory bowel disease, or IBD, tauopathies and neurodegenerative diseases such as amyotrophic lateral sclerosis, or ALS, multiple sclerosis, or MS, and Huntington&#8217;s disease, some of which we are developing with our collaborators Biogen MA, Inc. and Biogen International GmbH, which we refer to together as Biogen, Novartis Institutes for BioMedical Research, Inc., or Novartis, Pfizer, and Takeda Pharmaceutical Company Limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple collaborations with biopharmaceutical companies bring us important financial and strategic benefits and reinforce the potential of our research and development efforts and our ZF technology platform. They leverage our collaborators&#8217; therapeutic and clinical expertise and commercial resources with the goal to bring our medicines more rapidly to patients. We believe these collaborations reflect the value of our ZF technology platform and will potentially expand the addressable markets of our product candidates. To date, we have received approximately $815.0 million in upfront licensing fees, milestone payments and proceeds from sales of our common stock to collaborators and have the right to earn up to $6.7 billion in future milestone payments from our collaborations, in addition to potential product royalties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our in-house manufacturing capacity provides us a competitive advantage. We currently operate an adeno-associated virus, or AAV, manufacturing facility in our Brisbane, California headquarters and cell therapy manufacturing facilities in Brisbane, California and Valbonne, France. Our manufacturing strategy is to provide greater flexibility, quality and control by building a balanced and necessary capacity achieved through our in-house manufacturing and contract manufacturing organization, or CMO, partnerships, investing in manufacturing processes and analytics and developing a strong supply chain.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our business, see &#8220;Business&#8221; in Part I, Item 1 of the 2021 Annual Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Fabry Disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We recently dosed three additional patients in our Phase 1/2 STAAR study evaluating isaralgagene civaparvovec for the treatment of Fabry disease. One of these patients was the third patient treated in Cohort 3 at the dose of 3e13 vg/kg and the other two patients were treated in Cohort 4 at the dose of 5e13 vg/kg. This brings the total number of patients dosed in the STAAR study to nine and completes the dose escalation portion of this Phase 1/2 study. Enzyme replacement therapy, or ERT, withdrawal was completed for a second patient, with no reports to date that the resumption of ERT is required in either patient. We expect to present updated data from the STAAR study in the second half of 2022. We are currently preparing to dose patients in the expansion cohorts of the STAAR study. We also continue to actively plan for a potential pivotal Phase 3 trial and are engaging with health authorities, patient advocacy groups and investigators.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Sickle Cell Disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We recently dosed the fifth patient in the Phase 1/2 PRECIZN-1 study of SAR445136 for the treatment of sickle cell disease that is under development with Sanofi. This product candidate was the first in the study manufactured using improved methods that have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. We plan to complete dosing of patients in this study in the third quarter of 2022 and expect to present updated data in the second half of 2022. We are undertaking enabling activities for a potential Phase 3 trial. We continue to collaborate with Sanofi on an orderly transition of Sanofi&#8217;s rights and obligations related to this product candidate to us on June 28, 2022. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hemophilia A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Pfizer recently announced that, in March 2022, the U.S. Food and Drug Administration, or FDA, lifted the clinical hold that it had placed on the Phase 3 AFFINE trial of giroctocogene fitelparvovec, which the FDA had instituted following the announcement by Pfizer and us that Pfizer had voluntarily paused screening and dosing of additional patients in the trial following the observation of Factor VIII, or FVIII, levels greater than 150% in some treated patients. Despite the lifting of the FDA clinical hold, Pfizer has announced that the trial remains on a voluntary pause until all necessary conditions are met, including approval of updated trial protocols by regulatory authorities. In addition, Pfizer announced that a treated patient with elevated FVIII levels reported a below-the-knee deep vein thrombosis. This patient had a history of thrombotic events prior to participation in the trial, which is both a known risk factor for subsequent events as well as an exclusion criterion for participation in the AFFINE trial. The case was assessed to understand all potential contributing factors, including missed doses of investigator-prescribed direct oral anti-coagulants. This patient continues to be under the care of their physician and is reported to be doing well. This information has been shared with study investigators and health authorities, and the independent external Data Monitoring Committee is reviewing the data. All participants in the AFFINE trial continue to be closely monitored, and there have been no other thrombotic events reported in the trial at this time. Pfizer has announced that it expects to resume the AFFINE trial in the third quarter of 2022, with a pivotal data readout estimated in the second half of 2023.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Renal Transplant Rejection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2022, we dosed the first patient in our Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned Chimeric Antigen Receptor, or CAR, engineered regulatory T cell, or CAR-Treg, cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. No adverse events related to treatment have been reported to date. We expect to dose the second patient in the STEADFAST study around the middle of 2022, based on the patient's transplant schedule. We expect to complete dosing of the first cohort, comprised of three patients, by the end of 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impacts of the Ongoing COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and continue to experience impacts from the ongoing and evolving COVID-19 pandemic on our business and operations and could continue to experience these or potentially more severe impacts as the pandemic evolves in the United States, France, the United Kingdom and locations of our clinical studies and trials. For example, we have experienced periodic short-term disruptions to our onsite operations while addressing positive cases of COVID-19 by onsite workers and clinical trial patients, and our operations could experience longer term disruptions in the future in the event of a significant outbreak of COVID-19 among our onsite workers or clinical trial patients. Moreover, from time to time, we have been required to reorganize and prioritize our resources to mitigate moderate COVID-19 impacts arising from travel restrictions, density restrictions and supply constraints. If our programs encounter longer-term disruptions, it could impact our ability to support our biopharmaceutical partners as contemplated in our collaboration agreements and could result in adjustments to our timelines.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our Phase&#160;1/2 STAAR clinical study evaluating isaralgagene civaparvovec has experienced and continues to experience delays in its timeline due in part to COVID-19 impacts and the diversion of healthcare resources to fight the pandemic. For example, we estimate that the opening of the first clinical trial site in the United Kingdom for this study experienced a delay of approximately one year due to the significant prevalence of COVID-19 in the United Kingdom. Additionally, we have experienced delays in recruiting, enrolling and dosing patients for this study, due in part to the hesitation of patients to travel by plane to trial sites not within driving distance and to enter medical facilities during the pandemic and also due in part to trial sites prioritizing COVID-19 clinical care over research activities such as the STAAR study. The study has also experienced delays when certain patients have decided to take the COVID-19 vaccine or tested positive for COVID-19 prior to enrollment or dosing in the study. Moreover, we have experienced some short-term delays in sourcing the necessary raw materials to manufacture supplies for the STAAR study and in transporting clinical trial materials due to COVID-19 impacts. We estimate that these challenges have set back our STAAR study timelines by approximately three to six months. Clinical timelines for this study could be revised again if COVID-19 impacts to our recruitment, screening, enrollment and dosing of patients and to our sourcing of raw materials for this study intensify because of vaccination delays, new COVID-19 variants or unexpected events.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our STEADFAST study evaluating TX200, our wholly-owned CAR-Treg cell therapy product candidate for the treatment of kidney transplant rejection, has experienced delays in its timeline due to COVID-19 impacts related to manufacturing and technology transfer challenges with our CMOs and due to patients and donors testing positive for COVID-19. Our timelines for this study could be adjusted if COVID-19 impacts result in additional delays.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our partnered programs, the timelines for the studies and trials managed by our collaborators are also subject to potential delay in the future if these studies and trials experience similar challenges that we have experienced and continue to experience in our STAAR and STEADFAST studies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going forward, we will continue to monitor the impact of COVID-19 on our operations, research commitments and clinical trials and those of our collaborators, clinical trial sites and CMOs. The magnitude of these impacts will depend, in part, on the length and severity of the COVID-19 pandemic and related government orders and restrictions, and how the pandemic limits the ability of us and our business partners to operate business in the ordinary course. Disruptions to these operations, and possibly more severe disruptions in the future that could arise due to the extension of government orders or new government orders applicable in the places we operate or our industry generally or to us and our facilities specifically, could impede our ability to conduct research in a timely manner, comply with our research obligations to our collaborators and advance the development of our therapeutic programs. These delays and disruptions could result in adverse material impacts to our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate any material negative impact on our financial condition in 2022 as a result of the COVID-19 pandemic. We believe we are well positioned financially in the near term to execute on our wholly-owned and partnered research and clinical programs. As of March&#160;31, 2022, we had $400.3&#160;million in cash, cash equivalents, and marketable securities. Although we believe we are well-capitalized currently, the effects of the evolving pandemic could result in disruption of global financial markets, impairing our ability to access capital, which could negatively affect our liquidity in the future. We do not currently anticipate any material impairments to the valuation of the financial assets or goodwill on our balance sheet as a result of the COVID-19 pandemic. We do not believe that the remote workplace arrangements we have implemented for our office-based employees have affected our financial reporting or control systems.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic will impact our business, operations and financial condition, either directly or indirectly, will depend on future developments that remain highly uncertain at the present time. These developments include the ultimate duration and severity of the pandemic, the impacts of new COVID-19 variants, travel restrictions, new public health restrictions in the United States, France, the United Kingdom and other countries, business closures or business disruptions and the effectiveness and timeliness of actions taken in the United States, France, the United Kingdom and other countries to contain and treat the disease, including the effectiveness and timing of vaccination programs. The surge of new variants of the virus, including the recent Omicron variant, has resulted and may in the future result in the return of prior orders and restrictions or new quarantine and shelter-in-place orders or other restrictions. As our understanding of events evolves and additional information becomes available, we may materially change our guidance relating to our revenues, expenses and timelines for manufacturing, clinical trials and research and development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the section titled &#8220;Risk Factors&#8221; included in Part I, Item 1A of the 2021 Annual Report for additional information on risks and uncertainties related to the evolving COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Components of Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues have consisted primarily of revenues from upfront licensing fees, reimbursements for research services, milestone achievements and research grant funding. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner reimbursements will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since inception and expect to incur losses for at least the next several years as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities and revenues from collaborations and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our product candidates from research stage through clinical trials. Pursuant to the terms of our agreements with Biogen, Kite Pharma, Inc., or Kite, Novartis and Sanofi, certain expenses related to research and development activities will be reimbursed to us. The reimbursement funds to be received from Biogen, Kite, Novartis, Pfizer and Sanofi will be recognized as revenue as the related costs are incurred and collection is reasonably assured.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expenses, professional fees, allocated facilities expenses, patent prosecution expenses and other general corporate expenses. As we continue to advance our product candidates into and through the clinic, we expect the growth of our business to require increased general and administrative expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our Condensed Consolidated Financial Statements and the related disclosures, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies and estimates relating to revenue recognition and valuation of long-lived assets including goodwill and intangible assets are the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2022, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Part II, Item 7 of the 2021 Annual Report.</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_82"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three Months Ended March&#160;31, 2022 and 2021</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues primarily consisted of revenues from collaboration agreements. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Biogen, Novartis, Kite, and Pfizer as we continue to recognize upfront and milestone payments received under such agreements over time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $2.0&#160;million in revenues for the three months ended March&#160;31, 2022, compared to the same period in 2021, was primarily attributed to an increase of $1.0&#160;million related to our collaboration agreement with Novartis, an increase of $0.7&#160;million in revenue related to our collaboration agreement with Biogen, and an increase of $0.4&#160;million in revenue related to our collaboration agreement with Sanofi.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,148&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted primarily of compensation related expenses, including stock-based compensation, laboratory supplies, preclinical and clinical studies, manufacturing clinical supply, contracted research, and allocated facilities and information technology expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $2.2&#160;million in research and development expenses for the three months ended March&#160;31, 2022, compared to the same period in 2021, was primarily driven by a $1.1 million increase in compensation and other personnel costs as a result of increased headcount to support our clinical trials and manufacturing, a $0.6&#160;million increase in manufacturing and overhead costs as we ramp up our internal manufacturing operations, and a $0.5&#160;million increase in other research and development expenses due to the timing of our trials and increased activity attributed to our Biogen and Novartis collaborations. Stock-based compensation expense included in research and development expenses was $4.7&#160;million and $4.3&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our clinical programs and if we are able to progress our earlier stage product candidates into clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required to complete our development programs and our development costs for those programs may be impacted by the scope and timing of enrollment in clinical trials for our product candidates, our decisions to pursue development programs in other therapeutic areas, and whether we pursue development of our product candidates with a partner or collaborator or independently. For example, our product candidates are being developed in multiple therapeutic areas, and we do not yet know how many of those therapeutic areas we will continue to pursue. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued therapeutic area is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential therapeutic areas that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with our development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of any necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. The full extent of the impact of the COVID-19 pandemic on our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of the 2021 Annual Report, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation related expenses including stock-based compensation for executive, legal, finance and administrative personnel, professional fees, allocated facilities and information technology expenses, and other general corporate expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $1.2&#160;million in general and administrative expenses for the three months ended March&#160;31, 2022, compared to the same period in 2021, was primarily due to a $1.1&#160;million decrease in allocated overhead costs and a decrease of $0.5 million due to reduced headcount and related compensation and other personnel costs. These decreases were partially offset by a $0.2&#160;million increase in legal and professional fees. Stock-based compensation expense included in general and administrative expenses was $3.0&#160;million and $3.3&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to build out our product portfolio and advance our product candidates into the clinic, we expect higher general and administrative expenses to support the growth of the business.</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash, cash equivalents, and marketable securities totaling $400.3&#160;million compared to $464.7&#160;million as of December&#160;31, 2021. Our most significant use of capital was for employee compensation and external research and development expenses, including manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Our cash and investment balances are held in a variety of interest-bearing instruments, including U.S. government-sponsored entity debt securities, commercial paper securities, money market funds, corporate debt securities, asset-backed securities and certificates of deposit. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an Open Market Sale Agreement&#8480;, or the sales agreement, with Jefferies LLC, providing for the sale of up to $150.0&#160;million of our common stock from time to time in &#8220;at-the-market&#8221; offerings under an existing shelf registration statement. No shares were sold during the three months ended March&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we currently believe that our available cash, cash equivalents, and marketable securities and expected revenues from collaborations and strategic partnerships will be adequate to fund our currently planned operations through at least the next 12&#160;months from the date the Condensed Consolidated Financial Statements are issued. We may elect to raise additional capital through additional collaborative agreements or the sale of additional equity to fund our future needs beyond the next 12 months. During this period of uncertainty and volatility related to the COVID-19 pandemic, war in Ukraine and otherwise, we will continue to monitor our liquidity.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $59.0&#160;million for the three months ended March&#160;31, 2022, primarily reflecting our net loss of $44.0&#160;million, a decrease in deferred revenues of $21.0&#160;million, a decrease in accrued compensation and employee benefits by $8.3&#160;million mainly attributed to bonus pay-outs, a decrease in lease liabilities by $1.0&#160;million, and an increase in accounts receivable by $0.9&#160;million. These decreases were partially offset by $12.8&#160;million of non-cash expenses related to stock-based compensation, depreciation and amortization, amortization of premium on marketable securities, and amortization of operating lease right-of-use assets and a $3.6&#160;million increase in accounts payable and other accrued liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $68.6 million for the three months ended March&#160;31, 2021, primarily reflecting our net loss of $45.9 million, a decrease in deferred revenues of $20.0 million, a decrease in accrued compensation and employee benefits by $7.6 million mainly attributed to bonus pay-outs, and a decrease in accounts payable and accrued liabilities of $3.8 million due to timing of payments. These decreases were partially offset by $9.4 million of non-cash expenses related to stock-based compensation and depreciation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $1.7&#160;million for the three months ended March&#160;31, 2022, mostly related to net maturities and purchases of marketable securities, partially offset by $2.8&#160;million from purchases of property and equipment. Net cash provided by investing activities for the three months ended March&#160;31, 2021 was $45.3 million, mostly related to net maturities, sales and purchases of marketable securities, partially offset by $8.0&#160;million from purchases of property and equipment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $1.6&#160;million for the three months ended March&#160;31, 2022, mostly related to taxes paid related to net share settlement of equity awards of $1.6&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $15.2 million for the three months ended March 31, 2021, mostly related to $16.2 million proceeds from sales under our at-the-market offering program offset by the offering expenses of $0.5 million. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital and Capital Expenditure Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate continuing to incur operating losses for at least the next several years. Although we believe we are well capitalized currently, the effects of the ongoing COVID-19 pandemic, war in Ukraine and other economic uncertainty and volatility could result in significant disruption of global financial markets, impairing our ability to access capital, which could in the future negatively affect our liquidity. Future capital requirements beyond the next 12&#160;months will be substantial, and we will need to raise substantial additional capital to fund the development, manufacturing and potential commercialization of our product candidates through equity or debt financing. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approvals of our product candidates, a process that could cost in excess of hundreds of millions of dollars per product. We regularly consider fund-raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to advance our product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities, including sales pursuant to our at-the-market offering program, may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many forward-looking factors, including the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays that may be caused by changing regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and terms of future in-licensing and out-licensing transactions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of procuring clinical and commercial supplies of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products or technologies, including the costs associated with such acquisitions and investments; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of potential disputes and litigation.</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future minimum contractual obligations as of December&#160;31, 2021 were reported in the 2021 Annual Report. During the three months ended March&#160;31, 2022, there have been no other material changes outside the ordinary course of our business from the contractual obligations previously disclosed in our 2021 Annual Report.</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_94"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk relates to our cash, cash equivalents, and marketable securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities in our investment portfolio are not leveraged and are classified as available-for-sale. The majority of these available-for-sale securities are short-term in nature and subject to minimal interest rate risk. Our investments currently consist of U.S. government-sponsored entity debt securities, commercial paper securities, corporate debt securities, asset-backed securities and certificates of deposit. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. All investments are carried at market value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. Our market risks at March&#160;31, 2022 have not changed materially from those discussed in Item&#160;7A of our 2021 Annual Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in the United States as well as in Europe. The functional currency of each foreign subsidiary is the local currency. We are exposed to foreign currency risk, primarily through operations of our subsidiaries in Europe which conduct business primarily in Euros. We record gains and losses within our stockholders&#8217; equity due to the translation of our subsidiaries&#8217; financial statements into U.S. dollars. Our foreign currency exchange risk at March&#160;31, 2022 has not changed materially from that discussed in Item&#160;7A of our 2021 Annual Report.</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_97"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of March&#160;31, 2022. Based on that evaluation, as of March&#160;31, 2022, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_103"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_106"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below we are providing, in supplemental form, changes to our risk factors from those previously disclosed in Part I, Item 1A of the 2021 Annual Report. Our risk factors disclosed in Part I, Item 1A of the 2021 Annual Report provide additional discussion about these supplemental risks and we encourage you to read and carefully consider the risk factors disclosed in Part I, Item 1A of the 2021 Annual Report for a more complete understanding of the risks and uncertainties material to our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to identify, qualify and enroll sufficient patients for our clinical trials or complete our clinical trials in a timely manner, which could delay or prevent us from proceeding with the development of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying, qualifying and enrolling patients in clinical trials of our product candidates, and completing these clinical trials, is critical to our success. Patient enrollment and trial completion is affected by factors including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">size of the patient population and process for identifying patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">design of the trial protocol;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">eligibility and exclusion criteria;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">perceived risks and benefits of the product candidate under study;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">perceived risks and benefits of genomic approaches to treatment of diseases;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">availability of competing therapies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">potential additional delays related to the evolving COVID-19 global pandemic and the diversion of healthcare resources to fight the pandemic, including the decision of certain patients to take COVID-19 vaccines and certain patients testing positive for COVID-19 prior to enrolling or dosing in the study;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays or interruptions related to voluntary pauses of our clinical trials or those of our collaborators, such as the voluntary pause in enrolling and dosing additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the imposition of clinical holds by regulatory authorities on our clinical trials or those of our collaborators, such as the clinical hold imposed by the FDA on the Phase 3 AFFINE trial of giroctocogene fitelparvovec, and the potential inability of Sangamo and our collaborators to lift clinical holds imposed by regulatory authorities in a timely manner or on acceptable terms, or at all;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the transition of our SAR445136 sickle cell disease program from Sanofi to us due to the termination by Sanofi of our collaboration agreement, and delays or difficulties we may experience in enrolling and dosing the final patients in the related Phase 1/2 PRECIZN-1 study;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">availability of genetic testing for potential patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">proximity and availability of clinical trial sites for prospective patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">required and desired characteristics of patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ability to obtain and maintain patient consent;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risk that enrolled patients will drop out before completion of the trial;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">patient referral practices of physicians; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ability to monitor patients adequately during and after treatment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of our clinical trials depends on our ability to recruit patients to participate as well as completion of required follow-up periods. There are also a number of other product candidates in development by our competitors, who compete for the same limited patient populations. If we are not able to enroll the necessary number of patients in a timely manner, we may not be able to complete our clinical trials on our desired timelines or at all, which could negatively impact the competitive position and commercial viability of our product candidates or delay or reduce the product revenues, milestone </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments or royalty payments we expect to earn from our product candidates. For example, we have experienced delays and challenges in recruiting, screening, enrolling and dosing patients for our Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, due to challenges related to Brexit as well as the COVID-19 pandemic, patients testing positive for COVID-19, patients reconsidering their participation in the study and the limited number of screening sites, among other reasons. Our Phase 1/2 STEADFAST clinical study evaluating TX200 has experienced similar delays and challenges. In addition, we and Pfizer also announced that some of the patients treated in the Phase 3 AFFINE trial of giroctocogene fitelparvovec have experienced FVIII activity greater than 150% following treatment, and that Pfizer decided to voluntarily pause screening and dosing of additional patients in this trial to implement a proposed protocol amendment intended to provide guidelines for the clinical management of elevated FVIII levels. Subsequent to the voluntary pause, the FDA put this trial on clinical hold and then in March 2022, the FDA lifted the clinical hold. While the FDA has lifted the clinical hold, the voluntary pause initiated by Pfizer will remain in place until all necessary conditions are met, including but not limited to the approval of updated clinical trial protocols by applicable regulatory authorities. Accordingly, although Pfizer has announced that it anticipates to resume the Phase 3 AFFINE trial in the third quarter of 2022, we cannot assure you that the conditions necessary to resume the Phase 3 AFFINE trial will be met in a timely manner, or at all, or that the dosing of additional patients in the trial will restart promptly following any approvals of the updated clinical trial protocols, or at all, or that the presentation of data from such trial will be published in a timely manner, if at all. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued delays or additional pauses to the Phase 3 AFFINE trial could negatively impact the projected timelines for conducting and completing the trial and seeking regulatory approvals for giroctocogene fitelparvovec, which could in turn materially and adversely affect giroctocogene fitelparvovec&#8217;s competitive position and commercial viability and therefore our business, prospects and market price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if fewer patients are willing to participate in our clinical trials because of negative publicity from adverse events related to genomic medicines, competitive clinical trials for similar patient populations or for other reasons, the timelines for conducting clinical trials of our product candidates may be delayed. These delays could result in increased costs, limitation or termination of clinical trials, and delays in product development timelines. If we are forced to expand to additional jurisdictions to address these challenges, it could impose additional costs, delays and risks. If we are not successful in conducting our clinical trials as planned, it would have an adverse effect on our business, financial condition, results of operations, prospects and market price of our common stock.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing military action by Russia in Ukraine could have a negative impact on the global economy and our operations, which could materially and adversely affect our business, financial condition, results of operations, prospects and market price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, Russian forces launched significant military action against Ukraine, and sustained conflict and disruption in the region is possible. The impact to Ukraine as well as actions taken by other countries, including new and stricter sanctions imposed by Canada, the United Kingdom, the European Union, the U.S. and other countries and companies and organizations against officials, individuals, regions, and industries in Russia and Ukraine, and actions taken by Russia in response to such sanctions, and each country&#8217;s potential response to such sanctions, tensions, and military actions could adversely affect the global economy and financial markets and thus could affect our business, operations, operating results and financial condition as well as the price of our common stock and our ability to raise additional capital when needed on acceptable terms. In addition, any or all of these effects could disrupt our and our collaborators&#8217; supply chains and adversely affect our and our collaborators&#8217; ability to conduct ongoing and future clinical trials of our product candidates. The extent and duration of the military action, sanctions and resulting market and other disruptions are impossible to predict, but could be substantial. Any such disruptions caused by Russian military action or resulting sanctions may magnify the impact of the other risks described in the 2021 Annual Report.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_112"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_115"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_118"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Seventh Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 9, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">Fourth Certificate of Amendment of the Seventh Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed May 22, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">Fourth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 15, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20220331xex311.htm">Rule 13a &#8212; 14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20220331xex312.htm">Rule 13a &#8212; 14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20220331xex321.htm">Certifications Pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from Sangamo&#8217;s Quarterly Report on Form 10-Q for the three months ended March&#160;31,&#160;2022 is formatted in Inline XBRL and it is contained in Exhibit 101</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">#&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Indicates management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">+&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4456822efa7a4e3293b4821bff1ee4c1_7">Contents</a></span></div></div><div><span><br/></span></div><div id="i4456822efa7a4e3293b4821bff1ee4c1_124"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May&#160;5, 2022 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ALEXANDER D. MACRAE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Alexander D. Macrae</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ PRATHYUSHA DURAIBABU</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prathyusha Duraibabu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sgmo-20220331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i84529c3fca9042d9b9478d7c2844e6da_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alexander D. Macrae, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sgmo-20220331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4822f995bf0b4b7f8d22019da4cd4d5a_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Prathyusha Duraibabu, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sgmo-20220331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i25712152f12b4e7f9a1cf3f3ce61d53c_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in his or her capacity as an officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sgmo-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3c33364c-6fd7-4e66-b5dc-1ec40b4f7ba5,g:db557487-1255-4119-bfcf-47c79d663408-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail">
        <link:definition>2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail">
        <link:definition>2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail">
        <link:definition>2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2107102 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2308302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail">
        <link:definition>2409404 - Disclosure - FAIR VALUE MEASUREMENTS (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIES" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES">
        <link:definition>2110103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESTables" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables">
        <link:definition>2311303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>2412405 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails">
        <link:definition>2413406 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail">
        <link:definition>2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSPERSHARE" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE">
        <link:definition>2115104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail">
        <link:definition>2416408 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES">
        <link:definition>2117105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
        <link:definition>2318304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail">
        <link:definition>2419409 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail">
        <link:definition>2420410 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail">
        <link:definition>2421411 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail">
        <link:definition>2422412 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail">
        <link:definition>2423413 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail">
        <link:definition>2424414 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2125106 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2326305 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail">
        <link:definition>2427415 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2128107 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDetail" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail">
        <link:definition>2429416 - Disclosure - STOCKHOLDERS' EQUITY (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesMilestonesMember" abstract="true" name="AchievementOfSpecifiedSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementLicenseFee" abstract="false" name="CollaborativeArrangementLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_GainLossOnFreeShares" abstract="false" name="GainLossOnFreeShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AmortizationAndOtherChangesInRightOfUseAssets" abstract="false" name="AmortizationAndOtherChangesInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_StockOfferingProgramMaximumValue" abstract="false" name="StockOfferingProgramMaximumValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockExcessConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" abstract="false" name="CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneAxis" abstract="true" name="CollaborativeAgreementMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NumberOfOptionsToExtendInitialResearchTerm" abstract="false" name="NumberOfOptionsToExtendInitialResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_SeparateUpfrontFee" abstract="false" name="SeparateUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PfizerC9ORF72Member" abstract="true" name="PfizerC9ORF72Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAgreementTargetSelectionPeriod" abstract="false" name="CollaborationAgreementTargetSelectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionPeriod" abstract="false" name="CollaborativeArrangementStandstillRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneDomain" abstract="true" name="CollaborativeAgreementMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" abstract="false" name="CollaborativeArrangementNumberOfProductTargetsSelected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" abstract="false" name="CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" abstract="true" name="RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" abstract="false" name="CollaborativeArrangementMaximumMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_InitialResearchTermOfAgreement" abstract="false" name="InitialResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" abstract="false" name="CollaborativeArrangementNumberOfMilestonesAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" abstract="false" name="CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborationAgreementEquityIssued" abstract="false" name="CollaborationAgreementEquityIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ExtendedResearchTermOfAgreement" abstract="false" name="ExtendedResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_SalesBasedMilestoneMember" abstract="true" name="SalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NovartisInstitutesForBioMedicalResearchIncMember" abstract="true" name="NovartisInstitutesForBioMedicalResearchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargets" abstract="false" name="CollaborativeArrangementNumberOfProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborationArrangementResearchPeriod" abstract="false" name="CollaborationArrangementResearchPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" abstract="false" name="CollaborationAgreementNumberOfAdditionalProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_PreApprovalMilestoneMember" abstract="true" name="PreApprovalMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementPercentOfInitialRecognition" abstract="false" name="CollaborativeAgreementPercentOfInitialRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementResearchServiceFees" abstract="false" name="CollaborativeArrangementResearchServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" abstract="false" name="DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveAndOtherProductsMember" abstract="true" name="SBFiveTwoFiveAndOtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_NumberOfResearchProgram" abstract="false" name="NumberOfResearchProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" abstract="true" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sgmo-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3c33364c-6fd7-4e66-b5dc-1ec40b4f7ba5,g:db557487-1255-4119-bfcf-47c79d663408-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d1ca1512-37ff-42b2-8c08-a19e5386a35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d5e9e08c-216b-40d8-a457-ab136d20eca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d1ca1512-37ff-42b2-8c08-a19e5386a35f" xlink:to="loc_us-gaap_AssetsCurrent_d5e9e08c-216b-40d8-a457-ab136d20eca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d831456a-ae8c-426c-b3fb-b7d6caecebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d1ca1512-37ff-42b2-8c08-a19e5386a35f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d831456a-ae8c-426c-b3fb-b7d6caecebc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e306941c-af1b-46cb-9bbc-7f01a2d8ede9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d1ca1512-37ff-42b2-8c08-a19e5386a35f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e306941c-af1b-46cb-9bbc-7f01a2d8ede9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_981bcf4a-3804-41f9-b488-e7c12590b89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d1ca1512-37ff-42b2-8c08-a19e5386a35f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_981bcf4a-3804-41f9-b488-e7c12590b89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dcb59dae-1555-48ed-be50-e1426a99bb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d1ca1512-37ff-42b2-8c08-a19e5386a35f" xlink:to="loc_us-gaap_Goodwill_dcb59dae-1555-48ed-be50-e1426a99bb5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_45e0ae5e-3f4c-48e6-aed0-7516a64e3910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d1ca1512-37ff-42b2-8c08-a19e5386a35f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_45e0ae5e-3f4c-48e6-aed0-7516a64e3910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d8f8adb3-1943-4a13-a070-99761a2741f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d1ca1512-37ff-42b2-8c08-a19e5386a35f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d8f8adb3-1943-4a13-a070-99761a2741f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_bb68a245-9369-495c-939d-45923c2a2f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d1ca1512-37ff-42b2-8c08-a19e5386a35f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_bb68a245-9369-495c-939d-45923c2a2f90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_35ce942d-bb7a-4dbd-ba6e-e2e2e2022716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fc430765-9f09-469e-b97b-25c018c105e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_35ce942d-bb7a-4dbd-ba6e-e2e2e2022716" xlink:to="loc_us-gaap_Liabilities_fc430765-9f09-469e-b97b-25c018c105e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e3cb15ba-021c-4ac5-b355-3428c2ccfc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_35ce942d-bb7a-4dbd-ba6e-e2e2e2022716" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e3cb15ba-021c-4ac5-b355-3428c2ccfc4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0bf25241-6613-4049-afb8-823826016c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_35ce942d-bb7a-4dbd-ba6e-e2e2e2022716" xlink:to="loc_us-gaap_StockholdersEquity_0bf25241-6613-4049-afb8-823826016c12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b2a262b-be15-40b7-a69a-fa8f525d0448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9fa1b2af-b7b0-4ab4-8fc9-704b3ddc58a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b2a262b-be15-40b7-a69a-fa8f525d0448" xlink:to="loc_us-gaap_PreferredStockValue_9fa1b2af-b7b0-4ab4-8fc9-704b3ddc58a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_13cd5cf1-21e7-4ec9-80a2-9e1dcbb4f748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b2a262b-be15-40b7-a69a-fa8f525d0448" xlink:to="loc_us-gaap_CommonStockValue_13cd5cf1-21e7-4ec9-80a2-9e1dcbb4f748" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_37fc233e-5fa3-41b7-9106-e7e29214850a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b2a262b-be15-40b7-a69a-fa8f525d0448" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_37fc233e-5fa3-41b7-9106-e7e29214850a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8cf7553c-3e44-4ce5-a04d-f81e3aa4002b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b2a262b-be15-40b7-a69a-fa8f525d0448" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8cf7553c-3e44-4ce5-a04d-f81e3aa4002b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_72cf86a3-ba6d-45d5-a20e-159208b2a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b2a262b-be15-40b7-a69a-fa8f525d0448" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_72cf86a3-ba6d-45d5-a20e-159208b2a10a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_604d1db2-017b-4376-84c0-2ff6fdc7b775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bf2f183-d0a6-4ed1-ba38-c5b8463494e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_604d1db2-017b-4376-84c0-2ff6fdc7b775" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bf2f183-d0a6-4ed1-ba38-c5b8463494e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e4950808-7380-4f4a-8591-70e51ae481f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_604d1db2-017b-4376-84c0-2ff6fdc7b775" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e4950808-7380-4f4a-8591-70e51ae481f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_dbbf3ae2-f38b-4311-8465-86676a3e7a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_604d1db2-017b-4376-84c0-2ff6fdc7b775" xlink:to="loc_us-gaap_InterestReceivableCurrent_dbbf3ae2-f38b-4311-8465-86676a3e7a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f07c30f2-3793-49ea-b3ac-747e3de3584d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_604d1db2-017b-4376-84c0-2ff6fdc7b775" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f07c30f2-3793-49ea-b3ac-747e3de3584d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09b3a601-0324-4b2f-a958-9800f885e80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_604d1db2-017b-4376-84c0-2ff6fdc7b775" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09b3a601-0324-4b2f-a958-9800f885e80b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_08ad1ba9-61f4-4116-8c62-a4c2e6e040a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_db27f3e1-007a-4d09-9196-babd29127a10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08ad1ba9-61f4-4116-8c62-a4c2e6e040a9" xlink:to="loc_us-gaap_LiabilitiesCurrent_db27f3e1-007a-4d09-9196-babd29127a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6910bdc1-0ce8-4ac4-b99a-967914543fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08ad1ba9-61f4-4116-8c62-a4c2e6e040a9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6910bdc1-0ce8-4ac4-b99a-967914543fcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ea8330da-164a-442c-b3c0-c4401cd0d83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08ad1ba9-61f4-4116-8c62-a4c2e6e040a9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ea8330da-164a-442c-b3c0-c4401cd0d83c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ded72770-32d6-4f20-9ea2-b96d4e662bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08ad1ba9-61f4-4116-8c62-a4c2e6e040a9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ded72770-32d6-4f20-9ea2-b96d4e662bae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_318076f4-ff08-41bd-9d27-5c02a1366c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08ad1ba9-61f4-4116-8c62-a4c2e6e040a9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_318076f4-ff08-41bd-9d27-5c02a1366c5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_371bd313-90ae-486f-b5a9-c4f64f5b1781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5dcf3d6a-3595-4703-81bc-08f0ef07886b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_371bd313-90ae-486f-b5a9-c4f64f5b1781" xlink:to="loc_us-gaap_AccountsPayableCurrent_5dcf3d6a-3595-4703-81bc-08f0ef07886b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_fb4a2ffa-9153-4738-91fa-38fb81fbe4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_371bd313-90ae-486f-b5a9-c4f64f5b1781" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_fb4a2ffa-9153-4738-91fa-38fb81fbe4b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1d24d116-67a6-4750-826f-4af529c41854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_371bd313-90ae-486f-b5a9-c4f64f5b1781" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1d24d116-67a6-4750-826f-4af529c41854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dc7aedc5-a07d-4fc6-8c9c-afdaecdfcb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_371bd313-90ae-486f-b5a9-c4f64f5b1781" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dc7aedc5-a07d-4fc6-8c9c-afdaecdfcb59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c71905af-22c7-4d23-8f90-e3e804b8ab6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5e23f15-8352-4d33-b49f-f81dbb01be50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c71905af-22c7-4d23-8f90-e3e804b8ab6b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5e23f15-8352-4d33-b49f-f81dbb01be50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_189fa889-d200-42ac-b4de-e57606dfeae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c71905af-22c7-4d23-8f90-e3e804b8ab6b" xlink:to="loc_us-gaap_OperatingExpenses_189fa889-d200-42ac-b4de-e57606dfeae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12bf60d3-4642-4e4a-b372-ba3107b46aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0eb4ac86-82e2-4c30-9a2a-a42ef5baff1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_12bf60d3-4642-4e4a-b372-ba3107b46aae" xlink:to="loc_us-gaap_ProfitLoss_0eb4ac86-82e2-4c30-9a2a-a42ef5baff1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9641c1b-87df-4612-b737-def58f99183e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_12bf60d3-4642-4e4a-b372-ba3107b46aae" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9641c1b-87df-4612-b737-def58f99183e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_40329dd2-2ceb-4943-a68b-1f07e3bbbf91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_4f6a2402-4604-4383-9c30-347289a562f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_40329dd2-2ceb-4943-a68b-1f07e3bbbf91" xlink:to="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_4f6a2402-4604-4383-9c30-347289a562f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5f948ce6-0860-4473-9141-4c6f5cdec639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_40329dd2-2ceb-4943-a68b-1f07e3bbbf91" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5f948ce6-0860-4473-9141-4c6f5cdec639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_bb5b2564-dc75-4276-adb0-3feda5f53694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_757a2587-6a40-415d-9173-da831a1a9254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_bb5b2564-dc75-4276-adb0-3feda5f53694" xlink:to="loc_us-gaap_OperatingIncomeLoss_757a2587-6a40-415d-9173-da831a1a9254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_cc015173-da1a-42bb-8a66-27bc347c3a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_bb5b2564-dc75-4276-adb0-3feda5f53694" xlink:to="loc_us-gaap_InterestAndOtherIncome_cc015173-da1a-42bb-8a66-27bc347c3a21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8fd5c73c-e0b2-444e-a9de-cdfe6dd5ab42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8aa6df5a-7287-494e-9e5d-1ac056083544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8fd5c73c-e0b2-444e-a9de-cdfe6dd5ab42" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8aa6df5a-7287-494e-9e5d-1ac056083544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c2a7f7b7-4357-44d6-bc4d-c4fa45a74201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8fd5c73c-e0b2-444e-a9de-cdfe6dd5ab42" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c2a7f7b7-4357-44d6-bc4d-c4fa45a74201" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_10c97001-3734-4869-93d8-a72b28da9bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c3204636-d606-495a-a298-7c7c74d66204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_10c97001-3734-4869-93d8-a72b28da9bdf" xlink:to="loc_us-gaap_ProfitLoss_c3204636-d606-495a-a298-7c7c74d66204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4857d169-5ce9-40f9-94f3-ca4e8ca010a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_10c97001-3734-4869-93d8-a72b28da9bdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4857d169-5ce9-40f9-94f3-ca4e8ca010a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eeaa4c2c-7fa4-4c64-9428-628d77b83f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_10c97001-3734-4869-93d8-a72b28da9bdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eeaa4c2c-7fa4-4c64-9428-628d77b83f19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_0539fc51-eaf3-4e6f-897a-6997ba650c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_10c97001-3734-4869-93d8-a72b28da9bdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_0539fc51-eaf3-4e6f-897a-6997ba650c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0d191f1-0746-4eaa-92e7-971f98563671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_eb625a6c-5ecb-443d-97b4-40d590b6b288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0d191f1-0746-4eaa-92e7-971f98563671" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_eb625a6c-5ecb-443d-97b4-40d590b6b288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ad161946-0ef7-4632-9504-a50f13b763c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0d191f1-0746-4eaa-92e7-971f98563671" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ad161946-0ef7-4632-9504-a50f13b763c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8100eea-2cc1-4783-af2b-62d3f8d10175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8922d298-5e1b-4665-9229-2678534ea2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8100eea-2cc1-4783-af2b-62d3f8d10175" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8922d298-5e1b-4665-9229-2678534ea2cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_7bf37d13-2696-4af1-ac55-5adcbc1b5d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8100eea-2cc1-4783-af2b-62d3f8d10175" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_7bf37d13-2696-4af1-ac55-5adcbc1b5d1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_02e4cf18-47e9-4836-ad2b-a455f5e290fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8100eea-2cc1-4783-af2b-62d3f8d10175" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_02e4cf18-47e9-4836-ad2b-a455f5e290fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_ee86b628-79e0-4a6f-9eeb-f1d56bd5a1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8100eea-2cc1-4783-af2b-62d3f8d10175" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_ee86b628-79e0-4a6f-9eeb-f1d56bd5a1fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_d5517a98-5445-41fa-bbb0-ce16df86d4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8100eea-2cc1-4783-af2b-62d3f8d10175" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_d5517a98-5445-41fa-bbb0-ce16df86d4fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_28d0288b-6acd-43ad-b121-bc362c449679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_28d0288b-6acd-43ad-b121-bc362c449679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_511ee1ca-1d33-469a-9937-70bf5ed39726" xlink:href="sgmo-20220331.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_511ee1ca-1d33-469a-9937-70bf5ed39726" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3d40eab1-0bdf-4adc-9446-501d8f43198f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3d40eab1-0bdf-4adc-9446-501d8f43198f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_758d78be-5c61-405d-8e2a-df75c98af5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_ShareBasedCompensation_758d78be-5c61-405d-8e2a-df75c98af5d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares_4a508be9-4a4a-44d2-9e91-812fb5271f77" xlink:href="sgmo-20220331.xsd#sgmo_GainLossOnFreeShares"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_sgmo_GainLossOnFreeShares_4a508be9-4a4a-44d2-9e91-812fb5271f77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_566af99c-315d-4607-b7d5-874b5f5d6b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_566af99c-315d-4607-b7d5-874b5f5d6b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_cda69104-6538-49b5-98a2-31747c55915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_cda69104-6538-49b5-98a2-31747c55915b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ed58c59d-a983-4fc0-b811-e6a9f373da83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ed58c59d-a983-4fc0-b811-e6a9f373da83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dd910ae4-2f00-448b-897e-970c2d38898d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dd910ae4-2f00-448b-897e-970c2d38898d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_05acb0cb-34f7-4128-a3e6-1a243b5dc349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_ProfitLoss_05acb0cb-34f7-4128-a3e6-1a243b5dc349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_94168370-8d4a-4d33-ad7f-18b5444ba349" xlink:href="sgmo-20220331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_94168370-8d4a-4d33-ad7f-18b5444ba349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c65b524c-6b55-4c07-a682-c604a5dcd77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c65b524c-6b55-4c07-a682-c604a5dcd77a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_891887e7-6b78-448c-8a3a-e7885eecd509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fd3fd3a-4453-47e6-bb6d-941b6ec57645" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_891887e7-6b78-448c-8a3a-e7885eecd509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da29006c-8dad-488e-99fe-1696a4e4b50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c20f136a-6422-4e39-b705-cb8b409e7b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da29006c-8dad-488e-99fe-1696a4e4b50b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c20f136a-6422-4e39-b705-cb8b409e7b37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77977f6e-6622-4820-8e36-b8b3368f89a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da29006c-8dad-488e-99fe-1696a4e4b50b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77977f6e-6622-4820-8e36-b8b3368f89a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ee26fb8-2904-477a-bac0-41a8ad6a4019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da29006c-8dad-488e-99fe-1696a4e4b50b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ee26fb8-2904-477a-bac0-41a8ad6a4019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28386cd7-0ae1-4d0b-a757-92fd26c766a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da29006c-8dad-488e-99fe-1696a4e4b50b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28386cd7-0ae1-4d0b-a757-92fd26c766a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa96a59d-fb09-4bc2-8a15-1bb25770f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b530f098-fac9-42c5-92f2-a76d8767b164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa96a59d-fb09-4bc2-8a15-1bb25770f4c2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b530f098-fac9-42c5-92f2-a76d8767b164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8d17ced1-39a9-4fbb-8941-254058bbcb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa96a59d-fb09-4bc2-8a15-1bb25770f4c2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8d17ced1-39a9-4fbb-8941-254058bbcb3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2fa26946-4217-4cc3-adb0-db889a3c92bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa96a59d-fb09-4bc2-8a15-1bb25770f4c2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2fa26946-4217-4cc3-adb0-db889a3c92bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a2537856-e45c-4bc2-8013-381ae21acf31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c4df805-a2f4-44d5-9da5-f2c10c27b22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a2537856-e45c-4bc2-8013-381ae21acf31" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c4df805-a2f4-44d5-9da5-f2c10c27b22c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5e0a9b15-6eda-4d8b-ad21-92f1af082dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a2537856-e45c-4bc2-8013-381ae21acf31" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5e0a9b15-6eda-4d8b-ad21-92f1af082dd3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#FAIRVALUEMEASUREMENTSDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a3a2a33a-1ccb-44bc-a4e9-78a50bee8771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_208d844a-061a-45af-95e4-4731536e9539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a3a2a33a-1ccb-44bc-a4e9-78a50bee8771" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_208d844a-061a-45af-95e4-4731536e9539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5cb18539-1208-4d7a-99bc-99043e03c0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a3a2a33a-1ccb-44bc-a4e9-78a50bee8771" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5cb18539-1208-4d7a-99bc-99043e03c0dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_8ec0bc61-1412-4885-a36c-d756b088b24e" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67226fdd-d6bf-454d-bd32-2ba8c62bea93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_8ec0bc61-1412-4885-a36c-d756b088b24e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67226fdd-d6bf-454d-bd32-2ba8c62bea93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_756bb0f7-065c-461e-9131-d3395bb60754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_8ec0bc61-1412-4885-a36c-d756b088b24e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_756bb0f7-065c-461e-9131-d3395bb60754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_77335ce8-7c4c-41a3-a837-6ebb5cfd1b14" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_9817ec96-6612-44f3-b425-c8129b4fb749" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_77335ce8-7c4c-41a3-a837-6ebb5cfd1b14" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_9817ec96-6612-44f3-b425-c8129b4fb749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8f9b4ab6-870f-4b04-8c98-0eeacc7e7cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_77335ce8-7c4c-41a3-a837-6ebb5cfd1b14" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8f9b4ab6-870f-4b04-8c98-0eeacc7e7cd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_35717f01-ff52-4bec-9a9d-81782b500eaf" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_330271d8-cf21-468b-aa82-4f6481a05c51" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_35717f01-ff52-4bec-9a9d-81782b500eaf" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_330271d8-cf21-468b-aa82-4f6481a05c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_a382f7c8-bfe9-4f92-9ece-813b89d85d9f" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_35717f01-ff52-4bec-9a9d-81782b500eaf" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_a382f7c8-bfe9-4f92-9ece-813b89d85d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_9b94f4cb-f712-413d-81b9-29e10988a7dd" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_35717f01-ff52-4bec-9a9d-81782b500eaf" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_9b94f4cb-f712-413d-81b9-29e10988a7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c77ab98f-edab-4dc4-9a99-36183f6f5195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4f48b780-37a0-42eb-aaae-722c3e22ba95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c77ab98f-edab-4dc4-9a99-36183f6f5195" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4f48b780-37a0-42eb-aaae-722c3e22ba95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_268cf0ef-5cf0-4593-a9e9-ffb3a273c3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c77ab98f-edab-4dc4-9a99-36183f6f5195" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_268cf0ef-5cf0-4593-a9e9-ffb3a273c3bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e38d12e-b5b1-4754-87b7-196196e758cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c77ab98f-edab-4dc4-9a99-36183f6f5195" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e38d12e-b5b1-4754-87b7-196196e758cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_d85a117b-1f69-4a12-9761-24a8e34d76dd" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_7a3630f3-55d1-46fa-9359-9dd2c75c640f" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_d85a117b-1f69-4a12-9761-24a8e34d76dd" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_7a3630f3-55d1-46fa-9359-9dd2c75c640f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22ce1cc2-5155-45ad-982a-92fea3750cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_d85a117b-1f69-4a12-9761-24a8e34d76dd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_22ce1cc2-5155-45ad-982a-92fea3750cd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32012c85-d7f0-49c9-b3b1-3937b704ae80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_5bf51d87-a239-48aa-bf03-024fe4e67ffd" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32012c85-d7f0-49c9-b3b1-3937b704ae80" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_5bf51d87-a239-48aa-bf03-024fe4e67ffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_5b438fad-b715-4ca0-bf7e-dd8434d8ec22" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32012c85-d7f0-49c9-b3b1-3937b704ae80" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_5b438fad-b715-4ca0-bf7e-dd8434d8ec22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_44b552f1-3f64-4692-b7ac-590390bd6f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32012c85-d7f0-49c9-b3b1-3937b704ae80" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_44b552f1-3f64-4692-b7ac-590390bd6f3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents_6b7c531d-7820-4034-bcd1-8d9f2b8cd0fc" xlink:href="sgmo-20220331.xsd#sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_09c005b6-71e6-492e-866a-604037150baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents_6b7c531d-7820-4034-bcd1-8d9f2b8cd0fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_09c005b6-71e6-492e-866a-604037150baf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ea67725b-312d-498a-ad44-e88c7b003415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents_6b7c531d-7820-4034-bcd1-8d9f2b8cd0fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ea67725b-312d-498a-ad44-e88c7b003415" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sgmo-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3c33364c-6fd7-4e66-b5dc-1ec40b4f7ba5,g:db557487-1255-4119-bfcf-47c79d663408-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ia7bdb8bdaec44ad5bbf7086c5891a4bc_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_505d4461-5b9b-4fda-af8d-9f8fa4fe817e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_505d4461-5b9b-4fda-af8d-9f8fa4fe817e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c8de5aac-1ce9-4b7a-8c4e-d885ed898d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_CommonStockSharesIssued_c8de5aac-1ce9-4b7a-8c4e-d885ed898d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58866727-2dca-494f-a04d-16f5d7b297d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58866727-2dca-494f-a04d-16f5d7b297d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_929c96d4-4b97-4159-9d87-c98897b1cc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_929c96d4-4b97-4159-9d87-c98897b1cc6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e76e71d2-9693-4056-b7a3-748d3a6883a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e76e71d2-9693-4056-b7a3-748d3a6883a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_042e59af-0700-489d-a411-6fa0df6cffd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_042e59af-0700-489d-a411-6fa0df6cffd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5a5078da-48fd-4f87-ba0d-62fcf5bfdfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5a5078da-48fd-4f87-ba0d-62fcf5bfdfdb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e9d7b185-2dc5-44e6-ac07-fdf10ae7f17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e9d7b185-2dc5-44e6-ac07-fdf10ae7f17b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_f78afae6-ddf6-40cd-a846-7b9eb37b11c3" xlink:href="sgmo-20220331.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_f78afae6-ddf6-40cd-a846-7b9eb37b11c3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3ce14933-fc31-4254-abd6-c849da0b4623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3ce14933-fc31-4254-abd6-c849da0b4623" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_ffcfff79-c04c-4642-bc49-b4829601ac82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_ffcfff79-c04c-4642-bc49-b4829601ac82" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bc85b16e-9220-4077-a4ce-5e988804a3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bc85b16e-9220-4077-a4ce-5e988804a3fe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_063b6289-8a23-46cf-93d0-0719c62706a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_ProfitLoss_063b6289-8a23-46cf-93d0-0719c62706a0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_41b3d93f-08aa-4120-9c91-48493f965978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bf728eb4-8476-49b2-aa70-cd0ea20c9746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_afd0a143-8309-4d07-8337-a666dd6e0528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_505d4461-5b9b-4fda-af8d-9f8fa4fe817e" xlink:to="loc_us-gaap_StatementTable_afd0a143-8309-4d07-8337-a666dd6e0528" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_865e4dc3-7ee7-4f65-9370-20df96610802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_afd0a143-8309-4d07-8337-a666dd6e0528" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_865e4dc3-7ee7-4f65-9370-20df96610802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_865e4dc3-7ee7-4f65-9370-20df96610802_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_865e4dc3-7ee7-4f65-9370-20df96610802" xlink:to="loc_us-gaap_EquityComponentDomain_865e4dc3-7ee7-4f65-9370-20df96610802_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_865e4dc3-7ee7-4f65-9370-20df96610802" xlink:to="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7257d0cb-94eb-45a6-9c98-569318bff9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_CommonStockMember_7257d0cb-94eb-45a6-9c98-569318bff9bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_df56fc8a-6662-49fb-8054-5ca658e0413f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_df56fc8a-6662-49fb-8054-5ca658e0413f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ac7d587b-19a2-4515-ba6c-b96b84bd835b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_RetainedEarningsMember_ac7d587b-19a2-4515-ba6c-b96b84bd835b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_70864143-5e42-4053-8583-69ecf0ed034c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_70864143-5e42-4053-8583-69ecf0ed034c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_abe586bd-0850-414e-b957-ad765dc96d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_abe586bd-0850-414e-b957-ad765dc96d06" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="id27a1467e44140bf91d8eefc83144eb5_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a167e8d1-2d9d-42fe-997b-bb37ffca2233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:to="loc_us-gaap_ProfitLoss_a167e8d1-2d9d-42fe-997b-bb37ffca2233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_53967e62-1d1e-49b2-b3e3-7f35edaeed89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_53967e62-1d1e-49b2-b3e3-7f35edaeed89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3c328f89-7220-4dcc-a5de-7d4d6bd43c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3c328f89-7220-4dcc-a5de-7d4d6bd43c61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_e1702dae-b301-4bb8-86dd-4f4410a5805d" xlink:href="sgmo-20220331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_e1702dae-b301-4bb8-86dd-4f4410a5805d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares_e1e7ce74-2b94-4334-a329-91780029d013" xlink:href="sgmo-20220331.xsd#sgmo_GainLossOnFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_sgmo_GainLossOnFreeShares_e1e7ce74-2b94-4334-a329-91780029d013" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2ef6029b-5e95-4f03-9816-9d4c572eefea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_us-gaap_ShareBasedCompensation_2ef6029b-5e95-4f03-9816-9d4c572eefea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0104df09-d16b-4190-8a87-abb7a17f6440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0104df09-d16b-4190-8a87-abb7a17f6440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99845359-1185-4e79-bfc4-7229eb54df9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99845359-1185-4e79-bfc4-7229eb54df9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_60f1059a-a630-43c9-af6d-d0f86a37bc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_60f1059a-a630-43c9-af6d-d0f86a37bc2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f8b7762d-636c-406f-81b2-fa7454331ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f8b7762d-636c-406f-81b2-fa7454331ae0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a16b7424-f188-48ee-bea4-88c1aef277c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a16b7424-f188-48ee-bea4-88c1aef277c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_fb1cbfd4-f175-40be-90f6-c1b61ea6f5cf" xlink:href="sgmo-20220331.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_fb1cbfd4-f175-40be-90f6-c1b61ea6f5cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_430576e7-d1e8-4e12-b1f1-c7d90c88001d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_430576e7-d1e8-4e12-b1f1-c7d90c88001d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4585099c-e03c-4ae3-b0ba-f96b943ce06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4585099c-e03c-4ae3-b0ba-f96b943ce06e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5349e6a2-d80d-4c83-b18e-98de7d8c07dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5349e6a2-d80d-4c83-b18e-98de7d8c07dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_165164be-8eda-40bd-93a0-745b128f24f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_165164be-8eda-40bd-93a0-745b128f24f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_c4cdc2ed-e255-44ed-ae8a-d9e3e24ed0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_c4cdc2ed-e255-44ed-ae8a-d9e3e24ed0b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e83f62e8-2293-4230-a6e4-59072a536e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e83f62e8-2293-4230-a6e4-59072a536e22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_be4f40e1-4945-4947-acae-9a43417cc042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_be4f40e1-4945-4947-acae-9a43417cc042" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31332bb1-1fdd-463e-bab5-15c4f8de8cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31332bb1-1fdd-463e-bab5-15c4f8de8cef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4ca00623-c94d-4059-95ae-a05c1dc2d2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4ca00623-c94d-4059-95ae-a05c1dc2d2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6742746a-98f5-4c07-9fe8-2da6ceb6870b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6742746a-98f5-4c07-9fe8-2da6ceb6870b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ef6d9a81-5539-4090-b68e-531f47ce8d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ef6d9a81-5539-4090-b68e-531f47ce8d5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ccc0758c-b25a-43ea-8592-fa2cdac74e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ccc0758c-b25a-43ea-8592-fa2cdac74e60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f0cad3f-b078-44b9-8778-b301b05f3602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f0cad3f-b078-44b9-8778-b301b05f3602" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e1f2cad-7354-4a04-b157-e3caff385af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e1f2cad-7354-4a04-b157-e3caff385af9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4665ff75-6be3-4b13-b129-93a1002a8955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4665ff75-6be3-4b13-b129-93a1002a8955" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c20579fb-e228-44ab-8307-aa2038ddfac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_df9df217-4618-437c-8a90-e33b5b8e03b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_df9df217-4618-437c-8a90-e33b5b8e03b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2cdf080b-8c60-43ac-8860-0ab5d7fe2dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_df9df217-4618-437c-8a90-e33b5b8e03b5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2cdf080b-8c60-43ac-8860-0ab5d7fe2dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c9b08017-8ed8-4b28-94d4-7d4201ebdc22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_df9df217-4618-437c-8a90-e33b5b8e03b5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c9b08017-8ed8-4b28-94d4-7d4201ebdc22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d292c72d-ce73-4e07-9c3d-03475648cca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_StatementTable_d292c72d-ce73-4e07-9c3d-03475648cca4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fae73f4e-f9c2-4abd-824a-bfa2d7619d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d292c72d-ce73-4e07-9c3d-03475648cca4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fae73f4e-f9c2-4abd-824a-bfa2d7619d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fae73f4e-f9c2-4abd-824a-bfa2d7619d06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fae73f4e-f9c2-4abd-824a-bfa2d7619d06" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fae73f4e-f9c2-4abd-824a-bfa2d7619d06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58aab6c-9af5-4d0d-88f7-072d6aae8c78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fae73f4e-f9c2-4abd-824a-bfa2d7619d06" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58aab6c-9af5-4d0d-88f7-072d6aae8c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember_20e5923b-5a43-4d0d-998c-3e7e62959137" xlink:href="sgmo-20220331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58aab6c-9af5-4d0d-88f7-072d6aae8c78" xlink:to="loc_sgmo_AtTheMarketOfferingMember_20e5923b-5a43-4d0d-998c-3e7e62959137" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended" id="i9876a1950bfd4c3b80d0a71f0aab0167_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9b00c8e3-9213-40df-8fdf-0ad93902deec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_eb7037f5-89eb-49b9-8c26-9de4d9c78f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9b00c8e3-9213-40df-8fdf-0ad93902deec" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_eb7037f5-89eb-49b9-8c26-9de4d9c78f76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9b00c8e3-9213-40df-8fdf-0ad93902deec" xlink:to="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_14531e40-225b-4f52-9f99-464ebec51fcc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:to="loc_srt_CounterpartyNameAxis_14531e40-225b-4f52-9f99-464ebec51fcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_14531e40-225b-4f52-9f99-464ebec51fcc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_14531e40-225b-4f52-9f99-464ebec51fcc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_14531e40-225b-4f52-9f99-464ebec51fcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_14531e40-225b-4f52-9f99-464ebec51fcc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_24c1e659-b16d-4f4d-9519-5e2430b5b0d9" xlink:href="sgmo-20220331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:to="loc_sgmo_BiogenMAIncMember_24c1e659-b16d-4f4d-9519-5e2430b5b0d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_e0dbb7ce-e365-4e8d-8ecc-d94333d2ad05" xlink:href="sgmo-20220331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_e0dbb7ce-e365-4e8d-8ecc-d94333d2ad05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_0553be5a-72f7-481a-8eaf-a2e898f136e9" xlink:href="sgmo-20220331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:to="loc_sgmo_KitePharmaIncMember_0553be5a-72f7-481a-8eaf-a2e898f136e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_f5187113-3357-4e94-addd-039cfe089169" xlink:href="sgmo-20220331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:to="loc_sgmo_SanofiMember_f5187113-3357-4e94-addd-039cfe089169" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b47e3a1-ffdc-4f4c-8e5d-3c0d91c09e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b47e3a1-ffdc-4f4c-8e5d-3c0d91c09e33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3b47e3a1-ffdc-4f4c-8e5d-3c0d91c09e33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b47e3a1-ffdc-4f4c-8e5d-3c0d91c09e33" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3b47e3a1-ffdc-4f4c-8e5d-3c0d91c09e33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9cf7781-1fc6-4dd6-afd9-40a541248250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b47e3a1-ffdc-4f4c-8e5d-3c0d91c09e33" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9cf7781-1fc6-4dd6-afd9-40a541248250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_99d1d8ce-c3db-4687-ba50-3d1c75aa2c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9cf7781-1fc6-4dd6-afd9-40a541248250" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_99d1d8ce-c3db-4687-ba50-3d1c75aa2c20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_87380192-a758-450f-8243-9c2e38ccc2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_87380192-a758-450f-8243-9c2e38ccc2e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_87380192-a758-450f-8243-9c2e38ccc2e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_87380192-a758-450f-8243-9c2e38ccc2e5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_87380192-a758-450f-8243-9c2e38ccc2e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e8305520-0c6c-4c26-9535-4b608289c593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_87380192-a758-450f-8243-9c2e38ccc2e5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e8305520-0c6c-4c26-9535-4b608289c593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_4960f59a-e2dc-4b54-aa39-b32a67dde81c" xlink:href="sgmo-20220331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e8305520-0c6c-4c26-9535-4b608289c593" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_4960f59a-e2dc-4b54-aa39-b32a67dde81c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#FAIRVALUEMEASUREMENTSDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail" xlink:type="extended" id="i7787d07650c34c4696cfb08c128dac06_FAIRVALUEMEASUREMENTSDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9309d430-da22-49ff-a840-67b375205ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9309d430-da22-49ff-a840-67b375205ba2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2fe1164f-6ca4-4828-acac-d387cf47504e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2fe1164f-6ca4-4828-acac-d387cf47504e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_17f19245-9911-46a0-ab54-5ec561719203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_17f19245-9911-46a0-ab54-5ec561719203" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5bab9358-cd1d-4d2e-bc51-c6ea7fa80760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5bab9358-cd1d-4d2e-bc51-c6ea7fa80760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5bab9358-cd1d-4d2e-bc51-c6ea7fa80760_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5bab9358-cd1d-4d2e-bc51-c6ea7fa80760" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5bab9358-cd1d-4d2e-bc51-c6ea7fa80760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9bbdaca9-85ab-4225-9072-2096e06c26ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5bab9358-cd1d-4d2e-bc51-c6ea7fa80760" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9bbdaca9-85ab-4225-9072-2096e06c26ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_923adeb3-8576-43c1-aacf-5ac439190735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9bbdaca9-85ab-4225-9072-2096e06c26ee" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_923adeb3-8576-43c1-aacf-5ac439190735" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de36bd39-3e14-4146-911c-4c5b4939942d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de36bd39-3e14-4146-911c-4c5b4939942d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de36bd39-3e14-4146-911c-4c5b4939942d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de36bd39-3e14-4146-911c-4c5b4939942d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de36bd39-3e14-4146-911c-4c5b4939942d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de36bd39-3e14-4146-911c-4c5b4939942d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9ae0e319-418e-4e30-aa96-fc2e417081bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9ae0e319-418e-4e30-aa96-fc2e417081bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bd74ee4c-d5b5-4db9-9610-c7c6ff58c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bd74ee4c-d5b5-4db9-9610-c7c6ff58c64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_21c89bec-2a40-4c38-9329-71b4a733cdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_21c89bec-2a40-4c38-9329-71b4a733cdb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_50e674cf-1a26-4ca5-9df6-f74ef6194c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:to="loc_us-gaap_FinancialInstrumentAxis_50e674cf-1a26-4ca5-9df6-f74ef6194c83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50e674cf-1a26-4ca5-9df6-f74ef6194c83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_50e674cf-1a26-4ca5-9df6-f74ef6194c83" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50e674cf-1a26-4ca5-9df6-f74ef6194c83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_50e674cf-1a26-4ca5-9df6-f74ef6194c83" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4f725e7b-543c-4f06-b1cb-758e89e073ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4f725e7b-543c-4f06-b1cb-758e89e073ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_438495d6-8c83-4a82-9a1e-b42877678afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_438495d6-8c83-4a82-9a1e-b42877678afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b7dc750b-c49d-45a8-bd4e-c14bd0e2dc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_CommercialPaperMember_b7dc750b-c49d-45a8-bd4e-c14bd0e2dc06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_49f323e6-2a99-49a7-a1d0-27b662ee3b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_49f323e6-2a99-49a7-a1d0-27b662ee3b6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_f794cf72-6e1a-47ac-be08-2ba8cb4ed198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_f794cf72-6e1a-47ac-be08-2ba8cb4ed198" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bb5b2b71-1a63-472a-974d-789a93ac9760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bb5b2b71-1a63-472a-974d-789a93ac9760" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ca0192ce-b9cc-4d01-8b84-f92685c77013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ca0192ce-b9cc-4d01-8b84-f92685c77013" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="i3ecbaf4605014e46b3ac447dd03adc5d_CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b106e037-6020-4768-9885-464dab22e37d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b106e037-6020-4768-9885-464dab22e37d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_5cda3336-b09d-476c-bc58-b4ae381bf10a" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_5cda3336-b09d-476c-bc58-b4ae381bf10a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_09013105-f8b1-40c9-bdb1-8c74189592b1" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_09013105-f8b1-40c9-bdb1-8c74189592b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_12cacb4a-f208-4520-a701-f6009ec37460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_12cacb4a-f208-4520-a701-f6009ec37460" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be5a98b1-2c9c-4f01-acbc-fd60ea2d0872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be5a98b1-2c9c-4f01-acbc-fd60ea2d0872" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_13baa898-64eb-420f-93ce-f728def6ec0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_13baa898-64eb-420f-93ce-f728def6ec0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2b360dac-d68b-4350-90b6-c58be79e7e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2b360dac-d68b-4350-90b6-c58be79e7e58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5397d0f0-a247-4681-b46a-ae46fea22e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5397d0f0-a247-4681-b46a-ae46fea22e01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_6acf33f7-a2e6-460d-9d6d-d0e89c4a5a5c" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_6acf33f7-a2e6-460d-9d6d-d0e89c4a5a5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_05b25c58-1dee-455c-851f-247b859ed62a" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_05b25c58-1dee-455c-851f-247b859ed62a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_3b026f75-8882-4713-b960-83cc1d694061" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_3b026f75-8882-4713-b960-83cc1d694061" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_011179aa-53f2-4444-ad02-0d31e36005f1" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_011179aa-53f2-4444-ad02-0d31e36005f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f50e184d-8ca1-4c08-8586-c075b9fcb114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f50e184d-8ca1-4c08-8586-c075b9fcb114" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a417704a-534f-4de0-8644-8cfa39cfb340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f50e184d-8ca1-4c08-8586-c075b9fcb114" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a417704a-534f-4de0-8644-8cfa39cfb340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a417704a-534f-4de0-8644-8cfa39cfb340_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a417704a-534f-4de0-8644-8cfa39cfb340" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a417704a-534f-4de0-8644-8cfa39cfb340_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a417704a-534f-4de0-8644-8cfa39cfb340" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_44655a7b-dd03-4b48-9785-1b4de624330b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_44655a7b-dd03-4b48-9785-1b4de624330b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_60f20451-376f-4cc0-93cc-8ff417066b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_CashEquivalentsMember_60f20451-376f-4cc0-93cc-8ff417066b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_183d7b7a-d5c0-4a9b-86ca-03682392ba10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_183d7b7a-d5c0-4a9b-86ca-03682392ba10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6b2baa47-5d61-4273-be4a-221f2f027595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_CommercialPaperMember_6b2baa47-5d61-4273-be4a-221f2f027595" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_26573f47-294a-41c9-a38e-98b5448b4bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_26573f47-294a-41c9-a38e-98b5448b4bd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_932a29ac-e5f1-45f7-b6f6-d3b97963aa56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_932a29ac-e5f1-45f7-b6f6-d3b97963aa56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_be12605c-722a-47b3-a115-592c0957b167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_be12605c-722a-47b3-a115-592c0957b167" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7e925d76-5754-4698-9bc9-045149b46483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7e925d76-5754-4698-9bc9-045149b46483" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended" id="i610b6212e98a4717be8efc0ebf02579f_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d78e0d3f-999c-4b78-8556-cc8479275aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_f862ac72-54bd-4f68-9c29-9968c3e5c6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d78e0d3f-999c-4b78-8556-cc8479275aba" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_f862ac72-54bd-4f68-9c29-9968c3e5c6a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e6937a39-adaf-4671-82aa-f46c3513b726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d78e0d3f-999c-4b78-8556-cc8479275aba" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e6937a39-adaf-4671-82aa-f46c3513b726" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_237c1a40-801b-40d6-a3de-4311b8d0e711" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e6937a39-adaf-4671-82aa-f46c3513b726" xlink:to="loc_srt_CounterpartyNameAxis_237c1a40-801b-40d6-a3de-4311b8d0e711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_237c1a40-801b-40d6-a3de-4311b8d0e711_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_237c1a40-801b-40d6-a3de-4311b8d0e711" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_237c1a40-801b-40d6-a3de-4311b8d0e711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_237c1a40-801b-40d6-a3de-4311b8d0e711" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_e57cab2d-fec1-4614-8b13-127df236a7a2" xlink:href="sgmo-20220331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_e57cab2d-fec1-4614-8b13-127df236a7a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_cc75469c-8146-40b8-bb69-d9e19659097d" xlink:href="sgmo-20220331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:to="loc_sgmo_BiogenMAIncMember_cc75469c-8146-40b8-bb69-d9e19659097d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_a7471ee0-6f91-4196-9b45-59b61c037ff2" xlink:href="sgmo-20220331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:to="loc_sgmo_KitePharmaIncMember_a7471ee0-6f91-4196-9b45-59b61c037ff2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_68499143-2bdf-48d1-8a1f-303fd6bdfbcd" xlink:href="sgmo-20220331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:to="loc_sgmo_SanofiMember_68499143-2bdf-48d1-8a1f-303fd6bdfbcd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail" xlink:type="extended" id="i0ad02a493ae74ef985fff9d1a75059b6_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_382d27e4-c2ae-460b-83f7-97b9f3c25107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_us-gaap_ProceedsFromCollaborators_382d27e4-c2ae-460b-83f7-97b9f3c25107" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_a347b04c-5947-46b4-9702-fe668aabe579" xlink:href="sgmo-20220331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_a347b04c-5947-46b4-9702-fe668aabe579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_88d81f05-7b15-49c0-a9ff-329620843a6f" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_88d81f05-7b15-49c0-a9ff-329620843a6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_7b72c630-0470-413c-a6c3-64c377f18890" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_7b72c630-0470-413c-a6c3-64c377f18890" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_e2afe5c2-c73f-41d4-95c3-daf5b37fa8e1" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_e2afe5c2-c73f-41d4-95c3-daf5b37fa8e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_da66c7c8-02fa-4b76-9e10-2c135977a51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_da66c7c8-02fa-4b76-9e10-2c135977a51d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8518dfca-bdf5-4c89-9ac3-2aa51c23b416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8518dfca-bdf5-4c89-9ac3-2aa51c23b416" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_bd95112d-455d-4f7a-a702-32c3213fc4bc" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_bd95112d-455d-4f7a-a702-32c3213fc4bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_04015241-130d-43ec-8e9f-48dfda2b1492" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_04015241-130d-43ec-8e9f-48dfda2b1492" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_8a72a3ad-029f-437d-ada3-15d16bfc2326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_8a72a3ad-029f-437d-ada3-15d16bfc2326" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_14812972-29e4-4c64-b520-37fc0cd15bcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:to="loc_srt_CounterpartyNameAxis_14812972-29e4-4c64-b520-37fc0cd15bcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_14812972-29e4-4c64-b520-37fc0cd15bcb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_14812972-29e4-4c64-b520-37fc0cd15bcb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_14812972-29e4-4c64-b520-37fc0cd15bcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f852b57-85ed-4f22-a37a-807b06cd1536" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_14812972-29e4-4c64-b520-37fc0cd15bcb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f852b57-85ed-4f22-a37a-807b06cd1536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d03ffcbe-8da6-4eda-a426-718d42eb91d8" xlink:href="sgmo-20220331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f852b57-85ed-4f22-a37a-807b06cd1536" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d03ffcbe-8da6-4eda-a426-718d42eb91d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_999bbf24-9174-4c4d-9bb3-6cce022777b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_999bbf24-9174-4c4d-9bb3-6cce022777b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999bbf24-9174-4c4d-9bb3-6cce022777b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_999bbf24-9174-4c4d-9bb3-6cce022777b3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999bbf24-9174-4c4d-9bb3-6cce022777b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46adc8e5-cf58-4d88-9ba9-c9df7b650876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_999bbf24-9174-4c4d-9bb3-6cce022777b3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46adc8e5-cf58-4d88-9ba9-c9df7b650876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_6eb9cf43-340c-4e2f-aad6-e055544d6f1a" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46adc8e5-cf58-4d88-9ba9-c9df7b650876" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_6eb9cf43-340c-4e2f-aad6-e055544d6f1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_53bdfb2f-f1c1-40cb-94b2-11bd8965eff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_53bdfb2f-f1c1-40cb-94b2-11bd8965eff2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_53bdfb2f-f1c1-40cb-94b2-11bd8965eff2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_53bdfb2f-f1c1-40cb-94b2-11bd8965eff2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_53bdfb2f-f1c1-40cb-94b2-11bd8965eff2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_565fcdb3-7b94-43a4-b981-1aeffdf01ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_53bdfb2f-f1c1-40cb-94b2-11bd8965eff2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_565fcdb3-7b94-43a4-b981-1aeffdf01ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_f68418dc-fbee-4ff7-a912-2a66e3d74081" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_565fcdb3-7b94-43a4-b981-1aeffdf01ac6" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_f68418dc-fbee-4ff7-a912-2a66e3d74081" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_4137448e-0453-4ee1-b3da-5085dc32dcb0" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_565fcdb3-7b94-43a4-b981-1aeffdf01ac6" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_4137448e-0453-4ee1-b3da-5085dc32dcb0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended" id="i7d7b8f9168214fca87e359efa88deb98_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_63fbf74a-4e9a-449c-ab14-5c22ba376652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d5dc9b3-855a-4c82-965b-c10df18cb8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_63fbf74a-4e9a-449c-ab14-5c22ba376652" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d5dc9b3-855a-4c82-965b-c10df18cb8a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_41bc9953-5a25-40d9-b4eb-77da3201fdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_63fbf74a-4e9a-449c-ab14-5c22ba376652" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_41bc9953-5a25-40d9-b4eb-77da3201fdfe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0dd66a2a-2f79-43ac-8eca-3242e05565ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_41bc9953-5a25-40d9-b4eb-77da3201fdfe" xlink:to="loc_srt_CounterpartyNameAxis_0dd66a2a-2f79-43ac-8eca-3242e05565ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0dd66a2a-2f79-43ac-8eca-3242e05565ac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0dd66a2a-2f79-43ac-8eca-3242e05565ac" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0dd66a2a-2f79-43ac-8eca-3242e05565ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0dd66a2a-2f79-43ac-8eca-3242e05565ac" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_1557fab7-854f-481e-988c-145635343f85" xlink:href="sgmo-20220331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_1557fab7-854f-481e-988c-145635343f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_4fc62e49-5c9c-421e-9e27-7209383e2c53" xlink:href="sgmo-20220331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:to="loc_sgmo_BiogenMAIncMember_4fc62e49-5c9c-421e-9e27-7209383e2c53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_91ad3257-0b21-41c4-84cb-455bf757e316" xlink:href="sgmo-20220331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:to="loc_sgmo_KitePharmaIncMember_91ad3257-0b21-41c4-84cb-455bf757e316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_002a9280-69c4-4ecc-821b-b855089fcf64" xlink:href="sgmo-20220331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:to="loc_sgmo_SanofiMember_002a9280-69c4-4ecc-821b-b855089fcf64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0aa15a9e-d4e4-442b-ab9b-9f07e2a7dd7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_41bc9953-5a25-40d9-b4eb-77da3201fdfe" xlink:to="loc_srt_ProductOrServiceAxis_0aa15a9e-d4e4-442b-ab9b-9f07e2a7dd7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0aa15a9e-d4e4-442b-ab9b-9f07e2a7dd7e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0aa15a9e-d4e4-442b-ab9b-9f07e2a7dd7e" xlink:to="loc_srt_ProductsAndServicesDomain_0aa15a9e-d4e4-442b-ab9b-9f07e2a7dd7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0aa15a9e-d4e4-442b-ab9b-9f07e2a7dd7e" xlink:to="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_efe7344d-afb0-4f9c-ad40-4994df987e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:to="loc_us-gaap_LicenseAndServiceMember_efe7344d-afb0-4f9c-ad40-4994df987e42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_becfafaa-c5f0-436e-bf15-fc6d187f626b" xlink:href="sgmo-20220331.xsd#sgmo_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:to="loc_sgmo_ResearchServicesMember_becfafaa-c5f0-436e-bf15-fc6d187f626b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_a7693b77-d596-4a1b-a8bc-cde83adefcc7" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:to="loc_sgmo_MilestoneAchievementMember_a7693b77-d596-4a1b-a8bc-cde83adefcc7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail" xlink:type="extended" id="ia5e888a771714806a3b18832d9dda5ad_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_285919d9-8f7d-42f0-a492-7e0b1a9cfa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_285919d9-8f7d-42f0-a492-7e0b1a9cfa1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_560b4865-4c72-4163-ba10-fa1a9e8f7558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_560b4865-4c72-4163-ba10-fa1a9e8f7558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_32ec5e24-61c8-43d4-b3c9-628584f8fd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_32ec5e24-61c8-43d4-b3c9-628584f8fd3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_e3f1a670-32f5-4be6-b226-d5fc3fc930f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_ProceedsFromCollaborators_e3f1a670-32f5-4be6-b226-d5fc3fc930f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_0c061a9f-77e9-48c3-bef2-005f156eb31d" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_0c061a9f-77e9-48c3-bef2-005f156eb31d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_f5d445f2-81df-4e3b-9120-9c354b2bd639" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_f5d445f2-81df-4e3b-9120-9c354b2bd639" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_0f46f587-fae8-4948-a5ce-d0b29083819c" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_0f46f587-fae8-4948-a5ce-d0b29083819c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_71bc0622-71b4-497a-a2e6-67c76ecd6792" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_71bc0622-71b4-497a-a2e6-67c76ecd6792" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_1591ccbb-f656-44e0-b91a-bd37561d2cce" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_1591ccbb-f656-44e0-b91a-bd37561d2cce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_13ce18ca-1584-44d3-8735-47f98cc8a24b" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_13ce18ca-1584-44d3-8735-47f98cc8a24b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_15bb7040-02a4-4a09-a68b-17f7a9fc2dcc" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_15bb7040-02a4-4a09-a68b-17f7a9fc2dcc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_17d95978-9e17-4643-9352-71bfb7dc100c" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_17d95978-9e17-4643-9352-71bfb7dc100c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_fc67a035-5a8d-4e28-8f0a-6e0e28e91a45" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_fc67a035-5a8d-4e28-8f0a-6e0e28e91a45" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_da7faed9-830f-4701-ad38-98e7782c02a0" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_da7faed9-830f-4701-ad38-98e7782c02a0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_6431d8d6-d753-4e6a-bd68-7e9a5031fd64" xlink:href="sgmo-20220331.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_6431d8d6-d753-4e6a-bd68-7e9a5031fd64" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_0af759d8-9159-4759-959d-ef5eec8324b5" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_0af759d8-9159-4759-959d-ef5eec8324b5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f0d1c223-ff80-4f01-aecb-7b3d638715cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f0d1c223-ff80-4f01-aecb-7b3d638715cf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3d750fe2-c588-455a-be39-105df9119191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3d750fe2-c588-455a-be39-105df9119191" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_38dff54f-bc20-4f41-ace2-33d4a2518a7c" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_38dff54f-bc20-4f41-ace2-33d4a2518a7c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_46b96b9a-e189-4cf9-b844-66858954bc59" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_46b96b9a-e189-4cf9-b844-66858954bc59" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_2a1880d7-2462-44db-918b-c964859ef3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_2a1880d7-2462-44db-918b-c964859ef3bc" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_ca8c70b3-a338-4e3d-86ac-d28c0f187e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_ca8c70b3-a338-4e3d-86ac-d28c0f187e43" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d916b7bf-03b4-4923-b01c-ce2ff445f7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d916b7bf-03b4-4923-b01c-ce2ff445f7d7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4505143c-e683-4475-ac15-682531c17957" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:to="loc_srt_CounterpartyNameAxis_4505143c-e683-4475-ac15-682531c17957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4505143c-e683-4475-ac15-682531c17957_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4505143c-e683-4475-ac15-682531c17957" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4505143c-e683-4475-ac15-682531c17957_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52a8f36-cdf2-444e-92bb-2f444d4cec52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4505143c-e683-4475-ac15-682531c17957" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52a8f36-cdf2-444e-92bb-2f444d4cec52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_62965604-0677-4bfe-9982-056f715afb3e" xlink:href="sgmo-20220331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52a8f36-cdf2-444e-92bb-2f444d4cec52" xlink:to="loc_sgmo_BiogenMAIncMember_62965604-0677-4bfe-9982-056f715afb3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_987cacd0-ab4f-484e-b71c-df6c632d146f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_987cacd0-ab4f-484e-b71c-df6c632d146f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_987cacd0-ab4f-484e-b71c-df6c632d146f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_987cacd0-ab4f-484e-b71c-df6c632d146f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_987cacd0-ab4f-484e-b71c-df6c632d146f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed94b370-dc4d-49ff-9005-029313ee9d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_987cacd0-ab4f-484e-b71c-df6c632d146f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed94b370-dc4d-49ff-9005-029313ee9d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_062c5304-fec9-4524-883e-67ef52a8074f" xlink:href="sgmo-20220331.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed94b370-dc4d-49ff-9005-029313ee9d6b" xlink:to="loc_sgmo_StockPurchaseAgreementMember_062c5304-fec9-4524-883e-67ef52a8074f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_79be90d9-1953-48e0-847b-ba8c77e1cb4d" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed94b370-dc4d-49ff-9005-029313ee9d6b" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_79be90d9-1953-48e0-847b-ba8c77e1cb4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_be0da2be-f7cc-4ea0-9241-74186a7f51e7" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_be0da2be-f7cc-4ea0-9241-74186a7f51e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_be0da2be-f7cc-4ea0-9241-74186a7f51e7_default" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_be0da2be-f7cc-4ea0-9241-74186a7f51e7" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_be0da2be-f7cc-4ea0-9241-74186a7f51e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_200bc042-b1a9-455a-b781-4fccdc0365c8" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_be0da2be-f7cc-4ea0-9241-74186a7f51e7" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_200bc042-b1a9-455a-b781-4fccdc0365c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_d41cb443-33a3-4f4b-8738-13ac1f15596d" xlink:href="sgmo-20220331.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_200bc042-b1a9-455a-b781-4fccdc0365c8" xlink:to="loc_sgmo_PreApprovalMilestoneMember_d41cb443-33a3-4f4b-8738-13ac1f15596d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_df4b9030-192b-440e-bf8f-a4c6acb0900a" xlink:href="sgmo-20220331.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_200bc042-b1a9-455a-b781-4fccdc0365c8" xlink:to="loc_sgmo_SalesBasedMilestoneMember_df4b9030-192b-440e-bf8f-a4c6acb0900a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail" xlink:type="extended" id="i7956f3f9cc0c4d49a439eb9a346c2e5d_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_9f8573fe-2c60-4edb-866f-598521973338" xlink:href="sgmo-20220331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_MilestonePaymentsReceived_9f8573fe-2c60-4edb-866f-598521973338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_95f1120c-75b0-4289-be6d-ecf29ac87088" xlink:href="sgmo-20220331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_95f1120c-75b0-4289-be6d-ecf29ac87088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_f64cf151-678b-48f3-a60f-de43a20a1119" xlink:href="sgmo-20220331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_f64cf151-678b-48f3-a60f-de43a20a1119" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_eb41c825-696d-4384-acf5-f12e2e3aa998" xlink:href="sgmo-20220331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_eb41c825-696d-4384-acf5-f12e2e3aa998" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_0d224b3f-68e8-4904-9af8-a6f89c9b0317" xlink:href="sgmo-20220331.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_0d224b3f-68e8-4904-9af8-a6f89c9b0317" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_8ee0c72a-35be-4ce2-9d28-afa77edbf0ef" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_8ee0c72a-35be-4ce2-9d28-afa77edbf0ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_b96a2446-6a2f-40f3-b45e-0e019e62fd9f" xlink:href="sgmo-20220331.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_b96a2446-6a2f-40f3-b45e-0e019e62fd9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_3fc52b8c-6d34-4f8a-8e00-7b38bf7c658a" xlink:href="sgmo-20220331.xsd#sgmo_SeparateUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_SeparateUpfrontFee_3fc52b8c-6d34-4f8a-8e00-7b38bf7c658a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_5e628a14-9cb6-4cce-ae70-200f442bc783" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_5e628a14-9cb6-4cce-ae70-200f442bc783" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_f4aebf0a-ba1e-46f4-ae3d-dbbc940c6805" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_f4aebf0a-ba1e-46f4-ae3d-dbbc940c6805" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_ebe195ec-23e5-4cf5-b03f-893687fd77ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_ebe195ec-23e5-4cf5-b03f-893687fd77ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_3516d0e7-6ff0-4259-836d-cc9fbde6631e" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_3516d0e7-6ff0-4259-836d-cc9fbde6631e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4a3b0dfa-d0e8-495c-bf41-f8e0602efd42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4a3b0dfa-d0e8-495c-bf41-f8e0602efd42" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f1366f78-c215-4b90-8001-8c9b30f815e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f1366f78-c215-4b90-8001-8c9b30f815e3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8be8355c-1c49-4408-b2fa-748576923888" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:to="loc_srt_CounterpartyNameAxis_8be8355c-1c49-4408-b2fa-748576923888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8be8355c-1c49-4408-b2fa-748576923888_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8be8355c-1c49-4408-b2fa-748576923888" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8be8355c-1c49-4408-b2fa-748576923888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae541ad5-a649-4b06-8d5d-2d471365cbd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8be8355c-1c49-4408-b2fa-748576923888" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae541ad5-a649-4b06-8d5d-2d471365cbd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_32fd3618-035a-4161-b638-ea93fe08c1cf" xlink:href="sgmo-20220331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae541ad5-a649-4b06-8d5d-2d471365cbd0" xlink:to="loc_sgmo_KitePharmaIncMember_32fd3618-035a-4161-b638-ea93fe08c1cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_521c294d-b88f-45f5-a761-45e9fb92de77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:to="loc_us-gaap_TypeOfArrangementAxis_521c294d-b88f-45f5-a761-45e9fb92de77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_521c294d-b88f-45f5-a761-45e9fb92de77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_521c294d-b88f-45f5-a761-45e9fb92de77" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_521c294d-b88f-45f5-a761-45e9fb92de77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4f4f196-35ff-4503-8fef-5934c38c0ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_521c294d-b88f-45f5-a761-45e9fb92de77" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4f4f196-35ff-4503-8fef-5934c38c0ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_5615c79d-e420-466f-8050-f42a1cb7ab5d" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4f4f196-35ff-4503-8fef-5934c38c0ff8" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_5615c79d-e420-466f-8050-f42a1cb7ab5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_740dd322-d3cb-4cf2-ae72-2b027edfbd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_740dd322-d3cb-4cf2-ae72-2b027edfbd35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_740dd322-d3cb-4cf2-ae72-2b027edfbd35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_740dd322-d3cb-4cf2-ae72-2b027edfbd35" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_740dd322-d3cb-4cf2-ae72-2b027edfbd35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_abeebba7-4104-4d77-809b-44262129a6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_740dd322-d3cb-4cf2-ae72-2b027edfbd35" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_abeebba7-4104-4d77-809b-44262129a6b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_539746f1-53d7-4964-b509-cb2edcc30327" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_abeebba7-4104-4d77-809b-44262129a6b9" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_539746f1-53d7-4964-b509-cb2edcc30327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_dc640127-a3e0-4a7b-8e3a-c2174c8ecbd4" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_abeebba7-4104-4d77-809b-44262129a6b9" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_dc640127-a3e0-4a7b-8e3a-c2174c8ecbd4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail" xlink:type="extended" id="ia2d547cfd7ad4909bed180b988e1509e_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_ae84e65c-c605-4c5c-b156-58ff52e41af0" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfResearchProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_NumberOfResearchProgram_ae84e65c-c605-4c5c-b156-58ff52e41af0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_34da6bc5-ec03-4ea0-8839-1460ab8edaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_34da6bc5-ec03-4ea0-8839-1460ab8edaf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_f96c7a55-5ad5-4161-8fe2-213a6c5fb99a" xlink:href="sgmo-20220331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_f96c7a55-5ad5-4161-8fe2-213a6c5fb99a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_189b4313-1c39-4423-a9f8-ab475ef6a88e" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_MilestoneRevenueReceivable_189b4313-1c39-4423-a9f8-ab475ef6a88e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0c83588d-6e74-4f0b-af36-5faed998d89c" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0c83588d-6e74-4f0b-af36-5faed998d89c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_150fae8e-6d66-4462-8c90-0e05a3a3e4d6" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_150fae8e-6d66-4462-8c90-0e05a3a3e4d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_fdc5a3a3-003d-408a-aae3-c6b295d8fc84" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_fdc5a3a3-003d-408a-aae3-c6b295d8fc84" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_b39741be-a999-421d-9b48-dd2b63aa6d57" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_b39741be-a999-421d-9b48-dd2b63aa6d57" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_592d53e0-81c2-4cf5-8692-6a3c07def72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_592d53e0-81c2-4cf5-8692-6a3c07def72c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a4f7717e-acdb-4b9b-9080-6ba3b61a3135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a4f7717e-acdb-4b9b-9080-6ba3b61a3135" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_486230ee-d33e-4aac-b335-c418d70f3bfd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:to="loc_srt_CounterpartyNameAxis_486230ee-d33e-4aac-b335-c418d70f3bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486230ee-d33e-4aac-b335-c418d70f3bfd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_486230ee-d33e-4aac-b335-c418d70f3bfd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486230ee-d33e-4aac-b335-c418d70f3bfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d06bfcf-da77-4732-b99e-3171fa47a48c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_486230ee-d33e-4aac-b335-c418d70f3bfd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d06bfcf-da77-4732-b99e-3171fa47a48c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_fd5283a9-76f1-44c2-a95a-8ca0cf298cb1" xlink:href="sgmo-20220331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d06bfcf-da77-4732-b99e-3171fa47a48c" xlink:to="loc_sgmo_SanofiMember_fd5283a9-76f1-44c2-a95a-8ca0cf298cb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_938997b9-f7a2-412f-b9bd-4df5c2f50205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_938997b9-f7a2-412f-b9bd-4df5c2f50205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_938997b9-f7a2-412f-b9bd-4df5c2f50205_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_938997b9-f7a2-412f-b9bd-4df5c2f50205" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_938997b9-f7a2-412f-b9bd-4df5c2f50205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b929920c-bb2e-4f71-932c-efbe7c82e877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_938997b9-f7a2-412f-b9bd-4df5c2f50205" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b929920c-bb2e-4f71-932c-efbe7c82e877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_ec7663aa-0535-420b-ab8b-b1de2f9d6007" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b929920c-bb2e-4f71-932c-efbe7c82e877" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_ec7663aa-0535-420b-ab8b-b1de2f9d6007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_895fc7a6-8754-4460-8b4f-4e8a7c885a82" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b929920c-bb2e-4f71-932c-efbe7c82e877" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_895fc7a6-8754-4460-8b4f-4e8a7c885a82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7179c959-5d6c-487f-90e0-9bde31f044fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7179c959-5d6c-487f-90e0-9bde31f044fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7179c959-5d6c-487f-90e0-9bde31f044fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7179c959-5d6c-487f-90e0-9bde31f044fb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7179c959-5d6c-487f-90e0-9bde31f044fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ed2c68-fbc0-4ad5-802e-85cdd9d39057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7179c959-5d6c-487f-90e0-9bde31f044fb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ed2c68-fbc0-4ad5-802e-85cdd9d39057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_a703e9c3-f38f-4572-82ae-18e657e0c3cb" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ed2c68-fbc0-4ad5-802e-85cdd9d39057" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_a703e9c3-f38f-4572-82ae-18e657e0c3cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d567f7c-c7cb-4ab9-b39b-f84c9b632411" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d567f7c-c7cb-4ab9-b39b-f84c9b632411" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_7d567f7c-c7cb-4ab9-b39b-f84c9b632411_default" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d567f7c-c7cb-4ab9-b39b-f84c9b632411" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_7d567f7c-c7cb-4ab9-b39b-f84c9b632411_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_9c814bdc-a874-40c0-a54e-0aef645898d6" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d567f7c-c7cb-4ab9-b39b-f84c9b632411" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_9c814bdc-a874-40c0-a54e-0aef645898d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_3e0f2634-734c-4db8-ba98-ccb4f009bc65" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_9c814bdc-a874-40c0-a54e-0aef645898d6" xlink:to="loc_sgmo_MilestoneTwoMember_3e0f2634-734c-4db8-ba98-ccb4f009bc65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_532c25c1-06b3-444d-95fb-403ceb8a98aa" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_9c814bdc-a874-40c0-a54e-0aef645898d6" xlink:to="loc_sgmo_MilestoneThreeMember_532c25c1-06b3-444d-95fb-403ceb8a98aa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail" xlink:type="extended" id="ibd9c175d6676436e86b1c5e039d9c665_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_929baa0d-0818-47b7-9d11-c6943c13fcee" xlink:href="sgmo-20220331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_AgreementTerminationTerm_929baa0d-0818-47b7-9d11-c6943c13fcee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_50a414b2-f69d-4af8-9589-7a1f768303d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_50a414b2-f69d-4af8-9589-7a1f768303d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_a0b27683-3916-4ac1-a706-687659eb5f3b" xlink:href="sgmo-20220331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_a0b27683-3916-4ac1-a706-687659eb5f3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_24b0f921-596d-4a8a-9f35-9128e8f5bb97" xlink:href="sgmo-20220331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_24b0f921-596d-4a8a-9f35-9128e8f5bb97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_84f60369-4661-4d19-a3e9-06019f53a391" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_MilestoneRevenueReceivable_84f60369-4661-4d19-a3e9-06019f53a391" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_966ca3c1-537f-4499-aa06-7d3716f44591" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_966ca3c1-537f-4499-aa06-7d3716f44591" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_2876135e-55a2-435d-aa69-2f0a305d34bd" xlink:href="sgmo-20220331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_MilestonePaymentsReceived_2876135e-55a2-435d-aa69-2f0a305d34bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_f8a2bdcb-8084-4d9c-af9e-a6f007092ef0" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_f8a2bdcb-8084-4d9c-af9e-a6f007092ef0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_96b7e974-1bb2-4024-949e-8a7504197bf2" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_96b7e974-1bb2-4024-949e-8a7504197bf2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_25689bf5-83c5-42f0-ae9b-deae29d123ea" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_25689bf5-83c5-42f0-ae9b-deae29d123ea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_2f5554e8-e26b-4e52-b5a6-03eda52fae31" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_2f5554e8-e26b-4e52-b5a6-03eda52fae31" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68d79ea3-6c59-44ce-9f4c-47bfb3afe978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68d79ea3-6c59-44ce-9f4c-47bfb3afe978" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_df8aa442-6084-4977-9f11-58cef2a7f6f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:to="loc_srt_CounterpartyNameAxis_df8aa442-6084-4977-9f11-58cef2a7f6f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_df8aa442-6084-4977-9f11-58cef2a7f6f1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_df8aa442-6084-4977-9f11-58cef2a7f6f1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_df8aa442-6084-4977-9f11-58cef2a7f6f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_df8aa442-6084-4977-9f11-58cef2a7f6f1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_4edf57b1-0f69-4872-b2a9-0aad9cd93e0e" xlink:href="sgmo-20220331.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:to="loc_sgmo_PfizerMember_4edf57b1-0f69-4872-b2a9-0aad9cd93e0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_e3a771b1-34dc-4180-a20d-fcdce2be82e5" xlink:href="sgmo-20220331.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:to="loc_sgmo_PfizerSB525Member_e3a771b1-34dc-4180-a20d-fcdce2be82e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_37329afa-6d27-4619-9bf8-bae2c5ab798a" xlink:href="sgmo-20220331.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:to="loc_sgmo_PfizerC9ORF72Member_37329afa-6d27-4619-9bf8-bae2c5ab798a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c8f3f20-a7f8-4cbe-accb-2ae573e0ae00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:to="loc_srt_ProductOrServiceAxis_8c8f3f20-a7f8-4cbe-accb-2ae573e0ae00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c8f3f20-a7f8-4cbe-accb-2ae573e0ae00_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c8f3f20-a7f8-4cbe-accb-2ae573e0ae00" xlink:to="loc_srt_ProductsAndServicesDomain_8c8f3f20-a7f8-4cbe-accb-2ae573e0ae00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c8f3f20-a7f8-4cbe-accb-2ae573e0ae00" xlink:to="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_ce12f437-de7f-4ce7-a01e-775d206ce3b3" xlink:href="sgmo-20220331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_ce12f437-de7f-4ce7-a01e-775d206ce3b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_5244875b-7c0c-4fe4-ad5c-54065e465ca9" xlink:href="sgmo-20220331.xsd#sgmo_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:to="loc_sgmo_OtherProductsMember_5244875b-7c0c-4fe4-ad5c-54065e465ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_e30a277b-66f9-4020-b312-32a0ace7736f" xlink:href="sgmo-20220331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:to="loc_sgmo_CNineORFSevenTwoMember_e30a277b-66f9-4020-b312-32a0ace7736f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f4b77bb-9677-43ad-a073-3de34357a815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f4b77bb-9677-43ad-a073-3de34357a815" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0f4b77bb-9677-43ad-a073-3de34357a815_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f4b77bb-9677-43ad-a073-3de34357a815" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0f4b77bb-9677-43ad-a073-3de34357a815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f4b77bb-9677-43ad-a073-3de34357a815" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_d9f1cb1a-fb97-4290-8e92-024ba00c1639" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_d9f1cb1a-fb97-4290-8e92-024ba00c1639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_5bff9fc4-3eae-4779-945e-82177ecbda1c" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_5bff9fc4-3eae-4779-945e-82177ecbda1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_b1e03b77-1748-4e3f-880a-becdd56238ae" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_b1e03b77-1748-4e3f-880a-becdd56238ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_e59a2762-adc6-446f-a466-b4fafbc6ade4" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_e59a2762-adc6-446f-a466-b4fafbc6ade4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1518969d-b455-4097-83a7-8b2baec57986" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:to="loc_srt_RangeAxis_1518969d-b455-4097-83a7-8b2baec57986" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1518969d-b455-4097-83a7-8b2baec57986_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1518969d-b455-4097-83a7-8b2baec57986" xlink:to="loc_srt_RangeMember_1518969d-b455-4097-83a7-8b2baec57986_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1842afac-aec1-4f8f-9889-70818623e19f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1518969d-b455-4097-83a7-8b2baec57986" xlink:to="loc_srt_RangeMember_1842afac-aec1-4f8f-9889-70818623e19f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0388aac6-0f74-44a9-b784-8bd5894b6a4f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1842afac-aec1-4f8f-9889-70818623e19f" xlink:to="loc_srt_MaximumMember_0388aac6-0f74-44a9-b784-8bd5894b6a4f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended" id="if9b9f17d095d4c1fbd04f9157db1db39_STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b8d14f5-acd8-4d79-a880-168ece5f56b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2ea9d44-003c-4806-9e89-6e0e5be87746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b8d14f5-acd8-4d79-a880-168ece5f56b8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2ea9d44-003c-4806-9e89-6e0e5be87746" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_32749f92-4a73-4512-9867-d9fd958e9f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b8d14f5-acd8-4d79-a880-168ece5f56b8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_32749f92-4a73-4512-9867-d9fd958e9f17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3332c8d2-a81d-4870-bc78-631b8d2ccd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_32749f92-4a73-4512-9867-d9fd958e9f17" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3332c8d2-a81d-4870-bc78-631b8d2ccd70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3332c8d2-a81d-4870-bc78-631b8d2ccd70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3332c8d2-a81d-4870-bc78-631b8d2ccd70" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3332c8d2-a81d-4870-bc78-631b8d2ccd70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7af66989-347d-4159-8f7a-5cc8ad75b9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3332c8d2-a81d-4870-bc78-631b8d2ccd70" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7af66989-347d-4159-8f7a-5cc8ad75b9d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_96d67056-ea86-4eec-b028-cd0a3dd06584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7af66989-347d-4159-8f7a-5cc8ad75b9d2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_96d67056-ea86-4eec-b028-cd0a3dd06584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5ea98dd8-e1c0-408a-832c-2a30436ab6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7af66989-347d-4159-8f7a-5cc8ad75b9d2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5ea98dd8-e1c0-408a-832c-2a30436ab6a4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#STOCKHOLDERSEQUITYDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail" xlink:type="extended" id="i62ee703608b346258dc0ff70e8a8c688_STOCKHOLDERSEQUITYDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_87c6c0a5-98c1-4074-939b-a25b09114b15" xlink:href="sgmo-20220331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_87c6c0a5-98c1-4074-939b-a25b09114b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bd7e5b28-9175-4568-babe-a18cee91f4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bd7e5b28-9175-4568-babe-a18cee91f4a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06622735-7db3-4285-ac81-a36572cd4bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06622735-7db3-4285-ac81-a36572cd4bc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6020032-09d7-494e-996e-03df7d9102e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6020032-09d7-494e-996e-03df7d9102e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a6a2d122-52af-40ab-88cb-46ca77721a61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6020032-09d7-494e-996e-03df7d9102e2" xlink:to="loc_srt_CounterpartyNameAxis_a6a2d122-52af-40ab-88cb-46ca77721a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6a2d122-52af-40ab-88cb-46ca77721a61_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a6a2d122-52af-40ab-88cb-46ca77721a61" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6a2d122-52af-40ab-88cb-46ca77721a61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57b8641f-7c89-4d77-aeca-f7aff1523f0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a6a2d122-52af-40ab-88cb-46ca77721a61" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57b8641f-7c89-4d77-aeca-f7aff1523f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_f31bedea-72d1-4e5b-855c-dac6a73d8c2f" xlink:href="sgmo-20220331.xsd#sgmo_JefferiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57b8641f-7c89-4d77-aeca-f7aff1523f0a" xlink:to="loc_sgmo_JefferiesLLCMember_f31bedea-72d1-4e5b-855c-dac6a73d8c2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ee1e14bc-e1e7-4ab8-b82f-566937d32669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6020032-09d7-494e-996e-03df7d9102e2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ee1e14bc-e1e7-4ab8-b82f-566937d32669" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee1e14bc-e1e7-4ab8-b82f-566937d32669_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ee1e14bc-e1e7-4ab8-b82f-566937d32669" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee1e14bc-e1e7-4ab8-b82f-566937d32669_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce010caf-a058-49f0-b2c4-00766271bb82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ee1e14bc-e1e7-4ab8-b82f-566937d32669" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce010caf-a058-49f0-b2c4-00766271bb82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_f7820916-8e9d-4f45-ba78-185b462b6f7c" xlink:href="sgmo-20220331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce010caf-a058-49f0-b2c4-00766271bb82" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_f7820916-8e9d-4f45-ba78-185b462b6f7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sgmo-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3c33364c-6fd7-4e66-b5dc-1ec40b4f7ba5,g:db557487-1255-4119-bfcf-47c79d663408-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_a1dcce4e-f625-460b-bfc0-df45b949c336_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_91287819-4c69-4e0c-8592-ad83939f719c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8b67755d-4953-4480-853f-8ddf0d62bc86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_02085e13-808f-4057-9a47-44656fe6ef98_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_948bd6ab-9bd0-4219-9ced-d2d281e56262_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_82df9e2b-1bac-4b2f-a83c-e842ced16f23_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_128a015d-0756-478c-b492-b2d70048d30c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1ec41992-803c-4fa7-a7b1-f78e39289f7e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_84e13112-c06a-4f5e-81dc-af9df0b50ec2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6a6646f6-cc8a-4b47-98c4-bdb7f98e62d5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c96cf6c9-d27f-4bc1-9dc0-d78564f8fae7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_f075a2a9-3823-4b2a-9db7-fc4c0e8b54cd_terseLabel_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember" xlink:href="sgmo-20220331.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockPurchaseAgreementMember" xlink:to="lab_sgmo_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherProductsMember_dfe58061-5130-4228-aada-921b11034d15_terseLabel_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_label_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember" xlink:href="sgmo-20220331.xsd#sgmo_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherProductsMember" xlink:to="lab_sgmo_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2117fa68-48e4-4d53-be12-d32514cbc2ba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_eb4490d3-3167-461a-aa98-f100d42e6165_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_JefferiesLLCMember_a6c4d8c9-f9d9-4861-8440-9e4f1519f2a7_terseLabel_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_label_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_documentation_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember" xlink:href="sgmo-20220331.xsd#sgmo_JefferiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_JefferiesLLCMember" xlink:to="lab_sgmo_JefferiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9097c53d-eac6-4ac2-8e0a-c604feed6872_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_34f0c4c5-8f78-4c2e-9975-3f11eb99cfe5_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e7e639c9-4905-4fc6-92d0-1193cb7e2381_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_51a52d7a-d2a0-49b2-b525-d391636c6edb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other impairment charges related to marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_41187270-c134-418b-bf6d-b518f30d26f3_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_cc95ef46-aafc-475a-9625-4d8190597dde_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_bcf4386c-86e1-4338-9d5a-96885c926e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_08e83a2a-4f76-4d04-b8f6-ca1fe80233f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_51c30f37-6d8a-43ab-882e-070f29ccbec9_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restriction period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_5fab886f-e1a3-4cf8-9876-e63b9a8a2df5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_b8c1f5ad-ddc3-4fd3-a0d4-13497881aafb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_dde19338-72bd-408d-a97b-dc896e41742e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_572acfd9-324e-49da-bd74-622012da8e2d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8fef7d3f-cfef-4fb7-996c-f669bdad7c7b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11b24c37-8988-4d0d-9173-5988b49a7fc7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0d5cf45-efe4-431a-ae90-4591818f5a59_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SanofiMember_27cfeacd-321b-41a4-bd4b-56324e62389d_terseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi S.A.</link:label>
    <link:label id="lab_sgmo_SanofiMember_761e7a2f-4f81-4f77-ab86-d3982191e2b0_verboseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sgmo_SanofiMember_label_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_sgmo_SanofiMember_documentation_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember" xlink:href="sgmo-20220331.xsd#sgmo_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SanofiMember" xlink:to="lab_sgmo_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3e9a0bd8-b6d4-4827-8617-cb3aea786902_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_97579f6a-613b-46d5-8d9f-c468a2c96e9d_terseLabel_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_label_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_documentation_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:href="sgmo-20220331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:to="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cb4cea0f-7c7f-4c0e-8306-1d43c8214c2a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_03b6ae5f-0ea8-4d84-8777-c59f49052a45_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5a032c95-d3d8-46e2-9c3a-204fad55fb57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d30ff1fa-24a6-4d94-9c0f-d49b9bc6411b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b2b56419-c057-4d77-9220-4c687a94f84e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_69cf7050-6dc4-4dba-ba27-84b738b3919c_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_07d4c8ca-29be-49ce-8d97-f1bbf9e2b9bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f9cac33e-4024-4036-9911-b46ac84f400c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_f50f9fc1-c8a5-49a3-9877-796bed4b9010_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restriction, ownership threshold percentage ownership percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_347cece5-0865-49cc-b834-5f4f6d357426_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_65d26b7a-ac6e-4b64-afa9-26fad358cef6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0dac811b-4e64-4ef6-9a27-ca3d102e43f6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4b98433a-d77d-49de-957f-567c2bb1e117_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0aaf0514-35a6-4f19-a810-ec2d1bac1745_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_cca898d7-c64c-4fc9-ad90-34394065b553_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fe62dbe4-5fa2-471f-8dbb-8c7cb04afd56_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_3e2b1e7e-0844-4f05-9340-aaa94e0df8f9_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:href="sgmo-20220331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:to="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_852ae21e-387e-4c56-95cc-a980421ccd71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b5610793-67f5-443d-94fd-9d0dfa894e16_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7a4c9e27-fa2f-4600-9429-3c987804f47f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_adbcf882-a9cb-461e-839a-7f3fa15560a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9de4dfb1-f945-4a2e-96de-643e4cb74b63_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_3455830d-28ba-4d0b-961f-3e90722dde4b_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payment receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:to="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_28c2bd92-bd4b-4a46-b7ad-93ce8e17381a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_7fcc7709-2c4a-4bb6-9d1b-bb56a96ef123_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_40fe1df6-270e-4790-8f5d-d46528da355d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_4d502f38-2a71-49db-a7ef-5062c3c4be4f_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_2af80f93-47c9-463c-87b2-5ad6e488668c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_KitePharmaIncMember_072b9e66-b136-47ff-86e4-7d3a61d3aae5_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma, Inc.</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember" xlink:href="sgmo-20220331.xsd#sgmo_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember" xlink:to="lab_sgmo_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c8070c37-cd76-4912-9f87-12d43efc9792_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_7bb9d68d-2e0d-4818-91e4-fde657ff65a8_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:href="sgmo-20220331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7a8fcc56-c4e7-4fd1-a2cb-58297b94cbb8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fe9442f9-7058-408b-ad33-9feeb10667cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eabee240-df34-4225-a17f-0030fb7f395d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3adab695-8fe2-45c3-844e-36093a1d56d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8dfc343c-a832-4251-80d1-319ff9a6be8c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_54cf103c-a3d1-4625-af5c-264bf225f313_terseLabel_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of additional shares of Sangamo France</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_label_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:href="sgmo-20220331.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:to="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eb9183ec-2a3e-4127-8659-94bbd7b3573c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bc7d5ac6-da1d-4f18-8245-af4902d06ba7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2e2f8bc3-3be7-4318-ae81-b2284f6c2719_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_aff29094-8034-4443-99a4-05216f24d38b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_80b75428-6434-466c-acbf-c638ace26a6b_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3f5fbc47-cebb-4e48-8889-7a201d9a56b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3a86019a-7bbe-4825-880c-ad0e683829ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneThreeMember_7f4638db-19ab-4e3f-995d-562824fc30a8_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone three</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_label_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneThreeMember" xlink:to="lab_sgmo_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_d438f6e1-5ee6-429e-8067-daf22104dee5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_780b7625-18a9-438a-9a3d-6c37364a5e74_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_3c189a8e-a896-48b0-a197-ce1c240bc99b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_b1e76862-275d-41b7-b35c-88b26a85f04a_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a04723a4-8973-4719-9a73-060adabc7bb8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e868eae4-48d3-4ae5-b711-eec34ecb1cca_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1d797ceb-afc8-4a61-b5c9-97fc2e9513f0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fff14904-7608-4811-9cab-ead49461f6f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and restricted stock units</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0379ed6c-1419-420b-a74c-2a7c8f088d41_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_52554cf2-6f7d-47f7-92fd-d922b642e073_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_42a662c3-7762-4dcd-b027-f10f66096573_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e98f2169-9b04-494e-a284-c0b0ed38c800_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6dbcd6d8-19c8-4f3b-a09f-5979a34c2c56_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c7114d10-e079-4e00-8b60-d55282e0a1d4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_c30f165e-169e-4498-9c50-deedd925367b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e2a0e781-cb06-48ca-8133-404931d3bb14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8457e8db-408e-44a9-8319-097fafc85bdd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_4a6076e2-946d-4da8-9543-5c338c7d7cb2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_0f11c274-eecd-4bb5-bbdc-d80340fe523f_negatedTotalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_3da87cb5-0663-4086-b943-38c189aaa91f_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_22e946df-d4fd-4ff8-8183-1b0ae6d0ef26_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6b70d3fc-1829-4d13-a968-999be97826c8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_be41b9c9-5b75-4991-b9af-a9b3ef850ff1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6e36801e-f9e7-4164-8699-6653283a2051_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in unpaid liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfResearchProgram_a4b61bdc-3fd2-4221-9b63-72a4cbf2b8ac_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_label_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Research Program</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_documentation_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfResearchProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfResearchProgram" xlink:to="lab_sgmo_NumberOfResearchProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6663c99e-5d47-4997-87b6-882659d2845f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_20b34ab9-58cc-405b-8913-a869a4a81b64_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3100ff76-2a7c-4f38-bc10-c24bd5309599_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_12ec9233-bee8-499c-a96f-44635d276162_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Estimated Fair Value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e4b3ac47-bc8e-4c6d-8f9f-9dfa341c8ea2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_871a99a8-022c-408f-852a-77607a49215a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c688af88-dcb8-4657-90a2-729ffdbc3e88_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at-the-market offering, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_77b4105b-f5d9-4bfb-bb95-33b30ffdcd33_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_94aa69a6-32d0-452c-9585-8cff51955949_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_18a1d3a5-7d22-436c-b807-beeef6ef5ad3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_4b4825cd-55b1-4d65-8a6c-c0c32e883541_terseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement" xlink:href="sgmo-20220331.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_InitialResearchTermOfAgreement" xlink:to="lab_sgmo_InitialResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_160847dd-9de3-49eb-870f-0f7c6cb5a779_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pension gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e6e3cd4f-83a3-4fbb-b52b-f1b8c1128c1b_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_eb8dc3f7-35f5-44b8-b552-2cd0bd94fe91_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_cf5b509f-4468-45f1-b160-1ab199e9c99b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ea92e104-b19a-456b-8f88-8fa60424d5b7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_adfdd35a-fdba-46dd-a9fa-55177bfc90f6_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93f719f2-99a2-42b7-b1f6-b14db614e670_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_310161d7-e5ee-46cf-b806-8556afdaae2c_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, number of milestones achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerSB525Member_faf26250-54ec-417e-bdf6-7550fdee9550_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member" xlink:href="sgmo-20220331.xsd#sgmo_PfizerSB525Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member" xlink:to="lab_sgmo_PfizerSB525Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c37e91bd-5009-4480-aa1c-59845697ceba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_fd2b51e1-4146-4571-8f59-4cfd853f0be0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6282cd15-2306-48ef-8c3b-29767eb0b9e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_e9262840-14f7-4f47-b15c-50c56c2732e1_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs for new research plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9a3bb5c9-3cde-4f0c-8506-201d744c56ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_888e6703-ad2e-4c11-b3e5-73a0ea239640_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_446c64f6-656b-480c-b462-15c1de0a1f2f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_358b5bcd-8dce-48e3-a208-eb2ca9efc8c5_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_685cefda-af18-4a80-8cea-84c7e084233b_terseLabel_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72</link:label>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_label_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_documentation_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member" xlink:href="sgmo-20220331.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerC9ORF72Member" xlink:to="lab_sgmo_PfizerC9ORF72Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_94434aad-643b-4556-a5bb-a334e3ede55a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c2335192-7a5e-4e95-933f-028ad6af2865_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_53c46873-1afa-43c4-b2bb-39e2ef35f0c2_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of upfront fee</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_c1487ffe-7772-41be-a912-56f0e47e70d2_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Commercial Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_be232074-036e-4e83-8934-2beff4d988e7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ecfce608-c17d-4b9c-8a53-9c54b16380d4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_88aa38c4-94fe-4714-8319-7eb089b41ff2_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9c3278f8-2eaf-4370-9707-1324d1f42a7a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerMember_2b667490-2773-4212-924f-937bfa4e8ded_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:label id="lab_sgmo_PfizerMember_label_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_documentation_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember" xlink:href="sgmo-20220331.xsd#sgmo_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember" xlink:to="lab_sgmo_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_2bbceda3-68e6-46e0-8d57-cd387dc71a55_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities and free shares asset</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_0579c687-fe13-4f18-890f-a33780e01f6a_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ec3cff45-3d53-4307-8b01-78dc15a6cee9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c0671137-c261-4006-b47a-ac392caa25c1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_11fd45c9-37d9-4a97-be36-d84f625259fa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d9b0c016-8b4d-4221-84cf-7e7de95a7e71_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_50003e12-fc92-42aa-bb15-de584d2f782e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_fd9a085a-8f38-4cc7-8a78-ff77a5d9ab06_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingMember_f474d132-71d2-4c3a-bd49-346f016e57a9_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember" xlink:href="sgmo-20220331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingMember" xlink:to="lab_sgmo_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5dd6698a-acf6-4be1-aa02-64ada2c6ed3d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa517e9c-44b9-4d43-81ea-00d12ac5d8b9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_96e4f3e7-99ee-4781-bf30-64c25f8720d8_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_ad67aba1-6c54-476a-b49a-24d4fa38e807_terseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember" xlink:href="sgmo-20220331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember" xlink:to="lab_sgmo_CNineORFSevenTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_19e701b9-5b12-45a3-91fa-d592adde7908_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_21feae3a-a7a2-43b7-81a9-614708ef861c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_abccbcc0-85af-44b7-993c-6938c95a1249_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_589c79fc-1819-4db5-bc1e-d3850df41436_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7307e15c-16d1-4404-89e3-db37daf7b403_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_697aacee-959a-4e14-baef-d7e55f592423_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e428912a-0d16-43a2-86f1-52b32fb21b16_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_84b37b33-50b4-47a6-bc21-ddbb6b62dddb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_e3e7c66d-8fff-4c1f-95e4-334bd8a14050_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_b40f991b-4e03-409e-91c2-aedcfc236d81_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of contract asset recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_37c655dc-6bfc-41a2-9f6b-9078ddbe30d8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIC AND DILUTED NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b1c97ef-c473-48e0-9aa0-819e4a475db4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_fd80b31f-60d5-4f74-a571-89ad20c4fd8d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_679a8df6-1aac-4b82-ae44-19e9b9505187_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_033e4d59-34da-46e5-ae42-99ee6b76748a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_fac91f90-4439-4f4b-87b8-29d05f593788_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:to="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_80611d61-fbcd-4c9b-a5d6-7a33f20f902c_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8f58e33b-33bd-4b7e-9f4c-48533cc4975c_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development - and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments To Be Received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development and sales based milestone payments to be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:href="sgmo-20220331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_064b983d-f7ff-47ff-a9fa-2e3312f927fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of additional Sangamo France shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_058d18c6-fb4a-42f2-b2e1-f8b833586c34_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_c163c1ef-8f43-456d-a9e3-da79b410c28f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to marketable securities, not previously recorded</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_93b9f1c0-5d78-4f0f-b89f-70047984c008_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d0aaa3e-a526-4a94-8e2c-c99006192642_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e420cd83-6919-4b77-b6ae-fad25d03b4a5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_5119a2be-562b-4790-ab44-eedf6fc012c2_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_1d625aeb-e02f-4905-9a46-2e00a1851ad9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42462f20-7763-4154-8485-fd3d003cc417_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_093d6510-fb72-4408-9514-1fa45adb01de_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b7c568a-d131-4a4a-9352-cf13d09b91a3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9ed08519-12d5-4aef-8a46-f94795649931_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f645ec1c-a78e-4f9a-a54c-ceaf0cdbec3e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ff1111a7-66d4-4d1b-b356-57e713714f6a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_42f8115d-c29d-4957-8a0d-3de5be622c7d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_5a6f14ec-1341-4dbc-837b-a0ff80e1b7b7_terseLabel_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes for BioMedical Research, Inc.</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_label_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc. [Member]</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_documentation_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:href="sgmo-20220331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_bd5e5c79-f830-4977-8e93-1a3ebbfa8758_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_6e2070d2-10cd-4f9c-b928-4120345128d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_68ceaa2c-c796-48b2-8cce-6aed780ba9f5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e950fecf-29a7-4532-b7ae-a2001a559c50_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with at-the-market offering, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3bff8650-fb67-40a8-b4ac-16a448e8ab15_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_452eaac2-c9c0-48e1-9f81-587907209539_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneTwoMember_eef34e5e-1504-4834-affc-f4b5fd93a999_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone two</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_label_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneTwoMember" xlink:to="lab_sgmo_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_fd222c91-7624-4448-8fd3-2a7af707e765_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c7f3df6b-7a28-4ede-bc3c-703d3efebd3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f8d99d58-5836-452c-a512-2803df045b4f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0a62fc2a-cce8-4a8e-bf58-b29672b47d46_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_1fa99462-361a-48ea-b562-54d2fecc894f_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Long Term Portion Of Lease Liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in long-term portion of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:href="sgmo-20220331.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:to="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_3e856323-44f3-4ec2-bbd0-ea559640d842_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional product targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:to="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39ca4df9-5be0-4153-819d-bc1c9ca3cd19_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_87e0a5eb-a95e-4ef5-adfb-a9453ef10396_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_4509c7a1-f99d-4488-bbaf-f5e73de47fd9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6c20be9d-4048-4c3b-9f34-164d64d357d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_65432936-2c51-4af1-ad07-19b07f29f3da_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with at-the-market offering, net of offering expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7dca9ef6-5bcb-48b1-941a-a46eb5f39da2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_e12bc347-4c9c-4598-918b-b8b6066e621e_negatedLabel_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other changes in operating lease right-of-use assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_label_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_documentation_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:href="sgmo-20220331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:to="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_833ab35b-c3ee-445d-a6a0-89ffccf3ab43_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit established as a deposit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_64381535-198a-48cf-a7d2-04d554c3ee26_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_afa46601-d66d-48e6-8303-2e00cc7af892_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2b812659-596a-4403-b7c8-63a5a47910f5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0ee44f49-087f-4c50-ac01-1baca80e9f5f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1f696476-8069-4dd3-88e4-6c5721be0230_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_778f496b-d90b-41e7-ae69-c644765b321b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4f0d2a5d-8e0b-4f4c-a01d-d6265414c2f9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_ffd21940-f9ff-4db1-a6c3-53fda01058a6_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable" xlink:to="lab_sgmo_MilestoneRevenueReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d0a8a10d-92e0-4e56-8f68-d2d823c7ce4b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_d753c38d-94ab-490c-aafb-9881915b9a60_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial advisory fees</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:to="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AgreementTerminationTerm_3faba77d-69aa-438d-88de-a54f4ec5b63b_terseLabel_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_label_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_documentation_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm" xlink:href="sgmo-20220331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AgreementTerminationTerm" xlink:to="lab_sgmo_AgreementTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_7e138543-ced9-4120-a7c6-f0ab7c02ea8a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_764f8d17-068a-49b4-a901-0d74a71ee49a_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b956f654-4aef-43e4-9f63-2ceb87d1dea0_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a32f7ea3-3636-4f86-85db-8cdd6102e260_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_4b906ed6-cebd-4401-846a-dc4ff43472f9_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target selection period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:to="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_e5b7b30f-1292-47a8-91eb-425ead4770a2_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_69704919-40b4-4ae0-9abc-b776eac94045_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_99faf644-26a3-4713-81bf-4f9d2271b00d_terseLabel_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval milestone</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_label_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone [Member]</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember" xlink:href="sgmo-20220331.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PreApprovalMilestoneMember" xlink:to="lab_sgmo_PreApprovalMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_40da4c11-4ccb-47ce-894e-503a06f5bf41_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_462a037c-9bce-4cc2-890a-8802c937e11d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_02fd12a0-bba8-4005-ae2b-f7a403ad3895_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:to="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchServicesMember_1610754d-bfeb-4e8c-add2-caade5fa9b67_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_label_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services [Member]</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember" xlink:href="sgmo-20220331.xsd#sgmo_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesMember" xlink:to="lab_sgmo_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e5045085-51c3-4677-8453-21217edb2e73_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_d354dc94-ba0a-4aee-adef-3492652f2d73_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f33e685-9729-495a-9e4c-4d2fe50fe9f6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d1678ce-bf2f-407a-afa0-49a3c00e8ad9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d787ba0-02e0-4914-bb16-e877400ef915_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_22a00188-ee5c-42a3-80da-658d16cf8d2f_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering Agreement</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:href="sgmo-20220331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:to="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7de2c29a-e4dc-4452-94c1-a0bbdc2593cb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_3b214637-70e1-45e4-a46d-2e646d21f8a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_99a1e33a-53ef-41ef-862b-d3b56cc8b4da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_02c23a4d-c06f-4832-9624-94f3f598d703_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_4cd30096-57a2-4182-a25b-74cc2a3b4862_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8a0916ba-2293-47c3-b86b-da49389dd116_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2e34e250-d4bb-4aa4-84d9-36eaad13d472_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_238efe1d-c3f1-4052-8794-9a5acb5e6feb_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_eea8e691-3aa9-4379-a3dc-154812d3882e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_823137ff-cfec-43bc-b7c5-358372610caa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_382e418c-79b3-432d-8641-a88fc9938b28_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_25c029c4-12f5-4577-920b-aadd28ac6561_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_14c4c818-c6f8-4cda-b026-a5d629c264c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1d73e73a-0e08-4766-913e-c54e49625039_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c3e45011-8eab-4623-a6ae-75b7a08edcf9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_06837a0e-84b3-4865-b95e-ee5bb4b10a27_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_cc894880-04ca-43ea-9c50-5e51eb9524d0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f8aa6472-eecd-4a29-8d2c-88b2f4608ba6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2e862c48-a140-4754-842b-a849d93775ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_133e5e6b-621b-4e95-81b5-e2778aa4a527_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_049eb664-ab36-408b-a158-057c4f101897_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of product targets replaced</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:to="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9805e36c-d06c-42ea-a2c5-4bb3291a7a66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_12e1a7f8-4838-4df3-b17b-1459e9cd1d7a_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7c157e0f-23b8-4dd0-b2da-44e46fcfd226_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_10a9b3dd-4c0c-45ea-b349-e510fa6dcabb_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research service fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:to="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_290c6bbb-65bd-4a2d-8e76-640f360e321c_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of achieved milestones to receive payment</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Receive Payment</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:href="sgmo-20220331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c84ed612-f014-4ce9-8b26-9e839b03d16f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized portion of equity issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_d87fe458-5633-473d-b0ca-459ee516d31c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_7b972fde-93ae-43c9-a87b-d71ef76afd72_terseLabel_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_label_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone [Member]</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember" xlink:href="sgmo-20220331.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SalesBasedMilestoneMember" xlink:to="lab_sgmo_SalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_77ae20da-f55f-4271-b54e-0d394390fed2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d6cc45d1-c8c4-41c5-8530-e6d7def7173f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_285b8069-ec3a-45dd-9551-b397e9d42c9f_terseLabel_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock offering program, maximum value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_label_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_documentation_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue" xlink:href="sgmo-20220331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockOfferingProgramMaximumValue" xlink:to="lab_sgmo_StockOfferingProgramMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_caac5614-a043-48be-bfc5-b529e9d4d79a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_29017cd3-1b4b-4a95-beb5-d7ca704bc685_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived" xlink:href="sgmo-20220331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived" xlink:to="lab_sgmo_MilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_4c1cf521-2e21-425e-b1a1-e4b5bee79b08_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_733f125f-3401-4d23-82b0-0f20716acc77_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e98e3919-78aa-450f-8c8a-e5661f36190e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_92d1d24e-d217-43dd-abac-fcc7639ba0b6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2f3ea0cc-49ee-41b2-ac89-35d2ad24ae54_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_06d6370e-c9df-4b32-82a7-ab6b457e933f_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:href="sgmo-20220331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b26ee03a-b9ae-4dce-a5ec-0e9956738351_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d385fe4-fafb-4c04-8f87-ab648378f746_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_496c86cf-8357-49fb-879a-7e3fe385eeb1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_f335abf7-fa71-4454-a4a8-cf4443cb81fe_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, equity issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementEquityIssued" xlink:to="lab_sgmo_CollaborationAgreementEquityIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8120cecd-e4ab-42fb-a7cc-f3d90e6b6c0c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0f21f7f9-05e0-48c2-bbb8-bc83f432b5f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4266aa37-6825-45fd-9734-a1b4e6a447a4_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_b047464b-530a-43df-9ea7-493c4d1c142f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e4b0da50-d90c-4ea8-b571-82f098311b7d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_622dadca-575b-4669-857f-bfdc34a2dd78_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_862efe0a-b682-4226-bdba-f1a2cd83cdfc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c3b0284-a571-4e8a-b8d7-8ac52d4b7922_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6c84eb5f-8226-4ca6-8cb7-eca1754c5149_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_65600399-97a7-4f37-b049-f183b2952ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6c19dc40-0e28-4c54-880a-f6cb1795a590_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_104b05ab-ba44-4fcf-840d-fd39f79ca994_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7aac491-a7e5-4681-bd7f-887fb0ae3570_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ddfd3242-8191-483e-b2cb-673547a92b8b_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_33c7fe7e-2fad-49ff-99f6-715f8ee38635_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development And regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Clinical Development and Regulatory Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_32d46314-9d07-4664-98e9-ecd936ee1858_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb5eea9f-bee2-4039-8e0d-eb833b5d83fc_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_c49e91fe-ffb1-4055-8f06-d033ba7ad8f4_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_f9e4425a-253d-48f7-b737-32ab9aecea8e_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess consideration received on transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:href="sgmo-20220331.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:to="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_b47419cd-6932-481e-884c-38d934aff14a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_71ddfba3-a99e-4ebd-a12e-20eade40bc45_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b2c1add3-4a45-4a32-b5eb-3a9c43d9e804_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_1d1f468a-e7af-48d3-87c5-d69dbfd61436_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_685967b0-fa29-4a3b-9f89-a95387f3ced3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a4056642-6464-43ef-b194-6f875f85acf1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0a244af6-b6fe-434d-aeaa-853cd7c63cd8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BiogenMAIncMember_e71d7e57-2977-42e0-ad4d-eb0f9c5d6363_terseLabel_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_label_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc. [Member]</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_documentation_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember" xlink:href="sgmo-20220331.xsd#sgmo_BiogenMAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BiogenMAIncMember" xlink:to="lab_sgmo_BiogenMAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0b2c1b8f-00d8-43d9-8e0d-23af4fbbfa2d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be6ce214-178a-42c7-9e70-ff2862a258d9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_75a2932e-5b34-40ad-a361-2e39fa6e1201_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SeparateUpfrontFee_a0b709d8-4615-4c45-8149-532621b07ffb_terseLabel_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_label_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Upfront Fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_documentation_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee" xlink:href="sgmo-20220331.xsd#sgmo_SeparateUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SeparateUpfrontFee" xlink:to="lab_sgmo_SeparateUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_538d0558-f3c0-41df-921a-88b2114869ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized under Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2b60afff-54f2-4bb1-8fb7-9fe0e7951e44_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_0d9cc1e1-8cf0-4581-80c6-896549a6a59b_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="sgmo-20220331.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7eabb805-5ec1-4f59-8f9f-daf0150ec880_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d1eb50ba-612d-4225-8367-a4742857cb61_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_af167304-dd6b-4a37-ae26-046ebadd923d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneAchievementMember_17a74e48-58d7-4bc6-b6fb-3c3baf283c09_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_label_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneAchievementMember" xlink:to="lab_sgmo_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5cb23f0d-1de4-42a5-af6b-42d7ca4e2906_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1c047c6c-97a8-4a78-8672-ff72d09d629f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GainLossOnFreeShares_e761f005-730b-4224-bb0e-2c83c4017295_negatedLabel_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on free shares</link:label>
    <link:label id="lab_sgmo_GainLossOnFreeShares_label_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Free Shares</link:label>
    <link:label id="lab_sgmo_GainLossOnFreeShares_documentation_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on free shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares" xlink:href="sgmo-20220331.xsd#sgmo_GainLossOnFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GainLossOnFreeShares" xlink:to="lab_sgmo_GainLossOnFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_25f3a45d-c611-4c81-9c8c-9b44e92771f8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9cb2852f-686b-4fdc-ada4-7b4cda2374b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents_71d791d7-f039-4382-a8e6-21747b16b60a_totalLabel_en-US" xlink:label="lab_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents_label_en-US" xlink:label="lab_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Including US Government-Sponsored Enterprises Classified as Cash and Cash Equivalents</link:label>
    <link:label id="lab_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Including US Government-Sponsored Enterprises Classified as Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" xlink:href="sgmo-20220331.xsd#sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" xlink:to="lab_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41f1c240-579e-4621-88bd-0ebf1c3349ec_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_9a5f5ffb-5301-44f7-9e63-14d04170eb83_terseLabel_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended research term of agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:href="sgmo-20220331.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:to="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9ca57658-ca0b-4674-9e94-9e9e7918d3f9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ec53150e-76ac-45fb-85ac-e5840b18c3a3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_7af30b39-5df0-4a1b-9aed-33182e391c9b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_0d9d968a-7962-42fe-8aff-d4d1997ee2c4_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend initial research term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_label_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_documentation_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:to="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_d6c2bc06-3968-4ebc-ac3f-559c0ddc6c3f_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Sales Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_ed3c4822-72ab-44ef-9d85-9aa7abf9f0b2_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of initial recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:to="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_def44eec-1932-4117-a3f9-7f69f881f36a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sgmo-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3c33364c-6fd7-4e66-b5dc-1ec40b4f7ba5,g:db557487-1255-4119-bfcf-47c79d663408-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_97008a1a-edc2-427c-983b-925c0e32eaf0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_DocumentType_97008a1a-edc2-427c-983b-925c0e32eaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4c56df00-e049-479e-aabf-987c521b1624" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_DocumentQuarterlyReport_4c56df00-e049-479e-aabf-987c521b1624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_135caad7-acab-4427-85a3-f239058b8367" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_DocumentPeriodEndDate_135caad7-acab-4427-85a3-f239058b8367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a20b3393-770d-4cc3-89c5-8ab097c99589" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_DocumentTransitionReport_a20b3393-770d-4cc3-89c5-8ab097c99589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_dff2fab5-50d4-44d5-983c-689e769dd03b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityFileNumber_dff2fab5-50d4-44d5-983c-689e769dd03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2652e9ec-651d-476a-88b6-fd35d0928666" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityRegistrantName_2652e9ec-651d-476a-88b6-fd35d0928666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3620f90b-2997-4218-b1a1-7b90439596fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3620f90b-2997-4218-b1a1-7b90439596fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8e9b385a-ced0-420f-b753-c8b79a69e190" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityTaxIdentificationNumber_8e9b385a-ced0-420f-b753-c8b79a69e190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_629b075d-079b-42a1-bae8-dfe7cd33a686" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityAddressAddressLine1_629b075d-079b-42a1-bae8-dfe7cd33a686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_42a9ac3f-b5d7-4093-8569-d62dbcaefe33" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityAddressCityOrTown_42a9ac3f-b5d7-4093-8569-d62dbcaefe33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_db7217c6-e9ae-4141-9e38-0ea8ce860eee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityAddressStateOrProvince_db7217c6-e9ae-4141-9e38-0ea8ce860eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_568b3024-df3b-4b7b-9248-d03ba741322a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityAddressPostalZipCode_568b3024-df3b-4b7b-9248-d03ba741322a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_11eee938-3e4a-49bb-811b-8a57d24a2bd9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_CityAreaCode_11eee938-3e4a-49bb-811b-8a57d24a2bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ab5d8723-747c-472e-9c8a-ac5d41f2cfc5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_LocalPhoneNumber_ab5d8723-747c-472e-9c8a-ac5d41f2cfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1d194bce-cce9-47a5-b5e2-696dab0bfac6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_Security12bTitle_1d194bce-cce9-47a5-b5e2-696dab0bfac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d2925e5c-7dad-4058-a579-97a70c0ff632" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_TradingSymbol_d2925e5c-7dad-4058-a579-97a70c0ff632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ec4237ae-e6cc-476a-96b7-c3c0d779034d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_SecurityExchangeName_ec4237ae-e6cc-476a-96b7-c3c0d779034d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5ec8d0df-97f5-40ca-8a10-04ebcc565992" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityCurrentReportingStatus_5ec8d0df-97f5-40ca-8a10-04ebcc565992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_41ac2359-bc54-4c0c-bd45-7bcbbd232c8c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityInteractiveDataCurrent_41ac2359-bc54-4c0c-bd45-7bcbbd232c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e1541bc6-9845-44b7-a46a-9c541abc35f8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityFilerCategory_e1541bc6-9845-44b7-a46a-9c541abc35f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0ef9ce24-7530-450b-8816-7d895f9868c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntitySmallBusiness_0ef9ce24-7530-450b-8816-7d895f9868c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f72d571a-5c5e-459c-9850-c663f4ddea66" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityEmergingGrowthCompany_f72d571a-5c5e-459c-9850-c663f4ddea66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8345ba9f-c1ed-4316-873c-d189f9ca67ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityShellCompany_8345ba9f-c1ed-4316-873c-d189f9ca67ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5b539dba-5acc-44ff-91b1-4afdcd694e95" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5b539dba-5acc-44ff-91b1-4afdcd694e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_828c84f7-349a-4122-8744-9367b7108dca" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_AmendmentFlag_828c84f7-349a-4122-8744-9367b7108dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_33bebed1-436b-4874-9bd1-a3e0b091d48c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_DocumentFiscalYearFocus_33bebed1-436b-4874-9bd1-a3e0b091d48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f520ccb5-15df-4a7c-9fe7-d5a93c5f3230" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f520ccb5-15df-4a7c-9fe7-d5a93c5f3230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_09c1e23b-3c48-47b4-b498-eff9635b6612" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_EntityCentralIndexKey_09c1e23b-3c48-47b4-b498-eff9635b6612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3065bae6-6293-432f-a853-c5525dfa9238" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85bd995a-db95-4770-930f-a0b1bc2a52b1" xlink:to="loc_dei_CurrentFiscalYearEndDate_3065bae6-6293-432f-a853-c5525dfa9238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_12d6acf7-4a27-4ecf-9553-1c1f9ebb9970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12d6acf7-4a27-4ecf-9553-1c1f9ebb9970" xlink:to="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c6f0019d-3b4b-4296-9449-0898c58bf218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c6f0019d-3b4b-4296-9449-0898c58bf218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_855d374e-0283-414f-b1b6-bb929fe57556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c6f0019d-3b4b-4296-9449-0898c58bf218" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_855d374e-0283-414f-b1b6-bb929fe57556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_05c229b5-1512-4429-97b9-f6168861ecdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c6f0019d-3b4b-4296-9449-0898c58bf218" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_05c229b5-1512-4429-97b9-f6168861ecdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_b6c05a0b-334d-4448-89ba-bbf00684e67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c6f0019d-3b4b-4296-9449-0898c58bf218" xlink:to="loc_us-gaap_InterestReceivableCurrent_b6c05a0b-334d-4448-89ba-bbf00684e67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_28ee0362-0f3f-4740-86af-e9eff34f2d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c6f0019d-3b4b-4296-9449-0898c58bf218" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_28ee0362-0f3f-4740-86af-e9eff34f2d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fcd272e-dacb-43a4-9fc9-d35d4b32ce44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c6f0019d-3b4b-4296-9449-0898c58bf218" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fcd272e-dacb-43a4-9fc9-d35d4b32ce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b9d24b75-1d87-4592-8f92-a4511379f024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c6f0019d-3b4b-4296-9449-0898c58bf218" xlink:to="loc_us-gaap_AssetsCurrent_b9d24b75-1d87-4592-8f92-a4511379f024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8f979864-287d-458e-ae39-0245dd0b3bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8f979864-287d-458e-ae39-0245dd0b3bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7d9493c1-e67e-4e05-bf47-6327ae962754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7d9493c1-e67e-4e05-bf47-6327ae962754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_50fece4a-0a4a-4d57-bfd8-dcd078d75f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_50fece4a-0a4a-4d57-bfd8-dcd078d75f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a7281896-5e18-44cf-807a-102da998689d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:to="loc_us-gaap_Goodwill_a7281896-5e18-44cf-807a-102da998689d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_75e9e4e4-66f0-4ec7-b6ec-7b52d3ead07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_75e9e4e4-66f0-4ec7-b6ec-7b52d3ead07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6cf4c41c-eb4d-4fdd-bf58-101beb0d1f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6cf4c41c-eb4d-4fdd-bf58-101beb0d1f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3512ac27-3a98-4c8a-ae14-f82c1c081de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3512ac27-3a98-4c8a-ae14-f82c1c081de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dfe49e06-76ff-4f65-baae-341ea8e401d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_497e8610-7a5f-4ead-a9c3-cbaea78750f4" xlink:to="loc_us-gaap_Assets_dfe49e06-76ff-4f65-baae-341ea8e401d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12d6acf7-4a27-4ecf-9553-1c1f9ebb9970" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bd449ec5-0547-4312-83d8-c29098cd9ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bd449ec5-0547-4312-83d8-c29098cd9ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a7209e69-4da2-4120-b3d6-878487985aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bd449ec5-0547-4312-83d8-c29098cd9ebc" xlink:to="loc_us-gaap_AccountsPayableCurrent_a7209e69-4da2-4120-b3d6-878487985aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8f5ab3a0-16de-4125-a182-036b6a58b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bd449ec5-0547-4312-83d8-c29098cd9ebc" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8f5ab3a0-16de-4125-a182-036b6a58b3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5ed91a54-c4ef-4085-b112-d55a76d21862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bd449ec5-0547-4312-83d8-c29098cd9ebc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5ed91a54-c4ef-4085-b112-d55a76d21862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bea5ea33-8a45-4c08-8643-4bf176c8eb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bd449ec5-0547-4312-83d8-c29098cd9ebc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bea5ea33-8a45-4c08-8643-4bf176c8eb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_445d8582-ef83-4a3f-9793-c9c6a4411cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bd449ec5-0547-4312-83d8-c29098cd9ebc" xlink:to="loc_us-gaap_LiabilitiesCurrent_445d8582-ef83-4a3f-9793-c9c6a4411cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c105a89b-f232-4160-9f2b-fc0854485a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c105a89b-f232-4160-9f2b-fc0854485a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_50d51d36-eadc-4cb4-989b-4ce5cc677863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_50d51d36-eadc-4cb4-989b-4ce5cc677863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_800f8280-7a4d-44df-b09b-3b9f0924c89a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_800f8280-7a4d-44df-b09b-3b9f0924c89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c8e279fe-f715-4f59-951b-0f91909f04d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c8e279fe-f715-4f59-951b-0f91909f04d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0a56405b-6e2e-4ec1-bcff-8b68c3540839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:to="loc_us-gaap_Liabilities_0a56405b-6e2e-4ec1-bcff-8b68c3540839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_42cfef96-7acf-434c-915e-02e39ad1bb95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:to="loc_us-gaap_CommitmentsAndContingencies_42cfef96-7acf-434c-915e-02e39ad1bb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_17c9d581-5913-44c6-bbfd-280da9278f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_17c9d581-5913-44c6-bbfd-280da9278f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_348a75e4-424c-45b1-b13b-a389669488a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_17c9d581-5913-44c6-bbfd-280da9278f8a" xlink:to="loc_us-gaap_PreferredStockValue_348a75e4-424c-45b1-b13b-a389669488a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0387589e-aee9-4e33-accc-f6228f70ad2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_17c9d581-5913-44c6-bbfd-280da9278f8a" xlink:to="loc_us-gaap_CommonStockValue_0387589e-aee9-4e33-accc-f6228f70ad2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_80798167-55d4-4158-b49e-55eaa4ff5e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_17c9d581-5913-44c6-bbfd-280da9278f8a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_80798167-55d4-4158-b49e-55eaa4ff5e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99bf60c3-21a1-41a4-99a6-05374c476e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_17c9d581-5913-44c6-bbfd-280da9278f8a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99bf60c3-21a1-41a4-99a6-05374c476e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_14da6f64-1c2b-47eb-b45f-f127ff7a04c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_17c9d581-5913-44c6-bbfd-280da9278f8a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_14da6f64-1c2b-47eb-b45f-f127ff7a04c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_03efcbe0-ea40-4fd0-a7e1-783e19250248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_17c9d581-5913-44c6-bbfd-280da9278f8a" xlink:to="loc_us-gaap_StockholdersEquity_03efcbe0-ea40-4fd0-a7e1-783e19250248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_62f08268-ffb0-401c-8c73-4da6addcb8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a851c18a-b38f-48fd-a681-44e0dc23a6ab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_62f08268-ffb0-401c-8c73-4da6addcb8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_67f86eda-79d5-4cc5-99f6-dc7b07847022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_67f86eda-79d5-4cc5-99f6-dc7b07847022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2fcc07fe-00e4-48bf-816a-755715b00d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2fcc07fe-00e4-48bf-816a-755715b00d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1c30e6b1-1e37-4565-90a4-b583840a5988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2fcc07fe-00e4-48bf-816a-755715b00d46" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1c30e6b1-1e37-4565-90a4-b583840a5988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ef445acc-9ca2-4ffc-8280-a88c2def0066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2fcc07fe-00e4-48bf-816a-755715b00d46" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ef445acc-9ca2-4ffc-8280-a88c2def0066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_726d3b22-d3d3-49e9-89c9-22382a453edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2fcc07fe-00e4-48bf-816a-755715b00d46" xlink:to="loc_us-gaap_OperatingExpenses_726d3b22-d3d3-49e9-89c9-22382a453edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73140145-cc13-446c-9eeb-f7eba10e36a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_OperatingIncomeLoss_73140145-cc13-446c-9eeb-f7eba10e36a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_edca54f5-5d51-4c9b-9bf2-84f23627c10e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_InterestAndOtherIncome_edca54f5-5d51-4c9b-9bf2-84f23627c10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_edd73f0e-a835-41a9-8f04-c9139cfa8ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_edd73f0e-a835-41a9-8f04-c9139cfa8ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d63278fb-59a4-419d-8865-d677ef1e8004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d63278fb-59a4-419d-8865-d677ef1e8004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9c04453f-efed-42f2-bc74-ae1a2e156cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_ProfitLoss_9c04453f-efed-42f2-bc74-ae1a2e156cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_973c59c6-85ab-4745-9a87-811bc9e3677e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_973c59c6-85ab-4745-9a87-811bc9e3677e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e3361c8c-06c2-41de-91d6-009f598b8278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_NetIncomeLoss_e3361c8c-06c2-41de-91d6-009f598b8278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9baea28c-10fd-4fe0-af03-2904ada7d9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_EarningsPerShareBasic_9baea28c-10fd-4fe0-af03-2904ada7d9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_80c67066-21a0-4530-b4d8-2286c5fe6132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_EarningsPerShareDiluted_80c67066-21a0-4530-b4d8-2286c5fe6132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_58288754-b76c-4a54-9a64-bb6c99c111cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_58288754-b76c-4a54-9a64-bb6c99c111cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e3a0e392-2083-4690-9056-08bcac1d8f65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e3452295-de97-4af7-a98d-0147d4979489" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e3a0e392-2083-4690-9056-08bcac1d8f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7471cc82-67fe-46f8-bbb0-5c949dbd7c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_28f3d934-89cc-4c8b-8163-190dc7c38fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7471cc82-67fe-46f8-bbb0-5c949dbd7c9d" xlink:to="loc_us-gaap_ProfitLoss_28f3d934-89cc-4c8b-8163-190dc7c38fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7a3fe810-0e35-4658-926e-96637cd1a79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7471cc82-67fe-46f8-bbb0-5c949dbd7c9d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7a3fe810-0e35-4658-926e-96637cd1a79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_307040fa-f29c-47e0-ade6-132ca9dd4fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7471cc82-67fe-46f8-bbb0-5c949dbd7c9d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_307040fa-f29c-47e0-ade6-132ca9dd4fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_67e3f366-f4f7-47d9-9460-3a2f7c5a7152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7471cc82-67fe-46f8-bbb0-5c949dbd7c9d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_67e3f366-f4f7-47d9-9460-3a2f7c5a7152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_39515aa4-e0e3-4dbe-a850-1e1443fd4409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7471cc82-67fe-46f8-bbb0-5c949dbd7c9d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_39515aa4-e0e3-4dbe-a850-1e1443fd4409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e39ca67b-6d16-47ff-8fc2-c1d788ddbca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7471cc82-67fe-46f8-bbb0-5c949dbd7c9d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e39ca67b-6d16-47ff-8fc2-c1d788ddbca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_44401c12-8517-46d3-ad58-05b6ce3717a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7471cc82-67fe-46f8-bbb0-5c949dbd7c9d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_44401c12-8517-46d3-ad58-05b6ce3717a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_26744aa7-0d7a-4710-9b87-079dc811a860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_afd0a143-8309-4d07-8337-a666dd6e0528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_26744aa7-0d7a-4710-9b87-079dc811a860" xlink:to="loc_us-gaap_StatementTable_afd0a143-8309-4d07-8337-a666dd6e0528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_865e4dc3-7ee7-4f65-9370-20df96610802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_afd0a143-8309-4d07-8337-a666dd6e0528" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_865e4dc3-7ee7-4f65-9370-20df96610802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_865e4dc3-7ee7-4f65-9370-20df96610802" xlink:to="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7257d0cb-94eb-45a6-9c98-569318bff9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_CommonStockMember_7257d0cb-94eb-45a6-9c98-569318bff9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_df56fc8a-6662-49fb-8054-5ca658e0413f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_df56fc8a-6662-49fb-8054-5ca658e0413f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ac7d587b-19a2-4515-ba6c-b96b84bd835b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_RetainedEarningsMember_ac7d587b-19a2-4515-ba6c-b96b84bd835b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_70864143-5e42-4053-8583-69ecf0ed034c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_70864143-5e42-4053-8583-69ecf0ed034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_abe586bd-0850-414e-b957-ad765dc96d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dcc67d31-0853-4953-aff1-7802dc8d632b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_abe586bd-0850-414e-b957-ad765dc96d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_505d4461-5b9b-4fda-af8d-9f8fa4fe817e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_afd0a143-8309-4d07-8337-a666dd6e0528" xlink:to="loc_us-gaap_StatementLineItems_505d4461-5b9b-4fda-af8d-9f8fa4fe817e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_505d4461-5b9b-4fda-af8d-9f8fa4fe817e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c8de5aac-1ce9-4b7a-8c4e-d885ed898d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_CommonStockSharesIssued_c8de5aac-1ce9-4b7a-8c4e-d885ed898d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58866727-2dca-494f-a04d-16f5d7b297d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58866727-2dca-494f-a04d-16f5d7b297d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_929c96d4-4b97-4159-9d87-c98897b1cc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_929c96d4-4b97-4159-9d87-c98897b1cc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e76e71d2-9693-4056-b7a3-748d3a6883a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e76e71d2-9693-4056-b7a3-748d3a6883a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_042e59af-0700-489d-a411-6fa0df6cffd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_042e59af-0700-489d-a411-6fa0df6cffd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5a5078da-48fd-4f87-ba0d-62fcf5bfdfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5a5078da-48fd-4f87-ba0d-62fcf5bfdfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e9d7b185-2dc5-44e6-ac07-fdf10ae7f17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e9d7b185-2dc5-44e6-ac07-fdf10ae7f17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_f78afae6-ddf6-40cd-a846-7b9eb37b11c3" xlink:href="sgmo-20220331.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_f78afae6-ddf6-40cd-a846-7b9eb37b11c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3ce14933-fc31-4254-abd6-c849da0b4623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3ce14933-fc31-4254-abd6-c849da0b4623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_ffcfff79-c04c-4642-bc49-b4829601ac82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_ffcfff79-c04c-4642-bc49-b4829601ac82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bc85b16e-9220-4077-a4ce-5e988804a3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bc85b16e-9220-4077-a4ce-5e988804a3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_063b6289-8a23-46cf-93d0-0719c62706a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_ProfitLoss_063b6289-8a23-46cf-93d0-0719c62706a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_41b3d93f-08aa-4120-9c91-48493f965978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_CommonStockSharesIssued_41b3d93f-08aa-4120-9c91-48493f965978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bf728eb4-8476-49b2-aa70-cd0ea20c9746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95b6174b-a1aa-4e40-bd05-286d85558993" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bf728eb4-8476-49b2-aa70-cd0ea20c9746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ca8c6ba5-bea3-44c5-bf09-e62f8f0c872a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d292c72d-ce73-4e07-9c3d-03475648cca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ca8c6ba5-bea3-44c5-bf09-e62f8f0c872a" xlink:to="loc_us-gaap_StatementTable_d292c72d-ce73-4e07-9c3d-03475648cca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fae73f4e-f9c2-4abd-824a-bfa2d7619d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d292c72d-ce73-4e07-9c3d-03475648cca4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fae73f4e-f9c2-4abd-824a-bfa2d7619d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58aab6c-9af5-4d0d-88f7-072d6aae8c78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fae73f4e-f9c2-4abd-824a-bfa2d7619d06" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58aab6c-9af5-4d0d-88f7-072d6aae8c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember_20e5923b-5a43-4d0d-998c-3e7e62959137" xlink:href="sgmo-20220331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58aab6c-9af5-4d0d-88f7-072d6aae8c78" xlink:to="loc_sgmo_AtTheMarketOfferingMember_20e5923b-5a43-4d0d-998c-3e7e62959137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d292c72d-ce73-4e07-9c3d-03475648cca4" xlink:to="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a167e8d1-2d9d-42fe-997b-bb37ffca2233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:to="loc_us-gaap_ProfitLoss_a167e8d1-2d9d-42fe-997b-bb37ffca2233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_53967e62-1d1e-49b2-b3e3-7f35edaeed89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_53967e62-1d1e-49b2-b3e3-7f35edaeed89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3c328f89-7220-4dcc-a5de-7d4d6bd43c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3c328f89-7220-4dcc-a5de-7d4d6bd43c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_e1702dae-b301-4bb8-86dd-4f4410a5805d" xlink:href="sgmo-20220331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_e1702dae-b301-4bb8-86dd-4f4410a5805d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares_e1e7ce74-2b94-4334-a329-91780029d013" xlink:href="sgmo-20220331.xsd#sgmo_GainLossOnFreeShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_sgmo_GainLossOnFreeShares_e1e7ce74-2b94-4334-a329-91780029d013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2ef6029b-5e95-4f03-9816-9d4c572eefea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c79e61ee-8c37-4a2a-a76a-f272ca89f15b" xlink:to="loc_us-gaap_ShareBasedCompensation_2ef6029b-5e95-4f03-9816-9d4c572eefea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0104df09-d16b-4190-8a87-abb7a17f6440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0104df09-d16b-4190-8a87-abb7a17f6440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99845359-1185-4e79-bfc4-7229eb54df9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99845359-1185-4e79-bfc4-7229eb54df9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_60f1059a-a630-43c9-af6d-d0f86a37bc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_60f1059a-a630-43c9-af6d-d0f86a37bc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f8b7762d-636c-406f-81b2-fa7454331ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f8b7762d-636c-406f-81b2-fa7454331ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a16b7424-f188-48ee-bea4-88c1aef277c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a16b7424-f188-48ee-bea4-88c1aef277c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_fb1cbfd4-f175-40be-90f6-c1b61ea6f5cf" xlink:href="sgmo-20220331.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_fb1cbfd4-f175-40be-90f6-c1b61ea6f5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_430576e7-d1e8-4e12-b1f1-c7d90c88001d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9eb0a86b-20dd-4a01-9a77-c7f42c76ae8f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_430576e7-d1e8-4e12-b1f1-c7d90c88001d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4585099c-e03c-4ae3-b0ba-f96b943ce06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_461d962a-bbfb-4785-93d2-488c1397421e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4585099c-e03c-4ae3-b0ba-f96b943ce06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5349e6a2-d80d-4c83-b18e-98de7d8c07dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5349e6a2-d80d-4c83-b18e-98de7d8c07dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_165164be-8eda-40bd-93a0-745b128f24f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_165164be-8eda-40bd-93a0-745b128f24f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_c4cdc2ed-e255-44ed-ae8a-d9e3e24ed0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_c4cdc2ed-e255-44ed-ae8a-d9e3e24ed0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e83f62e8-2293-4230-a6e4-59072a536e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e83f62e8-2293-4230-a6e4-59072a536e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_be4f40e1-4945-4947-acae-9a43417cc042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_be4f40e1-4945-4947-acae-9a43417cc042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31332bb1-1fdd-463e-bab5-15c4f8de8cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bba1968e-83e6-4e88-9374-0baee1e131b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31332bb1-1fdd-463e-bab5-15c4f8de8cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4ca00623-c94d-4059-95ae-a05c1dc2d2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4ca00623-c94d-4059-95ae-a05c1dc2d2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6742746a-98f5-4c07-9fe8-2da6ceb6870b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6742746a-98f5-4c07-9fe8-2da6ceb6870b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ef6d9a81-5539-4090-b68e-531f47ce8d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ef6d9a81-5539-4090-b68e-531f47ce8d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ccc0758c-b25a-43ea-8592-fa2cdac74e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dccf61c-0d96-4bf4-9127-571ebe65f710" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ccc0758c-b25a-43ea-8592-fa2cdac74e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f0cad3f-b078-44b9-8778-b301b05f3602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f0cad3f-b078-44b9-8778-b301b05f3602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e1f2cad-7354-4a04-b157-e3caff385af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e1f2cad-7354-4a04-b157-e3caff385af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4665ff75-6be3-4b13-b129-93a1002a8955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4665ff75-6be3-4b13-b129-93a1002a8955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c20579fb-e228-44ab-8307-aa2038ddfac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c20579fb-e228-44ab-8307-aa2038ddfac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_df9df217-4618-437c-8a90-e33b5b8e03b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5c8fe24-ebaf-4d0a-8151-7e230602bfb6" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_df9df217-4618-437c-8a90-e33b5b8e03b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2cdf080b-8c60-43ac-8860-0ab5d7fe2dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_df9df217-4618-437c-8a90-e33b5b8e03b5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2cdf080b-8c60-43ac-8860-0ab5d7fe2dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c9b08017-8ed8-4b28-94d4-7d4201ebdc22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_df9df217-4618-437c-8a90-e33b5b8e03b5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c9b08017-8ed8-4b28-94d4-7d4201ebdc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20220331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1be64e6c-2e69-4920-bc56-9e84c155a5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f3f5999d-6129-4606-bc83-ffe2dfd7a87c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1be64e6c-2e69-4920-bc56-9e84c155a5e4" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f3f5999d-6129-4606-bc83-ffe2dfd7a87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20220331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4ad1d474-0344-49a0-a9f1-2e06351d6adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_48e1951c-e422-4932-a053-66785a8348d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4ad1d474-0344-49a0-a9f1-2e06351d6adf" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_48e1951c-e422-4932-a053-66785a8348d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_69e6845e-8529-4ded-9c7e-513cf0d136b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4ad1d474-0344-49a0-a9f1-2e06351d6adf" xlink:to="loc_us-gaap_UseOfEstimates_69e6845e-8529-4ded-9c7e-513cf0d136b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_554cb138-464a-4549-a2f8-9aa9ab00f5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4ad1d474-0344-49a0-a9f1-2e06351d6adf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_554cb138-464a-4549-a2f8-9aa9ab00f5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_34f7855a-b6d2-4123-ba5d-7388a67a017a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4ad1d474-0344-49a0-a9f1-2e06351d6adf" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_34f7855a-b6d2-4123-ba5d-7388a67a017a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1d755e58-caf9-4bf2-9da9-d2dfa25bd19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4ad1d474-0344-49a0-a9f1-2e06351d6adf" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1d755e58-caf9-4bf2-9da9-d2dfa25bd19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c7261ea0-7b85-4f94-8bd9-0c62337a431e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4ad1d474-0344-49a0-a9f1-2e06351d6adf" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c7261ea0-7b85-4f94-8bd9-0c62337a431e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20220331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f52aadf9-5382-4a61-94f2-6a88b096497a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_8215a2df-6980-4090-a82e-4aa8d9e863a4" xlink:href="sgmo-20220331.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f52aadf9-5382-4a61-94f2-6a88b096497a" xlink:to="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_8215a2df-6980-4090-a82e-4aa8d9e863a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_fbac450b-c18f-43a1-9960-2b0830a897db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f52aadf9-5382-4a61-94f2-6a88b096497a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_fbac450b-c18f-43a1-9960-2b0830a897db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_331603f5-c28a-4300-81a4-34cf0c588ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f52aadf9-5382-4a61-94f2-6a88b096497a" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_331603f5-c28a-4300-81a4-34cf0c588ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4de8a66d-3c35-48e3-8718-12e7a77a82ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_3e4426bf-d2c5-461b-a81a-f37a07f4e8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4de8a66d-3c35-48e3-8718-12e7a77a82ab" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_3e4426bf-d2c5-461b-a81a-f37a07f4e8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf7a3bda-7601-4145-90da-a28597df4e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf7a3bda-7601-4145-90da-a28597df4e98" xlink:to="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_14531e40-225b-4f52-9f99-464ebec51fcc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:to="loc_srt_CounterpartyNameAxis_14531e40-225b-4f52-9f99-464ebec51fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_14531e40-225b-4f52-9f99-464ebec51fcc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_24c1e659-b16d-4f4d-9519-5e2430b5b0d9" xlink:href="sgmo-20220331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:to="loc_sgmo_BiogenMAIncMember_24c1e659-b16d-4f4d-9519-5e2430b5b0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_e0dbb7ce-e365-4e8d-8ecc-d94333d2ad05" xlink:href="sgmo-20220331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_e0dbb7ce-e365-4e8d-8ecc-d94333d2ad05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_0553be5a-72f7-481a-8eaf-a2e898f136e9" xlink:href="sgmo-20220331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:to="loc_sgmo_KitePharmaIncMember_0553be5a-72f7-481a-8eaf-a2e898f136e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_f5187113-3357-4e94-addd-039cfe089169" xlink:href="sgmo-20220331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b327f832-ed83-4dd5-a530-b5f96dd17b18" xlink:to="loc_sgmo_SanofiMember_f5187113-3357-4e94-addd-039cfe089169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b47e3a1-ffdc-4f4c-8e5d-3c0d91c09e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b47e3a1-ffdc-4f4c-8e5d-3c0d91c09e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9cf7781-1fc6-4dd6-afd9-40a541248250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b47e3a1-ffdc-4f4c-8e5d-3c0d91c09e33" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9cf7781-1fc6-4dd6-afd9-40a541248250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_99d1d8ce-c3db-4687-ba50-3d1c75aa2c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f9cf7781-1fc6-4dd6-afd9-40a541248250" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_99d1d8ce-c3db-4687-ba50-3d1c75aa2c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_87380192-a758-450f-8243-9c2e38ccc2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_87380192-a758-450f-8243-9c2e38ccc2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e8305520-0c6c-4c26-9535-4b608289c593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_87380192-a758-450f-8243-9c2e38ccc2e5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e8305520-0c6c-4c26-9535-4b608289c593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_4960f59a-e2dc-4b54-aa39-b32a67dde81c" xlink:href="sgmo-20220331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e8305520-0c6c-4c26-9535-4b608289c593" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_4960f59a-e2dc-4b54-aa39-b32a67dde81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9b00c8e3-9213-40df-8fdf-0ad93902deec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8056a410-6888-4643-9087-8b7e2a4ee1ec" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_9b00c8e3-9213-40df-8fdf-0ad93902deec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_eb7037f5-89eb-49b9-8c26-9de4d9c78f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9b00c8e3-9213-40df-8fdf-0ad93902deec" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_eb7037f5-89eb-49b9-8c26-9de4d9c78f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b20563f4-0a7b-4a5f-a5b8-8c791bb3444d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b357982-9fd1-4edb-86b9-a9a1a665abcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b20563f4-0a7b-4a5f-a5b8-8c791bb3444d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b357982-9fd1-4edb-86b9-a9a1a665abcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e6c79a7c-0715-4f5f-8c29-8ff1671f8720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b20563f4-0a7b-4a5f-a5b8-8c791bb3444d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e6c79a7c-0715-4f5f-8c29-8ff1671f8720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5131992-081a-4ad1-bbce-93672ba81047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b20563f4-0a7b-4a5f-a5b8-8c791bb3444d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5131992-081a-4ad1-bbce-93672ba81047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20220331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9883def2-459c-446c-9e4e-a051f10209d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4ecb9216-f688-469a-b306-52d2b3da4b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9883def2-459c-446c-9e4e-a051f10209d5" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4ecb9216-f688-469a-b306-52d2b3da4b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20220331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3ecd1b61-e835-4df9-96f1-c2919c5f88cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c4bec646-a780-4832-968f-07eeb78cb45f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3ecd1b61-e835-4df9-96f1-c2919c5f88cd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c4bec646-a780-4832-968f-07eeb78cb45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#FAIRVALUEMEASUREMENTSDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f0c39b96-0142-4b80-be7a-db8fe7bb0f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0c39b96-0142-4b80-be7a-db8fe7bb0f4d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5bab9358-cd1d-4d2e-bc51-c6ea7fa80760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5bab9358-cd1d-4d2e-bc51-c6ea7fa80760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9bbdaca9-85ab-4225-9072-2096e06c26ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5bab9358-cd1d-4d2e-bc51-c6ea7fa80760" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9bbdaca9-85ab-4225-9072-2096e06c26ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_923adeb3-8576-43c1-aacf-5ac439190735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9bbdaca9-85ab-4225-9072-2096e06c26ee" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_923adeb3-8576-43c1-aacf-5ac439190735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de36bd39-3e14-4146-911c-4c5b4939942d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de36bd39-3e14-4146-911c-4c5b4939942d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de36bd39-3e14-4146-911c-4c5b4939942d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9ae0e319-418e-4e30-aa96-fc2e417081bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9ae0e319-418e-4e30-aa96-fc2e417081bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bd74ee4c-d5b5-4db9-9610-c7c6ff58c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bd74ee4c-d5b5-4db9-9610-c7c6ff58c64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_21c89bec-2a40-4c38-9329-71b4a733cdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9722324-b83e-457f-9051-c7cd618e6369" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_21c89bec-2a40-4c38-9329-71b4a733cdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_50e674cf-1a26-4ca5-9df6-f74ef6194c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:to="loc_us-gaap_FinancialInstrumentAxis_50e674cf-1a26-4ca5-9df6-f74ef6194c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_50e674cf-1a26-4ca5-9df6-f74ef6194c83" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4f725e7b-543c-4f06-b1cb-758e89e073ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4f725e7b-543c-4f06-b1cb-758e89e073ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_438495d6-8c83-4a82-9a1e-b42877678afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_438495d6-8c83-4a82-9a1e-b42877678afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b7dc750b-c49d-45a8-bd4e-c14bd0e2dc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_CommercialPaperMember_b7dc750b-c49d-45a8-bd4e-c14bd0e2dc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_49f323e6-2a99-49a7-a1d0-27b662ee3b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_49f323e6-2a99-49a7-a1d0-27b662ee3b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_f794cf72-6e1a-47ac-be08-2ba8cb4ed198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_f794cf72-6e1a-47ac-be08-2ba8cb4ed198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bb5b2b71-1a63-472a-974d-789a93ac9760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bb5b2b71-1a63-472a-974d-789a93ac9760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ca0192ce-b9cc-4d01-8b84-f92685c77013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_66d97279-5266-4eb2-8f93-25bce02a10a0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ca0192ce-b9cc-4d01-8b84-f92685c77013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b92c23e-b433-47ed-87fb-1ff10f619d48" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9309d430-da22-49ff-a840-67b375205ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9309d430-da22-49ff-a840-67b375205ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2fe1164f-6ca4-4828-acac-d387cf47504e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2fe1164f-6ca4-4828-acac-d387cf47504e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_17f19245-9911-46a0-ab54-5ec561719203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8a9815f-ec54-4f50-b627-96da36ba5e0a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_17f19245-9911-46a0-ab54-5ec561719203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9f249c76-2558-42de-8e5b-be2dcbf48ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9f3e0080-63ce-44e7-8850-c5d5ef660c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9f249c76-2558-42de-8e5b-be2dcbf48ed9" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9f3e0080-63ce-44e7-8850-c5d5ef660c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8dff0d83-6ed5-4843-8c52-e169aca28527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_80e4afd8-0ea1-45e9-a3f5-320e7f96d630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8dff0d83-6ed5-4843-8c52-e169aca28527" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_80e4afd8-0ea1-45e9-a3f5-320e7f96d630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_170c18fb-74c3-4083-8a0e-64a83b595cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8dff0d83-6ed5-4843-8c52-e169aca28527" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_170c18fb-74c3-4083-8a0e-64a83b595cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e307a86c-fcd0-4960-b51a-322cf894cd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f50e184d-8ca1-4c08-8586-c075b9fcb114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e307a86c-fcd0-4960-b51a-322cf894cd01" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f50e184d-8ca1-4c08-8586-c075b9fcb114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a417704a-534f-4de0-8644-8cfa39cfb340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f50e184d-8ca1-4c08-8586-c075b9fcb114" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a417704a-534f-4de0-8644-8cfa39cfb340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a417704a-534f-4de0-8644-8cfa39cfb340" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_44655a7b-dd03-4b48-9785-1b4de624330b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_44655a7b-dd03-4b48-9785-1b4de624330b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_60f20451-376f-4cc0-93cc-8ff417066b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_CashEquivalentsMember_60f20451-376f-4cc0-93cc-8ff417066b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_183d7b7a-d5c0-4a9b-86ca-03682392ba10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_183d7b7a-d5c0-4a9b-86ca-03682392ba10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6b2baa47-5d61-4273-be4a-221f2f027595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_CommercialPaperMember_6b2baa47-5d61-4273-be4a-221f2f027595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_26573f47-294a-41c9-a38e-98b5448b4bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_26573f47-294a-41c9-a38e-98b5448b4bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_932a29ac-e5f1-45f7-b6f6-d3b97963aa56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_932a29ac-e5f1-45f7-b6f6-d3b97963aa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_be12605c-722a-47b3-a115-592c0957b167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_be12605c-722a-47b3-a115-592c0957b167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7e925d76-5754-4698-9bc9-045149b46483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a6a35a3-57f0-4762-82ac-30046add498b" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7e925d76-5754-4698-9bc9-045149b46483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f50e184d-8ca1-4c08-8586-c075b9fcb114" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b106e037-6020-4768-9885-464dab22e37d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b106e037-6020-4768-9885-464dab22e37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_5cda3336-b09d-476c-bc58-b4ae381bf10a" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_5cda3336-b09d-476c-bc58-b4ae381bf10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_09013105-f8b1-40c9-bdb1-8c74189592b1" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_09013105-f8b1-40c9-bdb1-8c74189592b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_12cacb4a-f208-4520-a701-f6009ec37460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_12cacb4a-f208-4520-a701-f6009ec37460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be5a98b1-2c9c-4f01-acbc-fd60ea2d0872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be5a98b1-2c9c-4f01-acbc-fd60ea2d0872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_13baa898-64eb-420f-93ce-f728def6ec0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_13baa898-64eb-420f-93ce-f728def6ec0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2b360dac-d68b-4350-90b6-c58be79e7e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2b360dac-d68b-4350-90b6-c58be79e7e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5397d0f0-a247-4681-b46a-ae46fea22e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22134295-e71a-410f-8b5e-4771345c6919" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5397d0f0-a247-4681-b46a-ae46fea22e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_6acf33f7-a2e6-460d-9d6d-d0e89c4a5a5c" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_6acf33f7-a2e6-460d-9d6d-d0e89c4a5a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_05b25c58-1dee-455c-851f-247b859ed62a" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_05b25c58-1dee-455c-851f-247b859ed62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_3b026f75-8882-4713-b960-83cc1d694061" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_3b026f75-8882-4713-b960-83cc1d694061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_011179aa-53f2-4444-ad02-0d31e36005f1" xlink:href="sgmo-20220331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e97fd1e6-4030-4102-aa11-2fbb7ba23b2c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_011179aa-53f2-4444-ad02-0d31e36005f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e74a153a-bb5a-4c7b-b276-a0fbf84da206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3571d0ae-51d3-43f8-9008-01d15c67474a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e74a153a-bb5a-4c7b-b276-a0fbf84da206" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3571d0ae-51d3-43f8-9008-01d15c67474a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_22542118-1bed-442f-a72a-4c9afb4a55ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e74a153a-bb5a-4c7b-b276-a0fbf84da206" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_22542118-1bed-442f-a72a-4c9afb4a55ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents_bd6f4626-9a4a-4153-96d0-37e78a9be7a2" xlink:href="sgmo-20220331.xsd#sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e74a153a-bb5a-4c7b-b276-a0fbf84da206" xlink:to="loc_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents_bd6f4626-9a4a-4153-96d0-37e78a9be7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_17962e44-af09-43e0-9353-c6fd35b41593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_9e60a93e-64bd-407e-94aa-e6c8b957d2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_17962e44-af09-43e0-9353-c6fd35b41593" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_9e60a93e-64bd-407e-94aa-e6c8b957d2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_1b9a80e0-892a-4ead-be62-d4957d9f2ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_17962e44-af09-43e0-9353-c6fd35b41593" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_1b9a80e0-892a-4ead-be62-d4957d9f2ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_483fee45-c87d-4de7-8a72-82e22fc51eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_17962e44-af09-43e0-9353-c6fd35b41593" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_483fee45-c87d-4de7-8a72-82e22fc51eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20220331.xsd#BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_333831e7-8dc6-4737-88e6-dac3339ecc01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_656611b5-6499-4301-af68-834265a9b3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_333831e7-8dc6-4737-88e6-dac3339ecc01" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_656611b5-6499-4301-af68-834265a9b3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_095c6eb8-2d84-475f-a05e-975197866a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0546dece-c3af-40e7-875b-077514d17b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_095c6eb8-2d84-475f-a05e-975197866a2d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0546dece-c3af-40e7-875b-077514d17b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_304a5553-a5e6-4ef2-b714-314b0b0bacf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1c336049-350a-4287-bc11-e7c34cb49226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_304a5553-a5e6-4ef2-b714-314b0b0bacf8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1c336049-350a-4287-bc11-e7c34cb49226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb91c8ec-ab61-4d80-9214-1ca1495a31e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e6937a39-adaf-4671-82aa-f46c3513b726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb91c8ec-ab61-4d80-9214-1ca1495a31e8" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e6937a39-adaf-4671-82aa-f46c3513b726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_237c1a40-801b-40d6-a3de-4311b8d0e711" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e6937a39-adaf-4671-82aa-f46c3513b726" xlink:to="loc_srt_CounterpartyNameAxis_237c1a40-801b-40d6-a3de-4311b8d0e711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_237c1a40-801b-40d6-a3de-4311b8d0e711" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_e57cab2d-fec1-4614-8b13-127df236a7a2" xlink:href="sgmo-20220331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_e57cab2d-fec1-4614-8b13-127df236a7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_cc75469c-8146-40b8-bb69-d9e19659097d" xlink:href="sgmo-20220331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:to="loc_sgmo_BiogenMAIncMember_cc75469c-8146-40b8-bb69-d9e19659097d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_a7471ee0-6f91-4196-9b45-59b61c037ff2" xlink:href="sgmo-20220331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:to="loc_sgmo_KitePharmaIncMember_a7471ee0-6f91-4196-9b45-59b61c037ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_68499143-2bdf-48d1-8a1f-303fd6bdfbcd" xlink:href="sgmo-20220331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b96e4be-2ccf-4af3-b7d1-961eda32e463" xlink:to="loc_sgmo_SanofiMember_68499143-2bdf-48d1-8a1f-303fd6bdfbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d78e0d3f-999c-4b78-8556-cc8479275aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e6937a39-adaf-4671-82aa-f46c3513b726" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d78e0d3f-999c-4b78-8556-cc8479275aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_f862ac72-54bd-4f68-9c29-9968c3e5c6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d78e0d3f-999c-4b78-8556-cc8479275aba" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_f862ac72-54bd-4f68-9c29-9968c3e5c6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_c3996847-3d5d-4d02-9628-ff9ae604f06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_c3996847-3d5d-4d02-9628-ff9ae604f06a" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_14812972-29e4-4c64-b520-37fc0cd15bcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:to="loc_srt_CounterpartyNameAxis_14812972-29e4-4c64-b520-37fc0cd15bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f852b57-85ed-4f22-a37a-807b06cd1536" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_14812972-29e4-4c64-b520-37fc0cd15bcb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f852b57-85ed-4f22-a37a-807b06cd1536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d03ffcbe-8da6-4eda-a426-718d42eb91d8" xlink:href="sgmo-20220331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f852b57-85ed-4f22-a37a-807b06cd1536" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d03ffcbe-8da6-4eda-a426-718d42eb91d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_999bbf24-9174-4c4d-9bb3-6cce022777b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_999bbf24-9174-4c4d-9bb3-6cce022777b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46adc8e5-cf58-4d88-9ba9-c9df7b650876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_999bbf24-9174-4c4d-9bb3-6cce022777b3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46adc8e5-cf58-4d88-9ba9-c9df7b650876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_6eb9cf43-340c-4e2f-aad6-e055544d6f1a" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46adc8e5-cf58-4d88-9ba9-c9df7b650876" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_6eb9cf43-340c-4e2f-aad6-e055544d6f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_53bdfb2f-f1c1-40cb-94b2-11bd8965eff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_53bdfb2f-f1c1-40cb-94b2-11bd8965eff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_565fcdb3-7b94-43a4-b981-1aeffdf01ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_53bdfb2f-f1c1-40cb-94b2-11bd8965eff2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_565fcdb3-7b94-43a4-b981-1aeffdf01ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_f68418dc-fbee-4ff7-a912-2a66e3d74081" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_565fcdb3-7b94-43a4-b981-1aeffdf01ac6" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_f68418dc-fbee-4ff7-a912-2a66e3d74081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_4137448e-0453-4ee1-b3da-5085dc32dcb0" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_565fcdb3-7b94-43a4-b981-1aeffdf01ac6" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_4137448e-0453-4ee1-b3da-5085dc32dcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_eec53c02-152c-4d45-92c3-84e8b082119c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_382d27e4-c2ae-460b-83f7-97b9f3c25107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_us-gaap_ProceedsFromCollaborators_382d27e4-c2ae-460b-83f7-97b9f3c25107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_a347b04c-5947-46b4-9702-fe668aabe579" xlink:href="sgmo-20220331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_a347b04c-5947-46b4-9702-fe668aabe579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_88d81f05-7b15-49c0-a9ff-329620843a6f" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_88d81f05-7b15-49c0-a9ff-329620843a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_7b72c630-0470-413c-a6c3-64c377f18890" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_7b72c630-0470-413c-a6c3-64c377f18890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_e2afe5c2-c73f-41d4-95c3-daf5b37fa8e1" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_e2afe5c2-c73f-41d4-95c3-daf5b37fa8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_da66c7c8-02fa-4b76-9e10-2c135977a51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_da66c7c8-02fa-4b76-9e10-2c135977a51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8518dfca-bdf5-4c89-9ac3-2aa51c23b416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8518dfca-bdf5-4c89-9ac3-2aa51c23b416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_bd95112d-455d-4f7a-a702-32c3213fc4bc" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_bd95112d-455d-4f7a-a702-32c3213fc4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_04015241-130d-43ec-8e9f-48dfda2b1492" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_04015241-130d-43ec-8e9f-48dfda2b1492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_8a72a3ad-029f-437d-ada3-15d16bfc2326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62f8f561-a72c-46e4-94cd-6f090ca695c6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_8a72a3ad-029f-437d-ada3-15d16bfc2326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0ab83ef-935f-4499-bcf5-90db2168802f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_41bc9953-5a25-40d9-b4eb-77da3201fdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0ab83ef-935f-4499-bcf5-90db2168802f" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_41bc9953-5a25-40d9-b4eb-77da3201fdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0dd66a2a-2f79-43ac-8eca-3242e05565ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_41bc9953-5a25-40d9-b4eb-77da3201fdfe" xlink:to="loc_srt_CounterpartyNameAxis_0dd66a2a-2f79-43ac-8eca-3242e05565ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0dd66a2a-2f79-43ac-8eca-3242e05565ac" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_1557fab7-854f-481e-988c-145635343f85" xlink:href="sgmo-20220331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_1557fab7-854f-481e-988c-145635343f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_4fc62e49-5c9c-421e-9e27-7209383e2c53" xlink:href="sgmo-20220331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:to="loc_sgmo_BiogenMAIncMember_4fc62e49-5c9c-421e-9e27-7209383e2c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_91ad3257-0b21-41c4-84cb-455bf757e316" xlink:href="sgmo-20220331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:to="loc_sgmo_KitePharmaIncMember_91ad3257-0b21-41c4-84cb-455bf757e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_002a9280-69c4-4ecc-821b-b855089fcf64" xlink:href="sgmo-20220331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90ccb4e6-8a5e-4dba-aec1-b6f200e663e0" xlink:to="loc_sgmo_SanofiMember_002a9280-69c4-4ecc-821b-b855089fcf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0aa15a9e-d4e4-442b-ab9b-9f07e2a7dd7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_41bc9953-5a25-40d9-b4eb-77da3201fdfe" xlink:to="loc_srt_ProductOrServiceAxis_0aa15a9e-d4e4-442b-ab9b-9f07e2a7dd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0aa15a9e-d4e4-442b-ab9b-9f07e2a7dd7e" xlink:to="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_efe7344d-afb0-4f9c-ad40-4994df987e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:to="loc_us-gaap_LicenseAndServiceMember_efe7344d-afb0-4f9c-ad40-4994df987e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_becfafaa-c5f0-436e-bf15-fc6d187f626b" xlink:href="sgmo-20220331.xsd#sgmo_ResearchServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:to="loc_sgmo_ResearchServicesMember_becfafaa-c5f0-436e-bf15-fc6d187f626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_a7693b77-d596-4a1b-a8bc-cde83adefcc7" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_04eec344-3a57-46a9-b73f-a5fb4b6fefd4" xlink:to="loc_sgmo_MilestoneAchievementMember_a7693b77-d596-4a1b-a8bc-cde83adefcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_63fbf74a-4e9a-449c-ab14-5c22ba376652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_41bc9953-5a25-40d9-b4eb-77da3201fdfe" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_63fbf74a-4e9a-449c-ab14-5c22ba376652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d5dc9b3-855a-4c82-965b-c10df18cb8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_63fbf74a-4e9a-449c-ab14-5c22ba376652" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d5dc9b3-855a-4c82-965b-c10df18cb8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_92c280eb-7e52-4f64-98aa-401b4abea4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_92c280eb-7e52-4f64-98aa-401b4abea4b0" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4505143c-e683-4475-ac15-682531c17957" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:to="loc_srt_CounterpartyNameAxis_4505143c-e683-4475-ac15-682531c17957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52a8f36-cdf2-444e-92bb-2f444d4cec52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4505143c-e683-4475-ac15-682531c17957" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52a8f36-cdf2-444e-92bb-2f444d4cec52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_62965604-0677-4bfe-9982-056f715afb3e" xlink:href="sgmo-20220331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52a8f36-cdf2-444e-92bb-2f444d4cec52" xlink:to="loc_sgmo_BiogenMAIncMember_62965604-0677-4bfe-9982-056f715afb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_987cacd0-ab4f-484e-b71c-df6c632d146f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_987cacd0-ab4f-484e-b71c-df6c632d146f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed94b370-dc4d-49ff-9005-029313ee9d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_987cacd0-ab4f-484e-b71c-df6c632d146f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed94b370-dc4d-49ff-9005-029313ee9d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_062c5304-fec9-4524-883e-67ef52a8074f" xlink:href="sgmo-20220331.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed94b370-dc4d-49ff-9005-029313ee9d6b" xlink:to="loc_sgmo_StockPurchaseAgreementMember_062c5304-fec9-4524-883e-67ef52a8074f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_79be90d9-1953-48e0-847b-ba8c77e1cb4d" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed94b370-dc4d-49ff-9005-029313ee9d6b" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_79be90d9-1953-48e0-847b-ba8c77e1cb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_be0da2be-f7cc-4ea0-9241-74186a7f51e7" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_be0da2be-f7cc-4ea0-9241-74186a7f51e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_200bc042-b1a9-455a-b781-4fccdc0365c8" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_be0da2be-f7cc-4ea0-9241-74186a7f51e7" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_200bc042-b1a9-455a-b781-4fccdc0365c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_d41cb443-33a3-4f4b-8738-13ac1f15596d" xlink:href="sgmo-20220331.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_200bc042-b1a9-455a-b781-4fccdc0365c8" xlink:to="loc_sgmo_PreApprovalMilestoneMember_d41cb443-33a3-4f4b-8738-13ac1f15596d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_df4b9030-192b-440e-bf8f-a4c6acb0900a" xlink:href="sgmo-20220331.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_200bc042-b1a9-455a-b781-4fccdc0365c8" xlink:to="loc_sgmo_SalesBasedMilestoneMember_df4b9030-192b-440e-bf8f-a4c6acb0900a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0c7e21cd-fa64-4bc0-8c40-37239e43c21d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_285919d9-8f7d-42f0-a492-7e0b1a9cfa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_285919d9-8f7d-42f0-a492-7e0b1a9cfa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_560b4865-4c72-4163-ba10-fa1a9e8f7558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_560b4865-4c72-4163-ba10-fa1a9e8f7558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_32ec5e24-61c8-43d4-b3c9-628584f8fd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_32ec5e24-61c8-43d4-b3c9-628584f8fd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_e3f1a670-32f5-4be6-b226-d5fc3fc930f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_ProceedsFromCollaborators_e3f1a670-32f5-4be6-b226-d5fc3fc930f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_0c061a9f-77e9-48c3-bef2-005f156eb31d" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_0c061a9f-77e9-48c3-bef2-005f156eb31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_f5d445f2-81df-4e3b-9120-9c354b2bd639" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_f5d445f2-81df-4e3b-9120-9c354b2bd639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_0f46f587-fae8-4948-a5ce-d0b29083819c" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_0f46f587-fae8-4948-a5ce-d0b29083819c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_71bc0622-71b4-497a-a2e6-67c76ecd6792" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_71bc0622-71b4-497a-a2e6-67c76ecd6792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_1591ccbb-f656-44e0-b91a-bd37561d2cce" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_1591ccbb-f656-44e0-b91a-bd37561d2cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_13ce18ca-1584-44d3-8735-47f98cc8a24b" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_13ce18ca-1584-44d3-8735-47f98cc8a24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_15bb7040-02a4-4a09-a68b-17f7a9fc2dcc" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_15bb7040-02a4-4a09-a68b-17f7a9fc2dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_17d95978-9e17-4643-9352-71bfb7dc100c" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_17d95978-9e17-4643-9352-71bfb7dc100c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_fc67a035-5a8d-4e28-8f0a-6e0e28e91a45" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_fc67a035-5a8d-4e28-8f0a-6e0e28e91a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_da7faed9-830f-4701-ad38-98e7782c02a0" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_da7faed9-830f-4701-ad38-98e7782c02a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_6431d8d6-d753-4e6a-bd68-7e9a5031fd64" xlink:href="sgmo-20220331.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_6431d8d6-d753-4e6a-bd68-7e9a5031fd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_0af759d8-9159-4759-959d-ef5eec8324b5" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_0af759d8-9159-4759-959d-ef5eec8324b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f0d1c223-ff80-4f01-aecb-7b3d638715cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f0d1c223-ff80-4f01-aecb-7b3d638715cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3d750fe2-c588-455a-be39-105df9119191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3d750fe2-c588-455a-be39-105df9119191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_38dff54f-bc20-4f41-ace2-33d4a2518a7c" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_38dff54f-bc20-4f41-ace2-33d4a2518a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_46b96b9a-e189-4cf9-b844-66858954bc59" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_46b96b9a-e189-4cf9-b844-66858954bc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_2a1880d7-2462-44db-918b-c964859ef3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_2a1880d7-2462-44db-918b-c964859ef3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_ca8c70b3-a338-4e3d-86ac-d28c0f187e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_ca8c70b3-a338-4e3d-86ac-d28c0f187e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d916b7bf-03b4-4923-b01c-ce2ff445f7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b0910b02-0777-46a7-b56a-a460d8f5c3c7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d916b7bf-03b4-4923-b01c-ce2ff445f7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_a25ac8fe-cf9b-4b15-ba75-ef197a9097ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_a25ac8fe-cf9b-4b15-ba75-ef197a9097ec" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8be8355c-1c49-4408-b2fa-748576923888" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:to="loc_srt_CounterpartyNameAxis_8be8355c-1c49-4408-b2fa-748576923888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae541ad5-a649-4b06-8d5d-2d471365cbd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8be8355c-1c49-4408-b2fa-748576923888" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae541ad5-a649-4b06-8d5d-2d471365cbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_32fd3618-035a-4161-b638-ea93fe08c1cf" xlink:href="sgmo-20220331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae541ad5-a649-4b06-8d5d-2d471365cbd0" xlink:to="loc_sgmo_KitePharmaIncMember_32fd3618-035a-4161-b638-ea93fe08c1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_521c294d-b88f-45f5-a761-45e9fb92de77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:to="loc_us-gaap_TypeOfArrangementAxis_521c294d-b88f-45f5-a761-45e9fb92de77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4f4f196-35ff-4503-8fef-5934c38c0ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_521c294d-b88f-45f5-a761-45e9fb92de77" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4f4f196-35ff-4503-8fef-5934c38c0ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_5615c79d-e420-466f-8050-f42a1cb7ab5d" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4f4f196-35ff-4503-8fef-5934c38c0ff8" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_5615c79d-e420-466f-8050-f42a1cb7ab5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_740dd322-d3cb-4cf2-ae72-2b027edfbd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_740dd322-d3cb-4cf2-ae72-2b027edfbd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_abeebba7-4104-4d77-809b-44262129a6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_740dd322-d3cb-4cf2-ae72-2b027edfbd35" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_abeebba7-4104-4d77-809b-44262129a6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_539746f1-53d7-4964-b509-cb2edcc30327" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_abeebba7-4104-4d77-809b-44262129a6b9" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_539746f1-53d7-4964-b509-cb2edcc30327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_dc640127-a3e0-4a7b-8e3a-c2174c8ecbd4" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_abeebba7-4104-4d77-809b-44262129a6b9" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_dc640127-a3e0-4a7b-8e3a-c2174c8ecbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a4e457d7-551a-4055-acea-377469a47844" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_9f8573fe-2c60-4edb-866f-598521973338" xlink:href="sgmo-20220331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_MilestonePaymentsReceived_9f8573fe-2c60-4edb-866f-598521973338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_95f1120c-75b0-4289-be6d-ecf29ac87088" xlink:href="sgmo-20220331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_95f1120c-75b0-4289-be6d-ecf29ac87088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_f64cf151-678b-48f3-a60f-de43a20a1119" xlink:href="sgmo-20220331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_f64cf151-678b-48f3-a60f-de43a20a1119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_eb41c825-696d-4384-acf5-f12e2e3aa998" xlink:href="sgmo-20220331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_eb41c825-696d-4384-acf5-f12e2e3aa998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_0d224b3f-68e8-4904-9af8-a6f89c9b0317" xlink:href="sgmo-20220331.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_0d224b3f-68e8-4904-9af8-a6f89c9b0317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_8ee0c72a-35be-4ce2-9d28-afa77edbf0ef" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_8ee0c72a-35be-4ce2-9d28-afa77edbf0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_b96a2446-6a2f-40f3-b45e-0e019e62fd9f" xlink:href="sgmo-20220331.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_b96a2446-6a2f-40f3-b45e-0e019e62fd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_3fc52b8c-6d34-4f8a-8e00-7b38bf7c658a" xlink:href="sgmo-20220331.xsd#sgmo_SeparateUpfrontFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_SeparateUpfrontFee_3fc52b8c-6d34-4f8a-8e00-7b38bf7c658a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_5e628a14-9cb6-4cce-ae70-200f442bc783" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_5e628a14-9cb6-4cce-ae70-200f442bc783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_f4aebf0a-ba1e-46f4-ae3d-dbbc940c6805" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_f4aebf0a-ba1e-46f4-ae3d-dbbc940c6805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_ebe195ec-23e5-4cf5-b03f-893687fd77ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_ebe195ec-23e5-4cf5-b03f-893687fd77ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_3516d0e7-6ff0-4259-836d-cc9fbde6631e" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_3516d0e7-6ff0-4259-836d-cc9fbde6631e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4a3b0dfa-d0e8-495c-bf41-f8e0602efd42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4a3b0dfa-d0e8-495c-bf41-f8e0602efd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f1366f78-c215-4b90-8001-8c9b30f815e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84add738-2d50-4d17-af43-83fe551bdebd" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f1366f78-c215-4b90-8001-8c9b30f815e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_a3e7014a-194b-4201-8fd9-b0a2af884f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_a3e7014a-194b-4201-8fd9-b0a2af884f47" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_486230ee-d33e-4aac-b335-c418d70f3bfd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:to="loc_srt_CounterpartyNameAxis_486230ee-d33e-4aac-b335-c418d70f3bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d06bfcf-da77-4732-b99e-3171fa47a48c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_486230ee-d33e-4aac-b335-c418d70f3bfd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d06bfcf-da77-4732-b99e-3171fa47a48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_fd5283a9-76f1-44c2-a95a-8ca0cf298cb1" xlink:href="sgmo-20220331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d06bfcf-da77-4732-b99e-3171fa47a48c" xlink:to="loc_sgmo_SanofiMember_fd5283a9-76f1-44c2-a95a-8ca0cf298cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_938997b9-f7a2-412f-b9bd-4df5c2f50205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_938997b9-f7a2-412f-b9bd-4df5c2f50205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b929920c-bb2e-4f71-932c-efbe7c82e877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_938997b9-f7a2-412f-b9bd-4df5c2f50205" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b929920c-bb2e-4f71-932c-efbe7c82e877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_ec7663aa-0535-420b-ab8b-b1de2f9d6007" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b929920c-bb2e-4f71-932c-efbe7c82e877" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_ec7663aa-0535-420b-ab8b-b1de2f9d6007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_895fc7a6-8754-4460-8b4f-4e8a7c885a82" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b929920c-bb2e-4f71-932c-efbe7c82e877" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_895fc7a6-8754-4460-8b4f-4e8a7c885a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7179c959-5d6c-487f-90e0-9bde31f044fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7179c959-5d6c-487f-90e0-9bde31f044fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ed2c68-fbc0-4ad5-802e-85cdd9d39057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7179c959-5d6c-487f-90e0-9bde31f044fb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ed2c68-fbc0-4ad5-802e-85cdd9d39057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_a703e9c3-f38f-4572-82ae-18e657e0c3cb" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ed2c68-fbc0-4ad5-802e-85cdd9d39057" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_a703e9c3-f38f-4572-82ae-18e657e0c3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d567f7c-c7cb-4ab9-b39b-f84c9b632411" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d567f7c-c7cb-4ab9-b39b-f84c9b632411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_9c814bdc-a874-40c0-a54e-0aef645898d6" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d567f7c-c7cb-4ab9-b39b-f84c9b632411" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_9c814bdc-a874-40c0-a54e-0aef645898d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_3e0f2634-734c-4db8-ba98-ccb4f009bc65" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_9c814bdc-a874-40c0-a54e-0aef645898d6" xlink:to="loc_sgmo_MilestoneTwoMember_3e0f2634-734c-4db8-ba98-ccb4f009bc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_532c25c1-06b3-444d-95fb-403ceb8a98aa" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_9c814bdc-a874-40c0-a54e-0aef645898d6" xlink:to="loc_sgmo_MilestoneThreeMember_532c25c1-06b3-444d-95fb-403ceb8a98aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_56a1d77f-ff45-46ba-a6f0-ef6ab4024756" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_ae84e65c-c605-4c5c-b156-58ff52e41af0" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfResearchProgram"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_NumberOfResearchProgram_ae84e65c-c605-4c5c-b156-58ff52e41af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_34da6bc5-ec03-4ea0-8839-1460ab8edaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_34da6bc5-ec03-4ea0-8839-1460ab8edaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_f96c7a55-5ad5-4161-8fe2-213a6c5fb99a" xlink:href="sgmo-20220331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_f96c7a55-5ad5-4161-8fe2-213a6c5fb99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_189b4313-1c39-4423-a9f8-ab475ef6a88e" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_MilestoneRevenueReceivable_189b4313-1c39-4423-a9f8-ab475ef6a88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0c83588d-6e74-4f0b-af36-5faed998d89c" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0c83588d-6e74-4f0b-af36-5faed998d89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_150fae8e-6d66-4462-8c90-0e05a3a3e4d6" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_150fae8e-6d66-4462-8c90-0e05a3a3e4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_fdc5a3a3-003d-408a-aae3-c6b295d8fc84" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_fdc5a3a3-003d-408a-aae3-c6b295d8fc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_b39741be-a999-421d-9b48-dd2b63aa6d57" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_b39741be-a999-421d-9b48-dd2b63aa6d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_592d53e0-81c2-4cf5-8692-6a3c07def72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_592d53e0-81c2-4cf5-8692-6a3c07def72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a4f7717e-acdb-4b9b-9080-6ba3b61a3135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_230d7642-93d0-4514-8e6b-027aff640e83" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a4f7717e-acdb-4b9b-9080-6ba3b61a3135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_9b9aaec9-4a97-4f40-befc-67b55015b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_9b9aaec9-4a97-4f40-befc-67b55015b9f4" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_df8aa442-6084-4977-9f11-58cef2a7f6f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:to="loc_srt_CounterpartyNameAxis_df8aa442-6084-4977-9f11-58cef2a7f6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_df8aa442-6084-4977-9f11-58cef2a7f6f1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_4edf57b1-0f69-4872-b2a9-0aad9cd93e0e" xlink:href="sgmo-20220331.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:to="loc_sgmo_PfizerMember_4edf57b1-0f69-4872-b2a9-0aad9cd93e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_e3a771b1-34dc-4180-a20d-fcdce2be82e5" xlink:href="sgmo-20220331.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:to="loc_sgmo_PfizerSB525Member_e3a771b1-34dc-4180-a20d-fcdce2be82e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_37329afa-6d27-4619-9bf8-bae2c5ab798a" xlink:href="sgmo-20220331.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_682728c6-9919-4544-98c1-a87ccb0518df" xlink:to="loc_sgmo_PfizerC9ORF72Member_37329afa-6d27-4619-9bf8-bae2c5ab798a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c8f3f20-a7f8-4cbe-accb-2ae573e0ae00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:to="loc_srt_ProductOrServiceAxis_8c8f3f20-a7f8-4cbe-accb-2ae573e0ae00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8c8f3f20-a7f8-4cbe-accb-2ae573e0ae00" xlink:to="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_ce12f437-de7f-4ce7-a01e-775d206ce3b3" xlink:href="sgmo-20220331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_ce12f437-de7f-4ce7-a01e-775d206ce3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_5244875b-7c0c-4fe4-ad5c-54065e465ca9" xlink:href="sgmo-20220331.xsd#sgmo_OtherProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:to="loc_sgmo_OtherProductsMember_5244875b-7c0c-4fe4-ad5c-54065e465ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_e30a277b-66f9-4020-b312-32a0ace7736f" xlink:href="sgmo-20220331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_90e6236b-61a1-409b-a823-707403d6a10f" xlink:to="loc_sgmo_CNineORFSevenTwoMember_e30a277b-66f9-4020-b312-32a0ace7736f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f4b77bb-9677-43ad-a073-3de34357a815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f4b77bb-9677-43ad-a073-3de34357a815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f4b77bb-9677-43ad-a073-3de34357a815" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_d9f1cb1a-fb97-4290-8e92-024ba00c1639" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_d9f1cb1a-fb97-4290-8e92-024ba00c1639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_5bff9fc4-3eae-4779-945e-82177ecbda1c" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_5bff9fc4-3eae-4779-945e-82177ecbda1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_b1e03b77-1748-4e3f-880a-becdd56238ae" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_b1e03b77-1748-4e3f-880a-becdd56238ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_e59a2762-adc6-446f-a466-b4fafbc6ade4" xlink:href="sgmo-20220331.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d71c7af0-a823-441e-9793-5756b4f470bc" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_e59a2762-adc6-446f-a466-b4fafbc6ade4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1518969d-b455-4097-83a7-8b2baec57986" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:to="loc_srt_RangeAxis_1518969d-b455-4097-83a7-8b2baec57986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1842afac-aec1-4f8f-9889-70818623e19f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1518969d-b455-4097-83a7-8b2baec57986" xlink:to="loc_srt_RangeMember_1842afac-aec1-4f8f-9889-70818623e19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0388aac6-0f74-44a9-b784-8bd5894b6a4f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1842afac-aec1-4f8f-9889-70818623e19f" xlink:to="loc_srt_MaximumMember_0388aac6-0f74-44a9-b784-8bd5894b6a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_913156ac-412c-44fb-9d90-535273e41b5b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_929baa0d-0818-47b7-9d11-c6943c13fcee" xlink:href="sgmo-20220331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_AgreementTerminationTerm_929baa0d-0818-47b7-9d11-c6943c13fcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_50a414b2-f69d-4af8-9589-7a1f768303d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_50a414b2-f69d-4af8-9589-7a1f768303d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_a0b27683-3916-4ac1-a706-687659eb5f3b" xlink:href="sgmo-20220331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_a0b27683-3916-4ac1-a706-687659eb5f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_24b0f921-596d-4a8a-9f35-9128e8f5bb97" xlink:href="sgmo-20220331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_24b0f921-596d-4a8a-9f35-9128e8f5bb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_84f60369-4661-4d19-a3e9-06019f53a391" xlink:href="sgmo-20220331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_MilestoneRevenueReceivable_84f60369-4661-4d19-a3e9-06019f53a391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_966ca3c1-537f-4499-aa06-7d3716f44591" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_966ca3c1-537f-4499-aa06-7d3716f44591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_2876135e-55a2-435d-aa69-2f0a305d34bd" xlink:href="sgmo-20220331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_MilestonePaymentsReceived_2876135e-55a2-435d-aa69-2f0a305d34bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_f8a2bdcb-8084-4d9c-af9e-a6f007092ef0" xlink:href="sgmo-20220331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_f8a2bdcb-8084-4d9c-af9e-a6f007092ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_96b7e974-1bb2-4024-949e-8a7504197bf2" xlink:href="sgmo-20220331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_96b7e974-1bb2-4024-949e-8a7504197bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_25689bf5-83c5-42f0-ae9b-deae29d123ea" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_25689bf5-83c5-42f0-ae9b-deae29d123ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_2f5554e8-e26b-4e52-b5a6-03eda52fae31" xlink:href="sgmo-20220331.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_2f5554e8-e26b-4e52-b5a6-03eda52fae31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68d79ea3-6c59-44ce-9f4c-47bfb3afe978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5feb6d3-2989-47dd-918e-e91615569ad8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68d79ea3-6c59-44ce-9f4c-47bfb3afe978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20220331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24b7e1c8-bbca-4acb-bc84-d989157846d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6b93bae9-7547-4170-8574-ac03d4ef90e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24b7e1c8-bbca-4acb-bc84-d989157846d9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6b93bae9-7547-4170-8574-ac03d4ef90e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20220331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10a2bbeb-fc93-4bb5-8dae-387b135ee124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_580efe5a-da3b-4e5a-af50-10608401a78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10a2bbeb-fc93-4bb5-8dae-387b135ee124" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_580efe5a-da3b-4e5a-af50-10608401a78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_795d26b0-2374-49b7-9c78-d3012c8aeefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_32749f92-4a73-4512-9867-d9fd958e9f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_795d26b0-2374-49b7-9c78-d3012c8aeefd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_32749f92-4a73-4512-9867-d9fd958e9f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3332c8d2-a81d-4870-bc78-631b8d2ccd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_32749f92-4a73-4512-9867-d9fd958e9f17" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3332c8d2-a81d-4870-bc78-631b8d2ccd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7af66989-347d-4159-8f7a-5cc8ad75b9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3332c8d2-a81d-4870-bc78-631b8d2ccd70" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7af66989-347d-4159-8f7a-5cc8ad75b9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_96d67056-ea86-4eec-b028-cd0a3dd06584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7af66989-347d-4159-8f7a-5cc8ad75b9d2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_96d67056-ea86-4eec-b028-cd0a3dd06584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5ea98dd8-e1c0-408a-832c-2a30436ab6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7af66989-347d-4159-8f7a-5cc8ad75b9d2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5ea98dd8-e1c0-408a-832c-2a30436ab6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b8d14f5-acd8-4d79-a880-168ece5f56b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_32749f92-4a73-4512-9867-d9fd958e9f17" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b8d14f5-acd8-4d79-a880-168ece5f56b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2ea9d44-003c-4806-9e89-6e0e5be87746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b8d14f5-acd8-4d79-a880-168ece5f56b8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2ea9d44-003c-4806-9e89-6e0e5be87746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20220331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0d911e54-3fe1-477a-949c-d3189ef9104b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_52cf1de7-8986-4882-8830-0bd84c202cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0d911e54-3fe1-477a-949c-d3189ef9104b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_52cf1de7-8986-4882-8830-0bd84c202cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail" xlink:type="simple" xlink:href="sgmo-20220331.xsd#STOCKHOLDERSEQUITYDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2df63bf0-4e0b-48c8-89e5-7ae6f0c57d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6020032-09d7-494e-996e-03df7d9102e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2df63bf0-4e0b-48c8-89e5-7ae6f0c57d93" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6020032-09d7-494e-996e-03df7d9102e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a6a2d122-52af-40ab-88cb-46ca77721a61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6020032-09d7-494e-996e-03df7d9102e2" xlink:to="loc_srt_CounterpartyNameAxis_a6a2d122-52af-40ab-88cb-46ca77721a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57b8641f-7c89-4d77-aeca-f7aff1523f0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a6a2d122-52af-40ab-88cb-46ca77721a61" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57b8641f-7c89-4d77-aeca-f7aff1523f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_f31bedea-72d1-4e5b-855c-dac6a73d8c2f" xlink:href="sgmo-20220331.xsd#sgmo_JefferiesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57b8641f-7c89-4d77-aeca-f7aff1523f0a" xlink:to="loc_sgmo_JefferiesLLCMember_f31bedea-72d1-4e5b-855c-dac6a73d8c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ee1e14bc-e1e7-4ab8-b82f-566937d32669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6020032-09d7-494e-996e-03df7d9102e2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ee1e14bc-e1e7-4ab8-b82f-566937d32669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce010caf-a058-49f0-b2c4-00766271bb82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ee1e14bc-e1e7-4ab8-b82f-566937d32669" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce010caf-a058-49f0-b2c4-00766271bb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_f7820916-8e9d-4f45-ba78-185b462b6f7c" xlink:href="sgmo-20220331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce010caf-a058-49f0-b2c4-00766271bb82" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_f7820916-8e9d-4f45-ba78-185b462b6f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6020032-09d7-494e-996e-03df7d9102e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_87c6c0a5-98c1-4074-939b-a25b09114b15" xlink:href="sgmo-20220331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_87c6c0a5-98c1-4074-939b-a25b09114b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bd7e5b28-9175-4568-babe-a18cee91f4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bd7e5b28-9175-4568-babe-a18cee91f4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06622735-7db3-4285-ac81-a36572cd4bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916f1058-d7c6-4e8c-b2b5-5c029406e64f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06622735-7db3-4285-ac81-a36572cd4bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659812161624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,687,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659814309192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,257<span></span>
</td>
<td class="nump">$ 178,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">197,539<span></span>
</td>
<td class="nump">197,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">6,938<span></span>
</td>
<td class="nump">6,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,975<span></span>
</td>
<td class="nump">15,859<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">340,065<span></span>
</td>
<td class="nump">398,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">82,515<span></span>
</td>
<td class="nump">88,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">51,600<span></span>
</td>
<td class="nump">51,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">52,679<span></span>
</td>
<td class="nump">53,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">38,935<span></span>
</td>
<td class="nump">39,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">70,899<span></span>
</td>
<td class="nump">73,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">16,117<span></span>
</td>
<td class="nump">15,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">654,310<span></span>
</td>
<td class="nump">721,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,147<span></span>
</td>
<td class="nump">9,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">12,493<span></span>
</td>
<td class="nump">20,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">14,103<span></span>
</td>
<td class="nump">11,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">80,783<span></span>
</td>
<td class="nump">85,711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">118,526<span></span>
</td>
<td class="nump">127,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">150,700<span></span>
</td>
<td class="nump">166,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">42,815<span></span>
</td>
<td class="nump">44,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="nump">6,511<span></span>
</td>
<td class="nump">6,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">319,788<span></span>
</td>
<td class="nump">346,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,340,254<span></span>
</td>
<td class="nump">1,334,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,000,244)<span></span>
</td>
<td class="num">(956,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,955)<span></span>
</td>
<td class="num">(3,987)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">334,522<span></span>
</td>
<td class="nump">375,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 654,310<span></span>
</td>
<td class="nump">$ 721,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659813411112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 28,231<span></span>
</td>
<td class="nump">$ 26,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">58,584<span></span>
</td>
<td class="nump">56,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,908<span></span>
</td>
<td class="nump">16,148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">73,492<span></span>
</td>
<td class="nump">72,582<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(45,261)<span></span>
</td>
<td class="num">(46,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(43,919)<span></span>
</td>
<td class="num">(45,677)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(43,977)<span></span>
</td>
<td class="num">(45,939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</a></td>
<td class="num">$ (43,977)<span></span>
</td>
<td class="num">$ (45,933)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</a></td>
<td class="nump">146,218<span></span>
</td>
<td class="nump">143,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</a></td>
<td class="nump">146,218<span></span>
</td>
<td class="nump">143,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659812013624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (43,977)<span></span>
</td>
<td class="num">$ (45,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,904)<span></span>
</td>
<td class="num">(4,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension gains</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(46,945)<span></span>
</td>
<td class="num">(50,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</a></td>
<td class="num">$ (46,945)<span></span>
</td>
<td class="num">$ (50,638)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659813120216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Non- Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,063,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 497,366<span></span>
</td>
<td class="nump">$ 1,421<span></span>
</td>
<td class="nump">$ 1,269,375<span></span>
</td>
<td class="num">$ (777,981)<span></span>
</td>
<td class="nump">$ 5,419<span></span>
</td>
<td class="num">$ (868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at-the-market offering, net of offering expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with at-the-market offering, net of offering expenses</a></td>
<td class="nump">15,651<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">15,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="num">(416)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">(422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(4,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(45,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,713,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">469,417<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
<td class="nump">1,292,118<span></span>
</td>
<td class="num">(823,914)<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="num">$ (938)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,921,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">375,343<span></span>
</td>
<td class="nump">$ 1,459<span></span>
</td>
<td class="nump">1,334,138<span></span>
</td>
<td class="num">(956,267)<span></span>
</td>
<td class="num">(3,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="num">(1,567)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">(1,575)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension gains</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(43,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,664,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 334,522<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 1,340,254<span></span>
</td>
<td class="num">$ (1,000,244)<span></span>
</td>
<td class="num">$ (6,955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816733976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (43,977)<span></span>
</td>
<td class="num">$ (45,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,832<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on marketable securities</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets', window );">Amortization and other changes in operating lease right-of-use assets</a></td>
<td class="nump">2,106<span></span>
</td>
<td class="nump">2,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GainLossOnFreeShares', window );">Loss on free shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,691<span></span>
</td>
<td class="nump">7,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(925)<span></span>
</td>
<td class="num">(1,522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(248)<span></span>
</td>
<td class="num">(1,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">3,609<span></span>
</td>
<td class="num">(3,829)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(8,270)<span></span>
</td>
<td class="num">(7,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="num">(21,004)<span></span>
</td>
<td class="num">(20,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities', window );">Long-term portion of lease liabilities</a></td>
<td class="num">(972)<span></span>
</td>
<td class="num">(1,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(58,975)<span></span>
</td>
<td class="num">(68,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(65,756)<span></span>
</td>
<td class="num">(97,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">70,300<span></span>
</td>
<td class="nump">144,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Sales of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,839)<span></span>
</td>
<td class="num">(7,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="nump">45,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(1,641)<span></span>
</td>
<td class="num">(2,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and restricted stock units</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">1,818<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,567)<span></span>
</td>
<td class="nump">15,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">222<span></span>
</td>
<td class="num">(328)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(58,615)<span></span>
</td>
<td class="num">(8,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">180,372<span></span>
</td>
<td class="nump">132,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">121,757<span></span>
</td>
<td class="nump">124,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in unpaid liabilities</a></td>
<td class="nump">2,257<span></span>
</td>
<td class="nump">2,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingMember', window );">At the Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the-market offering, net of offering expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization And Other Changes In Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AmortizationAndOtherChangesInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GainLossOnFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GainLossOnFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in long-term portion of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816449768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The Condensed Consolidated Balance Sheet data at December&#160;31, 2021 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;2021 Annual Report&#8221;) as filed with the SEC on February&#160;24,&#160;2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2021, included in the 2021 Annual Report.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents, and marketable securities as of March&#160;31, 2022, and expected future milestones and research services revenue from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12&#160;months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, if at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in estimates during the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC&#160;Topic&#160;606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:74.368%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi S.A.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,257&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,975&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,757&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,372&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,475&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816296776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities, and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,889&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816491256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,054&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,377)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2022 and 2021. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that are in a </span></div>continuous unrealized loss position for greater than 12 months as of March&#160;31, 2022 and December&#160;31, 2021. Based on the scheduled maturities of its investments, the Company determined that it was more likely than not that it will hold these investments for a period of time sufficient for a recovery of its cost basis. Total unrealized gains for securities with net gains in accumulated other comprehensive income were not material for the three months ended March&#160;31, 2022. The unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, the Company determined that no allowance for credit losses related to its marketable securities was required at either March&#160;31, 2022 or December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816260072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS PER SHARE</a></td>
<td class="text">BASIC AND DILUTED NET LOSS PER SHARE<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of March&#160;31, 2022 and 2021 totaled 19,128,238 and 17,614,376, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816440856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</a></td>
<td class="text">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#8220;ZFP&#8221;) transcription factors (&#8220;ZFP-TFs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company is performing early research activities over the collaboration period for each gene target and manufacture the ZFP-TFs required for such research, costs of which is funded by Novartis. Novartis is responsible for additional research activities, studies enabling investigational new drug applications (&#8220;INDs&#8221;), clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement, when earned, are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and estimated research costs of $20.1&#160;million to be provided over the estimated research period. All clinical or regulatory milestone amounts were considered fully constrained at inception of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the agreement. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic&#160;606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $1.9&#160;million for both periods and deferred revenue of $33.9&#160;million and $40.9&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $1.5&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic&#160;340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC Topic&#160;340&#8221;). The Company amortized $0.1&#160;million during each of the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.4&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.5&#160;billion in first commercial sale and other sales-based milestone payments. In addition, the Company is eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to twelve&#160;neurological disease gene targets selected by Biogen. Biogen has already selected four of these: ST-501 to treat tauopathies, ST-502 to treat synucleinopathies including Parkinson&#8217;s disease, a third product candidate targeting DM1, a neuromuscular disease, and a fourth undisclosed neurological disease gene target. Biogen has exclusive rights to nominate up to eight additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performs early research activities, costs of which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e., through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to ten targets. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price of $204.6&#160;million includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $3.4&#160;million and $2.8&#160;million, respectively, and deferred revenue of $146.7&#160;million and $154.0&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:74.404%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and the stock purchase agreement for the sale of shares. The Company believes that </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the transaction price of $204.6&#160;million, as a contract asset. This balance is amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340. The Company amortized $0.1&#160;million during each of the three months ended March&#160;31, 2022 and 2021. The Company recognized $2.9&#160;million, which represented 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in net proceeds.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), a Gilead Sciences, Inc. subsidiary, which became effective in April 2018, and was amended and restated in September 2019, for the research, development, and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex&#160;vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions, except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the effective date, the Company received a $150.0&#160;million upfront payment from Kite. In addition, Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.0&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.3&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.8&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product and, (ii)&#160;only for the first 10 times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term in the agreement is six years. Kite has an option to extend the research term for up to two additional one-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $3.4&#160;million, which is included in the total transaction price. The Company concluded the total transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic&#160;606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the primary performance obligations within the Kite agreement as: (1)&#160;a license to the technology along with the stand-ready obligation to perform research services, and (2)&#160;the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through April 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $0.1&#160;million for both periods, and deferred revenue of $50.3&#160;million and $56.5&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:74.439%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi S.A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company was originally jointly conducting two research programs: a beta thalassemia program, which was discontinued in the third quarter of 2021, and the SCD program, which resulted in the development of SAR445136, a ZF nuclease, gene-edited cell therapy product candidate for the treatment of SCD, which remains active.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the SCD program, the Company and Sanofi were jointly responsible for research and development activities prior to filing of an IND, but Sanofi is now responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. Subject to the terms of the agreement, the Company had granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company had also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company received an upfront license fee of $20.0&#160;million and was eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, was up to $276.3&#160;million. In addition, the Company was to receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi was to reimburse Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST&#8209;400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Sanofi notified the Company of its termination for convenience, effective June 28, 2022 (the &#8220;Termination Date&#8221;), of the collaboration agreement. In its notice to the Company, Sanofi indicated that its termination relates to Sanofi&#8217;s change in strategic direction to focus on allogeneic universal genomic medicine approaches rather than autologous personalized cell therapies. As of the Termination Date, the collaboration agreement will be terminated in its entirety and following the Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Sanofi. As of the Termination Date, Sanofi will have no further obligations to develop or to fund the development of any collaboration research programs under the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All contingent payments under the agreement, when earned, were non-refundable and non-creditable. The transaction price of $96.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones in the amount of $13.5&#160;million and estimated research costs of $62.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Sanofi in accordance with ASC Topic&#160;606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through June 28, 2022, the estimated period the Company will perform research services pursuant to the agreement. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $1.0&#160;million and $0.6&#160;million, respectively, and deferred revenue of $0.6&#160;million and $1.1&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:74.368%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The total transaction price under this agreement is $134.0&#160;million, which represents the upfront fee and research services fees of $79.0&#160;million and fees related to two achieved milestones in an aggregate amount of $55.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and no revenues have been recognized during the three months ended March 31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) 15 years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million in commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $17.0&#160;million, which represents the upfront fees of $12.0&#160;million and fees related to achievement of one milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services.  </span></div>The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $5.0&#160;million milestone, which the Company recognized on a cumulative basis during the year ended December 31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and no revenues have been recognized during the three months ended March 31, 2022 and 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816326200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:74.439%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816496984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. During the three months ended March&#160;31, 2021, the Company sold 1,034,762 shares of its common stock for net proceeds of approximately $15.7&#160;million. No shares were sold during the three months ended March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659812118408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The Condensed Consolidated Balance Sheet data at December&#160;31, 2021 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;2021 Annual Report&#8221;) as filed with the SEC on February&#160;24,&#160;2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2021, included in the 2021 Annual Report.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for </span></div>making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC&#160;Topic&#160;606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:74.368%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi S.A.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities, and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659814275608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:74.368%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi S.A.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,257&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,975&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,757&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,372&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,475&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,257&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,975&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,757&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,372&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,475&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816431688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,889&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659813374328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,054&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,377)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair value of investments available-for-sale</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659813146264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:74.404%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:74.439%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:74.368%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816325480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:74.439%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816272744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit established as a deposit</a></td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659814246632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail) - Revenue from contract with customer - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659809455976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,257<span></span>
</td>
<td class="nump">$ 178,872<span></span>
</td>
<td class="nump">$ 122,975<span></span>
</td>
<td class="nump">$ 131,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 121,757<span></span>
</td>
<td class="nump">$ 180,372<span></span>
</td>
<td class="nump">$ 124,475<span></span>
</td>
<td class="nump">$ 132,829<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659808192152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 280,054<span></span>
</td>
<td class="nump">$ 285,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">49,827<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">15,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">24,441<span></span>
</td>
<td class="nump">30,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">117,325<span></span>
</td>
<td class="nump">105,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">17,373<span></span>
</td>
<td class="nump">33,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">67,515<span></span>
</td>
<td class="nump">70,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">2,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">50,405<span></span>
</td>
<td class="nump">45,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">64,835<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">280,054<span></span>
</td>
<td class="nump">285,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">344,889<span></span>
</td>
<td class="nump">405,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">49,827<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">15,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">24,441<span></span>
</td>
<td class="nump">30,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">117,325<span></span>
</td>
<td class="nump">105,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">17,373<span></span>
</td>
<td class="nump">33,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">67,515<span></span>
</td>
<td class="nump">70,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">2,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">50,405<span></span>
</td>
<td class="nump">45,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">49,827<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">49,827<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">49,827<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">15,008<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">280,054<span></span>
</td>
<td class="nump">285,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">295,062<span></span>
</td>
<td class="nump">285,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">15,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">24,441<span></span>
</td>
<td class="nump">30,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">117,325<span></span>
</td>
<td class="nump">105,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">17,373<span></span>
</td>
<td class="nump">33,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">67,515<span></span>
</td>
<td class="nump">70,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">2,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">50,405<span></span>
</td>
<td class="nump">45,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659809282952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 120,257<span></span>
</td>
<td class="nump">$ 178,872<span></span>
</td>
<td class="nump">$ 122,975<span></span>
</td>
<td class="nump">$ 131,329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">281,430<span></span>
</td>
<td class="nump">286,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(1,376)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">280,054<span></span>
</td>
<td class="nump">285,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost', window );">Total cash equivalents and available-for-sale securities, Amortized Cost</a></td>
<td class="nump">346,266<span></span>
</td>
<td class="nump">406,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(1,377)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">344,889<span></span>
</td>
<td class="nump">405,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">49,827<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">49,827<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">64,836<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">64,835<span></span>
</td>
<td class="nump">119,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">15,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">15,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">24,788<span></span>
</td>
<td class="nump">30,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(347)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">24,441<span></span>
</td>
<td class="nump">30,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">117,709<span></span>
</td>
<td class="nump">105,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(384)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">117,325<span></span>
</td>
<td class="nump">105,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">17,522<span></span>
</td>
<td class="nump">33,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">17,373<span></span>
</td>
<td class="nump">33,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">67,890<span></span>
</td>
<td class="nump">70,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">67,515<span></span>
</td>
<td class="nump">70,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">2,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">2,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">50,526<span></span>
</td>
<td class="nump">45,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">$ 50,405<span></span>
</td>
<td class="nump">$ 45,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents Gross Unrealized Gain Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659812119560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturing in one year or less</a></td>
<td class="nump">$ 212,547<span></span>
</td>
<td class="nump">$ 197,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Maturing after one year through five years</a></td>
<td class="nump">82,515<span></span>
</td>
<td class="nump">88,169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents', window );">Total</a></td>
<td class="nump">$ 295,062<span></span>
</td>
<td class="nump">$ 285,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Including US Government-Sponsored Enterprises Classified as Cash and Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659813385080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded', window );">Allowance for credit loss related to marketable securities, not previously recorded</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings', window );">Other impairment charges related to marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss related to marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816307096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options and RSUs outstanding (in shares)</a></td>
<td class="nump">19,128,238<span></span>
</td>
<td class="nump">17,614,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659809167496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">$ 95,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementLicenseFee', window );">License fee</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Financial advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement | Achievement Of Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Percent Of Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementPercentOfInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659809248728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 28,231<span></span>
</td>
<td class="nump">$ 26,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8,895<span></span>
</td>
<td class="nump">7,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,018<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,877<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">11,193<span></span>
</td>
<td class="nump">10,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,306<span></span>
</td>
<td class="nump">7,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,887<span></span>
</td>
<td class="nump">3,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,308<span></span>
</td>
<td class="nump">6,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">978<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659812802472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>product_target </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod', window );">Standstill restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage', window );">Standstill restriction, ownership threshold percentage ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction', window );">Excess consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementEquityIssued', window );">Collaboration agreement, equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Recognized portion of equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargets', window );">Number of product targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets', window );">Number of additional product targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementTargetSelectionPeriod', window );">Target selection period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected', window );">Number of product targets selected | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementResearchPeriod', window );">Research period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace', window );">Maximum number of product targets replaced | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Financial advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Portion of contract asset recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration And License Agreement | Pre-approval milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration And License Agreement | Sales-based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementEquityIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementEquityIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Additional Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementNumberOfAdditionalProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementTargetSelectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Target Selection Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementTargetSelectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementResearchPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Research Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementResearchPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Percent Of Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementPercentOfInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Number Of Product Targets To Replace</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets Selected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Excess Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659808160632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,938<span></span>
</td>
<td class="nump">$ 6,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Initial research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm', window );">Number of options to extend initial research term | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExtendedResearchTermOfAgreement', window );">Extended research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SeparateUpfrontFee', window );">Separate upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan', window );">Collaborative arrangement estimated reimbursable service costs for new research plan</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">189,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="nump">$ 39,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,300<span></span>
</td>
<td class="nump">$ 56,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment', window );">Maximum amount of achieved milestones to receive payment | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent development and sales based milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExtendedResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended Research Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ExtendedResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Extend Initial Research Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfOptionsToExtendInitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SeparateUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Separate upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SeparateUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659809250904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,938<span></span>
</td>
<td class="nump">$ 6,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs | program</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">276,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">96,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="nump">62,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | Collaboration And License Agreement | Milestone two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | Collaboration And License Agreement | Milestone three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | Achievement of specified clinical development And regulatory milestones | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">115,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | Achievement of specified sales milestones | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 160,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659808525272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Detail)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">52 Months Ended</th>
<th class="th" colspan="1">59 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>royalty_fee</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,231,000<span></span>
</td>
<td class="nump">$ 26,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products | Achievement of specified clinical development intellectual property and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products | Achievement of first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementResearchServiceFees', window );">Research service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | S B Five Two Five And Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved', window );">Collaborative arrangement, number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | royalty_fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72 | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72 | Achievement Of Commercial Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementResearchServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Research Service Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementResearchServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659809241608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7,691<span></span>
</td>
<td class="nump">$ 7,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,670<span></span>
</td>
<td class="nump">4,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,021<span></span>
</td>
<td class="nump">$ 3,272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139659816889832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Detail) - Jefferies LLC - At-The-Market Offering Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_StockOfferingProgramMaximumValue', window );">Stock offering program, maximum value</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,034,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockOfferingProgramMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Offering Program, Maximum Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockOfferingProgramMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>sgmo-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20220331.xsd" xlink:type="simple"/>
    <context id="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie82ebd2afdea4a1990f6789118d0eb42_I20220502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="i49808b7d5a184b629b594c228b0d228f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i98eb94bb16d64b339437154eeb6a8c7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41b9a853412a4de5bbfc5086f43609a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37f8868245aa4443834ca54fd2f6d165_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia25b49838a1e4216a648cda338998cd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16363a48a1db4200a557e20f74a6663e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic0831195cbcb42c78e3d9a80acb8bd55_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i415e7d08c2134893996d32a46190bba6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9bdbe1eebb07447cadf7cd259b6f2ca8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2e2ecbeebddf486b8f3eeebae6987fca_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i662af85bbcb24003939aa4e3f3b753ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83b558b1d1b24287b972767cc449ee9c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icd50e43eaec244a6a48c48e150d26257_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib1dcfc8af9f54d79891a8e4f97258d64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb68b7a02dc941ddb5eaea5f9e94cea0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i147ac2e91ee24c898b9135e2412019b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7736e400eca2413e926ef07b420d3523_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79928d1c5b534f9297876cf1cd9f42a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if027201194ec44b2a8a8aaa563d56062_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i133d4b1be36148219d4c9ca2c70121af_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic0a5d019cb57482287e3752a44cd9473_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7621415fb2b84296bc6b90e3b825982c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib41c6577ca4a47df91565832e4f8c52f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib0ac3d6b9a014f3fb9c09c50fb836aa1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1696ceaafa594b6e8a7aa213973bb86f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i179494c7d70e4d1980c455d43a0ccccd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i76ac39ac4cc046d3891f2f198d2f40a6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9c1c94341c8140bb850188c07c23add8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i66b727537ef44d20a3118a3b2f4aae71_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i88c52382b7dc4becb1cb30fb680833c0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i21ce04a30e5b4a2f9c36548cda5a8458_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib44f00bdda5c4a5e8fdf09b0b409881d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0fd799de345849b7bde24906fccf9e47_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idb254f83fdd54a5394d3789ac0432acd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icb3e3c9e9fc34bada2506884b81bcc4a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib77a01f4821e403fbaed538181093649_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i399ab68bf5a34a708f1ac215d91b5ef3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idf49db6b57ed4468b600943a63027618_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2e569774fd874df0b2278b667d3537b1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i40ec91078cbd4fef9b2ff9b118a62896_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e8560aa3fb044e2afe37becdf007481_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaf2e671b261e4b9a9510eea1dd524ffe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i143dc860af4e41ca8ad56c89389f8c0e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9ff2db9628f4469aa4b0d9190c623367_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i16bb308b033f4cfd8478d6ed83ab7469_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i09f7155daf244fe2847f5df4bca90b38_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i50c2af11dc0945a1a2b563bdd67a34e9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i708b092c6ed84bd1bbf020943bc286ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id893d7bf0fe340b493ce98b8ad036faa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie45eb48d4aac42dcb834ce4d4238cbc5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8b546e6ad858449f9375bab65733a9ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i30b4f1bdb97d4271beba4b63564701b1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ied809edebcb648f59c57c3137795b9c2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1456174ba11d44a79cda4fef54a9527a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i304cf3079db74ee581bad5edc8ea8eb6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic21a61daf2da4126898da412720ef0c1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic156a4b9bcd648ffabb65ad460686df9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7eb75b0131d244f9b44926706c6e6e1a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i08f31b20a2b442a592d8b411d50e9a36_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05c76a773d414d409fa20c7e798a1ead_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8c6006abfadc42c5890e9f29785dbba5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0b0b1b7628b74a32bf1f89c76bd39253_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie9f93a4e5c614d898f2dba36b145b91a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie9d2ad076baf46aa95e6b9a86a08f8fc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i021e4eb600444817b880d3c34fb52136_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id96bcec60508420a9f72a54a34521d52_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i906b3eb7e3734168ba335e172b1fa959_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5adf2fec9bea4ba899e404e902cb35bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if05b14fccaf44e1180d2ef8bbe382fec_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1c37e7249d9345dc9330907394eb067f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i412513ce57b94ec0bf641412ee64ef34_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib0a823a89d644a15b67b9a1a84a15ea6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26d1cbbf6bfc4b6fae628fbceab20e0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e70945d068e421d8e7e13119a342d96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c70fd8f212a44f0b0fd39c5da686631_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d5062dc4f6c4aea9b5af1b8206788f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa8460203d45415f877cfffa51733070_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e5e6402ec45427eae4f571d473ddedf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i752f160556a747deb9e6619b306a9579_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba495162727d4dc1ad3ca1981bbe7c17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa05cd9050654d27a2da2817cacdacc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib156eb5be64c4a22a4011ee880db1829_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f1034cd2a6148f9a0d34eccdef2cb56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c0f076cbacf47db8a333a0ba2a9744c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15c97739d5bf4f7aaf30ff5711b7b551_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id90c35cf8bca444c9fe316fa99c0ccc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8eb71551dfe411696e39c0e4a98ac05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85f2894d23e54b5c8bc3535256e6f430_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia241ff32633d44d0995fa41d3b30c749_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i652c08590692478dbad26f055bd24b22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1900186abb04fcd8679b20fe15aa9eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie94522ff63b14c7c8f42c47bc206bcf9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96a079914a6f4629944a16c5c8f8c67f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b82c587da8e49dba0a77764e4e9678f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89392c2987434d09bae08df932002bb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iadab9f649ee64aa18743fe966255becd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd13862a3fc0418f8cf10ae64ad1ac6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0369288ea6d34134bdc95a49a5e089a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c2de2dac42941aea08c2173d245c90d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i667d8119170448249bd6a172234e2142_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i92b3b84611284755a34ba8152a2646d0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i75f59c89b2b44fd2919394b10858dd42_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7e69bac7be71489fac652fab2215a8a9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib47a4b1baad248318523c5fba0c2d164_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9333aab4cdd548f1818b9a801558d624_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i417758d232ed45199817bccf384dfcad_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7428cfc7656446308caa6ab7f38e8fc4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d0041f6579043f2bee5ca967b1a19d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4cc59f044c84fa483597e518c67dd8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i149b1f00b3f944a699030236b1718bb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i708da3120a854222abfec0d32c8d9c70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a473804e0f74354bf949e0a954fac9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4e67faf817f4852b243d3c63990d266_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ib56fb168b92b405fb217588fffb34483_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="id6efcae223674852a4973214fc153fa8_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i37db8a6698834ba296ee551626e923fb_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="id8c1aa614e1a4775b6bbd58069fa1667_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4b7eb1bd518d40e1b0ab1d54a66550cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01e697d1114342af9aab4ece3ebe09d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i900d4a285bf74e898040e450e39bae33_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i517982897103458981bfa35ceae5ab4c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib06b72ef26254e088a29f9eb02ae084f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3be9da6c94aa4aeda66aa0067113c02e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib750ba895b6945248f5dd3b66450ec06_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i55716db833614f819cf9af228e7bacc0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab11137987e8447bb24585d1df56594e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaa9d46b5b32044e89d50e8f389f7bdd3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i26fa9295800a4f159a11564e07b29049_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i766f4d877bf6408b9503aa5663f38abe_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i15891adf431c452c86cb7e1beafbb9f8_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ib839a8edfdf240f293867c6246e5a8fa_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ib0e6b8fbf7904621a6d9173012bb2011_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i92e1ede754aa400bb099f3f7aed0dfb1_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ifc6738521b264171b6251397feadfc36_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i39ca1d92750e4fc887cd62b4bb56da6e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8ca29e9a3803412cb13b7748ae0de063_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2957eaa5fb949ba9103ee631650c838_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i041acd4815694161b1e7542a2e160c9c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f3e9b2076b04da29cf24d841569c73f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8a105ad9f2c44de8af6b7d8886dbfe92_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib0037c3659814babb6528aeace32f367_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i41afe851c52346368324b29729905d65_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if6ae54d9711045f5b069428dadfcf2ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0b2dfb4d52545a4945d9acab347bcee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idadbcdba5852493e8a7279c2071547c9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i01e8a0ae4fe34fcbbda1cb1a13234369_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id4be5c493833416e94842f25e42f4ed2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i5797d08acc004769826046653f737b78_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="idc36d4cf8fee4657a85ef91caf216030_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i98c4d875d4a2406e8c1ed49500a382d3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i63eac9ce149544bc82e859b7f3bbb3b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib70ee13d8d7a427da05f3f516bfa3b24_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2986c1f9c44f4c47b92d4e4fe0632ce1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia07682bb1e1c4e59a83b477d9c74c798_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i11fedbfa9d70466daba921e2e917b72b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ba81ecb70cf48beb5b5bc44b8920a30_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia7245852459b450a993c961a809e0dfa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1aa617603ebd4abeb4444421df29e6bc_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="iadba8aa480b646cfbd9364a355e68cbe_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i58d8c1b745014cc8b8f4a724f1510553_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i415e26556db342079b36c2d48875c6cd_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i8e4a1930763f4519a9e4c291ee43d2e0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i220eb5b01a5049368db95372ebd0fd9b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8dc0ab2db92b44c1bdba051d96895b2a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i93cdf026a37d429da9fbaf18e0a75afd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if66d1819ab0a41bcae82ab0a30c2b5a0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i46b1460fe9b3430aaad2d02372d4e0fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7009d476b5214df7b02507f512948107_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7850a3329dd84fb9bb08174c06ab99e3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4014aec3ed654925849776520902d5b7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5055577b77d947f4bef796328015008c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1fe22c826474fe69f5ed5ada7ece18f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i792a74f3766e43feb0c12d95327cbf47_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if5834c04299d4d58ac0d606a80ed8b5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i195087e919f9493f90985edbce9e5c13_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id6d053e63e174530b26c614c63fbadbd_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i9ece67192c1d42a59cc7910bf5faa61c_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i42824e5c4da04a68abc1181162bd12fa_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i35e709748299454d8a4c0545d5caa0c0_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i775b57c0965745638063300c10bf719b_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i2b464e1bc69c4b89951ddb6d3fee56d9_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia4c9910cf6b742cf89b4a8a7d9606e71_D20171201-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia8bed9085c38465985a0d366ec10dc28_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="iccf2d29f1912433caabee4d25f53741b_D20170501-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0f51b07af0864153afac3abe30c851e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3b3dd93e1a194866bed6cbf58dde6ab6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i51e7fa3e99494ccabbb4f5480eae52b8_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib9f57259deda46369255333e92bf2fe1_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i644151b6138447f397ecbd47582bdb71_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie5b439ab1a3340e7a1a2684ce3f73c38_D20171201-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia544d315ec7d4af5a972efb96f552dba_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib257bf5eb1c3440fb565b1bc921fddb1_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i2de27440831843859499b5316c0123fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13d3e19bc1f941bfada2a1d34fbabcd0_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4ad9356ed1a4e1e8a0ce2245ba0883a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4f348bc656a048d89a2becabe2d582e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2ed88b3f0256493eb611d1c6df10aa32_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d78a85fa8bf4c2088761487072d070b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id9ccfc5457b247c9a4372c7a7b6fd8b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i87ae6a236ee94776b86d549585e14bb1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i03631c915ffa4c589e31bd1ac9a7dfc1_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i645065c4f11143f6a0bcdbb35e8a38f5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i75cd2dd96b0241acae7b413f811622f1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="product_target">
        <measure>sgmo:product_target</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <unit id="option">
        <measure>sgmo:option</measure>
    </unit>
    <unit id="program">
        <measure>sgmo:program</measure>
    </unit>
    <unit id="product">
        <measure>sgmo:product</measure>
    </unit>
    <unit id="royalty_fee">
        <measure>sgmo:royalty_fee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV8yLTEtMS0xLTM3MjYx_efa43bc6-03b0-4210-90bd-3ffd5276ac94">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV8zLTEtMS0xLTM3MjYx_1fe3a6c5-c10b-4d17-b583-81db4ba05eb9">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV80LTEtMS0xLTM3MjYx_afb639ee-afaf-4320-af5e-13b01ea6b673">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV81LTEtMS0xLTM3MjYx_50d8143e-7e38-4cf7-b94c-7dc728f2956d">0001001233</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80L2ZyYWc6MGZmMzYzMjEzY2RmNDJhYzg1YzcxYjlmMjMyNDNlYTgvdGFibGU6YmJiNDhmZDRhNWIzNDE4Y2FjMTU3MWJiZjU5YTQyZjEvdGFibGVyYW5nZTpiYmI0OGZkNGE1YjM0MThjYWMxNTcxYmJmNTlhNDJmMV82LTEtMS0xLTM3MjYx_33b575bc-fec0-47fd-b002-68d63dff11e2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY4_a8343189-65c4-44f1-a9e3-2885df01bfb7">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NjEwYzY5MGNhZjVlNDVjZGExMTI3MzBjNzE5NTFlZmQvdGFibGVyYW5nZTo2MTBjNjkwY2FmNWU0NWNkYTExMjczMGM3MTk1MWVmZF8wLTAtMS0xLTM3MjYx_ac94c31a-f399-4594-a348-5ef99e9af2b6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMzE_867713f8-2ddd-4a74-8a7a-a19bc0399a6e">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6YTU2NTNjMDQyYmExNDc5NjhlNmZjOTAwMDYzMTlkOTgvdGFibGVyYW5nZTphNTY1M2MwNDJiYTE0Nzk2OGU2ZmM5MDAwNjMxOWQ5OF8wLTAtMS0xLTM3MjYx_99e86113-d0ac-448f-ba75-3bbc5d9cfa1b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY5_a804ffe5-80b2-4f26-a921-5b41e5d888f7">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY0_33fb75d7-0a0a-4af6-9f6d-3ce1598aa056">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8wLTAtMS0xLTM3MjYx_a5c4cc38-aa91-4e2c-a25e-837c2560bbbb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8wLTQtMS0xLTM3MjYx_b3c3abcf-aa1c-40ca-b3d2-fe4b11a3a1f7">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8zLTAtMS0xLTM3MjYxL3RleHRyZWdpb246YjM2ZmM1YWYzNjQ3NDhkNGJkNmZjZjZjNzc1YmMwY2JfNA_d1d8dc27-af8e-4458-b2bb-002839079637">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8zLTAtMS0xLTM3MjYxL3RleHRyZWdpb246YjM2ZmM1YWYzNjQ3NDhkNGJkNmZjZjZjNzc1YmMwY2JfOA_6b0ff650-b44e-4908-b8cc-5ec5c9eec605">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8zLTAtMS0xLTM3MjYxL3RleHRyZWdpb246YjM2ZmM1YWYzNjQ3NDhkNGJkNmZjZjZjNzc1YmMwY2JfMTI_0065adf8-c3de-49de-9d19-2080c099d563">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6M2FjZTNjYmRhM2ZjNGNlMGExOWRmODJkNjc4YjAzMjgvdGFibGVyYW5nZTozYWNlM2NiZGEzZmM0Y2UwYTE5ZGY4MmQ2NzhiMDMyOF8zLTAtMS0xLTM3MjYxL3RleHRyZWdpb246YjM2ZmM1YWYzNjQ3NDhkNGJkNmZjZjZjNzc1YmMwY2JfMTY_f04ac794-f8b4-4c4a-bebd-c463d6f500af">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY1_27789246-c651-439f-ad33-98d6d72a32ba">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY2_e86c4bda-00bb-4eb5-9882-52724003777e">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NzA0YTQwZWMwYmVkNDQ4MzgyOTIwOGZkOWY1ZjAyMmMvdGFibGVyYW5nZTo3MDRhNDBlYzBiZWQ0NDgzODI5MjA4ZmQ5ZjVmMDIyY18xLTAtMS0xLTM3MjYx_49d00c1f-161f-4694-9559-91687c636c71">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NzA0YTQwZWMwYmVkNDQ4MzgyOTIwOGZkOWY1ZjAyMmMvdGFibGVyYW5nZTo3MDRhNDBlYzBiZWQ0NDgzODI5MjA4ZmQ5ZjVmMDIyY18xLTItMS0xLTM3MjYx_762b2a61-606f-49cc-95c3-2a660a426ef3">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NzA0YTQwZWMwYmVkNDQ4MzgyOTIwOGZkOWY1ZjAyMmMvdGFibGVyYW5nZTo3MDRhNDBlYzBiZWQ0NDgzODI5MjA4ZmQ5ZjVmMDIyY18xLTQtMS0xLTM3MjYx_8ead68f6-04d4-4a84-948d-4dae4bd9a505">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjY3_95ff7a2d-4c36-4307-bbb7-4cb7025f6327">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMjcw_bee2058c-5972-44c6-a766-930037e5376d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NDg4ZWE4YjZjMWYyNDk2YTkwZGJhZmY3ZDAzOGQwY2EvdGFibGVyYW5nZTo0ODhlYThiNmMxZjI0OTZhOTBkYmFmZjdkMDM4ZDBjYV8wLTAtMS0xLTM3MjYx_004cda35-e409-46f3-8e52-8c5f79922323">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NDg4ZWE4YjZjMWYyNDk2YTkwZGJhZmY3ZDAzOGQwY2EvdGFibGVyYW5nZTo0ODhlYThiNmMxZjI0OTZhOTBkYmFmZjdkMDM4ZDBjYV8xLTQtMS0xLTM3MjYx_0a4be115-89a9-423a-b931-fe5d3ad868b7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGFibGU6NDg4ZWE4YjZjMWYyNDk2YTkwZGJhZmY3ZDAzOGQwY2EvdGFibGVyYW5nZTo0ODhlYThiNmMxZjI0OTZhOTBkYmFmZjdkMDM4ZDBjYV8yLTQtMS0xLTM3MjYx_e07bda8c-5969-451d-8ff9-35ad8b21ba2d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM180OTQ3ODAyMzI3MjY3_d2d06523-8717-49ff-8247-f4df1cc682fc">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie82ebd2afdea4a1990f6789118d0eb42_I20220502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8xL2ZyYWc6Y2RhZDI4NjJlODBjNDZlN2FjZTkzNTdlYzEyMThhZTMvdGV4dHJlZ2lvbjpjZGFkMjg2MmU4MGM0NmU3YWNlOTM1N2VjMTIxOGFlM18yMTc4_21705de0-e9a0-465a-87fb-de7f5728adf5"
      unitRef="shares">146687251</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMy0xLTEtMS0zNzI2MQ_8c74a9b2-78dc-4e1a-bbcc-91925c5f2452"
      unitRef="usd">120257000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMy0zLTEtMS0zNzI2MQ_5d9acc56-81a5-48f6-ae76-6af08e2b2a6a"
      unitRef="usd">178872000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNC0xLTEtMS0zNzI2MQ_a0fdd490-4f35-4db8-8b58-ddab459d97e5"
      unitRef="usd">197539000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNC0zLTEtMS0zNzI2MQ_2afae9da-bd0f-4f98-b988-89df0f103f86"
      unitRef="usd">197676000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNS0xLTEtMS0zNzI2MQ_9247ee91-4c06-4dc0-ad87-1601c9d76bc9"
      unitRef="usd">356000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNS0zLTEtMS0zNzI2MQ_ecbca8cb-32e4-41e9-83f8-fbb4320b5d46"
      unitRef="usd">349000</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNi0xLTEtMS0zNzI2MQ_27464fc8-e89e-4f6b-8c11-089dda7d036d"
      unitRef="usd">6938000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNi0zLTEtMS0zNzI2MQ_2cd8cb19-f935-4ffc-aabd-9f2b337267a8"
      unitRef="usd">6013000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNy0xLTEtMS0zNzI2MQ_fc5c94de-2533-45d2-ad7a-80a089be8ecc"
      unitRef="usd">14975000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfNy0zLTEtMS0zNzI2MQ_0f5a86d2-4fdb-469d-86dc-3d18c1700846"
      unitRef="usd">15859000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfOC0xLTEtMS0zNzI2MQ_b7435950-7f82-4f2d-b569-3b57f569e864"
      unitRef="usd">340065000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfOC0zLTEtMS0zNzI2MQ_48089063-e854-4d22-a9d4-46f0610e74f8"
      unitRef="usd">398769000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfOS0xLTEtMS0zNzI2MQ_ca4aa176-7b3a-4c41-aff8-ea1bb6014d32"
      unitRef="usd">82515000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfOS0zLTEtMS0zNzI2MQ_01fdab55-0d7e-4e09-aacc-fad533bfff91"
      unitRef="usd">88169000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTAtMS0xLTEtMzcyNjE_c82e382b-5a96-4b00-ba48-7265ac49c1ba"
      unitRef="usd">51600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTAtMy0xLTEtMzcyNjE_f4640b6a-8f50-451c-98be-a6d5d6f6075b"
      unitRef="usd">51523000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTEtMS0xLTEtMzcyNjE_8b0c24c2-0007-4a41-a87d-07e90157a338"
      unitRef="usd">52679000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTEtMy0xLTEtMzcyNjE_548bef7c-2f61-413a-bb6a-6edf55c1d5e6"
      unitRef="usd">53760000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTItMS0xLTEtMzcyNjE_71f927e4-a1ca-4092-ad0a-112710dbd404"
      unitRef="usd">38935000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTItMy0xLTEtMzcyNjE_741bdc2e-8794-43a8-8c95-41866cab4340"
      unitRef="usd">39702000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTMtMS0xLTEtMzcyNjE_633a5fdc-0a6a-497e-a1bb-19601d730185"
      unitRef="usd">70899000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTMtMy0xLTEtMzcyNjE_68afe8ec-bae5-43d8-ba0a-19fbc60dd2e2"
      unitRef="usd">73181000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTQtMS0xLTEtMzcyNjE_7370835e-3e1b-4505-a45d-1247db9e8a65"
      unitRef="usd">16117000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTQtMy0xLTEtMzcyNjE_b9d4cfbf-3f63-4a7a-a129-2edb2d25fc02"
      unitRef="usd">15319000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTUtMS0xLTEtMzcyNjE_919b1ace-d311-4b2f-8524-934b60d4ddbe"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTUtMy0xLTEtMzcyNjE_c92b5a5c-6e0f-4a7e-8994-f808d318cbba"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTYtMS0xLTEtMzcyNjE_32e4c863-21bc-43b7-b6bf-ba4e34fa1fa5"
      unitRef="usd">654310000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTYtMy0xLTEtMzcyNjE_5b626a14-3aa7-4ff8-bcbc-49bd4be8a739"
      unitRef="usd">721923000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTktMS0xLTEtMzcyNjE_9e85f3a1-8404-48b7-bf31-a070df4f71d9"
      unitRef="usd">11147000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMTktMy0xLTEtMzcyNjE_1253165d-672d-446f-a281-ce5968d8ede5"
      unitRef="usd">9759000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjAtMS0xLTEtMzcyNjE_9031e37d-31ef-4624-a8a5-a0978c39cab1"
      unitRef="usd">12493000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjAtMy0xLTEtMzcyNjE_95ded760-a412-4142-a4af-dee59db039fd"
      unitRef="usd">20840000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjEtMS0xLTEtMzcyNjE_c1c986de-2b53-4985-adc2-12c1a3a85867"
      unitRef="usd">14103000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjEtMy0xLTEtMzcyNjE_485b9406-7022-4c85-9070-715bde091ba1"
      unitRef="usd">11577000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjItMS0xLTEtMzcyNjE_dc736d55-ed62-46cb-a6d7-4dad856a1012"
      unitRef="usd">80783000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjItMy0xLTEtMzcyNjE_2132b9a3-b96e-4d30-8185-80fd95cb939d"
      unitRef="usd">85711000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjMtMS0xLTEtMzcyNjE_84341239-1100-4b8e-b773-984ab7f903eb"
      unitRef="usd">118526000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjMtMy0xLTEtMzcyNjE_e8fee5f1-f8ac-4215-ac47-0705b31769a0"
      unitRef="usd">127887000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjQtMS0xLTEtMzcyNjE_5e9fbeb5-e594-4706-8981-4fda19a36878"
      unitRef="usd">150700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjQtMy0xLTEtMzcyNjE_7f9382e8-f0b9-4777-9025-69cfd1100211"
      unitRef="usd">166776000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjUtMS0xLTEtMzcyNjE_a95cb08c-5d59-4ba9-9e9f-d89802e121e2"
      unitRef="usd">42815000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjUtMy0xLTEtMzcyNjE_05142c6a-5814-407a-ac36-253d4e20a34e"
      unitRef="usd">44055000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjYtMS0xLTEtMzcyNjE_7becb873-7ba7-4377-9a29-11fb9a5ba4bd"
      unitRef="usd">6511000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjYtMy0xLTEtMzcyNjE_daf4fcd2-1650-4858-9362-faa7668910ff"
      unitRef="usd">6645000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjctMS0xLTEtMzcyNjE_45ebd16b-6bc0-4137-b9b9-f2f7703c4c90"
      unitRef="usd">1236000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjctMy0xLTEtMzcyNjE_0c964875-c741-42f2-bd65-ffee72f4392e"
      unitRef="usd">1217000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjgtMS0xLTEtMzcyNjE_fd717b45-e0bd-4d48-b80a-37f8b4823fab"
      unitRef="usd">319788000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjgtMy0xLTEtMzcyNjE_4555bf16-a948-4bc7-b817-bf66aee3480b"
      unitRef="usd">346580000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjktMS0xLTEtMzcyNjE_fc22d66f-deb2-48a1-abd4-5f32228a2cee"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMjktMy0xLTEtMzcyNjE_e6e16a0c-0ad5-4b7f-b6c3-8ba7efa60de6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzEtMS0xLTEtMzcyNjE_8ff10722-cd60-4dd7-9c99-a8542a786d2f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzEtMy0xLTEtMzcyNjE_f102a538-17c6-4127-a53b-2d448451e5ca"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzItMS0xLTEtMzcyNjE_650d2b67-4fc8-4322-914b-145a35683a89"
      unitRef="usd">1467000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzItMy0xLTEtMzcyNjE_98f8c3bb-34ef-4803-80c2-f1866f4f955e"
      unitRef="usd">1459000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzMtMS0xLTEtMzcyNjE_3d80108f-c36d-41d8-a29b-af105f5ef162"
      unitRef="usd">1340254000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzMtMy0xLTEtMzcyNjE_63be9b6a-62a0-491e-9154-8f80bb732a27"
      unitRef="usd">1334138000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzQtMS0xLTEtMzcyNjE_0ec447ba-119e-4b19-8abe-09ab99705c78"
      unitRef="usd">-1000244000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzQtMy0xLTEtMzcyNjE_0a4b7bd3-2ef6-4ca8-a8a2-fa68582caf90"
      unitRef="usd">-956267000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzUtMS0xLTEtMzcyNjE_48a41542-8680-4e72-8c1b-21716823ebbd"
      unitRef="usd">-6955000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzUtMy0xLTEtMzcyNjE_bfada623-003b-44fc-acc3-b31947dfb29b"
      unitRef="usd">-3987000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzYtMS0xLTEtMzcyNjE_b44417fb-06cf-4ab3-954f-edba30050b06"
      unitRef="usd">334522000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzYtMy0xLTEtMzcyNjE_7e9a4129-8dbf-4781-bcb4-56196e55680b"
      unitRef="usd">375343000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzktMS0xLTEtMzcyNjE_30720e01-370e-40c0-a62a-2cef64fd5e57"
      unitRef="usd">654310000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yMi9mcmFnOjQ1ZTdlYzcxYWY0NDQzYjA5MWQ1YzBhM2JlZjRmZmFlL3RhYmxlOjZiMzY4MTc3ZjUxMzQxNGI4Yzk5NzIxYTM4ZGZhNmNkL3RhYmxlcmFuZ2U6NmIzNjgxNzdmNTEzNDE0YjhjOTk3MjFhMzhkZmE2Y2RfMzktMy0xLTEtMzcyNjE_26e4053f-069f-4d64-a272-4c970eca56a4"
      unitRef="usd">721923000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMi01LTEtMS0zNzI2MQ_4f614625-9e10-4345-8894-945a2e46ce5a"
      unitRef="usd">28231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMi03LTEtMS0zNzI2MQ_820211dd-844e-4907-8a0e-8fdef991d854"
      unitRef="usd">26280000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNC01LTEtMS0zNzI2MQ_3e04c410-341e-4d2d-97b7-f8e85d15aad5"
      unitRef="usd">58584000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNC03LTEtMS0zNzI2MQ_62e80a45-768a-4611-9309-0444f18388f9"
      unitRef="usd">56434000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNS01LTEtMS0zNzI2MQ_05ae905c-1014-4dfb-a68a-99fdcd3142e2"
      unitRef="usd">14908000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNS03LTEtMS0zNzI2MQ_3962a64b-ab3b-4c84-a708-b407e0650948"
      unitRef="usd">16148000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNi01LTEtMS0zNzI2MQ_eca27375-7f1c-401c-849b-94ceb460b15d"
      unitRef="usd">73492000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNi03LTEtMS0zNzI2MQ_ad12beef-571e-4c0f-a6e5-8de570968d10"
      unitRef="usd">72582000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNy01LTEtMS0zNzI2MQ_744eb115-5425-40c5-a4cb-20e5445f32de"
      unitRef="usd">-45261000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfNy03LTEtMS0zNzI2MQ_a63156fc-8396-4fa7-975e-fceeb9bb6a55"
      unitRef="usd">-46302000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfOC01LTEtMS0zNzI2MQ_11fe4196-8df6-4dae-ab56-412be6ed6c1b"
      unitRef="usd">1342000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfOC03LTEtMS0zNzI2MQ_5be27725-bd6e-49b7-9d59-4450f49308ae"
      unitRef="usd">625000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfOS01LTEtMS0zNzI2MQ_e613e4e5-419a-41e8-9f17-7ea9eca0cecf"
      unitRef="usd">-43919000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfOS03LTEtMS0zNzI2MQ_abc990bb-2f4e-4b50-bba4-e3bd4d39ade2"
      unitRef="usd">-45677000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTAtNS0xLTEtMzcyNjE_54f51ca9-732d-42a8-917d-463e0058a6f7"
      unitRef="usd">58000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTAtNy0xLTEtMzcyNjE_a0ae4b9b-6794-4793-9411-cadf2dadab4c"
      unitRef="usd">262000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTEtNS0xLTEtMzcyNjE_354755a7-2dc2-4e19-9e48-c6775ba09476"
      unitRef="usd">-43977000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTEtNy0xLTEtMzcyNjE_1d04e98b-cfca-4779-a1e3-45852a4567b5"
      unitRef="usd">-45939000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTItNS0xLTEtMzcyNjE_2d222e79-0e48-44b8-8a94-4bba6ef7a9d5"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTItNy0xLTEtMzcyNjE_d98559a6-c421-4588-9087-22130b5816e2"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTMtNS0xLTEtMzcyNjE_980a897c-aade-4b1e-bd20-13b6f7af81b2"
      unitRef="usd">-43977000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTMtNy0xLTEtMzcyNjE_0868a8d2-3d3c-409d-9a43-8b032a3bbc0b"
      unitRef="usd">-45933000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTQtNS0xLTEtMzcyNjE_06821f7b-40af-44cc-8f42-49e2aaefbf38"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTQtNS0xLTEtMzcyNjE_9259763c-1885-4a9e-acd7-30edce5f47d8"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTQtNy0xLTEtMzcyNjE_0f3634d7-e333-41eb-ae55-27daab1d4d5f"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTQtNy0xLTEtMzcyNjE_b12e84bf-8516-4051-8ab0-4399213c6636"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTUtNS0xLTEtMzcyNjE_9175871d-89fb-4670-9e72-2c3730edfabe"
      unitRef="shares">146218000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTUtNS0xLTEtMzcyNjE_b0d62144-7d6e-4b26-8e71-ce7e177c67d5"
      unitRef="shares">146218000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTUtNy0xLTEtMzcyNjE_69551e6b-f443-4baa-b7e5-8e9005761063"
      unitRef="shares">143112000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yNS9mcmFnOjNmMzJiNGE5MjEwZDRmOGQ4NGE4YTQ5YzkyNTExMzg3L3RhYmxlOjAwZTE1ZDk4OTc5OTQzMTBhY2UwNjZjNGQ1NTk5YzczL3RhYmxlcmFuZ2U6MDBlMTVkOTg5Nzk5NDMxMGFjZTA2NmM0ZDU1OTljNzNfMTUtNy0xLTEtMzcyNjE_dbdd9c66-20f6-45db-bf9c-49adff5ee410"
      unitRef="shares">143112000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfMi01LTEtMS0zNzI2MQ_354755a7-2dc2-4e19-9e48-c6775ba09476"
      unitRef="usd">-43977000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfMi03LTEtMS0zNzI2MQ_a2005f4e-c850-4298-b819-1faa5407388b"
      unitRef="usd">-45939000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfMy01LTEtMS0zNzI2MQ_bc49de8b-ea20-442c-ad2b-0bc3c0ea33ab"
      unitRef="usd">-1904000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfMy03LTEtMS0zNzI2MQ_ce912ed9-90da-4e81-b670-77a56050e802"
      unitRef="usd">-4749000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNC01LTEtMS00MTEwOQ_058b0604-f501-4e10-b3e0-7c76fe6793b6"
      unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNC03LTEtMS00MTEwOQ_d00dd45e-dd98-4409-aa9e-b7a5d4fd35a0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNC01LTEtMS0zNzI2MQ_9c4ffe27-a9c1-484e-9fed-6b006eb0dc46"
      unitRef="usd">-1083000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNC03LTEtMS0zNzI2MQ_e4bf596d-6704-48b7-ad52-f02ced15f8a3"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNi01LTEtMS0zNzI2MQ_b5f110ce-6877-401e-8adf-cdb3f3a1d333"
      unitRef="usd">-46945000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNi03LTEtMS0zNzI2MQ_2fb24634-ac94-4c25-9271-5f079e4422fd"
      unitRef="usd">-50644000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNy01LTEtMS0zNzI2MQ_c1bdb4ea-bf33-4bd7-9963-80e21f80fef0"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfNy03LTEtMS0zNzI2MQ_4e36d8a3-b3c1-42c7-bb05-346e1af47f11"
      unitRef="usd">-6000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfOC01LTEtMS0zNzI2MQ_b75cdd17-5801-4d4d-8d7b-e5475b7bf6fc"
      unitRef="usd">-46945000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8yOC9mcmFnOjA3MjE2MzExY2QwNDRjN2JhYTdiYWVmMzU1ZTdlOGEyL3RhYmxlOjU2N2IyNjUzNzFjYTQ3OTk4OTNjNTFmNzI2NWEzY2NjL3RhYmxlcmFuZ2U6NTY3YjI2NTM3MWNhNDc5OTg5M2M1MWY3MjY1YTNjY2NfOC03LTEtMS0zNzI2MQ_8a1bd8cb-74fb-4d19-8466-e18c22d0cb1e"
      unitRef="usd">-50638000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i98eb94bb16d64b339437154eeb6a8c7e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy0xLTEtMS0zNzI2MQ_230a636b-efbd-4560-98ab-1fd633027047"
      unitRef="shares">145921530</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98eb94bb16d64b339437154eeb6a8c7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy0zLTEtMS0zNzI2MQ_63ca0f9c-7dc6-468b-bcbb-e39fd1aea707"
      unitRef="usd">1459000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41b9a853412a4de5bbfc5086f43609a9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy01LTEtMS0zNzI2MQ_2cda2669-7b35-45ac-94d5-ab37172a6b0e"
      unitRef="usd">1334138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37f8868245aa4443834ca54fd2f6d165_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy03LTEtMS0zNzI2MQ_fc9443c3-b051-4450-bd3d-ad0aa290e5a9"
      unitRef="usd">-956267000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia25b49838a1e4216a648cda338998cd0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy05LTEtMS0zNzI2MQ_1230ff74-4546-4a88-9ec5-c9013417b550"
      unitRef="usd">-3987000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMy0xMy0xLTEtMzcyNjE_6dba0860-94ea-43fe-935f-191586605ab0"
      unitRef="usd">375343000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i16363a48a1db4200a557e20f74a6663e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNS0xLTEtMS0zNzI2MQ_283efac5-ed7a-4e10-9206-269d65c7e061"
      unitRef="shares">743230</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i16363a48a1db4200a557e20f74a6663e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNS0zLTEtMS0zNzI2MQ_3d91dbf1-073d-4ca8-90e8-a41b8495f034"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic0831195cbcb42c78e3d9a80acb8bd55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNS01LTEtMS0zNzI2MQ_399b359e-426c-418e-b4a3-5ad1cf3f8a6c"
      unitRef="usd">-1575000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNS0xMy0xLTEtMzcyNjE_78f87618-e4f2-47b8-871e-5049e477a849"
      unitRef="usd">-1567000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic0831195cbcb42c78e3d9a80acb8bd55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNy01LTEtMS0zNzI2MQ_ed26ca96-f068-4d39-8599-17328e43a930"
      unitRef="usd">7691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfNy0xMy0xLTEtMzcyNjE_1b91f7ba-475b-45f1-929b-6bdf6089b42a"
      unitRef="usd">7691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i415e7d08c2134893996d32a46190bba6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfOS05LTEtMS0zNzI2MQ_acc2c0da-0a66-4c79-bf11-426f7550c829"
      unitRef="usd">1904000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfOS0xMy0xLTEtMzcyNjE_db1d999e-9607-40ae-9400-c3735866e290"
      unitRef="usd">1904000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i415e7d08c2134893996d32a46190bba6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTEtOS0xLTEtNDExMTU_fa5d9615-434e-44c2-a4f9-d5f85b6efe6f"
      unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTEtMTMtMS0xLTQxMTE1_32a8e175-726b-426e-806e-9b9aaa344c26"
      unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i415e7d08c2134893996d32a46190bba6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTEtOS0xLTEtMzcyNjE_368d1645-9b47-44d6-bb59-1551a518f3af"
      unitRef="usd">-1083000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTEtMTMtMS0xLTM3MjYx_e90afeb9-9122-41fd-86e5-37af04be31de"
      unitRef="usd">-1083000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i9bdbe1eebb07447cadf7cd259b6f2ca8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTMtNy0xLTEtMzcyNjE_4738c110-5381-4571-95b8-036ec5e1c7da"
      unitRef="usd">-43977000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTMtMTMtMS0xLTM3MjYx_e18b38ec-ebea-41b4-9af5-5a53ffaa54be"
      unitRef="usd">-43977000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2e2ecbeebddf486b8f3eeebae6987fca_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtMS0xLTEtMzcyNjE_d7665df9-8bd0-4165-b2c5-d7554d13eab5"
      unitRef="shares">146664760</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e2ecbeebddf486b8f3eeebae6987fca_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtMy0xLTEtMzcyNjE_2bb8e5d3-531e-49ce-9263-3d0cf38f4119"
      unitRef="usd">1467000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i662af85bbcb24003939aa4e3f3b753ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtNS0xLTEtMzcyNjE_38e293f5-0ba0-4f1f-af70-15d96ea766bc"
      unitRef="usd">1340254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83b558b1d1b24287b972767cc449ee9c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtNy0xLTEtMzcyNjE_23c7b0b5-05db-4ebd-9189-ed1874ab2e46"
      unitRef="usd">-1000244000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd50e43eaec244a6a48c48e150d26257_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtOS0xLTEtMzcyNjE_f9b1af05-5544-452f-b8ff-550208574905"
      unitRef="usd">-6955000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOmY5ZjZhY2NiN2NlMTQxMzhiZDNmY2Y3MmQyNDA5ZmQ5L3RhYmxlcmFuZ2U6ZjlmNmFjY2I3Y2UxNDEzOGJkM2ZjZjcyZDI0MDlmZDlfMTQtMTMtMS0xLTM3MjYx_c32247e9-e842-4203-a61d-b40c77c98214"
      unitRef="usd">334522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib1dcfc8af9f54d79891a8e4f97258d64_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy0xLTEtMS0zNzI2MQ_a7d0e97a-dbc4-4101-9d2e-e8e6f111be9e"
      unitRef="shares">142063203</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1dcfc8af9f54d79891a8e4f97258d64_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy0zLTEtMS0zNzI2MQ_f5725e1f-2a32-4844-96df-ac4620f0360e"
      unitRef="usd">1421000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb68b7a02dc941ddb5eaea5f9e94cea0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy01LTEtMS0zNzI2MQ_80e329ea-7397-4636-a100-77ffc3ddaa0e"
      unitRef="usd">1269375000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i147ac2e91ee24c898b9135e2412019b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy03LTEtMS0zNzI2MQ_ed69a0f4-58db-45ab-89ef-2c87c0b18d74"
      unitRef="usd">-777981000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7736e400eca2413e926ef07b420d3523_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy05LTEtMS0zNzI2MQ_00617d20-738b-480b-82be-f3b27c0b9fbe"
      unitRef="usd">5419000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79928d1c5b534f9297876cf1cd9f42a0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy0xMS0xLTEtMzcyNjE_f700986b-4792-4f66-b483-0c1dcde9f5d6"
      unitRef="usd">-868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMy0xMy0xLTEtMzcyNjE_dc3dc409-417b-4cfd-8e49-aade84250d24"
      unitRef="usd">497366000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNC0xLTEtMS0zNzI2MQ_6283eb53-5048-4ab4-9975-c92d9e83f630"
      unitRef="shares">1034762</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNC0zLTEtMS0zNzI2MQ_cc1729af-bd07-418c-858a-cd70db43a038"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i133d4b1be36148219d4c9ca2c70121af_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNC01LTEtMS0zNzI2MQ_95c687ee-7383-4e0b-976c-25e8ba7e4d15"
      unitRef="usd">15641000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNC0xMy0xLTEtMzcyNjE_ece5de92-1bf9-43b9-ac9b-0acaf0b5791d"
      unitRef="usd">15651000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNS0xLTEtMS0zNzI2MQ_b1bfa446-5443-4fba-8fcc-7d90af3d57bd"
      unitRef="shares">615800</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0d143e0b08df402b84c60ad38a5ae636_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNS0zLTEtMS0zNzI2MQ_05478e3d-ce23-4ffa-86be-e4a56ed5dd1b"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i133d4b1be36148219d4c9ca2c70121af_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNS01LTEtMS0zNzI2MQ_eef61f6c-3a5e-44b6-8080-9fae8672bbbb"
      unitRef="usd">-422000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNS0xMy0xLTEtMzcyNjE_375bb2ca-21d9-4caa-ae8b-d6931c07ddf3"
      unitRef="usd">-416000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i133d4b1be36148219d4c9ca2c70121af_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNy01LTEtMS0zNzI2MQ_4b179124-e132-4b78-bf77-a546aac76ba9"
      unitRef="usd">7524000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfNy0xMy0xLTEtMzcyNjE_87676362-1751-4dc6-a7a8-b74e17cd5d23"
      unitRef="usd">7524000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="ic0a5d019cb57482287e3752a44cd9473_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfOC0xMS0xLTEtMzcyNjE_0282e4a8-4a8f-41d3-aa62-640b06afb232"
      unitRef="usd">-64000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfOC0xMy0xLTEtMzcyNjE_85962e6f-7137-4e22-8c10-28af1e479568"
      unitRef="usd">-64000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i7621415fb2b84296bc6b90e3b825982c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfOS05LTEtMS0zNzI2MQ_014553de-e541-45d6-96ff-60756a7659d4"
      unitRef="usd">4749000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfOS0xMy0xLTEtMzcyNjE_4a90525b-6f79-4241-85a7-afd198f2e52d"
      unitRef="usd">4749000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7621415fb2b84296bc6b90e3b825982c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTEtOS0xLTEtMzcyNjE_7c1b72e8-96cf-40fc-b615-cc724da19838"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTEtMTMtMS0xLTM3MjYx_2555f561-a8a4-44ba-9b54-b6c98ebe9e8d"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ib41c6577ca4a47df91565832e4f8c52f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTItNy0xLTEtMzcyNjE_e05bf1cf-5b12-445a-9be0-83906c5f4407"
      unitRef="usd">-45933000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic0a5d019cb57482287e3752a44cd9473_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTItMTEtMS0xLTM3MjYx_97d90a81-84f2-4ef5-bdf4-5ec42fe78638"
      unitRef="usd">-6000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTItMTMtMS0xLTM3MjYx_afb1ae16-9ff3-4332-9cb7-5aec6b0222d0"
      unitRef="usd">-45939000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib0ac3d6b9a014f3fb9c09c50fb836aa1_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtMS0xLTEtMzcyNjE_35a94522-28c1-44b3-bbf9-7a4b9d9d537b"
      unitRef="shares">143713765</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib0ac3d6b9a014f3fb9c09c50fb836aa1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtMy0xLTEtMzcyNjE_931180e3-2ec7-4c2d-8c97-d579cca9b415"
      unitRef="usd">1437000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1696ceaafa594b6e8a7aa213973bb86f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtNS0xLTEtMzcyNjE_5026d36a-59c1-4580-86c7-a9c45e651e52"
      unitRef="usd">1292118000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i179494c7d70e4d1980c455d43a0ccccd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtNy0xLTEtMzcyNjE_93133610-2824-4513-843e-a668d1e5b5f2"
      unitRef="usd">-823914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76ac39ac4cc046d3891f2f198d2f40a6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtOS0xLTEtMzcyNjE_5a8fb4af-ec64-453b-8201-d954a6384160"
      unitRef="usd">714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c1c94341c8140bb850188c07c23add8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtMTEtMS0xLTM3MjYx_651ba6e1-bab4-4186-a186-d397d4653e24"
      unitRef="usd">-938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zMS9mcmFnOjdjZDNjNjBjNDg1NTQwOGVhYTQ0Y2UwN2Q5NTIxOTQwL3RhYmxlOjQ3OTI1MTVhNjYwZTQzZmRiMjlhNjY3NzQwZjg1YWIwL3RhYmxlcmFuZ2U6NDc5MjUxNWE2NjBlNDNmZGIyOWE2Njc3NDBmODVhYjBfMTMtMTMtMS0xLTM3MjYx_5ed3e85c-ac6d-4ef6-805d-aaa4d5ac28e1"
      unitRef="usd">469417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMy0xLTEtMS0zNzI2MQ_0236cdf8-0565-402a-b7db-20b437e53cb5"
      unitRef="usd">-43977000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMy0zLTEtMS0zNzI2MQ_975aed2e-f851-4790-a076-c4feac7e8ac4"
      unitRef="usd">-45939000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNS0xLTEtMS0zNzI2MQ_3b576969-5aa6-45d2-84b0-749ae2da0cd5"
      unitRef="usd">2832000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNS0zLTEtMS0zNzI2MQ_183bfe04-dad8-441c-8a92-e0fc1d8f8905"
      unitRef="usd">1875000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNi0xLTEtMS0zNzI2MQ_2a76b4e6-8915-4dd5-b3fe-bd42cbd2e909"
      unitRef="usd">-164000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNi0zLTEtMS0zNzI2MQ_c90f5a69-025a-47e6-b8ff-7f748c2314df"
      unitRef="usd">-824000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNy0xLTEtMS0zNzI2MQ_639e2b8a-30cf-446b-8e45-a29970876537"
      unitRef="usd">-2106000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNy0zLTEtMS0zNzI2MQ_b2e0b62b-2a3a-467d-8495-41f2d7204119"
      unitRef="usd">-2023000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:GainLossOnFreeShares
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfOC0xLTEtMS0zNzI2MQ_0753fd33-010a-47b8-b190-27a422649871"
      unitRef="usd">0</sgmo:GainLossOnFreeShares>
    <sgmo:GainLossOnFreeShares
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfOC0zLTEtMS0zNzI2MQ_be93fc8e-aae9-4d5f-9ef4-da406e2143ef"
      unitRef="usd">-27000</sgmo:GainLossOnFreeShares>
    <us-gaap:ShareBasedCompensation
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfOS0xLTEtMS0zNzI2MQ_4ad75651-b388-4e8e-a8d7-0bb2880e7af3"
      unitRef="usd">7691000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfOS0zLTEtMS0zNzI2MQ_b61ab17b-49b0-4b9c-83ca-c34c723a8ef3"
      unitRef="usd">7524000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTMtMS0xLTEtMzcyNjE_973c7143-ba40-405c-84fe-03a5709161ab"
      unitRef="usd">925000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTMtMy0xLTEtMzcyNjE_b3a4d002-e24e-4d1a-9c9a-9b76c9f12f22"
      unitRef="usd">1522000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTQtMS0xLTEtMzcyNjE_5f690995-9941-41e0-9054-e5ebe91d7720"
      unitRef="usd">248000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTQtMy0xLTEtMzcyNjE_511cc0cb-ff3a-4162-bb51-a80319b12bbc"
      unitRef="usd">1680000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTUtMS0xLTEtMzcyNjE_bced7a70-db9b-4039-85fc-f067ea441535"
      unitRef="usd">3609000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTUtMy0xLTEtMzcyNjE_5d614db2-f39d-419c-9cf3-17ddfb03ca6e"
      unitRef="usd">-3829000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTctMS0xLTEtMzcyNjE_eeeea7a0-0961-4832-9954-7f24a51f631b"
      unitRef="usd">-8270000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTctMy0xLTEtMzcyNjE_ccea1a23-9dc7-4947-98df-f760a7c983a7"
      unitRef="usd">-7561000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTktMS0xLTEtMzcyNjE_579d508e-a790-44db-8e28-7701f5e3d7ca"
      unitRef="usd">-21004000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMTktMy0xLTEtMzcyNjE_6ec69f46-68c0-48c9-94d0-1e8bf2308f04"
      unitRef="usd">-20047000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjAtMS0xLTEtMzcyNjE_78887217-bb13-49ae-93e7-9b3aa415a6aa"
      unitRef="usd">-972000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjAtMy0xLTEtMzcyNjE_17e520e5-55b7-4e75-aa35-12b22fca89c7"
      unitRef="usd">-1045000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjEtMS0xLTEtMzcyNjE_c6033073-33fd-4151-a33a-fc14f64b5dc9"
      unitRef="usd">19000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjEtMy0xLTEtMzcyNjE_3b2f7a06-ce47-4ddd-bc21-ada5e98a6467"
      unitRef="usd">800000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjItMS0xLTEtMzcyNjE_7f2d3c3e-0a7b-4bcf-ac82-0925076ce814"
      unitRef="usd">-58975000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjItMy0xLTEtMzcyNjE_699ba0bf-3873-4c7e-9c18-6697f52b1897"
      unitRef="usd">-68550000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjQtMS0xLTEtMzcyNjE_e8792ed8-94de-4433-8d9f-687ac31f7757"
      unitRef="usd">65756000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjQtMy0xLTEtMzcyNjE_8e083949-0abb-4f4b-b375-ad350f6ac7cf"
      unitRef="usd">97935000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjUtMS0xLTEtMzcyNjE_2c163c73-211c-4cf8-812e-f295281e3ba9"
      unitRef="usd">70300000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjUtMy0xLTEtMzcyNjE_e54a5698-4ecb-4ea9-b3e4-ba72da402246"
      unitRef="usd">144369000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjYtMS0xLTEtMzcyNjE_ff078586-b7ea-4fad-a569-39b979183eae"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjYtMy0xLTEtMzcyNjE_e7e1a424-5022-4a5e-82ff-76132e3409c9"
      unitRef="usd">6870000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjctMS0xLTEtMzcyNjE_eefc263f-3876-48de-bee1-3ce658d75e9a"
      unitRef="usd">2839000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjctMy0xLTEtMzcyNjE_8d1a2a71-526f-46dc-9a32-497ef744e2f9"
      unitRef="usd">7950000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjgtMS0xLTEtMzcyNjE_5a3e5fd3-1ebe-486a-a2b6-a57b4acd8f45"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMjgtMy0xLTEtMzcyNjE_d811de30-f2a6-477d-851e-1dc641c946ee"
      unitRef="usd">65000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzAtMS0xLTEtMzcyNjE_27d619a3-915e-4b38-ae02-3910e971b0ef"
      unitRef="usd">1705000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzAtMy0xLTEtMzcyNjE_b0ce95af-3a86-48d5-8f0f-3055c07be3a3"
      unitRef="usd">45289000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i88c52382b7dc4becb1cb30fb680833c0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzItMS0xLTEtMzcyNjE_1ef186b1-9747-4d2d-95b6-92c5d1bc41b4"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i21ce04a30e5b4a2f9c36548cda5a8458_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzItMy0xLTEtMzcyNjE_7c775072-8e43-49b6-9bcb-34eeb532329d"
      unitRef="usd">15651000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzQtMS0xLTEtMzcyNjE_ceb5b51c-3321-4f8b-ab4b-a7c9da413a61"
      unitRef="usd">1641000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzQtMy0xLTEtMzcyNjE_b7e39acc-e274-45b3-85eb-fd71c76c9c06"
      unitRef="usd">2234000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzUtMS0xLTEtMzcyNjE_fea53eba-b5f3-4342-b2c9-f1e653c9f71f"
      unitRef="usd">74000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzUtMy0xLTEtMzcyNjE_abde58f7-2201-4395-9163-f1dab67af98e"
      unitRef="usd">1818000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzctMS0xLTEtMzcyNjE_269aed37-1a6b-4787-862e-e311ac0eff73"
      unitRef="usd">-1567000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzctMy0xLTEtMzcyNjE_93a0640e-d249-42ba-926d-7b3df74f89f9"
      unitRef="usd">15235000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzgtMS0xLTEtMzcyNjE_1c10484c-66d2-4393-88de-c91b04155de6"
      unitRef="usd">222000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzgtMy0xLTEtMzcyNjE_abdf7fce-d609-43c8-8354-457bba37a8e8"
      unitRef="usd">-328000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzktMS0xLTEtMzcyNjE_6a137384-a035-41cc-8f24-5584e64f4604"
      unitRef="usd">-58615000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfMzktMy0xLTEtMzcyNjE_78afd387-7e98-402f-97b5-fbf34e5dcf4b"
      unitRef="usd">-8354000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDAtMS0xLTEtMzcyNjE_6109f509-a431-47ed-92d5-f7a73b9ce429"
      unitRef="usd">180372000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDAtMy0xLTEtMzcyNjE_a8206b34-3d88-4b63-b307-749fdb459ef8"
      unitRef="usd">132829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDEtMS0xLTEtMzcyNjE_f46c7150-823f-4364-a045-9bf27e24f583"
      unitRef="usd">121757000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDEtMy0xLTEtMzcyNjE_2fa3db48-64b8-4665-a8a5-61bef2327e45"
      unitRef="usd">124475000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDMtMS0xLTEtMzcyNjE_9942c92e-35a8-4d0b-be68-a77f6c3e0394"
      unitRef="usd">2257000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDMtMy0xLTEtMzcyNjE_8ccc3cbe-8984-48cf-9e64-d3466b7ffc1f"
      unitRef="usd">2953000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDQtMS0xLTEtMzcyNjE_1bb16565-bdfe-4c76-b818-17433db215ea"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV8zNC9mcmFnOjExN2E1NTAzMDI2ZDQ2MDA4MGM0NGUzZjc5OTc2NjlhL3RhYmxlOjVlNjI0MzZkYzZkMTRmNjA4N2U2MmI2YzE3YjM1OTk0L3RhYmxlcmFuZ2U6NWU2MjQzNmRjNmQxNGY2MDg3ZTYyYjZjMTdiMzU5OTRfNDQtMy0xLTEtMzcyNjE_9c77e6c0-b874-4984-8860-8458c3b4d1b7"
      unitRef="usd">1356000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxNDQ_f46328af-44c9-4c9b-9352-f80676a3ecd4">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or &#x201c;the Company&#x201d;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The Condensed Consolidated Balance Sheet data at December&#160;31, 2021 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#x201c;2021 Annual Report&#x201d;) as filed with the SEC on February&#160;24,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2021, included in the 2021 Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Management&#x2019;s Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents, and marketable securities as of March&#160;31, 2022, and expected future milestones and research services revenue from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12&#160;months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, if at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#x2019;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#x2019;s stockholders, and any debt financing may include covenants that restrict the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in estimates during the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC&#160;Topic&#160;606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received from the Company&#x2019;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxNDE_9e1fab9d-6dcf-4e58-9392-523e4df3b758">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The Condensed Consolidated Balance Sheet data at December&#160;31, 2021 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#x201c;2021 Annual Report&#x201d;) as filed with the SEC on February&#160;24,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2021, included in the 2021 Annual Report.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxNDA_4b3afd73-dd0d-4d33-a4a3-04f084341351">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for &lt;/span&gt;&lt;/div&gt;making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMTY_23ac2b21-bd1f-49a0-9ddb-b2469d099317">&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC&#160;Topic&#160;606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received from the Company&#x2019;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMTk_390f50c2-e966-4389-ab3e-4c60264a83c3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib44f00bdda5c4a5e8fdf09b0b409881d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfMi01LTEtMS0zODA4Mw_350887df-af12-48b3-a09a-4be898a02901"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0fd799de345849b7bde24906fccf9e47_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfMi03LTEtMS0zODA4Mw_ee183212-038d-4c48-bd0a-116071eea9fd"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb254f83fdd54a5394d3789ac0432acd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfMi01LTEtMS0zNzI2MQ_fba78b03-0314-4390-ba55-49d1b56133b1"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icb3e3c9e9fc34bada2506884b81bcc4a_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfMi03LTEtMS0zNzI2MQ_df764cc1-4692-4d75-af19-bfdd8f73d84a"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib77a01f4821e403fbaed538181093649_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfNC01LTEtMS0zNzI2MQ_0070df7e-fc35-434f-9319-ed94dc0137db"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i399ab68bf5a34a708f1ac215d91b5ef3_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfNC03LTEtMS0zNzI2MQ_b35097b2-4683-482f-91f7-8a3ea7506715"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idf49db6b57ed4468b600943a63027618_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfNS01LTEtMS0zNzI2MQ_ad4adb06-a283-4cc6-bb2b-d0aaa4876e31"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2e569774fd874df0b2278b667d3537b1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmVmZGFjOTVmNWNhNzQ2N2Y5YjRlNTM1YzNkM2RmMjdkL3RhYmxlcmFuZ2U6ZWZkYWM5NWY1Y2E3NDY3ZjliNGU1MzVjM2QzZGYyN2RfNS03LTEtMS0zNzI2MQ_bc422348-48dc-46d9-b297-c405f143e901"
      unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMzY_6235aae3-2edd-4077-8028-e2c5d8268b15">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMTcwMTg_9b3f73bc-fa28-4936-be1d-de138b281ade"
      unitRef="usd">1500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMzI_641230c5-da3b-436f-99c3-c82c5ac894e7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMzI_c3a01cc3-6efc-4056-aebf-8b200f611614">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMS0xLTEtMS0zNzI2MQ_f4806808-4444-4a8c-93bf-bbb3af7188c0"
      unitRef="usd">120257000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMS0zLTEtMS0zNzI2MQ_c5aaa511-fa6e-4abb-99b5-437bd8a18dbe"
      unitRef="usd">178872000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMS01LTEtMS0zNzI2MQ_eacb1f04-ec2d-46ab-af89-d047028187b8"
      unitRef="usd">122975000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMS03LTEtMS0zNzI2MQ_d028c43d-b3ff-4af8-940a-f5ef9dc35e26"
      unitRef="usd">131329000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMi0xLTEtMS0zNzI2MQ_37ebee5c-5460-4baa-b2a3-9cd0243891c3"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMi0zLTEtMS0zNzI2MQ_8caf13fd-822a-4cc5-8881-94c137dec393"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMi01LTEtMS0zNzI2MQ_2852136d-2c21-47cc-a709-1aeb65fbc96f"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMi03LTEtMS0zNzI2MQ_4c92eb8d-f433-4e53-bde7-b946cc6a019e"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMy0xLTEtMS0zNzI2MQ_3685c2e0-a800-47f1-aac7-fc04f1da8429"
      unitRef="usd">121757000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMy0zLTEtMS0zNzI2MQ_85ff7109-12cb-4c83-b072-67313130b959"
      unitRef="usd">180372000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i66b727537ef44d20a3118a3b2f4aae71_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMy01LTEtMS0zNzI2MQ_44d55f7f-baea-40cd-8771-fcc7a8b30e9c"
      unitRef="usd">124475000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if027201194ec44b2a8a8aaa563d56062_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RhYmxlOmI4NDExODA2OGRkOTQwMTA5M2ViNWNlMzJkNDE0ZTNkL3RhYmxlcmFuZ2U6Yjg0MTE4MDY4ZGQ5NDAxMDkzZWI1Y2UzMmQ0MTRlM2RfMy03LTEtMS0zNzI2MQ_20a27cb3-400c-4233-b789-cf91793f9062"
      unitRef="usd">132829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80MC9mcmFnOjkxM2VjMTk4MTIyZDQwMmFiZjlmNDM5MmMwZTMxYjk0L3RleHRyZWdpb246OTEzZWMxOTgxMjJkNDAyYWJmOWY0MzkyYzBlMzFiOTRfMjMxMjQ_6a3de123-b8b2-42fa-91e9-236e077b7487">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RleHRyZWdpb246ZWJjZmNmNDFhYTg4NDRmYTllZWVmMDVjNGEyZDQxMGJfMzEwMg_8027386e-8028-4cd7-85e0-e6c73bf15586">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities, and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RleHRyZWdpb246ZWJjZmNmNDFhYTg4NDRmYTllZWVmMDVjNGEyZDQxMGJfNDk0NzgwMjMzMTQwNQ_1d40cc43-a262-4689-86d2-b0ec095c450e">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities, and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RleHRyZWdpb246ZWJjZmNmNDFhYTg4NDRmYTllZWVmMDVjNGEyZDQxMGJfMzA5OQ_5fb54e9d-4e63-4753-9630-bafa49c7ce4a">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i40ec91078cbd4fef9b2ff9b118a62896_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNS0xLTEtMS0zNzI2MQ_3d4a9677-a3a3-4ad2-8f9b-f08aa70fed15"
      unitRef="usd">49827000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1e8560aa3fb044e2afe37becdf007481_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNS0zLTEtMS0zNzI2MQ_f14ecd78-1621-442d-81cc-c5d27ed558ca"
      unitRef="usd">49827000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaf2e671b261e4b9a9510eea1dd524ffe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNS01LTEtMS0zNzI2MQ_b3a6ad29-3c12-46dc-a186-9e2a04569072"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i143dc860af4e41ca8ad56c89389f8c0e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNS03LTEtMS0zNzI2MQ_c7f77870-f475-44f2-aa4b-3cb969a4d006"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9ff2db9628f4469aa4b0d9190c623367_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy0xLTEtMS00MTEyNA_a5d7db16-ce9e-4a09-afc8-8416257bb11d"
      unitRef="usd">15008000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i16bb308b033f4cfd8478d6ed83ab7469_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy0zLTEtMS00MTEyNA_95817a1a-a42e-48eb-b240-f5633e13d9a9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i09f7155daf244fe2847f5df4bca90b38_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy01LTEtMS00MTEyNA_f4646ab4-7752-4541-9f53-bdc438bb86d7"
      unitRef="usd">15008000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i50c2af11dc0945a1a2b563bdd67a34e9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy03LTEtMS00MTEyNA_0023cc47-95a6-4de7-b3e1-bd16f3334876"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i708b092c6ed84bd1bbf020943bc286ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy0xLTEtMS0zNzI2MQ_82a6ba2f-399f-4f95-9417-7a50bc1aa13f"
      unitRef="usd">64835000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id893d7bf0fe340b493ce98b8ad036faa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy0zLTEtMS0zNzI2MQ_77f644fd-490c-4d51-a643-9f97cb897f49"
      unitRef="usd">49827000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie45eb48d4aac42dcb834ce4d4238cbc5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy01LTEtMS0zNzI2MQ_dcd8a784-a8a6-44f8-824d-8c4d0b05f22f"
      unitRef="usd">15008000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b546e6ad858449f9375bab65733a9ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfNy03LTEtMS0zNzI2MQ_c9fd5aa4-130e-4a19-9c0c-57bfb76cd429"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ff2db9628f4469aa4b0d9190c623367_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfOS0xLTEtMS0zNzI2MQ_85e6ade4-9b3a-4bc2-be11-bb99fda381ee"
      unitRef="usd">24441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16bb308b033f4cfd8478d6ed83ab7469_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfOS0zLTEtMS0zNzI2MQ_6f57e131-a801-454e-8394-a32b34eef9eb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i09f7155daf244fe2847f5df4bca90b38_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfOS01LTEtMS0zNzI2MQ_db89d589-c846-4e63-abd0-578a6afcf069"
      unitRef="usd">24441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50c2af11dc0945a1a2b563bdd67a34e9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfOS03LTEtMS0zNzI2MQ_1b41eec9-3cee-48fe-86ac-5557b5360f4f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i30b4f1bdb97d4271beba4b63564701b1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTAtMS0xLTEtMzcyNjE_0f870a18-0ea2-4d08-a1b6-3529d576166b"
      unitRef="usd">117325000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied809edebcb648f59c57c3137795b9c2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTAtMy0xLTEtMzcyNjE_c80b0a21-7a6e-4355-9f52-8e3cab8456ec"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1456174ba11d44a79cda4fef54a9527a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTAtNS0xLTEtMzcyNjE_2a2adaed-6341-4fa4-9dbe-f26b41bc3238"
      unitRef="usd">117325000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i304cf3079db74ee581bad5edc8ea8eb6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTAtNy0xLTEtMzcyNjE_fd40a67d-3b72-4dd5-92ff-dfbb38702187"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic21a61daf2da4126898da412720ef0c1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTEtMS0xLTEtMzcyNjE_c2416d2d-1a1e-494c-9ee3-522c2adc4399"
      unitRef="usd">17373000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic156a4b9bcd648ffabb65ad460686df9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTEtMy0xLTEtMzcyNjE_3ff963bb-0445-4564-9bd1-8a290bed2899"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7eb75b0131d244f9b44926706c6e6e1a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTEtNS0xLTEtMzcyNjE_34287f44-460c-4830-b8b5-9e0a1043dff9"
      unitRef="usd">17373000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08f31b20a2b442a592d8b411d50e9a36_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTEtNy0xLTEtMzcyNjE_93a4a90a-ff50-442f-8860-9e8f21e2fcaa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05c76a773d414d409fa20c7e798a1ead_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTItMS0xLTEtMzcyNjE_3dd4456e-f7c4-4dde-9681-cb7e9cc94ec4"
      unitRef="usd">67515000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c6006abfadc42c5890e9f29785dbba5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTItMy0xLTEtMzcyNjE_4062c700-b107-4cf7-a924-a461bb19d186"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b0b1b7628b74a32bf1f89c76bd39253_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTItNS0xLTEtMzcyNjE_2c480cc3-5ad3-430d-9b15-10d837b64959"
      unitRef="usd">67515000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9f93a4e5c614d898f2dba36b145b91a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTItNy0xLTEtMzcyNjE_24002e97-5db5-470d-9985-9ec472ac4c9c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9d2ad076baf46aa95e6b9a86a08f8fc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtMS0xLTEtNDA4MDI_52e4ecf6-5474-4aa3-a881-153be7c897cf"
      unitRef="usd">2995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i021e4eb600444817b880d3c34fb52136_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtMy0xLTEtNDA4MDg_ea4571f3-16b4-4b68-bd45-563292bfc6b6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id96bcec60508420a9f72a54a34521d52_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtNS0xLTEtNDA4MTQ_9a2ab5b8-a186-477b-90f0-3f1abc4eb6f0"
      unitRef="usd">2995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i906b3eb7e3734168ba335e172b1fa959_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtNy0xLTEtNDA3OTU_ba79abc5-4309-493e-8eef-b1e2b144e55f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5adf2fec9bea4ba899e404e902cb35bd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTMtMS0xLTEtMzcyNjE_7a563f65-3c10-43df-9be9-4fa4fb321667"
      unitRef="usd">50405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if05b14fccaf44e1180d2ef8bbe382fec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTMtMy0xLTEtMzcyNjE_f3351156-4915-44fd-a814-3355eee7a296"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c37e7249d9345dc9330907394eb067f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTMtNS0xLTEtMzcyNjE_d92fd2f3-2866-4ecf-b90f-d54ba00ec99b"
      unitRef="usd">50405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i412513ce57b94ec0bf641412ee64ef34_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTMtNy0xLTEtMzcyNjE_933989a7-ed01-4d59-bda2-0a8adf992eae"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i708b092c6ed84bd1bbf020943bc286ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtMS0xLTEtMzcyNjE_756f9d87-bc7e-4531-a9da-1a2a4ba130c0"
      unitRef="usd">280054000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id893d7bf0fe340b493ce98b8ad036faa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtMy0xLTEtMzcyNjE_df4f8940-8df5-43b0-975c-8e8002cf7589"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie45eb48d4aac42dcb834ce4d4238cbc5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtNS0xLTEtMzcyNjE_d4f61623-56d3-4f9b-ad0b-29e61ddd6a63"
      unitRef="usd">280054000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b546e6ad858449f9375bab65733a9ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTQtNy0xLTEtMzcyNjE_053799a3-6a4f-40c0-877b-e1c4e097d690"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i708b092c6ed84bd1bbf020943bc286ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTUtMS0xLTEtMzcyNjE_c15b3116-e0af-40b9-bacf-cd86ee933a24"
      unitRef="usd">344889000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id893d7bf0fe340b493ce98b8ad036faa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTUtMy0xLTEtMzcyNjE_07bca680-1879-4542-b5e3-6afceff76c8e"
      unitRef="usd">49827000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie45eb48d4aac42dcb834ce4d4238cbc5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTUtNS0xLTEtMzcyNjE_6ed3c5b8-25f3-4c40-a94d-c05e7677c6b7"
      unitRef="usd">295062000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b546e6ad858449f9375bab65733a9ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOmVhOWUxODNkMWM1YTQzMWM5YjEyNmMxMjdjMjI2YjdiL3RhYmxlcmFuZ2U6ZWE5ZTE4M2QxYzVhNDMxYzliMTI2YzEyN2MyMjZiN2JfMTUtNy0xLTEtMzcyNjE_e71ee58c-feb5-4e6d-bc20-b223ed99ee7c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib0a823a89d644a15b67b9a1a84a15ea6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNS0xLTEtMS0zNzI2MQ_32b456cf-eb4b-4c4d-878e-d21023655199"
      unitRef="usd">119919000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i26d1cbbf6bfc4b6fae628fbceab20e0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNS0zLTEtMS0zNzI2MQ_a27435fc-3b85-4499-9554-a6781b03da9f"
      unitRef="usd">119919000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2e70945d068e421d8e7e13119a342d96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNS01LTEtMS0zNzI2MQ_e71add87-2668-4433-903b-91973e66d7ba"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c70fd8f212a44f0b0fd39c5da686631_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNS03LTEtMS0zNzI2MQ_0491a4c0-f750-417a-9914-1c951affa9d7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6d5062dc4f6c4aea9b5af1b8206788f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNi0xLTEtMS0zNzI2MQ_a3f6993c-d832-401f-9a54-6dd77ebeb38b"
      unitRef="usd">119919000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifa8460203d45415f877cfffa51733070_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNi0zLTEtMS0zNzI2MQ_25f4a02b-55c3-45de-aa61-12a81d19137b"
      unitRef="usd">119919000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5e5e6402ec45427eae4f571d473ddedf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNi01LTEtMS0zNzI2MQ_2fd71643-4bc3-4a9a-9df4-010b437600d9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i752f160556a747deb9e6619b306a9579_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfNi03LTEtMS0zNzI2MQ_89a17100-78c2-4549-876c-c3bf6d3caf35"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba495162727d4dc1ad3ca1981bbe7c17_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOC0xLTEtMS0zNzI2MQ_eb6c3ed2-d3a4-43d4-8cee-30f74438e429"
      unitRef="usd">30614000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa05cd9050654d27a2da2817cacdacc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOC0zLTEtMS0zNzI2MQ_e3501c03-5654-481a-98fb-d36e603b3632"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib156eb5be64c4a22a4011ee880db1829_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOC01LTEtMS0zNzI2MQ_c55581d9-3707-45ad-9744-06fc6ec9ed37"
      unitRef="usd">30614000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f1034cd2a6148f9a0d34eccdef2cb56_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOC03LTEtMS0zNzI2MQ_1156a518-d5d9-4f6b-8980-550e797c5c23"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c0f076cbacf47db8a333a0ba2a9744c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOS0xLTEtMS0zNzI2MQ_5459a75f-207c-49db-b0c9-086279138ce7"
      unitRef="usd">105757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15c97739d5bf4f7aaf30ff5711b7b551_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOS0zLTEtMS0zNzI2MQ_5248c359-3c0c-4851-aab9-9bb31690f8e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id90c35cf8bca444c9fe316fa99c0ccc9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOS01LTEtMS0zNzI2MQ_9ade1487-4510-4a22-9a75-0fae9ed48abf"
      unitRef="usd">105757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8eb71551dfe411696e39c0e4a98ac05_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfOS03LTEtMS0zNzI2MQ_e2ec1a1a-f57a-466a-9a31-a8248dcc314f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85f2894d23e54b5c8bc3535256e6f430_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTAtMS0xLTEtMzcyNjE_2d2fab5a-dd22-4381-ae47-5bad814feef9"
      unitRef="usd">33682000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia241ff32633d44d0995fa41d3b30c749_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTAtMy0xLTEtMzcyNjE_2b1eaf33-1597-4283-8036-298cd4828efa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i652c08590692478dbad26f055bd24b22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTAtNS0xLTEtMzcyNjE_06d265a5-45df-4961-982d-141c4606c3e6"
      unitRef="usd">33682000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1900186abb04fcd8679b20fe15aa9eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTAtNy0xLTEtMzcyNjE_b2766a39-a467-467c-aa0f-71c75d23c10b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie94522ff63b14c7c8f42c47bc206bcf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTEtMS0xLTEtMzcyNjE_4a44f5ef-4522-4cb7-a71f-1eb8b6269502"
      unitRef="usd">70701000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96a079914a6f4629944a16c5c8f8c67f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTEtMy0xLTEtMzcyNjE_6d31df1d-4e03-49dc-b870-2861f697f341"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b82c587da8e49dba0a77764e4e9678f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTEtNS0xLTEtMzcyNjE_fe0324dd-0cc0-430e-a9fe-5599f7c34495"
      unitRef="usd">70701000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89392c2987434d09bae08df932002bb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTEtNy0xLTEtMzcyNjE_1dc93482-7671-45ea-82ab-c54775e4ff32"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadab9f649ee64aa18743fe966255becd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTItMS0xLTEtMzcyNjE_72993cf2-f814-47b2-8615-1c8d84a47dc1"
      unitRef="usd">45091000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd13862a3fc0418f8cf10ae64ad1ac6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTItMy0xLTEtMzcyNjE_1c9cfdc1-8c4b-45d1-8ab7-d98806586b2c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0369288ea6d34134bdc95a49a5e089a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTItNS0xLTEtMzcyNjE_8d47918b-c161-491c-8f1d-c29801dc7f5a"
      unitRef="usd">45091000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7c2de2dac42941aea08c2173d245c90d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTItNy0xLTEtMzcyNjE_bbccf775-751c-4054-8285-dd9d437aba6a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d5062dc4f6c4aea9b5af1b8206788f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTMtMS0xLTEtMzcyNjE_f19cc2b7-3f3a-4f2a-b472-df0c7274b675"
      unitRef="usd">285845000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa8460203d45415f877cfffa51733070_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTMtMy0xLTEtMzcyNjE_5e5603e2-2266-42ea-ad0b-6d27e3796007"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e5e6402ec45427eae4f571d473ddedf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTMtNS0xLTEtMzcyNjE_fdb941a4-397d-4014-9ad0-864bb94cf834"
      unitRef="usd">285845000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i752f160556a747deb9e6619b306a9579_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTMtNy0xLTEtMzcyNjE_35b65ea1-50bb-4521-bfe7-4ad3aef4f1ea"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6d5062dc4f6c4aea9b5af1b8206788f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTQtMS0xLTEtMzcyNjE_caaf1572-28f9-478d-b3ba-6565b81cd0f1"
      unitRef="usd">405764000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifa8460203d45415f877cfffa51733070_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTQtMy0xLTEtMzcyNjE_7ffcf665-3431-4c93-9f88-6b828f205cfe"
      unitRef="usd">119919000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5e5e6402ec45427eae4f571d473ddedf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTQtNS0xLTEtMzcyNjE_600c432e-900c-405b-b2d2-7ff017e9a249"
      unitRef="usd">285845000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i752f160556a747deb9e6619b306a9579_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80My9mcmFnOmViY2ZjZjQxYWE4ODQ0ZmE5ZWVlZjA1YzRhMmQ0MTBiL3RhYmxlOjNkZDkxZmJkMjljMDQwYTA5OWVjZGI3OWRjNWJjMjQ0L3RhYmxlcmFuZ2U6M2RkOTFmYmQyOWMwNDBhMDk5ZWNkYjc5ZGM1YmMyNDRfMTQtNy0xLTEtMzcyNjE_f3f1d43a-a499-492b-9b99-5a550dc78b97"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfMTk3NA_8b18112b-cf21-4b04-bfa3-21d5a9f6a167">CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2022 and 2021. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that are in a &lt;/span&gt;&lt;/div&gt;continuous unrealized loss position for greater than 12 months as of March&#160;31, 2022 and December&#160;31, 2021. Based on the scheduled maturities of its investments, the Company determined that it was more likely than not that it will hold these investments for a period of time sufficient for a recovery of its cost basis. Total unrealized gains for securities with net gains in accumulated other comprehensive income were not material for the three months ended March&#160;31, 2022. The unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#x2019;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#x2019;s ability and intent to hold the investments until maturity, the Company determined that no allowance for credit losses related to its marketable securities was required at either March&#160;31, 2022 or December&#160;31, 2021.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfMTk3Nw_8432189d-28cb-456d-a812-946f20968a5d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i667d8119170448249bd6a172234e2142_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNC0xLTEtMS0zNzI2MQ_e25f0e4d-c8c4-4ddd-a02c-a3cce2dce186"
      unitRef="usd">49827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i667d8119170448249bd6a172234e2142_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNC0zLTEtMS0zNzI2MQ_b2e18f02-aba1-48f7-9f55-0e1bf778164c"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i667d8119170448249bd6a172234e2142_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNC01LTEtMS0zNzI2MQ_77bb2e7a-020d-481e-afbf-c3f422c28f6d"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i667d8119170448249bd6a172234e2142_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNC03LTEtMS0zNzI2MQ_e54703b8-b34d-490c-9895-8475fb7cdde4"
      unitRef="usd">49827000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi0xLTEtMS00MTEzNA_cf736197-e45c-4cbc-a134-42958fbe471c"
      unitRef="usd">15009000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi0zLTEtMS00MTEzNA_de575253-f338-4347-ab12-6640701cba51"
      unitRef="usd"
      xsi:nil="true"/>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi01LTEtMS00MTEzNA_729f48d3-6152-41ca-854a-f54474d617f1"
      unitRef="usd">1000</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi03LTEtMS00MTEzNA_995a4268-d373-4d58-8c3b-1451506ca172"
      unitRef="usd">15008000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i75f59c89b2b44fd2919394b10858dd42_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi0xLTEtMS0zNzI2MQ_a9bb99e9-b4a0-4cf9-8c8d-2a074803aede"
      unitRef="usd">64836000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i75f59c89b2b44fd2919394b10858dd42_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi0zLTEtMS0zNzI2MQ_b72e8de1-38e8-4a1c-bd17-214e33340367"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i75f59c89b2b44fd2919394b10858dd42_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi01LTEtMS0zNzI2MQ_949dda22-762d-43fd-870b-a71a45869737"
      unitRef="usd">1000</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75f59c89b2b44fd2919394b10858dd42_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfNi03LTEtMS0zNzI2MQ_9c2b229d-2e0f-4b8c-b8e3-30c76f3af61c"
      unitRef="usd">64835000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOC0xLTEtMS0zNzI2MQ_665a07b3-10ce-4e43-9ce7-0cee58ffb458"
      unitRef="usd">24788000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOC0zLTEtMS0zNzI2MQ_d5282940-df6a-4aa7-bd02-dd325694efb1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOC01LTEtMS0zNzI2MQ_e24ef164-a197-4546-95bd-a6607b48b6d1"
      unitRef="usd">347000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i92b3b84611284755a34ba8152a2646d0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOC03LTEtMS0zNzI2MQ_42c813ed-01aa-4c6f-bbf5-63e8be6b0ae3"
      unitRef="usd">24441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7e69bac7be71489fac652fab2215a8a9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOS0xLTEtMS0zNzI2MQ_b74e2375-e2bf-4952-8ae5-337f73c459ed"
      unitRef="usd">117709000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7e69bac7be71489fac652fab2215a8a9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOS0zLTEtMS0zNzI2MQ_f286ee50-17b9-470b-9579-1905b6d9165e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7e69bac7be71489fac652fab2215a8a9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOS01LTEtMS0zNzI2MQ_9b43b549-b628-4168-9b11-1ad8afc7cd6e"
      unitRef="usd">384000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7e69bac7be71489fac652fab2215a8a9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfOS03LTEtMS0zNzI2MQ_4e85b927-5c4f-48fd-b567-dae4dacf6e40"
      unitRef="usd">117325000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib47a4b1baad248318523c5fba0c2d164_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTAtMS0xLTEtMzcyNjE_e5e4b05e-965f-4876-a2a9-95cc3ed52deb"
      unitRef="usd">17522000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib47a4b1baad248318523c5fba0c2d164_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTAtMy0xLTEtMzcyNjE_9698e798-ab5b-4a48-b506-cf5282510f0d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib47a4b1baad248318523c5fba0c2d164_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTAtNS0xLTEtMzcyNjE_69267f82-492c-4947-be3c-23ff306da096"
      unitRef="usd">149000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib47a4b1baad248318523c5fba0c2d164_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTAtNy0xLTEtMzcyNjE_aa850ff2-faa6-407c-a9b7-9f582ce948c9"
      unitRef="usd">17373000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9333aab4cdd548f1818b9a801558d624_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTEtMS0xLTEtMzcyNjE_3ed26c79-b3ff-4780-83ed-f7a923f90ef8"
      unitRef="usd">67890000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9333aab4cdd548f1818b9a801558d624_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTEtMy0xLTEtMzcyNjE_feff1e44-cfa2-4df1-bc39-7ad07068ce11"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9333aab4cdd548f1818b9a801558d624_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTEtNS0xLTEtMzcyNjE_feba99eb-3069-4087-9c4c-99e89319c98d"
      unitRef="usd">375000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9333aab4cdd548f1818b9a801558d624_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTEtNy0xLTEtMzcyNjE_6be52715-d304-4a2e-a588-97eaa900dbb4"
      unitRef="usd">67515000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i417758d232ed45199817bccf384dfcad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtMS0xLTEtNDA4MjE_1550673a-a6f9-444d-9432-d68dea4104ae"
      unitRef="usd">2995000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i417758d232ed45199817bccf384dfcad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtMy0xLTEtNDA4Mjg_2da4acf5-a1df-4a11-9cce-6ae8c0a4dcfc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i417758d232ed45199817bccf384dfcad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtNS0xLTEtNDA4MzQ_0377c39c-4388-4893-be9c-15b2282631eb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i417758d232ed45199817bccf384dfcad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtNy0xLTEtNDA4NDA_4d497afc-7a85-48d0-b362-594f23f6d2a0"
      unitRef="usd">2995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTItMS0xLTEtMzcyNjE_ca0a4576-f40f-4f60-beff-b3b5c769695b"
      unitRef="usd">50526000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTItMy0xLTEtMzcyNjE_e873fddd-ae49-4157-a6e4-441c79bcd0b7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTItNS0xLTEtMzcyNjE_27172d07-d795-4a32-b807-afbf83683d28"
      unitRef="usd">121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9fcc1f1dc2d455ab7ec77eb23351bfc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTItNy0xLTEtMzcyNjE_b0260e53-aae2-4bb6-bd58-7f709310302c"
      unitRef="usd">50405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtMS0xLTEtMzcyNjE_10c7a430-5b68-425f-b51a-d5d809046f39"
      unitRef="usd">281430000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtMy0xLTEtMzcyNjE_293f5cd7-22a2-465d-99a0-8c41a81047fd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtNS0xLTEtMzcyNjE_014787e8-de75-4c2e-a1ea-b236167cdfa3"
      unitRef="usd">1376000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTMtNy0xLTEtMzcyNjE_48609bdb-6e40-404e-8e2e-c3b8cf256116"
      unitRef="usd">280054000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTQtMS0xLTEtMzcyNjE_80f6626b-5555-4bb8-a4e8-05fdf5abf208"
      unitRef="usd">346266000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTQtMy0xLTEtMzcyNjE_dcf314a2-55fd-422f-81e8-9605189be476"
      unitRef="usd">0</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTQtNS0xLTEtMzcyNjE_7c1115b7-2963-46c7-8f57-e2249f985205"
      unitRef="usd">1377000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTQtNy0xLTEtMzcyNjE_ab582546-6c07-4fd5-a7a9-b120bc978f37"
      unitRef="usd">344889000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7428cfc7656446308caa6ab7f38e8fc4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTktMS0xLTEtMzcyNjE_aaf426b7-6fa4-4297-bb43-034ed7eecc11"
      unitRef="usd">119919000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i7428cfc7656446308caa6ab7f38e8fc4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTktMy0xLTEtMzcyNjE_f460a828-8e3f-4089-91ab-01ef0695d664"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i7428cfc7656446308caa6ab7f38e8fc4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTktNS0xLTEtMzcyNjE_0d643ce2-0392-432c-b4ab-cb9ade4b68fc"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7428cfc7656446308caa6ab7f38e8fc4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMTktNy0xLTEtMzcyNjE_c7dde923-e4c6-46be-9ab1-66345bc870e5"
      unitRef="usd">119919000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8d0041f6579043f2bee5ca967b1a19d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjAtMS0xLTEtMzcyNjE_c85cfa00-3ee7-4be1-90e2-1fd2b1aa8ea8"
      unitRef="usd">119919000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i8d0041f6579043f2bee5ca967b1a19d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjAtMy0xLTEtMzcyNjE_727b647c-6e0d-492a-80fa-81ca752d7dfa"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i8d0041f6579043f2bee5ca967b1a19d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjAtNS0xLTEtMzcyNjE_c9bce10d-16f7-4d5e-8e4f-4d59c1793aca"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d0041f6579043f2bee5ca967b1a19d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjAtNy0xLTEtMzcyNjE_97933616-269a-4722-a2b1-edf6b54be5e0"
      unitRef="usd">119919000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib4cc59f044c84fa483597e518c67dd8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjItMS0xLTEtMzcyNjE_03612a24-275b-4482-b702-090764d014c0"
      unitRef="usd">30700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib4cc59f044c84fa483597e518c67dd8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjItMy0xLTEtMzcyNjE_1a1979d5-383d-4bf7-bd38-ee31474ecdee"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib4cc59f044c84fa483597e518c67dd8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjItNS0xLTEtMzcyNjE_feb80f9b-5e82-44fe-b35f-e186c1f7235e"
      unitRef="usd">87000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib4cc59f044c84fa483597e518c67dd8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjItNy0xLTEtMzcyNjE_e4ab28a1-9c05-491d-91a1-ee158bf423df"
      unitRef="usd">30614000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i149b1f00b3f944a699030236b1718bb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjMtMS0xLTEtMzcyNjE_f99c1cb3-c85c-477b-83ba-3572e6417af0"
      unitRef="usd">105792000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i149b1f00b3f944a699030236b1718bb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjMtMy0xLTEtMzcyNjE_32abd707-a805-4487-b97e-f5e789959d4c"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i149b1f00b3f944a699030236b1718bb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjMtNS0xLTEtMzcyNjE_3e66dc6b-2172-47a4-af53-24e706e85437"
      unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i149b1f00b3f944a699030236b1718bb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjMtNy0xLTEtMzcyNjE_f842b726-455b-45d3-b89b-b157531aeed7"
      unitRef="usd">105757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i708da3120a854222abfec0d32c8d9c70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjQtMS0xLTEtMzcyNjE_1aead7c5-f5d9-450a-8654-af608c539875"
      unitRef="usd">33723000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i708da3120a854222abfec0d32c8d9c70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjQtMy0xLTEtMzcyNjE_a00ee437-12ea-4eed-94b2-c01d6abb9ef6"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i708da3120a854222abfec0d32c8d9c70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjQtNS0xLTEtMzcyNjE_2c8eeef7-5ad2-4393-b6b3-6785551b8ef0"
      unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i708da3120a854222abfec0d32c8d9c70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjQtNy0xLTEtMzcyNjE_8cfd10fb-1c72-4a91-a1e4-f4b57b5d9d91"
      unitRef="usd">33682000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjUtMS0xLTEtMzcyNjE_9b07d1b4-e890-460c-a720-ea8a92bd9adf"
      unitRef="usd">70807000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjUtMy0xLTEtMzcyNjE_0f75cb11-c9bf-44ff-b514-504678c8468d"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjUtNS0xLTEtMzcyNjE_261d5e41-94e3-43ef-b9db-8cc5a93724a9"
      unitRef="usd">107000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5523e8ec173b4690b06e17d10a8f0fc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjUtNy0xLTEtMzcyNjE_3978c04e-f7c1-4176-862b-f002bdcaa56a"
      unitRef="usd">70701000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8a473804e0f74354bf949e0a954fac9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjYtMS0xLTEtMzcyNjE_1863048f-6efa-469d-87e4-2996b8145955"
      unitRef="usd">45116000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a473804e0f74354bf949e0a954fac9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjYtMy0xLTEtMzcyNjE_7a8a9d77-42c7-4276-994c-9551b02e8f5b"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a473804e0f74354bf949e0a954fac9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjYtNS0xLTEtMzcyNjE_39024394-504e-40ab-ae52-b8c332359c74"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a473804e0f74354bf949e0a954fac9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjYtNy0xLTEtMzcyNjE_60f75ba9-f09e-47e4-bdea-a0d0a3571a6f"
      unitRef="usd">45091000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjctMS0xLTEtMzcyNjE_6e57a888-4712-44ed-874c-8c702a74e88a"
      unitRef="usd">286138000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjctMy0xLTEtMzcyNjE_d82c6da8-0cb1-4ad8-8d8a-bdf6e5d3c5c5"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjctNS0xLTEtMzcyNjE_87cabf13-f79d-46d5-b062-3a8c77648fb6"
      unitRef="usd">304000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjctNy0xLTEtMzcyNjE_0b59e92b-4ddf-4f5a-98d8-451231c4a675"
      unitRef="usd">285845000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjgtMS0xLTEtMzcyNjE_212a0967-7d3a-4617-a35f-43075d1d8ce6"
      unitRef="usd">406057000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjgtMy0xLTEtMzcyNjE_c0ac127c-14f5-49ff-83f9-b1f271478e17"
      unitRef="usd">11000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjgtNS0xLTEtMzcyNjE_007e452b-9679-46be-9c08-63a392966ec8"
      unitRef="usd">304000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOjc2MGY3YWEzZmE4OTRjMTRhYjFhMjJiNjkxN2IyYTNhL3RhYmxlcmFuZ2U6NzYwZjdhYTNmYTg5NGMxNGFiMWEyMmI2OTE3YjJhM2FfMjgtNy0xLTEtMzcyNjE_a07fb606-eb64-4433-9e48-c67c433c7289"
      unitRef="usd">405764000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfMTk3NQ_593582fe-0472-4179-8547-e932dfff56d2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMS0xLTEtMS0zNzI2MQ_cc3960bf-0d02-4f0f-9cc9-d35e68eec92f"
      unitRef="usd">212547000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMS0zLTEtMS0zNzI2MQ_cd3f0c94-9bd1-457f-871f-b299b80f0838"
      unitRef="usd">197676000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMi0xLTEtMS0zNzI2MQ_ffd62557-7ba2-445f-ba2a-b1c4386b94c0"
      unitRef="usd">82515000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMi0zLTEtMS0zNzI2MQ_247787de-ae8c-46f2-96ac-c3ebccf6a101"
      unitRef="usd">88169000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <sgmo:DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMy0xLTEtMS0zNzI2MQ_065def59-5426-4573-ab79-3f5acfeb606d"
      unitRef="usd">295062000</sgmo:DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents>
    <sgmo:DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RhYmxlOmRlYzI0NmMzMGUxNjQyZDI5ZTA4YzAyMzJiNTBiMjkxL3RhYmxlcmFuZ2U6ZGVjMjQ2YzMwZTE2NDJkMjllMDhjMDIzMmI1MGIyOTFfMy0zLTEtMS0zNzI2MQ_4c09d37d-94b4-4403-80b9-59fc1e14b7b0"
      unitRef="usd">285845000</sgmo:DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNTA1_330257f4-dd1b-48b3-9066-76579268ad2b"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNTA1_3a54404a-175d-45a3-bb1c-3911c4cfed59"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNTA1_b84296ba-bc87-4703-93e3-b1202100f7a0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNTA1_d924fbad-5c4e-4f46-8f12-ccfcaef85067"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i3107f05932b94c4bac5b9ef7bbe5b269_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNDk0NzgwMjMyODY0MA_17c8f157-c5ab-42e1-89b8-f18a71b04e3d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i49808b7d5a184b629b594c228b0d228f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV80OS9mcmFnOjBhYTgyOTFiMzk3NDQwMjE4MzMxZTk4NDY1NThhYmM2L3RleHRyZWdpb246MGFhODI5MWIzOTc0NDAyMTgzMzFlOTg0NjU1OGFiYzZfNDk0NzgwMjMyODY0MA_98a7ba60-d17e-4c88-8a03-3183077353a1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81Mi9mcmFnOjM5ODllNThiYjE1YzRhMWVhNGIyYjc2NzI0YTkyNjcwL3RleHRyZWdpb246Mzk4OWU1OGJiMTVjNGExZWE0YjJiNzY3MjRhOTI2NzBfMTA3NA_6ea55a1a-e71c-4c4d-9546-1c6eb1c0c4f9">BASIC AND DILUTED NET LOSS PER SHARE&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total number of shares subject to stock options and restricted stock units (&#x201c;RSUs&#x201d;) outstanding and the employee stock purchase plan (&#x201c;ESPP&#x201d;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of March&#160;31, 2022 and 2021 totaled 19,128,238 and 17,614,376, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81Mi9mcmFnOjM5ODllNThiYjE1YzRhMWVhNGIyYjc2NzI0YTkyNjcwL3RleHRyZWdpb246Mzk4OWU1OGJiMTVjNGExZWE0YjJiNzY3MjRhOTI2NzBfMTA1MA_4f4daf13-1461-49c7-8e07-bbb2070e8492"
      unitRef="shares">19128238</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81Mi9mcmFnOjM5ODllNThiYjE1YzRhMWVhNGIyYjc2NzI0YTkyNjcwL3RleHRyZWdpb246Mzk4OWU1OGJiMTVjNGExZWE0YjJiNzY3MjRhOTI2NzBfMTA1Nw_30758bb7-be6e-48c2-8a0b-4ff3e6906ca1"
      unitRef="shares">17614376</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NDU_28ce9d00-4105-4dd1-8023-d57e1a6b71f9">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#x201c;Novartis&#x201d;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#x201c;ZFP&#x201d;) transcription factors (&#x201c;ZFP-TFs&#x201d;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company is performing early research activities over the collaboration period for each gene target and manufacture the ZFP-TFs required for such research, costs of which is funded by Novartis. Novartis is responsible for additional research activities, studies enabling investigational new drug applications (&#x201c;INDs&#x201d;), clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#x2019;s proprietary adeno-associated viruses (&#x201c;AAVs&#x201d;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All payments received under the agreement, when earned, are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and estimated research costs of $20.1&#160;million to be provided over the estimated research period. All clinical or regulatory milestone amounts were considered fully constrained at inception of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the agreement. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Novartis in accordance with ASC Topic&#160;606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its performance obligation. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $1.9&#160;million for both periods and deferred revenue of $33.9&#160;million and $40.9&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $1.5&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic&#160;340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC Topic&#160;340&#x201d;). The Company amortized $0.1&#160;million during each of the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (together with BIMA, &#x201c;Biogen&#x201d;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#x2019;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#x2019;s common stock (the &#x201c;Biogen Shares&#x201d;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.4&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.5&#160;billion in first commercial sale and other sales-based milestone payments. In addition, the Company is eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to twelve&#160;neurological disease gene targets selected by Biogen. Biogen has already selected four of these: ST-501 to treat tauopathies, ST-502 to treat synucleinopathies including Parkinson&#x2019;s disease, a third product candidate targeting DM1, a neuromuscular disease, and a fourth undisclosed neurological disease gene target. Biogen has exclusive rights to nominate up to eight additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performs early research activities, costs of which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#x2019;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e., through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to ten targets. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#x2019;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#x2019;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price of $204.6&#160;million includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#x2019;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $3.4&#160;million and $2.8&#160;million, respectively, and deferred revenue of $146.7&#160;million and $154.0&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.404%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and the stock purchase agreement for the sale of shares. The Company believes that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the transaction price of $204.6&#160;million, as a contract asset. This balance is amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340. The Company amortized $0.1&#160;million during each of the three months ended March&#160;31, 2022 and 2021. The Company recognized $2.9&#160;million, which represented 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in net proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#x201c;Kite&#x201d;), a Gilead Sciences, Inc. subsidiary, which became effective in April 2018, and was amended and restated in September 2019, for the research, development, and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#x201c;ZFNs&#x201d;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#x201c;NK-cells&#x201d;) including the insertion of genes that encode chimeric antigen receptors (&#x201c;CARs&#x201d;), T-cell receptors (&#x201c;TCRs&#x201d;), and NK-cell receptors (&#x201c;NKRs&#x201d;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex&#160;vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the research program term and subject to certain exceptions, except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the effective date, the Company received a $150.0&#160;million upfront payment from Kite. In addition, Kite reimburses the Company&#x2019;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.0&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.3&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.8&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product and, (ii)&#160;only for the first 10 times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial research term in the agreement is six years. Kite has an option to extend the research term for up to two additional one-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $3.4&#160;million, which is included in the total transaction price. The Company concluded the total transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Kite in accordance with ASC Topic&#160;606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the primary performance obligations within the Kite agreement as: (1)&#160;a license to the technology along with the stand-ready obligation to perform research services, and (2)&#160;the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through April 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $0.1&#160;million for both periods, and deferred revenue of $50.3&#160;million and $56.5&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#x201c;SCD&#x201d;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company was originally jointly conducting two research programs: a beta thalassemia program, which was discontinued in the third quarter of 2021, and the SCD program, which resulted in the development of SAR445136, a ZF nuclease, gene-edited cell therapy product candidate for the treatment of SCD, which remains active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the SCD program, the Company and Sanofi were jointly responsible for research and development activities prior to filing of an IND, but Sanofi is now responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. Subject to the terms of the agreement, the Company had granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company had also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#x2019;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, the Company received an upfront license fee of $20.0&#160;million and was eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, was up to $276.3&#160;million. In addition, the Company was to receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi was to reimburse Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST&#x2011;400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, Sanofi notified the Company of its termination for convenience, effective June 28, 2022 (the &#x201c;Termination Date&#x201d;), of the collaboration agreement. In its notice to the Company, Sanofi indicated that its termination relates to Sanofi&#x2019;s change in strategic direction to focus on allogeneic universal genomic medicine approaches rather than autologous personalized cell therapies. As of the Termination Date, the collaboration agreement will be terminated in its entirety and following the Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Sanofi. As of the Termination Date, Sanofi will have no further obligations to develop or to fund the development of any collaboration research programs under the collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All contingent payments under the agreement, when earned, were non-refundable and non-creditable. The transaction price of $96.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones in the amount of $13.5&#160;million and estimated research costs of $62.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Sanofi in accordance with ASC Topic&#160;606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through June 28, 2022, the estimated period the Company will perform research services pursuant to the agreement. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had a receivable of $1.0&#160;million and $0.6&#160;million, respectively, and deferred revenue of $0.6&#160;million and $1.1&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Giroctocogene Fitelparvovec Global Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The total transaction price under this agreement is $134.0&#160;million, which represents the upfront fee and research services fees of $79.0&#160;million and fees related to two achieved milestones in an aggregate amount of $55.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and no revenues have been recognized during the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C9ORF72 Research Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) 15 years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following termination by the Company for Pfizer&#x2019;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time. Following termination by Pfizer for the Company&#x2019;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million in commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pfizer agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $17.0&#160;million, which represents the upfront fees of $12.0&#160;million and fees related to achievement of one milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services.  &lt;/span&gt;&lt;/div&gt;The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $5.0&#160;million milestone, which the Company recognized on a cumulative basis during the year ended December 31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and no revenues have been recognized during the three months ended March 31, 2022 and 2021.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ie4e67faf817f4852b243d3c63990d266_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTc4Nw_ca8dee78-9ea4-41e0-aa0f-1b82cb811df2"
      unitRef="usd">75000000</us-gaap:ProceedsFromCollaborators>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ib56fb168b92b405fb217588fffb34483_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk2MQ_1aa51626-3061-4953-915c-36a2d4c61edd"
      unitRef="usd">420000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="id6efcae223674852a4973214fc153fa8_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjAwMA_5a607a9b-3fae-489c-b60f-0bf14ae69c95"
      unitRef="usd">300000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i37db8a6698834ba296ee551626e923fb_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjk0NA_b7aa3e0d-1ffd-4c54-9488-536c44354d25"
      unitRef="usd">95100000</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementLicenseFee
      contextRef="i37db8a6698834ba296ee551626e923fb_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjk4Mw_2064ec32-137d-4d6b-a03c-5270b1a65c83"
      unitRef="usd">75000000</sgmo:CollaborativeArrangementLicenseFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i37db8a6698834ba296ee551626e923fb_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzAxOA_a7339245-da40-4d89-84ae-b5c6ef054bd1"
      unitRef="usd">20100000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id8c1aa614e1a4775b6bbd58069fa1667_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MjQyMw_6f7c0237-abca-46c2-bbd5-c52c083bd973"
      unitRef="usd">1900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4b7eb1bd518d40e1b0ab1d54a66550cc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MjQyMw_ec041743-932d-4996-a825-b0053122df8a"
      unitRef="usd">1900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id8c1aa614e1a4775b6bbd58069fa1667_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDYzOA_ceb9e579-9ab2-4f34-aae6-ec96fe47e997"
      unitRef="usd">33900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4b7eb1bd518d40e1b0ab1d54a66550cc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDY0NQ_8d6115f8-e4c1-4ffd-9152-e8fd5edaa720"
      unitRef="usd">40900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i01e697d1114342af9aab4ece3ebe09d4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NDQ_6e8cf805-04ef-4a08-af10-ee9d59eb67fa">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i900d4a285bf74e898040e450e39bae33_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfMy01LTEtMS0zNzI2MQ_85339b20-947a-42cd-9228-c938c91b011c"
      unitRef="usd">7018000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i517982897103458981bfa35ceae5ab4c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfMy03LTEtMS0zNzI2MQ_3c028f9a-0f2e-4729-9e1b-b2c33c96ae1b"
      unitRef="usd">6200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib06b72ef26254e088a29f9eb02ae084f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfNC01LTEtMS0zNzI2MQ_269dd09e-1413-4b40-b50b-b5d3c8a8dfb7"
      unitRef="usd">1877000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3be9da6c94aa4aeda66aa0067113c02e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfNC03LTEtMS0zNzI2MQ_fb4f0686-dcd7-436a-951a-4d0569a85048"
      unitRef="usd">1661000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01e697d1114342af9aab4ece3ebe09d4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfNS01LTEtMS0zNzI2MQ_11eefdf9-ccfa-4c00-a307-e4cd8622b6b1"
      unitRef="usd">8895000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib750ba895b6945248f5dd3b66450ec06_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOmJkZWVhNjU2ZDcyNzRmNTc4YzNmZmU3YTUwM2NkNDNiL3RhYmxlcmFuZ2U6YmRlZWE2NTZkNzI3NGY1NzhjM2ZmZTdhNTAzY2Q0M2JfNS03LTEtMS0zNzI2MQ_6bb7f2a4-1f89-4f1d-8d6e-fabe67b7105d"
      unitRef="usd">7861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="i55716db833614f819cf9af228e7bacc0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDc4MA_0916bb9d-38f9-4328-8ad9-df676ee4faca"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i55716db833614f819cf9af228e7bacc0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDg2MQ_8913cebe-6460-4972-bf04-b13b60c06fb0"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ie4e67faf817f4852b243d3c63990d266_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDg2Nw_15134c8f-fcc9-4195-b2e0-c8f966d77669"
      unitRef="usd">75000000</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="i55716db833614f819cf9af228e7bacc0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk5Ng_0916bb9d-38f9-4328-8ad9-df676ee4faca"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="iab11137987e8447bb24585d1df56594e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNTM0OQ_18e8f146-5c3f-405d-ad34-c063d80ed6ad"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="iaa9d46b5b32044e89d50e8f389f7bdd3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNTM0OQ_cbcd6e84-9b9e-45e0-9560-169d9330e440"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjExNA_394e45bd-6f0f-4c2c-ab0d-bac2e436f2be"
      unitRef="shares">24420157</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i766f4d877bf6408b9503aa5663f38abe_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjIwMQ_67d9a2c1-632a-481c-b18e-bbfd9ab38073"
      unitRef="usdPerShare">9.2137</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjI1NA_2f5601ec-6f02-4148-b35b-f5fff2c1c2b8"
      unitRef="usd">225000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjUyMg_31b59cc5-2bc5-481e-9800-a8c254a20ca4"
      unitRef="usd">225000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i15891adf431c452c86cb7e1beafbb9f8_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjY0OQ_f66b2909-739f-4265-bf8e-500a20da7319"
      unitRef="usd">125000000</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="ib839a8edfdf240f293867c6246e5a8fa_I20200430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjgxMA_68cfe1f6-ad94-46be-a079-1fc41a076407"
      unitRef="usd">2400000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="ib0e6b8fbf7904621a6d9173012bb2011_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNjk3Mw_115711ad-d592-4d4d-a14c-2ecc43c2fd0c"
      unitRef="usd">925000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i92e1ede754aa400bb099f3f7aed0dfb1_I20200430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNzAyMQ_5ef56b87-486a-42b8-8fe1-e34bea33a487"
      unitRef="usd">1500000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementNumberOfProductTargets
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNzcyNw_90e2f463-43a7-4245-a4e2-e114feffec15"
      unitRef="product_target">12</sgmo:CollaborativeArrangementNumberOfProductTargets>
    <sgmo:CollaborationAgreementNumberOfAdditionalProductTargets
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfODA2NQ_42a2ee95-dd47-4811-b13d-63acf486d946"
      unitRef="product_target">8</sgmo:CollaborationAgreementNumberOfAdditionalProductTargets>
    <sgmo:CollaborationAgreementTargetSelectionPeriod
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfODEyMQ_4bf5edea-1de8-45b3-a15b-90fb1b407af9">P5Y</sgmo:CollaborationAgreementTargetSelectionPeriod>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="ib839a8edfdf240f293867c6246e5a8fa_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfODcwNg_de12d110-6372-490d-a1b2-b37441804c39"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="ib839a8edfdf240f293867c6246e5a8fa_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfODk1Nw_f68c71f0-c56f-445a-b654-fc5dc7cd9a86"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborationArrangementResearchPeriod
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfOTA2OA_37ff9e4d-e02f-4689-8910-df94fb0c7617">P7Y</sgmo:CollaborationArrangementResearchPeriod>
    <sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfOTcwMA_49fef229-adf9-48b4-9b70-47eba023045d"
      unitRef="product_target">10</sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace>
    <sgmo:CollaborativeArrangementStandstillRestrictionPeriod
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NTY_b4927462-ccb4-4a24-8ed4-e2c9c7e0956d">P3Y</sgmo:CollaborativeArrangementStandstillRestrictionPeriod>
    <sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage
      contextRef="i766f4d877bf6408b9503aa5663f38abe_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA2NjQ_d678b78b-2f60-4fef-bff0-b07b87f597a4"
      unitRef="number">0.05</sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTIyMDA_bd9bd3a1-8edf-4957-b487-249e4da2472d"
      unitRef="usd">204600000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTIyMzk_cc790db3-ad52-428c-bd4b-422308b90ae5"
      unitRef="usd">125000000</us-gaap:ProceedsFromCollaborators>
    <sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTIyOTg_89918971-bc2e-43ac-a125-f9031aa1f8ea"
      unitRef="usd">79600000</sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTIzNDY_37bff2e9-be43-4446-abaa-045cf2653b20"
      unitRef="usd">225000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTI0MDQ_4bae553a-bc9d-4ab9-b13c-af02843116e6"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i39ca1d92750e4fc887cd62b4bb56da6e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MjgxMQ_20a5c712-17b2-4604-beba-1d5cdc5826cf"
      unitRef="usd">3400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8ca29e9a3803412cb13b7748ae0de063_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MjgwNA_7e63696b-2dcb-4add-af10-9ca4ca080faf"
      unitRef="usd">2800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i39ca1d92750e4fc887cd62b4bb56da6e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ0MjQ_830810fe-e479-4cf0-a47b-a38e3df93196"
      unitRef="usd">146700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8ca29e9a3803412cb13b7748ae0de063_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ0MzE_39766b6b-900c-4f90-97db-5e138afdaf2d"
      unitRef="usd">154000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ic2957eaa5fb949ba9103ee631650c838_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NDg_e485816f-6d20-4b15-8f14-afe603faacaf">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.404%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i041acd4815694161b1e7542a2e160c9c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfMy01LTEtMS0zNzI2MQ_dd7df132-43af-4ab1-b690-e6428ec303f4"
      unitRef="usd">7306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f3e9b2076b04da29cf24d841569c73f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfMy03LTEtMS0zNzI2MQ_8174d6de-694c-4a3f-ad55-82820733392d"
      unitRef="usd">7306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a105ad9f2c44de8af6b7d8886dbfe92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfNC01LTEtMS0zNzI2MQ_7b3a8948-c742-487e-8c35-128771a058d6"
      unitRef="usd">3887000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0037c3659814babb6528aeace32f367_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfNC03LTEtMS0zNzI2MQ_4528955c-5c63-4d2d-8641-dfa75fbf339d"
      unitRef="usd">3145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2957eaa5fb949ba9103ee631650c838_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfNS01LTEtMS0zNzI2MQ_f2a1cb75-2d99-4931-aafc-908ceaad76c1"
      unitRef="usd">11193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41afe851c52346368324b29729905d65_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjBhNjk4MGZlZmEzNTQ3NDdiZmNmZjFkOGI2ZmFlZWE0L3RhYmxlcmFuZ2U6MGE2OTgwZmVmYTM1NDc0N2JmY2ZmMWQ4YjZmYWVlYTRfNS03LTEtMS0zNzI2MQ_4c8f42e0-c539-4b7d-aab1-ee6b7ba1ee86"
      unitRef="usd">10451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="if6ae54d9711045f5b069428dadfcf2ac_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ1Njg_c76ed2f9-6b57-44b6-8f4f-56397ac35c64"
      unitRef="usd">7000000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="if6ae54d9711045f5b069428dadfcf2ac_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ2NDk_986d271f-33a2-4e3c-bcbc-6a00ab513b67"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ2NTU_37bff2e9-be43-4446-abaa-045cf2653b20"
      unitRef="usd">225000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="if6ae54d9711045f5b069428dadfcf2ac_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ2OTQ_df0e00ba-ba38-4da6-9545-200195dcb5f8"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTQ3MDA_cc790db3-ad52-428c-bd4b-422308b90ae5"
      unitRef="usd">125000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ic0b2dfb4d52545a4945d9acab347bcee_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUwMTI_55c53c0c-1ae1-47da-9df7-25541e72d439"
      unitRef="usd">4100000</us-gaap:ContractWithCustomerAssetNet>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUwMzM_a44e05e6-b026-4607-8d9f-124df911dc85"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUwNjQ_aa6718ca-d871-469f-bd1e-c39acc6f6278"
      unitRef="usd">204600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="idadbcdba5852493e8a7279c2071547c9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUzMDA_22f2b299-53ea-4957-8e8c-a9f063006ff4"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i01e8a0ae4fe34fcbbda1cb1a13234369_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTUzMDA_49b71b70-9e45-4eb3-af0a-0c229cf44fc6"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="id4be5c493833416e94842f25e42f4ed2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTU0NzU_435048d9-cd68-4c60-9fee-17974d5c7663"
      unitRef="usd">2900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="ifc6738521b264171b6251397feadfc36_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTU0OTc_f93a6968-1557-4f4e-8452-3427c54279b0"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="i26fa9295800a4f159a11564e07b29049_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTU1MDc_4bae553a-bc9d-4ab9-b13c-af02843116e6"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <sgmo:MilestonePaymentsReceived
      contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTc4NTI_d1d425a1-83f9-44c6-a6fd-1703b0822071"
      unitRef="usd">150000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTgwODI_a6f507a0-1ba3-4450-aaef-62ddce7da8b4"
      unitRef="usd">3000000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="i5797d08acc004769826046653f737b78_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTgxOTI_719eb908-225e-4507-809d-f0aad409f6ad"
      unitRef="usd">1300000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="idc36d4cf8fee4657a85ef91caf216030_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTgzMzQ_7afa7e7e-2737-49a0-86dc-adfaba8a56fc"
      unitRef="usd">1800000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment
      contextRef="idc36d4cf8fee4657a85ef91caf216030_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTg3MTQ_f048b51a-8f57-4ea3-bcd6-40fe9f647625"
      unitRef="milestone">10</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTkyODc_43ae6fae-8b85-482e-a28a-b07a548fe4ea">P6Y</sgmo:InitialResearchTermOfAgreement>
    <sgmo:NumberOfOptionsToExtendInitialResearchTerm
      contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTkzNjU_bde2d989-c760-4944-8bfe-1384a5d44e08"
      unitRef="option">2</sgmo:NumberOfOptionsToExtendInitialResearchTerm>
    <sgmo:ExtendedResearchTermOfAgreement
      contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NTA_75737a09-e994-4526-9734-8ab12772aa66">P1Y</sgmo:ExtendedResearchTermOfAgreement>
    <sgmo:SeparateUpfrontFee
      contextRef="i65f51596bbe948b39da9c94202af38ba_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk0MjU_12f656aa-c402-4091-8787-0ed31b80a0c5"
      unitRef="usd">10000000</sgmo:SeparateUpfrontFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan
      contextRef="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk3Mzg_85aea225-40d2-4905-9f3c-862e37c6007e"
      unitRef="usd">3400000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk4ODU_f87e2422-5610-4b93-afe4-85f268089aae"
      unitRef="usd">189300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk5Mjg_e3fa2945-609c-4ce2-aba5-61e229b752b3"
      unitRef="usd">150000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i3157cb304fdb4ea080d1d30b0615f2c2_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTk5MzU_b60fa3eb-77a7-4251-be14-27c4935887e4"
      unitRef="usd">39300000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i98c4d875d4a2406e8c1ed49500a382d3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY3MzI2OQ_f863e97a-ed70-4dd4-b9c9-2cf7b03b199a"
      unitRef="usd">100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i98c4d875d4a2406e8c1ed49500a382d3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjI0MzI_d3fa168c-da72-461f-9083-17e26bda902f"
      unitRef="usd">50300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i63eac9ce149544bc82e859b7f3bbb3b2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMjI0Mzk_6bcff910-0221-4372-b406-f44565f3338c"
      unitRef="usd">56500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ib70ee13d8d7a427da05f3f516bfa3b24_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NTM_a99b9f28-793f-4be4-a7f9-e51032a6cc71">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2986c1f9c44f4c47b92d4e4fe0632ce1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfMy01LTEtMS0zNzI2MQ_03d01c25-937f-4e34-8b32-fb8ee3cd26da"
      unitRef="usd">6159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia07682bb1e1c4e59a83b477d9c74c798_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfMy03LTEtMS0zNzI2MQ_4ed1204b-a7fa-49b2-bd8c-2fca08580cec"
      unitRef="usd">6159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11fedbfa9d70466daba921e2e917b72b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfNC01LTEtMS0zNzI2MQ_935c3d6b-4d9d-4d51-95be-aae611becb7e"
      unitRef="usd">149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ba81ecb70cf48beb5b5bc44b8920a30_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfNC03LTEtMS0zNzI2MQ_4ce69fff-25d9-4662-a56f-39dbfd0bde5e"
      unitRef="usd">129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib70ee13d8d7a427da05f3f516bfa3b24_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfNS01LTEtMS0zNzI2MQ_4cc6b360-3872-4ca2-9d81-e284da6537d3"
      unitRef="usd">6308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7245852459b450a993c961a809e0dfa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjU5YWFhZTRjNDNmMTRmMWNhN2ZiZTBmN2Q2NWRiOTQxL3RhYmxlcmFuZ2U6NTlhYWFlNGM0M2YxNGYxY2E3ZmJlMGY3ZDY1ZGI5NDFfNS03LTEtMS0zNzI2MQ_21ccb7ce-9a99-4f2c-bce9-1f431e296e95"
      unitRef="usd">6288000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:NumberOfResearchProgram
      contextRef="i1aa617603ebd4abeb4444421df29e6bc_D20140101-20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzYyMDA_1cec18ac-4807-448b-9c43-3596fbc3e9d5"
      unitRef="program">2</sgmo:NumberOfResearchProgram>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i1aa617603ebd4abeb4444421df29e6bc_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzg1NDE_bdfb0388-aa51-4a2c-890e-cc905517bc6a"
      unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="iadba8aa480b646cfbd9364a355e68cbe_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzg1Nzc_6779f528-a044-4581-b2bc-dd59dfbd8a81"
      unitRef="usd">115800000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i58d8c1b745014cc8b8f4a724f1510553_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzg2OTE_0dff6aa9-34a0-45e2-9468-97df9c73961e"
      unitRef="usd">160500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i415e26556db342079b36c2d48875c6cd_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzg5MzE_ac8b1059-d39e-4d77-9e7c-03d3c0df72a3"
      unitRef="usd">276300000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i8e4a1930763f4519a9e4c291ee43d2e0_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzkyNDA_c8e17db8-8616-4d22-b5d0-1bb61bf31864"
      unitRef="usd">6000000</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i220eb5b01a5049368db95372ebd0fd9b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzkzMjI_9eb5f182-b048-49a5-863e-77a6fd0ceead"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i8dc0ab2db92b44c1bdba051d96895b2a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzkzNzc_bb034ec7-7ba9-41f2-9c49-4071a43d7941"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i93cdf026a37d429da9fbaf18e0a75afd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk0MjI_66f2a211-9936-4016-b3ac-a84b090cb7f6"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i415e26556db342079b36c2d48875c6cd_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk2MDk_96771980-8556-4c31-9f12-56b8a33abbd5"
      unitRef="usd">96300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i415e26556db342079b36c2d48875c6cd_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk2NDg_aec71afd-debd-47e6-9c2d-69c8a721f8d0"
      unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:MilestoneRevenueReceivable
      contextRef="if66d1819ab0a41bcae82ab0a30c2b5a0_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk2OTg_3883b1dd-a430-4cb2-9a74-6095a4518f11"
      unitRef="usd">13500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i415e26556db342079b36c2d48875c6cd_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMzk3MzM_b77b9efe-88a7-4d79-b053-6121240b0137"
      unitRef="usd">62800000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i46b1460fe9b3430aaad2d02372d4e0fa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY5NDM5OQ_12674531-a04b-497d-99f3-60a01e44f274"
      unitRef="usd">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7009d476b5214df7b02507f512948107_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfMTA5OTUxMTY5NDM5Mw_145afb76-89ba-402a-b3f9-9f6bef18614e"
      unitRef="usd">600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i46b1460fe9b3430aaad2d02372d4e0fa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDE1NjU_f5b774f2-06c7-4d3e-8ee9-e37b4d2999ab"
      unitRef="usd">600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7009d476b5214df7b02507f512948107_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDE1NzI_711ac23d-1fa7-4639-807e-8526536495ee"
      unitRef="usd">1100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i8dc0ab2db92b44c1bdba051d96895b2a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDQ1NDY_533c4692-646f-40a3-80f2-d1b43a4827a7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7850a3329dd84fb9bb08174c06ab99e3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfMy01LTEtMS0zNzI2MQ_cbb89e08-37b2-40fc-962c-0e83f0603934"
      unitRef="usd">311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4014aec3ed654925849776520902d5b7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfMy03LTEtMS0zNzI2MQ_c51b88d6-f3ee-41ac-bef7-f3a10079ace0"
      unitRef="usd">227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5055577b77d947f4bef796328015008c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNC01LTEtMS0zNzI2MQ_55713665-4779-4062-9ec8-2a6eaaf6deb7"
      unitRef="usd">978000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1fe22c826474fe69f5ed5ada7ece18f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNC03LTEtMS0zNzI2MQ_36b61530-a10e-444c-bb0e-b1d892f0a3ca"
      unitRef="usd">679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i792a74f3766e43feb0c12d95327cbf47_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNS01LTEtMS0zNzI2MQ_b5d767a2-f134-4304-aea6-2853cc7c9ed3"
      unitRef="usd">210000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5834c04299d4d58ac0d606a80ed8b5f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNS03LTEtMS0zNzI2MQ_5561e27c-1fd1-4700-850b-128f7c33011e"
      unitRef="usd">154000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8dc0ab2db92b44c1bdba051d96895b2a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNi01LTEtMS0zNzI2MQ_565d00e2-1a20-4992-8ab7-02a816bda07f"
      unitRef="usd">1499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i195087e919f9493f90985edbce9e5c13_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RhYmxlOjg0MzM3MzFkOWNhODQ1ZDQ5ZmM1NTc4MmMwNjc5N2M1L3RhYmxlcmFuZ2U6ODQzMzczMWQ5Y2E4NDVkNDlmYzU1NzgyYzA2Nzk3YzVfNi03LTEtMS0zNzI2MQ_86df0177-3e22-4f87-8115-5082b40520fb"
      unitRef="usd">1060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm
      contextRef="id6d053e63e174530b26c614c63fbadbd_D20170501-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODA1NA_a8e2e0ac-e15f-4b29-a6af-c8e0add5fc0b">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i9ece67192c1d42a59cc7910bf5faa61c_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODA3NA_7d42e386-498a-4e7f-9095-37acd57b7ddb"
      unitRef="usd">70000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i42824e5c4da04a68abc1181162bd12fa_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODA4OQ_e5db206d-8a9e-475f-b228-37a9e1c436a3"
      unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
      contextRef="i9ece67192c1d42a59cc7910bf5faa61c_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODEwNQ_cfb079d2-6cfb-4276-963d-7373c15705ba"
      unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i35e709748299454d8a4c0545d5caa0c0_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODEyMQ_203e0b6d-f4b9-465e-848c-e2f7a9b80a97"
      unitRef="usd">475000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i775b57c0965745638063300c10bf719b_I20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODEzNw_fdce0d20-ac6e-4df1-83b9-1c64cd26dd9b"
      unitRef="usd">300000000</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i2b464e1bc69c4b89951ddb6d3fee56d9_I20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODE1Mw_a347813b-caba-41e5-992b-a6cd485b3d30"
      unitRef="usd">175000000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM4Mw_ff238df5-3a9b-4b66-b79a-d6de5d5a1990"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <sgmo:MilestonePaymentsReceived
      contextRef="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODE2OQ_e87868f5-b617-4609-b27e-32dd84a0476e"
      unitRef="usd">55000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODQxNQ_2e3778e2-b28e-4a96-a5a0-01c1e3a7507a"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="ia4c9910cf6b742cf89b4a8a7d9606e71_D20171201-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODQyMw_6dbe723e-775a-47c7-b2ee-f4273c330c23"
      unitRef="royalty_fee">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="ia8bed9085c38465985a0d366ec10dc28_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODE4NA_362c1e08-5d06-47b2-8802-2ab56c874e94"
      unitRef="usd">134000000</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementResearchServiceFees
      contextRef="ia8bed9085c38465985a0d366ec10dc28_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODIwMA_5e9c136b-5db1-4198-b7f6-4eac36ae3b8c"
      unitRef="usd">79000000</sgmo:CollaborativeArrangementResearchServiceFees>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="i05ac4cc6b4084fbc88f02fe3a8fd5ec2_D20170501-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM5MQ_5a833c12-f40a-41c3-aa70-f47c9d8bb5d4"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="iccf2d29f1912433caabee4d25f53741b_D20170501-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODIxNQ_0ca1528f-70e5-4778-a2fa-aae09537db58"
      unitRef="usd">55000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f51b07af0864153afac3abe30c851e0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODIzMQ_8042a3c4-25b3-464c-93cd-429744d06aae"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b3dd93e1a194866bed6cbf58dde6ab6_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODIzMQ_b1f03acf-c1df-49c9-a156-ef92b65fe847"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm
      contextRef="i51e7fa3e99494ccabbb4f5480eae52b8_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODI0Mg_498cbe6a-e62c-48db-abdd-600d6a6d5b0a">P15Y</sgmo:AgreementTerminationTerm>
    <sgmo:MilestonePaymentsReceived
      contextRef="i51e7fa3e99494ccabbb4f5480eae52b8_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODI1Nw_e4d3dd91-a1f8-4db3-b3f8-946a992a05f9"
      unitRef="usd">12000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ib9f57259deda46369255333e92bf2fe1_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODI3Mg_d344ee34-f221-4877-9935-ef9061828b47"
      unitRef="usd">60000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i644151b6138447f397ecbd47582bdb71_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODI4Nw_08eb6166-0204-4aee-b2aa-210ebeb4f010"
      unitRef="usd">90000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestonePaymentsReceived
      contextRef="ie5b439ab1a3340e7a1a2684ce3f73c38_D20171201-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODMwMg_a15a25bd-af1f-44a4-be5c-92f5dd827938"
      unitRef="usd">5000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="ie5b439ab1a3340e7a1a2684ce3f73c38_D20171201-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM5OQ_e559718e-4974-42ff-838b-a2318e8411f7"
      unitRef="milestone">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="ie5b439ab1a3340e7a1a2684ce3f73c38_D20171201-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODQwNw_054964a1-2eab-422b-bcb1-4936cfad3343"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="ia544d315ec7d4af5a972efb96f552dba_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODMxNg_5cc7de6c-374b-4385-bd76-56075d0a12d8"
      unitRef="usd">17000000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ib257bf5eb1c3440fb565b1bc921fddb1_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODMzMQ_709ebe63-f2e9-4ad8-b750-5776826fc590"
      unitRef="usd">12000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ia544d315ec7d4af5a972efb96f552dba_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM0Ng_5b846498-3f81-46e8-ad98-016394d3882a"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i2de27440831843859499b5316c0123fa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM2MA_0d10c079-d3af-42e8-810a-3c4dea7aca9a"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i13d3e19bc1f941bfada2a1d34fbabcd0_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM2MA_b3ae6905-9baa-480d-826f-6fefab639f7f"
      unitRef="usd">5000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4ad9356ed1a4e1e8a0ce2245ba0883a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM3NQ_bbdf453f-cc0f-4fcb-97f2-1e82afb9d515"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f348bc656a048d89a2becabe2d582e0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV81NS9mcmFnOjQ5NDM1Y2Y1ZjljYTQyMTc4ZjNiYzcwNDQzNjU5N2U3L3RleHRyZWdpb246NDk0MzVjZjVmOWNhNDIxNzhmM2JjNzA0NDM2NTk3ZTdfNDk0NzgwMjQ3ODM3NQ_f32f1197-856a-48d9-925e-4d8fda926733"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RleHRyZWdpb246YzMyOTQzMjExYmRhNDc5OWJiODk2MzhhYjk2Mjc3ODhfMTgy_2a07cedc-4f24-4962-80a8-45382acec8ea">STOCK-BASED COMPENSATION&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RleHRyZWdpb246YzMyOTQzMjExYmRhNDc5OWJiODk2MzhhYjk2Mjc3ODhfMTgz_9be2dcea-d6a8-4b79-a7f0-94c828d5452c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2ed88b3f0256493eb611d1c6df10aa32_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfMi01LTEtMS0zNzI2MQ_63053030-68ef-47a6-a958-1a0d00039831"
      unitRef="usd">4670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d78a85fa8bf4c2088761487072d070b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfMi03LTEtMS0zNzI2MQ_34466369-7563-4e4d-91a7-b6288a9276b0"
      unitRef="usd">4252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9ccfc5457b247c9a4372c7a7b6fd8b6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfMy01LTEtMS0zNzI2MQ_a3b0fe01-99ce-4618-905a-312bdd0558d9"
      unitRef="usd">3021000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87ae6a236ee94776b86d549585e14bb1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfMy03LTEtMS0zNzI2MQ_ae81e1b7-2c22-43e5-b4fd-6bbd0798caae"
      unitRef="usd">3272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfNC01LTEtMS0zNzI2MQ_9b07e758-7894-4225-9eef-4645e111d8a9"
      unitRef="usd">7691000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic96e14eb43f44a9ab61716519cfd1069_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82NC9mcmFnOmMzMjk0MzIxMWJkYTQ3OTliYjg5NjM4YWI5NjI3Nzg4L3RhYmxlOjgxN2JkYmZiOTk5YjQ3OGNiYTQ2ODhmMGRiNjNjZTJkL3RhYmxlcmFuZ2U6ODE3YmRiZmI5OTliNDc4Y2JhNDY4OGYwZGI2M2NlMmRfNC03LTEtMS0zNzI2MQ_26ddfe16-d7be-450b-8845-006c11aa9e39"
      unitRef="usd">7524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfNjc5_92c35977-c00a-453b-8e68-b6c8b2a6dcc0">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC (&#x201c;Jefferies&#x201d;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#x2019;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. During the three months ended March&#160;31, 2021, the Company sold 1,034,762 shares of its common stock for net proceeds of approximately $15.7&#160;million. No shares were sold during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <sgmo:StockOfferingProgramMaximumValue
      contextRef="i03631c915ffa4c589e31bd1ac9a7dfc1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfMzg4_d5431719-6bc6-4724-a5c7-ba55ce3bd939"
      unitRef="usd">150000000</sgmo:StockOfferingProgramMaximumValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i645065c4f11143f6a0bcdbb35e8a38f5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfMTA5OTUxMTYyODQ5Mg_95898900-7675-4b13-bdbd-fbd1bf6aea21"
      unitRef="shares">1034762</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i645065c4f11143f6a0bcdbb35e8a38f5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfMTA5OTUxMTYyODQ4OQ_c6c6a4d7-db6e-44d0-8fdc-ef12d40f1ba2"
      unitRef="usd">15700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i75cd2dd96b0241acae7b413f811622f1_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NTY4MjJlZmE3YTRlMzI5M2I0ODIxYmZmMWVlNGMxL3NlYzo0NDU2ODIyZWZhN2E0ZTMyOTNiNDgyMWJmZjFlZTRjMV82Ny9mcmFnOjIwNWNkOTNkMTk4NjQ4OGNhZmQ1OTkxMzhhNTM2NWExL3RleHRyZWdpb246MjA1Y2Q5M2QxOTg2NDg4Y2FmZDU5OTEzOGE1MzY1YTFfNDk0NzgwMjMyNTg5OQ_99e36160-7560-4b6c-ac26-5975cecb00f5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M\PV]_$2)3;8GMA!*B2@[7'/F<ZEO@.^70JCCB?Z!8EMU^!]02P,$%     @
MN("E5&O81N5!!@  &QH  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RM
MF6UOVS80Q[\*X17#!M2U2.HQ<PRD2;86:)N@3K?7C$S;0B31D^@\?/L=)4>2
MQ0>GP-XDDGT\_G@D[W^DYT^B>JBWG$OT7.1E?3[92KD[F\WJ=,L+5G\0.U["
M-VM1%4S":[69U;N*LU73J,AGQ//"6<&R<K*8-Y_=5HNYV,L\*_EMA>I]4;#J
MY2//Q=/Y!$]>/_B>;;92?3!;S'=LPY=<_MC=5O VZ[RLLH*7=29*5/'U^>0"
MGUW24#5H+/[.^%,]>$9J*/="/*B7SZOSB:>(>,Y3J5PP^/?(+WF>*T_ \>_!
MZ:3K4S4</K]Z_[,9/ SFGM7\4N3_9"NY/9_$$[3B:[;/Y7?Q](D?!A0H?ZG(
MZ^8O>FIM0SI!Z;Z6HC@T!H(B*]O_[/D0B$$#[%L:D$,#\M8&]-" -@-MR9IA
M73')%O-*/*%*68,W]=#$IFD-H\E*-8U+6<&W&;23B\N;;U?7WY;75PB>EC=?
M/E]=W,'+QXLO%]\NK]'RT_7UW1)-T8_E%?KMW>_H'<I*=+<5^YJ5JWH^D\"@
M/,W20W\?V_Z(I;^OK/J *'Z/B$>(H?FEN_D53[OF^+CY#$;>#9]TPR>-/VH;
M_KZJ>"D1JVLNZS.'1]IYI(U'W^:1U5L$L4&I>N#_[K-'ED,7QEBUKL+&E=IP
MCPL, PNB^>QQ&!.#613'$>G,CDC]CM1WDL)4/'#)[G..:I[NJTQFW$C9N@F&
MW2=10),1I=$LC$(S9=!1!D[*SZ7D%:\EY(R40RP!U\08:)W3(!P!&FS\Q$P7
M=G2AD^XB3<4>)O<$7:CU'"8T'N$9C#Q,S7Q1QQ<Y^6XKOF/9"O%GR/LUKYN5
M*>265Y!<ADO?1!WI$^K#Q(^P#59!'%CB&G?<L9/[3DB6OP$Q-DPI"-B8T6"6
MQ%%H@4PZR.3G-]![5(IR>B W(2<:2TP"/"8V6,78!HR]/MM[)]8#% "5?&G6
M@4I..Y!D"<S<R'KP-L0(<.AY(UBC64 L:Q</M F?VONLW&0JP/8E</!QU#D)
MHW%V,IG1*/0LC+V 8.)D_$N(U5.6YT8THJ^[.*'CN3:9)9%G2>^X5R+LEJ(;
MF&HFLW*#<@Z5#JI423,5Z^F^=@:4:CB1%R=:0 UF%,?80MVK$G;+TDV3G0:;
MR(5JT)P0X[%^FLP"BFV[J9<F[-:F[Z!+599*WJJ]D5 7'1SH&^B$U3%?+T[8
MK4YM%G6$SR Y@4^QAJ?;100GU@W>JQ..WE1^Y1F[S_(F?[IJ,-S+!W;K1Z?+
M._9B$V6LJP+&V-<6CVX&(FA;.[UV8+=X &&U5PM'%$J:67NH45FYV.7BA7-T
MSTN^SBPSI^L#)GY"Q^RZ&?%BW[*P2"\CQ"TC[1YEAR$,9L_$2G1UP#[VQJPF
M,QQ$D86U%Q'B%I$KON:PRE90HCWR<F]AU-4A]J)88S28!1&VY#PR.(6X1>2X
MW#D53UTN,(Y!\\:P!CNBS@T6VEY7B%M7M(B>K'F(KA60WR(M#YKLPC"RG2%(
M+RK$+2I?1+F9PD&B0#M1-5M-K ^J>"K:NG;X)-;J-9.9[P6!!;R7&.*6F"[6
M60F9@B/)GHV4NH"$P6!='B -5J%O8^QEAKAE1E?L4S'5]003JJU?DQ6VK=Y>
M<XC[2-3NM5.$^JD&Z@78/&-&@YT?!K$MP_8"1MP"=BF*(I.J.&_/;*DH527'
MR]1&[/2G;@//ZAU+^?ED!\=I7CWRR0*9+F#^!T?'8^XED23.:F I1?JP%?F*
M5_6OO\0PUW\T9Q3YXKR8Z56+GCK\O&ZF6O5DO)#116B<HYPFQV2]1E&W1JG9
MAIQDQ])U!_NA=DUDLK)5*K07)^H6IXO5*E,I$W:-NDN89B54N[L,=I$1U: Z
M<"8G@3^F-1E2'P_N18Z!!S=P;GV"TFI?['.FZO(5E%!I9A0EJHO-%'N>1WP-
MU6"9!"$)+<F(]KI$W;HT1#U<RT ]6/&MNBA_!'$2M?GB4)>;:9@$8U4RF:F;
M#PMVKTK4K4IM#JVM^]6(;+A^HWY R)C98!<%U+<<-F@O4_0MIZ%!XF\2ZT\.
M(M2N8HTG)H.=\<0T&]S<JY]-OK)JDY4UE"9K:.A]B" ,5?M+1/LBQ:ZYS+\7
M4HJB>=QR!O#* +Y?"R%?7]3O ]WO08O_ %!+ P04    " "X@*548.HLZ'D$
M  #<#P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;+V766_C-A#'OPIA
M[,,ND$2W+ >.@1S>UL#F0.QM'XH^T!)M"9%(EZ3B[+?OD))E1Z*4[3[TQ=8Q
M,_K]A\=PIGO&7T1*B$1O14[%U2B5<G=I62).28'%!=L1"F\VC!=8PBW?6F+'
M"4ZT4Y%;KFV'5H$S.II-];,G/INR4N89)4\<B;(H,/]Q0W*VOQHYH\.#YVR;
M2O7 FDUW>$N61'[?/7&XLYHH2580*C)&$2>;J]&U<WGK3)2#MO@C(WMQ<HV4
ME#5C+^IFD5R-;$5$<A)+%0+#WRNY)7FN(@''/W704?--Y7AZ?8C^58L',6LL
MR"W+_\P2F5Z-HA%*R :7N7QF^]])+2A0\6*6"_V+]K6M/4)Q*20K:F<@*#):
M_>.W.A$G#A#'[.#6#F[;P>]Q\&H'3PNMR+2L.RSQ;,K9'G%E#='4A<Z-]@8U
M&57#N)0<WF;@)V>WCP]W\X?E_ [!U?+QV^+N>@4WRQ7\W<\?5DOT^!4]/LV?
MKU<+,$#GZ/OR#GW^] 6)%',B4$;1*F6EP#019^C3N_NI)0%1?<B*:YR;"L?M
MP?'0/:,R%6A.$Y*\][= 6J///>B[<0<#WF-^@3SG#+FVZQIX;G_>W1G \9IT
M>SJ>UQ-O06-6$+246!)8#!+]=;T6DL-D_GL@NM]$]W5TOR?Z,WDEM"3&O%>>
MH?94:_MUYD:N!YI>3[-AL K=R&ZLWF$%#58P*/IQ1SB6&=TB\@;;CR#B<D!L
MV$0-/Q K".9QBF"FP<)]A1UIIU)J$E]%"DYD!5$0^2WQ!JO0]WRS^'&#.1[$
M_(U04)]K2IS "L[4>*N]RP0Z[B X_L2.6J &J]#Q(S-HU(!&@Z K)@&3=<;*
MA!EU ,:>/W%;F 8K-XA<,^:DP9P,8GYC0J -9\4!E5$CXJ3S\7,_<,/VA#>9
MA9[= ^G8QVW5'L1<4$E@>Y1ZW)E,"8>=4:W],T2)<8[6 =^-JN>W<VJP"MV@
MA_:D"#@?)W5-X%1 :DPD\9MY[.M0[U/F39Q)F]1D%X3C<0^L>X1U/TCM ? P
M1XV8KF'-MQ&[-K#=]? =MWC'&^1[@,-7#@DU4GG&Y)TDI28SV043;](#=ZP0
MSG")., A+"7/UJ7$ZQQRR1!E]#R&VLM9GJOEG]43V*C"[]#9;0%=D_.P!_Y8
M1YS@U^"7F&YQP>#D 5O"CI0RB^$P A/E L$)*GY)69X0;AZ1H%/RS"-BLH,1
M\7I$'<N8,US'YIA32+A L)U5AZHS=3#-8O09SE()# ?F)R^_&$54GQB?PMD7
M7EN"V:IOPA\KG#-<XDP*DBPO)4G^BX;Q3VDP6_5I.!8_9[CZ+:O3;"F &9!A
MA]F5N@Q60T$/,Z_1\*MS4&>D.CN;T]"MFHX?NDYG[S+9>8[3EXEC?76&"VQO
M)@Y#^C_FHEN=S;DPV1ER89WT207A6]T^"I!84EFU%,W3ID6]UHU9Z_F-:EUU
M_W4,4_6]T#!L,RI03C80TKX8 Q2O6LGJ1K*=[L;63$)OIR]3:+\)5P;P?L.8
M/-RH#S0-_>Q?4$L#!!0    ( +B I51:/NS_8 ,  '@)   8    >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&ULI59=;]LZ#/TKA+&'#5AKQW8^/"0!VB3#"JP?
MJ-OM8;@/BLTDOK6E7$EINOWZ4;+KI:F2;;@OB23S4.=0)*7A5L@'M4+4\%25
M7(V\E=;K#[ZOLA563)V*-7+ZLA"R8IJF<NFKM4266U!5^F$0]/R*%=P;#^W:
MC1P/Q4:7!<<;"6I354Q^/\=2;$=>QWM>N"V6*VT6_/%PS9:8HKY?WTB:^:V7
MO*B0JT)PD+@8>6>=#Y-.8 #6XDN!6[4S!B-E+L2#F5SD(R\PC+#$3!L7C/X>
M<8)E:3P1C_\:IUZ[IP'NCI^]?[3B2<R<*9R(\FN1Z]7(&WB0XX)M2GTKMI^P
M$=0U_C)1*OL+V\8V\"#;*"VJ!DP,JH+7_^RI"<0.@/RX 6$#"/<!\0% U  B
M*[1F9F5-F6;CH11;D,::O)F!C8U%DYJ"FV-,M:2O!>'T>')]-9U=I;,IT"B]
M_GPQ/;NC27I'?Y>SJ[L4KC_2I\N;V]DGLKOX,H//UVD*)W"?3N'MFW?P!@H.
M=RNQ48SG:NAK8F5\^UG#X+QF$!Y@$,&EX'JE8,9SS%_B?5+32@J?)9V'1QU>
M,GD*4><]A$$8.OA,_AS>.4(G:B,<67_1 7^I9AHI\36(!4Q$1=6V,F7PB'#!
M,U$A?#N;*RTIH?\YLEW<;A?;[>(#VUU1Z9=".0^B1O8LTM3WX_@DCI)^?^@_
M[L;'9=9-HJ0U>T&LVQ+K'B5&54<UQ2FII42>?0>2S%7)ZFK._Z5<-U%R\:X=
M=W<)=9(@WJ/ML(K[\0'6O99U[[?A7#==:TE=T1G7WJN=.\D>N=<F@9M8OR76
M/TKLGE/7+HL?F,-;<][O+#T@FM2.'U"S>8F@D*)=Z +5>^!H,U"S)Y>$OB/$
MP2#:4_':*H[=,@:MC,%1&2\+XE#B#AQ'VTOB[AX]AUDWZ!VBF+04D[^D"$QK
M6<PW=9"U "[X249=3(J2T$OJB!HE*F<R)T<RH9;QVN*DYY;0"7ZU^>#_BD@9
M7[)*4"]'R=:XT45&:4,]ZM39U -'EW"<B<N.#B4:["GR=^ZP"N727NT*,K'A
MNN[][6K[?#BSE^;>^KEY5MB[\9>;^DU"G7U)%0PE+LAE<-JG$,OZFJ\G6JSM
M33D7FNY=.US1TPBE,:#O"R'T\\1LT#ZVQC\!4$L#!!0    ( +B I52WV1/U
M4 8  %8;   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULS5EM;]LV$/XK
MA%%@#5#7(O5F%8Z!^"5IL#;)XG3#,.P#(]&Q%DET13I.]^MWE%7)IB@YW8:M
M7V)1NCL]]\*[A]%HR_-'L6),HN<TR<1I;R7E^MU@(,(52ZEXR]<L@R=+GJ=4
MPC)_&(AUSFA4**7)@%B6-TAIG/7&H^+>33X>\8U,XHS=Y$ALTI3F7R8LX=O3
M'NY]O7$;/ZRDNC$8C];T@2V8_+2^R6$UJ*Q$<<HR$?,,Y6QYVCO#[R[(4"D4
M$C_';"OVKI%RY9[S1[6XC$Y[ED+$$A9*98+"SQ.;LB11E@#'Y])HKWJG4MR_
M_FK]O' >G+FG@DUY\DL<R=5I;]A#$5O232)O^?8]*QURE;V0)Z+XB[:EK-5#
MX49(GI;*@""-L]TO?2X#L:> [18%4BJ0ERK8I8*M*1"_1<$I%1Q=H<T'MU1P
M-07':U'P2@5/?T.;@E\J^$6R=M$M4C.CDHY'.=^B7$F#-751Y+?0AHS$F2K%
MA<SA:0QZ<CR]OIK-KQ;S&8*KQ?6'R]G9'2P6=_#S<7YUMT#7Y["ZGO[X_OK#
M;'Z[^ '-?_IT>?<KZJ-/BQEZ_>H$O4)QANY6?"-H%HG10 (N97T0EA@F.PRD
M!<,=ES0QJ$V[U:8\3:&8%Y*'CP;M6;?V613%:C/0!-W0..J#"U.ZCLU(YD=L
MA>$FW214L@C-V#(.8VDP<OYR(]=RQ7($#D)[6:E]_\30ZP]<B!-TF84\90;S
M%]WFKWC6!XN9S'D"SQ[ D&0Y$QK2 =1/542D*B)2V'9:;$_80YQERN@]36@6
M E@(IUA1L'^"J(2@A&^1C=\@8A'+E.F=?;>PK[KGTQ@[Q/)L8MFCP9,!FEU!
ML[\1V@O@3'8VO3TX3N#;GE=AV:%NB@%J?"@T,P@1+[!]]U!NWI3K^[X?##5[
MYTTYU\'!H="%P=C0&YI#Z52A= HMNR644'DP[ 0D%^)77)VHC5_LOQ5/(I8+
M: Z?-['\@GZ[A2I#,"RV-(]^[R@QMWJYVYG'2R$V1?KX$H6[C2_4BQ6"D&=9
M.=FVL5Q!AONP?_HP6A]AEO/EDN50 &]05JRJ&X@]PT 73.Q7JZDXW69Q6K;C
M>\0<3Z]RR?O?7#(5M==TP_5<K;RF7K-<+:VBC88<;(Z&7T7#_WO1V*SADCVS
M/(Q%\71WFZ]5= 2"D6,*F.IL>1RJ9EJ:R6(IJH!)^GPLZW[#2P^[0\LRNSFL
MW!Q^7VZ:*F'8<*WO8+VY#1N%H$G,3&9(RZ8(JO@$G?$INDE?D<M(Q4=5,U7N
MFMP(&N_W7>)H((\('8#$5LV:K$Z89R'T.5$0"!5G6I.)746IFPN:/="4H_-<
M)=Q(BZQF!#W-@8LC0H<.[-$^W.D M&9@Z5!0FSQG6?@%24 I$KH['T1_ /.$
M X>)QDQ*RX=Y]QUM!)T?%3M$7G,-W$TVKJ"TU^59Z '.6F;"V204+1L7UTP"
M=U,)]>)-!H,OB?^$ZDR CB' L.O)]#YA2# ()Q0".[H#RU?MXW,</8"=,H=.
MU#,<.T>=4,B-H!Q#QMS UC([;Y.S]<HUR'DM#M0\ '<3@7D6=1#-CS2OF!TV
M'BD,P]RQ?6S[GML"K9[GN'N@:]!> &>"F[/4\0('^UHSQH:Q#+"U7F>PADE
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M2)5FJ;NJ_>CN_F*B/L]HO<)5@?]5=_'>TR-5=*%U=7P8$M2VD?_KK]$.W_+
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M6BJ/.7+9?_I6VXJ3H]!A3>'F.L\T$$T8+KAT-XO8$NU<(9HI]F(PPX^@<GB
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MB.B0,7.08!7*WA"9=X+_0:T LBS)AF"&((_+WA$<SID^Y24G7)H$U65I:D(
M9&($>HH[F:@U/=\U2WV+\."G=QHZAJ5%ZA3)#GIA*\H+B!E-Q%;(@"+@UO:]
M9#(04CDA]%K[FGSVKO-T8^V\H4#?JJ K:2D&SHIY.$@402ABA(2VI:TZ]L?8
M<%EZ)$KQ9>TJ$+>8?K03YW2, ]B#EDR4I7!('L8&3FNJ@&AOV@=-@_B3T1H)
M?V-7C5V"PB)T#HTO/@<&F+=!$#)$_*4.+4?6]W$M(B]4"LE0#)A]3Q)3(0SZ
M#+)4K;^@)&0)V"S(I'J3LI=B;KDT46]D%C,XSZ7L'V)9*2[&)(!K+%H(:K"0
M#BM'/RZH*9X,)3; SXXEI6#KY1:?T3,%!4=!>3[H79/%D1/],XE'P H))XF0
MP6>D^R2/#< UK:P'9EP%KO&N1EKIKU1YN*<BL=B9,)Z).E96<L2:,!D(R&"G
M"W@CV(C$4JT0GL<TW62,044-' 3307Q0ELH="(XU^D'G64 IZ3R2H*5P\5;+
M@,$Q]Y$ZHXB;43S*37P%-H!)"=IVG3[DJ7U]<Y%8!:0D@11@Q @M*JPONII0
MENOQL%N#6>[6%M4DCT78L<RH:IFH_-J5JQ@="]?)[H7VGF.#C1ONMVZ,T@B!
M1/NH>]0;FG1 -3:XJ!OACKK_MA/89PD+1J32(M!]JD9@]'VP,$_Q9M!I-"Y.
MJ3CO^J@J.^[(O['KA2+$$*?@AA*!'_L('%&CW#OQ"*7-I3WL34L L[<VI!')
M '>0@DVIJ=^X<"7C4CN<CLQO\G1$?7(;A,D/IS],LF!LE0LB]+I(8ZP+'HX#
M3X>+] _WPY9/!R"SB&OUFI '1VWUB+$HO8(YAUTE*87$IN,)FH%X3^X8]@F1
MQ/"Q T&BL!DR=KK"@917Z#=HMQO*K*JO!MT&(L'*@4"=&+B/3\(T1A@H=TBV
M7L A@_G)'BN;T"&"K;N::,EXC4SH0,FV TW<5E<<Z3!#Y'[Q09/MF?@'U\XQ
MKUZ#4@Z48]\MD!$H?%]IRH<M"#"$K\;I402?*[1QWA!=D'R/5B!QA3)'(H%0
M\T.KCFB3V-]&%P_F4[S_A-"A,@>5]V8PEL1#B.2E)9'#O1+O3E3VB#[U\=F]
M-?4GQ]S3#2S$4TC*(S@^]7TCUY*^U$J+--P !;/C[STST-!HR?US#YN9F]$7
MEK"7(Z-"B ^,51D)/#)4+&._TWQG;9HHOE2[7NJ\6A9?9O%,Y\'*WAB@H><;
M!0(V:!ME,H?R+Y/ () #+A#Y2EYTD!_9G9#+<'8O /&$U;BUH:TN0=\,F<(V
M"3P!W]YA1^*XPCID>1$E%:*LIPZCBH76<HD&0&B"0Y:M8CLBAN06+5MO/)1!
M*:4Z)>LM@4#NCIER:S;A)_7(/LYQ6 Q'J!0OM:7:O'(T*H7^N0V+)"DAWDNL
M@F62QGD5^(JKU!^L1EZ*0DJ/VJLWY!F#U;8"K3Q +MJA.-2'1?E'TD&\&E4>
M0).BG8.U'[I1,!1FN%]<@[I*V[2)A.QG**U_^Y@:&3<VX-[J@SG5(65[*I2J
M+UB4B=,F>CZ\Y!Q\A-T&Q&X81IP=CV@T'AZ/@H"X5U@28AF-8#XL 6C$/5?D
MW"GZD,]:^G*7SI:(:NC>*>3G@9N3[D4LL3(DE:#LH BS(:GMM/ZH[AZNM_=9
M,16XE*V>#M$124/HZF./F&K^$H(K+-N=2TH\G7'H?E#9TND+MQ24S*!Q9!*:
M_)@PP#8N]?NS"\&&F+#W,H%[@4_WTX^(#0D!QXDD*%_NRM,\5/?\"'K0)B++
M+#H"8SGC%MN8/!*)#M+24-C=,?F2T(IQGL\U(@T_[*2)ZD)*,=ML )XU<AOQ
M\LA.S134HZOY6.R6FBHFMD1&0L9R49TN4U0Y&D/T*<.W/N:)+\4IYR\BX)B.
MIB-1YS31#\1Z'DP)+J?L066$3>$7-I&.QTBL-)F+$B_7)QXE1ZI"1U!->4Q,
M?CO8"41RV%(/VL+4/I L^4B.)Q,"L3+*J2BB>:2W7-+I2KY38@R-YX!#3G*?
MFJ0F':2/&2*%J#Z>&_$XZ)YTZTO_:#-9>#A^$#_Q[)W&'U@/35=CDF]E'A@O
MRD]B_.QT6/+.T$$BEP55&$_3>QI%I@9M@)L'#1Y5GZJ+OM.1Z5S?[\ 5TA5I
M13]PJVQD8,#O#(T:Z]^YV(]/?[! ;-NDJ=SFQ24X'C)F3#AAE6)\!M&%X0Z=
M&G5 VF^=3+U8Z3V94@R7B>Y0NU3MBCB4CV<F<OXQZ@_S_=&%":US522G9"K3
M&_]PG4QE>J\LQB.4.F+_^+QAOXC:H(8"Q+H2'U^Z%-.6DP=HM9#I([?4TNW$
M?".[>707)/P <?9=++-7<JHK$(LHDVU,<<Y]KJ@TD17'Q%D28R6'V^X9V7$_
M]!D'[;UV^R.3I.%?J@@#VH)+/&K-)^>3>+@^GC@EX'9\+E(=<E)JG*5H-_L5
M@W&?7MHCU7NM>I <1GU?  :F!W\JUL?=)I8#"8P_6BGV-G3(([@QD5C688 Q
M<CK1=%2GI([1K9-8^FZMN9-6PB/C*QGUBIFHG=-THFE*^LBSM65E[AF;QI.#
MT?0)+$+[S"A;.L]=I1E[:>B%&AY1TQ G\,E%\L5@X!=[MC "V1V>7T/:/+K>
M&W^EDX-<6?:JB4"FKJAA'='.'./WU<N^C=UI#,8HTE%+]H7(^U"X;Q;C4$V!
M. ;XW_9-W0[1H[I,A9\/R(;]KM?I#'2G$$V(P@H/]7F$+#"2QG/D'SH6D+%L
M_QJ/$$4^"J1TJ7HZDD^[N"W-)7/'GU)W^CFH#/V\^QKC7S(LLKIA!1I3O5K_
MZAYBF ^,DA2SE9US=*[;>=\[&AO2ZQ;<2:*#_,13P>';EC(+Y)/B<^O 9M7[
M>7RQ[>FI^K/\<P7^#)0,^!T)WG;)'7CB/;V!QN?+(F5\]LD,CSVA9_]J@5C7
M=-JBX[4979L]Q3\WNG%+JVZF\ZEZ1IOAOW=\II2[]7P\MS_"&]HLG2+N<'(I
M[IE),U1$ NW+@T3]8!-_;\<K44Y+]K2SI^21(7.6J%U^([1WL?W7T^M1.=!5
M< =G-,-Y75[\P,!F=[(4Z5^:@J?,97NS\_B4]AYG-;T ?(PZ'.\3\G@V.2_.
M=4(V2P?"&2605G.:GNS->N2\X_#VW!J7M^FH7;"0>=RW-T=[T53NS*U 7_D,
MGOY5;W?/X#_&8STZNJ(;TOEQXA2!7\9;HR6JMNB)Z,T->I7"I%?S-AT\PH,(
M[H&!1"O;\#EOF\XI68_!40"-QO@858IB6B&>?C.)WWU?0'20 ^B=2RJ^&\BT
MC!4M0:B"E0/!$@R#:CG*PS:= ^6S!+K")X0K2IB&%#H.&SK \^G=I^W^6P\#
MB[$L<7\YH(%F;2LOI118Q K%_-/9]!G-=RMN9O/TD(?N2=P\:*77! ;A$%\?
M5FLD;V0<K-FYMV&A&T..18(XWUA-$QD*A:9 [<G#I8=>P? [RN2#3?+FPX>;
MH[<%PYA8AX,+?<MK3^-7M]CK[ZAP,'#D,@)HHB5=%Z!$>/S3X&!I]%+2/3_?
M'TQ_4F>ST\GLV7/Z]/S%Y,7S&?\VF_SX_!E]PN-/9C_RN4!B;[LV/)L\.ST]
M\._%=_A!_PLL2'J<39Z+;B].)T^B;D\G3Z-NL\D+Z/;1%/(ZR[QT_!KT\/#>
MNP:?B[@!S&"FA_[XX&3P]R"U\2O^JQ<^:&Q:^=.0_&O^PYJY_#U)?[O\50Y\
M"$@)R(LE'CV=/G]V)$.Z]*5U&_[KDH5K6U?S1TH6X^D&7*=WV-(7VB#_N='K
M_P-02P,$%     @ N("E5 &HP/;^!@  G1(  !@   !X;"]W;W)K<VAE971S
M+W-H965T."YX;6R]6&UOVS80_BN$-PP;H/I%EN.7)@'2-,4*-$/7--V'81]H
MB;:X2*)*4DF]7[_G2+U9:0*L&_;%%JGCW7-WSY%'G3XH?6=2(2S[DF>%.1NE
MUI:;R<3$J<BY&:M2%'BS4SKG%D.]GYA2"YZX17DV":?3DTG.93$Z/W5S[_7Y
MJ:IL)@OQ7C-3Y3G7AU<B4P]GH]FHF?@@]ZFEB<GY:<GWXD;8V_*]QFC2:DED
M+@HC5<&TV)V-+F:;5Q').X%/4CR8WC,C3[9*W='@;7(VFA(@D8G8D@:.OWMQ
M*;*,% '&YUKGJ#5)"_O/C?8WSG?XLN5&7*KL-YG8]&RT&K%$['B5V0_JX6=1
M^[,@?;'*C/ME#UYV'HU87!FK\GHQ$.2R\/_\2QV'WH+5](D%8;T@=+B](8?R
M-;?\_%2K!Z9)&MKHP;GJ5@.<+"@I-U;CK<0Z>_[FXNT']NGBW>T5N[ZZN+G]
M<'5]]<O'F].)A7(2F<2UHE=>4?B$HCF[5H5-#;LJ$I$<KY\ 5(LL;)"]"I]5
M>,WUF,UG 0NG8?B,OGGKZ=SIFS_E*9>:?>)9)=AK:>),F4H+PWZ_V!JK08X_
MGK$1M38B9R/Z]]'\)D7L8RK8I<I+7AQ8+KAW(1;:HOS83A:\B"7/&#=&6,-X
MD;!,\JW,I)40Y);M* KW+@I4$ZBKN-):%GOBMC0!DT6<50E-Q-RD3'RN),1%
M8?$.97LG+-]F@AE:Y[0&SHP%L)T6>)%RPN00C-F;SIPTJ!8K-$@L$E=)B8=@
M4ZQ[ 56:I?CA.DX/K *+M-/**YLJF.)4OFQ?R01.PIC2?6?J8.0$U %*>CFV
M*3POM20U\B\W 3Q%64&V(AP(GE= ?O>T<@,[&38NLV'OQ+W(V&S#;@N>_(G*
MQ+K/E:(_J(ZA53:;3!VHVC#B@7D(&$F1PPR9[P%F";?>(9E@*&.>!0@ D%LH
M)@-U/B'12^?+&E*X8;\.<3P"4"C;@",[WO>'5,:I>ZVV1NA[RFS A 0^C0""
M&S8[>/EF%#B<ID+1<$#E&01<[JLL8Y1=IG8^;02YC_CPTN7%8YYOV'L/5OE8
M<[='6Q&GA?Q<-3G31#_=YJKU9JMLRHS<%W*':"&"5GD4SQ"B*CHGV8]R+,8!
M_"A+I2ETVP. 6INY\!2J#J /&;#_-':E]Y3^VN>Z,G_X;A7.EB_-HPIR.+Y:
M1,XKG_V=I(1[DGCR$2DS"ALRAMP@O0-?N[+YT;U4E8$E\].&7=-TNXNRWAYX
MW<?_45GL&C7#&UHUJ6(7CGT;=CEP9T-;OC@TL=JA9@W[GD7K8!4N^P\N(.'+
MWM/M^&;,]NI>Z((0O#"E*HS2\)Q"8 _8*K:V'Y_9(IA.5^WZP=#C/XF"U7S1
MF!V(7'\M[)M_#B2,@BB:M6H'0S @%]KMP24O445]%V;+8!XN.A\&XTNE04;:
M"AXY#\'EO%MX/'3I>;'E\1U0]U:=+(/%K%,_&#K'K78L.#!4*-@5!NMU)W$\
MNL0AXZK-"L?W1)3*2,L6TR":=F*#H4],N)H&TT74:1Z,O=0_J);OV3Q"LE?K
M/LO"-3)^$O98]EK$(M\B"W4!S/Z? IC-UL%ZMCYZ>EP"WF0CT?PW;_]KVLZG
MP<FLB_A@^"QMIXM@N5AV[!N,GZ;M?!Z<K,+.YO'P*=HNI\%RVE748/@4#2/D
M?MV)#88-#1?!*NH1?##^!AI&%(R3Z"C5C=HNU8XW5P.5O<S>="K[#=Y>%-C7
MZ82-,QRG=#+@<,?R)XX0TQ!WS-X6Z!VJ^O##T=(J2'IB./]%T3OZ&Q[7;<11
M0](WU![#Z)L3WSUEZ&Z&S0])4'<U9K]]FYVV;[GG,O.]B:EPG,F!<TX/#GCC
MVEA1Q"D9P.U)WU-[VL[0:U FDW?'_2N>+3#LM:I*R+A&%YW7%Z>8%E&ZNB8E
M5PF.8M<0&/%HOD:DL!8IPM9:MR:-+KRZA[?:=3Y;K>[HD0R@\6XKB;.B<AL7
MX/K>I]^84Y]90L\7F9.PTHF7K#O<PZ87A(,468+56M2-CLL91<69GB0"E-2^
MD24CQE14_OZ"'S#[H%X824FNL]H+YU$,MY+$U6[7N(/+M="".G5TM[R'ODX^
MNEOAFI.RVF94SP@A@HJK=GN?J?4CA(?2W3.21)(86%(WA#G'T>59%E \C<I%
MTXQ1@YIPG?1EB4V01_3()!@U9E<^@4I[B>Z6T*Q+Y,YYXEIA1)X*$S0OX-?!
M<9=F6JCMO:9V,U:%!UW?DQR?L]:!3+I[A+LB-"QW2N$2JQL]T5$,2:=[A),0
M',%K[?:$AB#'7[O83GJ?#+#U[]V'$72LJBJL_WK0SK;?7B[\)X=.W'^XP4:V
M1TEB#]AAZ72\7(R8]A]#_,"JTGV 0-=N5>X>4]!+:!+ ^YT"^>H!&6B_2)W_
M#5!+ P04    " "X@*54DD2;CJL%   B#@  &    'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;+U766_;1A#^*P,U*"R L7B3<FP#LJ(V1N,@M>STH>C#BER)
M"Y-<9G=I1?WUG5E2A^,#<*\7B7O,S#???'N=KJ6ZTP7G!KY59:W/!H4QS<EH
MI+."5TP?RX;7.+*4JF(&FVHUTHWB++=&53GR73<>54S4@_-3V_=9G9_*UI2B
MYI\5Z+:JF-I<\%*NSP;>8-MQ+5:%H8[1^6G#5GS.S6WS66%KM/.2BXK76L@:
M%%^>#2;>R45(\^V$+X*O]<$W4"8+*>^H<9F?#5P"Q$N>&?+ \.^>3WE9DB.$
M\;7W.=B%),/#[ZWWGVSNF,N":3Z5Y6\B-\79(!U SI>L+<VU7'_@?3X1^<MD
MJ>TOK+NY$4;,6FUDU1MCNQ)U]\^^]3P<&*3N,P9^;^!;W%T@B_(],^S\5,DU
M*)J-WNC#IFJM$9RHJ2ASHW!4H)TYGT[F'V#VZ^WEE\G'V:>;.4P^O8>KR?4O
MLYO)Q<<9S&?3V^O+F\O9_'1D,!Y9C;+>]T7GVW_&=P!7LC:%AEF=\_RA_0AQ
M[L#Z6[ 7_HL.KY@ZAL!SP'=]_P5_P2[YP/H+GO%W6=]S;5!B1COPGB\,L#J'
MV==6F W,>=8J8037\/MDH8U" ?WQ0M!P%S2T0</_A/$7?=,*/M$-R_C9 )>H
MYNJ>#UX1$&X*#H8M2@X+6J[]4A5_(@<&AZ:R:EB]^?&'U/>2=QHRI@O@2-<]
M*XE$2Q\:W/'.B=Y3>"1J="%;C5/T\ 0FE50&'>?PLY):][\S;02N-.S%4F?%
MKM8PT9JC_^EW 4](87S3QX1EB\[A#81C)_43_+!(_7</OOK!V^/Y,:SD/5<U
M">"M;F2MI<+0V*+ZYZ2'@PR\R''=,1QYP^XSA1MI6 EQZ*1!O M X[8KHAP>
M,W'R^LA^Z"1INH\0A,F0.L/0HY)47&4"@32LX>H!8B]Q$H2\-TS#H>T-_ @M
M52,5DOTXT\2)D/-]1N%X2)U!$G2%>+M@V1WB/;")$R<=NP>ADFA(G9$7=0D;
M/#)TJS:P$&6).3GC<;2;OOWO>J<<I;$4&6&32X372"VP^I&+N Z9]I%K[ S=
MJ*^%GWI.&!S \!!TC&2EKN-&83_K%;)] T$8.WX</Y"0=8LUH%$L=3K&S2/C
MU0+I[Q7KO5*QGC=VQM[X&<EN1SOXV];WY&W[_RW9!2ZJQP4/CE+,%5NQ%[ZL
M-S=RDK$/"1R%_K!K1LD+0@L")_$#BD#SL16G_K,*2UPG=1.:[+F()R%TWK-:
M"2/'\V*:[6/]L>6.O9U(8L<+4N0+9>J&I([(2</H[Z@C=&,45F)K1,*P_J@;
M4X]#NY\NF5" OEH+\&E'BPUD>%32$=,B!-P":60#:ZXX, U+6>)V_'@7W>^2
M#P1X9>WK%>!T5!ML.%,@%91<$VA4BQ.%%O0X<>(DWANPI4$?.QM3*-FN"ECB
MS<GV:$A]NZ;3U/'BK2+1Y1@9CGWZZLF\YJRT^_L*;X8=B25N\9BLK.UAHI%>
M392(_2G<)8SSQ:JV5:T-Y!TR,D$XG$/572HX72J^/R<H#"V_8TM]?UXAGS5>
M,/&\0K4+ TKH.V152Y0QG35K80H@T>R1 "K6(.M"[CAX-*$4V<:!=2$00"DJ
M&F]:1,,H22.AP OAVZ]83ZJDT+KEJN.!E5IN+2@M5LD6/1(5Y.,@,C,HQQH/
MXSXR@L62,M#(""JH<_HPUUSD4$M,DF=282R<3MIA=8921 WT'&QK@<5&" H$
M6@ME,\,,%+&E>&GIP50(U]/*)9?_I#0%RZ&MU58L/:S_+70M:;%Q1?O9(Q@.
MDIV+>Y%C#<N-]2(Z[;+52O$5&CH6Q=/X;/F8U3.6[*F;X^C@WHZ[ZLJ^3E"F
M)(?N"K_KW3V )MV]?S^]>SUAQBM:9R5?HJE[G$0#U+E]D70-(QO["EA(@V\*
M^UG@(XXKFH#C2RG-MD$!=L_"\[\ 4$L#!!0    ( +B I52__RJN<@,  ,((
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;,U676_;-A3]*Q<:,&R
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M08%[UDBWT\</V.7SUO-Q+6WXAV.[=GP9 6^LTU4')@654.V3/70^/ %,1R\
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M[0OTLJU+7Y:WU9UD'@3E*W%/T-'P\FT$IJV8;<?I.E2I7#NJ>:%9TD<&&K^
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M!%@#,B:SIH*7#7DH\J6<2Q3*19&OS+J XM8"BAHAK,U;;7P$R&9LJ-<R89Z
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M:=9:Y#K" BJBI94;L&S*@?"[;I(R;5.Z6\K8*J_?*M#FRF^W:C5E@; 1WMV
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M<VAE970Q-"YX;6RU6FES([<1_2LHY:C=*HHZ]K"]5Q4E:QV5+:TBKIQ*4OD
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M<>!'U_&/UJSXTVJ(WIJ:?U*25I86X#U]ZA/_H /2M_;O_@-02P,$%     @
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MU+T=]"PBJIFJ$A0OS!RSX0JG(K--< P%H17P?LNY.@LZ0#W8SOX&4$L#!!0
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M6E$[!_J_4<H>-BY!/:Q'?P%02P,$%     @ N("E5#LXH#]  @  . 0  !D
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MT4VIEV+[.[0)G1N^5)2J?I)MN]:Q2+I16E0M&'=0,=Z\Z;=6B , \KP.\%J
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MAUXJ0"' >#A$ 1JR(0Z[JL[^SVJ;B!G,^B(&4!XZA?*PB]/&XP=&N_[C!R&
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MJKPVJ+Z?9UFY?5,_.G#WK,C+_P-02P,$%     @ N("E5!0Y/^PI!P  ?"L
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MD>7[5'9(K.T57PC2#X9M)OI)1VD >CX6@EX[YM6H_R0&_P%02P,$%     @
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M:PI+M2W;&D8V[M6OI*$><LN2IAPJZT#G:RG-WK 7]',S^0-02P,$%     @
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MS0OJIO%\%HGL$^QS6[L#_*V0+,Z=509QF!R^R?>\$2<.*DZU \H=4-G!J7'
MN4/6.>N065;6/9%D..!L#WAJK:*E!UEO,F]539BD,BXD5[^&RD\.IZ,OSW,P
M?EV\/$\?YHLK,!O-7Y[4T>?); %&3_=@\3(?O3S\-!F#T>/C9/0T?EB '\"<
M[FBRI4(=^&R=A'_1)=@F2\K!:,TI54)+\/&>2A)&GY3YZ^(>?/SP"7P 80)>
M K85)%F*@255"6DBEI^G>W=(%]6DB\&4)3(0X$'=:WGN;ZG2B_K1L?X[9 PX
M)?P:8'@%D(U013[C][M#0SJXD -G\7!-O#D5E' _ *H]X%[U.&*;K)<CSDFR
MSOIZ!<:J!UP] $ R,*,\?9B!^@#/,J!<@-\>550PD306OQMR<HJ<G"PGIS:G
M@]15:AT\W<PS)<9NB#R$52=VISVLL'*19Q=69VEUB[2ZQK2>V(YP&0HP280,
MY5:J/V/:A+N03>DR]$D$CMV\4C;^M:$5;G%/MS7R](J<>HWE.7AV3QKO>?UN
M29U+HY[GPFIQO"(I[[\5!_Q])$E&=[8"V\V*JT:"%:6&+O6+A/JM40[:&KYV
M8^URUS-=;.B5Q*NP<M407JT>/!D5X/^@7]YB0?DN],M5G6>"=":H/<)I3$/<
M7#A\(0GT>KVR<!56;MUC!S6KH1G62J U3<!T]";SH 8M[+9' HUBZ#:7P+UL
M+H1]7-:@PLQVNG4B:")#,Y)+(C1E&]2TA5Y[%-+(A?WF"O4OZ89MMRS0&U;G
MKWP:N\B,W2I]WL\NI"F*8&MD09JH"#66)7<];3CVO#*[JJR@TZV114,5F:'Z
M<R@IF 5$S<[>I!?21$1.>T303$7FMU>C"-W+,1W;Y9&_R@IY7HT(&JO(C-4+
M$9K2"VE<HEY[%-),1>976*-"WF7O8;=?5N@-J_/$-%:1&:O5"KV?7UAS$MNM
M$09KJF+SNZE)F-SU;$1WRKI4&:$:6;#&*C9C=4$2M@I-%9XL K1G%0!KD.+F
MZP"Y:ZGO%XVOL++=FLD*UBS%9I8>.M^44UBC$;=G]H\U/7'S^3^^G-MC6%Z=
MJ3!"J%<CBL8G-N/S1)1_@28-0=R>^;RC@>DTG\\[ES/U?J\\J%<8N;T:-#F:
MF(Z9F(46TS"B0C)5-/&#4"6;MLE4N::?TYYINJ-!ZC2?IN>N9ZN2T"[K<6D$
MNTY)#^MD^3VF?)WM2@C@LVTB#RO1Q=5BYV.4K?>7KM_!F_%A_T*'.6RG3 E?
MAXD $5VID/9U3_U#^&&'XG BV29;Y/_*I&1Q=AA0LJ0\-5"_KQB3QY/T!L4^
MT? ?4$L#!!0    ( +B I52L]EY<C08  ' <   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;,U9VV[;.!#]%<+H BW@QB+E:Y $<&RG39&DAIWL/BP6
M"T:B;:&2J)*TDQ3[\3N49-&.)-K-4_+@Z,(9'LX,SR'%LR<N?L@58PH]1V$L
MSQLKI9+35DMZ*Q91><(3%L.;!1<157 KEBV9"$;]U"@*6\1QNJV(!G'CXBQ]
M-A479WRMPB!F4X'D.HJH>+ED(7\Z;^#&]L$L6*Z4?M"Z.$OHDLV9>DBF NY:
MA1<_B%@L QXCP1;GC2$^_>+VM4':XL^ /<F=:Z2'\LCY#WUS[9\W'(V(A<Q3
MV@6%?QLV8F&H/0&.G[G31M&G-MR]WGJ_2@</@WFDDHUX^%?@J]5YH]] /EO0
M=:AF_.DKRP?4T?X\'LKT%SWE;9T&\M92\2@W!@11$&?_Z7,>B!T#4F= <@/R
MRJ"#:PS<W,!]W4.=03LW:!]KT,D-.L<:='.#[K$&O=R@ER8KBVZ:FC%5].),
M\"<D=&OPIB_2_*;6D)$@UJ4X5P+>!F"G+FZ'W[[/T.AA?O_]=C*;-]%T.+N_
M@ZNOU],Y&MZ-T?Q^-KR??+D>H>'-S?7P;C29H\_H,N!+%J/;81-=Q]X)^CAF
MB@;A)_0!M9!<4<$D"F+T$ =*-N$A7-^O^%K2V)=G+07(=?\M+T=YF:$D-2@Q
MNN6Q6DDTB7WF5]B/[?;N(?NK _T3BX,6A+R(.]G&_9)8/=[2%^3B)B(.<1[F
M8_3QPZ<*6".[DV$B3I#K['E)!/?7GOI74;%DRF0C^ZT*W2&@NH\,*:E'.CG>
M"Z[W<F7W,F;>R1%1^W*\EVHL>QEUBYGDIF[=&K<S)AD5W@I!B:,QVP#+)\#9
M"@V%H/&2Z>LF&D$9">!?I#B:,J&U!,$/^JY63$CT]PUX1=>*1?(?"Z9V@:F=
M8FK7%8CG\76L)(B&QX(-?0Q9505D3KJI$ZU=FXONP.V?M3:[0:UHY&"W:+2'
MKU/@ZUCQO6:1_]!<<>\'2M802! 81)>"I9&S!*-;=-9]-PGJ%9AZU@#<K:-'
M)A!?%)PIY9KYFBX!12QI)M@?X3YK\ EB5#N51UEGG9T<D7:;.+C3J\Y3OX#9
MM\*<TY"E('5VFB@1@<=0 L!3*"D\GX<AA0 53S520S]5:+,^!SMH!R<$N]V!
M^:N&/2A@#ZRP(9<R\)F@*ELXZ3D P>5[P:U"-BC5.B$=QW&JX6#'B*UCCZ/2
M^J>", 0T4D$84V00LX!7R=+H@#\7O4!)2TLAXIV% 'X#MB;B3S$4_BI(D%K!
MBQ4/?0W8@]D":]6=U^9AY4CLO7=.'.</VSB(&0<YD'0HQ$>ND[X! C%S>V]&
MI25<B9.4<^^TN[6Y-_* 72NNR;,'*HR\M]9D[GYW<O<&];B,1&"[1NS$2V\-
MMH3;1.SG.E O.2-5(FJ7$.%VIUT+R:@"MLO"D;*5>]GMW]WM/=.MBE:D7XO1
MB GN6C&.V8() 9D3H"3QNAI@MR) W5X98K=4<UC'L0ZD41=LEY<9\_@R#GX!
MS(2+-,' XH<2.\85.C*H16-$!-M5I*SV^[4W!%V^@6D9@_ /CQ!^;'0 #]Z-
M]!.C!L3.WF^6I]QOYTB.(D8#B)V%IX)[C/D2+02/@*JVV>&O-2;?XN!RW>[K
M9(X7E^>!14^)X7IBY_I;^AQ$ZP@VQB%(%H?T)/0E3:R5.4:D@N3U?*M%9%B>
MV%G>+.CRC1C*-F(2JGU_:U:)J\SQF-1 ,@1/[ 1O(%'?#W1-T?!MZ,I\WZ\!
M9ZB>V*G^/NT-F6]3]6NA YXZ!]="Q) [L9-[?18SH#!+CPI8F?]K-DS$4#HY
M1.DYE5D"9??0.QPH0^G$3NG;"1C7!DRP)*3>L0'KE^N_;DH:\B?V7<!5$-/8
M"Z#HJ;\))!<O:,$J=R17I+SP[]62@FN(WK43_31;&>OP!#',0*J7V*DRUS'\
M 8>DO%K.!O#[=OM#,DKA'E *LYSPMK))I61J.[)?U4L+MRP%;5P;82,$KET(
MAI'&\XO6Q'/LE@D?OY:IR8%&^]!V/@O9%>%-JQYH-17L,TU@SFR@7 J!LR7/
M*(+;?C?+(==(@6LG\+>*>>YV-VT#R^K"-2K@VE7@K9G37TOD9WU XA^7.$/^
M;N_]),Z(@'N<"/QVXOH5VYZJ55AKYWPC8B >^NA*;Z5ADYA]H"V>%L=CP_10
MZ-7S2WPZPA7/Q_ATDAU^&??96=PM:%402Q2R!73EG/2@V$1VO)7=*)ZDIRN/
M7"D>I9<K1F%5KQO ^P7G:GNC.R@.&2_^!U!+ P04    " "X@*54M3]D $4%
M  #<$P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6S-6-MNVS@0_96!
MT8<62*.++W$*QX!B>[?N)JEAI[L/BWV@9=HF*HE:DK(3H!^_0TJ6[%ABLXLM
MT#PXNG#.',X,SU <[+GX*K>4*GB*HT3>M+9*I1\<1X9;&A-YR5.:X)LU%S%1
M>"LVCDP%)2MC%$>.[[H])R8L:0T'YME,# <\4Q%+Z$R S.*8B.=;&O']3<MK
M'1[,V6:K] -G.$C)ABZH^I+.!-XY)<J*Q321C"<@Z/JF%7@?)GY7&Y@1OS.Z
MET?7H*>RY/RKOIFN;EJN9D0C&BH-0?#?CHYH%&DDY/%W =HJ?6K#X^L#^B]F
M\CB9)9%TQ*,_V$IM;UK]%JSHFF21FO/]1UI,R! ,>23-+^R+L6X+PDPJ'A?&
MR"!F2?Z?/!6!.#+PO08#OS#P7QBT>PT&[<*@_5H/G<*@\UJ#;F%@IN[D<S>!
M&Q-%A@/!]R#T:$33%R;ZQAKCQ1)=* LE\"U#.S6\#SY]GL/HR^+Q\_UDOKB
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MS2@<Y/4$^+[D7!T>] +E->WP/U!+ P04    " "X@*54;#C(Y_ &   P)@
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MHB3Q(X#Y%401AL#3B".8 M" (5'4G(-[YU&X.:?"[>\OD]]02P,$%     @
MN("E5)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC '
MT"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2
M:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=
MI3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8
M%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+
M P04    " "X@*54-%08]%$#   D&   #P   'AL+W=O<FMB;V]K+GAM;,68
M76^;,!1 _XK%RSJI78))T@\UE6B@#2N!#)-*V\M$B--8!1P9I]WZZV?(HAEM
MO=J+E2>PC<SQUSVVKU^Y>%YR_HQ^E$55CZV-E-NK7J_.-[3,ZD]\2RM5LN:B
MS*1*BJ=>O14T6]4;2F59]'"_/^J5&:NLF^M#77/1TQ-<TEPR7JG,)N.1T=?Z
M3WF31"^L9DM6,/ES;+7O!;50R2I6LC>Z&EM]"]4;_CKE@KWQ2F8%R04OBK%E
M[PL>J9 L_RN;-)!IMJS;')DMDTR!C*U17U6X9J*6[1=M_9EB?*'JXWUJ)_D=
M*R057B;IO>"[+:N>FFI4*WI:,]I^.#SWG7@E_J<;^7K-<NKQ?%?22N[[4="B
M :SJ#=O6%JJRDHZM"7^AHFF/^D&PVK=-*BBMI\054P4B6+5X!E'BR/,CXGM(
MO9$X##PW58E;-W2CB8\T2 Q XJ- DE0]9GZD03H I'-$R.]8@QP D(-C0CH:
MY!" '!X3<J!!C@#(D5G(.+EWH^";FP9Q=*K6"PD(BN_0//&)'Z6N!GD.0)Z;
MA;QS@P0]NN'"1S/?)8ND62XIT> N +@+P\/LDBGRORP"!=A0(3?RT,Q-'OS4
MO0U]#?(2@+PT"]D,[*0E\X)PT4S#R$]1&!."YGZBQT>[#T7QOEG,F?LY3M!D
M0=)XYB?D%,W=)(W4VS28JX[5,4'9&+:-PIL\G*D^;=?V;*Y6>;N =#[(,[9A
MT;1\TSCT5,]]:.=F^E5G@_1B&_8+&' Z?K$AP=B&#0-CZH:Q(<78AAWS3F1$
M9^A$;1@+'1.2C&W8,F",[ XZI!G;L&? \-/%A(1C&S;.>^'G]ZCKF)!R;,/.
M@9>0OO_!D'.P8>? F$,=$W(.-NP<&'.D8X)'',/J>2\@G7A49DP/2!BR$#9]
MR@$#DA[>,60A;/J< V)VEA!D(6SZI -B=I809"%LV$+@)K@3WC%D(7Q4"W7F
M)F0A;-A",&9G;D(6PH8M!&/J<].!+.0<\^33">\.9"''L(5@S',=$[*08]A"
M,.:%C@E>M1FV$+"1(Y+G.B9D(<>PA?YUG#P(_:,."3G(:1W4.]Q*K^B:5705
MJ1_4*C_/BGPN4//8GYX'PV;ONMX5Q43EQ57(L]7ADOMP07_S"U!+ P04
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M^F=DNR:U5,W!GW5_?&=?4$L! A0#%     @ N("E5 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "X
M@*5421:'\>X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " "X@*54F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +B I53FQU76
M/ 4  &(5   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " "X@*54:]A&Y4$&   ;&@  &
M@(%_#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ N("E
M5&#J+.AY!   W \  !@              ("!]A,  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( +B I51:/NS_8 ,  '@)   8
M      " @:48  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" "X@*54M]D3]5 &  !6&P  &               @($['   >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ N("E5,W0[L)A!P  2QT  !@
M             ("!P2(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( +B I53L>_-&H!(  'HT   8              " @5@J  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "X@*54 :C ]OX&  "=
M$@  &               @($N/0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ N("E5))$FXZK!0  (@X  !@              ("!8D0
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( +B I52__RJN
M<@,  ,((   9              " @4-*  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ N("E5(@'@^\3(0  *H8  !D
M ("![$T  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "X
M@*54G*K%D*@"  "^!0  &0              @($V;P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +B I537BV">3@,  $,'   9
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M970Q-RYX;6Q02P$"% ,4    " "X@*54K#CAA.P#  #B#0  &0
M    @(':DP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M +B I52"O07=N@(  +@%   9              " @?V7  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ N("E5#LXH#]  @  . 0  !D
M             ("![IH  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " "X@*54\F2'?U$#  #M"@  &0              @(%EG0  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( +B I53A;=8+* ,
M (H(   9              " @>V@  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ N("E5#L'<TP]"0  -U(  !D              ("!
M3*0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "X@*54
M%#D_["D'  !\*P  &0              @(' K0  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( +B I50G["#0J@(  # &   9
M      " @2"U  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ N("E5+9V;83/ @  9P<  !D              ("! ;@  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "X@*54-@<CIV,"  !#!0
M&0              @($'NP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( +B I53K[1&WC@0  %D1   9              " @:&]  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ N("E5-\,C!;I
M!   ,QH  !D              ("!9L(  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " "X@*54K/9>7(T&  !P'   &0
M@(&&QP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( +B
MI52U/V0 104  -P3   9              " @4K.  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ N("E5)(5&N, !0  LA4  !D
M         ("!QM,  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " "X@*54;#C(Y_ &   P)@  &0              @(']V   >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( +B I52APN++ZP(  / (
M   9              " @23@  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ N("E5+F.1=\! P  <0<  !D              ("!1N,
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "X@*54&Q.]
M(Q<#  ",$0  #0              @ %^Y@  >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( +B I527BKL<P    !,"   +              "  <#I  !?<F5L
M<R\N<F5L<U!+ 0(4 Q0    ( +B I50T5!CT40,  "08   /
M  "  :GJ  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "X@*542XJ@"W,!
M  !P%0  &@              @ $G[@  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " "X@*54WR$G&Y(!  #Y%0  $P
M@ '2[P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     *P K *0+  "5\0
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>213</ContextCount>
  <ElementCount>206</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2107102 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - FAIR VALUE MEASUREMENTS (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - STOCKHOLDERS' EQUITY (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sgmo-20220331.htm">sgmo-20220331.htm</File>
    <File>sgmo-20220331.xsd</File>
    <File>sgmo-20220331_cal.xml</File>
    <File>sgmo-20220331_def.xml</File>
    <File>sgmo-20220331_lab.xml</File>
    <File>sgmo-20220331_pre.xml</File>
    <File>sgmo-20220331xex311.htm</File>
    <File>sgmo-20220331xex312.htm</File>
    <File>sgmo-20220331xex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="497">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 13,
   "contextCount": 213,
   "dts": {
    "calculationLink": {
     "local": [
      "sgmo-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sgmo-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 327,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 46,
   "keyStandard": 160,
   "memberCustom": 30,
   "memberStandard": 22,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sangamo.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i01e697d1114342af9aab4ece3ebe09d4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i01e697d1114342af9aab4ece3ebe09d4_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - STOCK-BASED COMPENSATION - (Tables)",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "ib44f00bdda5c4a5e8fdf09b0b409881d_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "ib44f00bdda5c4a5e8fdf09b0b409881d_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - FAIR VALUE MEASUREMENTS (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail",
     "shortName": "FAIR VALUE MEASUREMENTS (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i708b092c6ed84bd1bbf020943bc286ea_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "ie4e67faf817f4852b243d3c63990d266_D20200801-20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i01e697d1114342af9aab4ece3ebe09d4_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i26fa9295800a4f159a11564e07b29049_D20200401-20200430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i65f51596bbe948b39da9c94202af38ba_D20180401-20180430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sgmo:MilestonePaymentsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i49808b7d5a184b629b594c228b0d228f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i1aa617603ebd4abeb4444421df29e6bc_D20140101-20140131",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sgmo:NumberOfResearchProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "id6d053e63e174530b26c614c63fbadbd_D20170501-20170531",
      "decimals": null,
      "lang": "en-US",
      "name": "sgmo:AgreementTerminationTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i03631c915ffa4c589e31bd1ac9a7dfc1_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:StockOfferingProgramMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - STOCKHOLDERS' EQUITY (Detail)",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail",
     "shortName": "STOCKHOLDERS' EQUITY (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i03631c915ffa4c589e31bd1ac9a7dfc1_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:StockOfferingProgramMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "ib1dcfc8af9f54d79891a8e4f97258d64_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "ib1dcfc8af9f54d79891a8e4f97258d64_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107102 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220331.htm",
      "contextRef": "i141b9b9841a64d79931e5c4d1eefd758_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Commercial Milestones.",
        "label": "Achievement Of Commercial Milestones [Member]",
        "terseLabel": "Achievement Of Commercial Milestones"
       }
      }
     },
     "localname": "AchievementOfCommercialMilestonesMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of first commercial sale milestones.",
        "label": "Achievement Of First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Specified Clinical Development and Regulatory Milestones.",
        "label": "Achievement Of Specified Clinical Development And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development And regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones.",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development intellectual property and regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones.",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones.",
        "label": "Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.",
        "label": "Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]",
        "terseLabel": "Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Specified Sales Milestones.",
        "label": "Achievement Of Specified Sales Milestones [Member]",
        "terseLabel": "Achievement of specified sales milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesMilestonesMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "label": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "terseLabel": "Acquisition of additional shares of Sangamo France"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive.",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones"
       }
      }
     },
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AgreementTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Termination, Term",
        "label": "Agreement Termination, Term",
        "terseLabel": "Agreement termination, term"
       }
      }
     },
     "localname": "AgreementTerminationTerm",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_AmortizationAndOtherChangesInRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization And Other Changes In Right-of-Use Assets",
        "label": "Amortization And Other Changes In Right-of-Use Assets",
        "negatedLabel": "Amortization and other changes in operating lease right-of-use assets"
       }
      }
     },
     "localname": "AmortizationAndOtherChangesInRightOfUseAssets",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering agreement.",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "At-The-Market Offering Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At the Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BiogenMAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen MA, Inc.",
        "label": "Biogen MA, Inc. [Member]",
        "terseLabel": "Biogen MA, Inc."
       }
      }
     },
     "localname": "BiogenMAIncMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CNineORFSevenTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C nine ORF seven two.",
        "label": "C Nine O R F Seven Two [Member]",
        "terseLabel": "C9ORF72"
       }
      }
     },
     "localname": "CNineORFSevenTwoMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities.",
        "label": "Cash Equivalents And Available For Sale Securities",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax.",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "negatedTotalLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "label": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash equivalents, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "label": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Cash equivalents, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationAgreementEquityIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Equity Issued",
        "label": "Collaboration Agreement, Equity Issued",
        "terseLabel": "Collaboration agreement, equity issued"
       }
      }
     },
     "localname": "CollaborationAgreementEquityIssued",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationAgreementNumberOfAdditionalProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Additional Product Targets",
        "label": "Collaboration Agreement, Number Of Additional Product Targets",
        "terseLabel": "Number of additional product targets"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfAdditionalProductTargets",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationAgreementTargetSelectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Target Selection Period",
        "label": "Collaboration Agreement, Target Selection Period",
        "terseLabel": "Target selection period"
       }
      }
     },
     "localname": "CollaborationAgreementTargetSelectionPeriod",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration And License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements number of products approved under agreement.",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "terseLabel": "Number of products approved"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "label": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "terseLabel": "Financial advisory fees"
       }
      }
     },
     "localname": "CollaborationArrangementCommissionFeePortionOfGrossProceedsValue",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationArrangementResearchPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Research Period",
        "label": "Collaboration Arrangement, Research Period",
        "terseLabel": "Research period"
       }
      }
     },
     "localname": "CollaborationArrangementResearchPeriod",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Axis]",
        "terseLabel": "Collaborative Agreement Milestone [Axis]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneAxis",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Domain]",
        "terseLabel": "Collaborative Agreement Milestone [Domain]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneDomain",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborativeAgreementPercentOfInitialRecognition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Percent Of Initial Recognition",
        "label": "Collaborative Agreement, Percent Of Initial Recognition",
        "terseLabel": "Percent of initial recognition"
       }
      }
     },
     "localname": "CollaborativeAgreementPercentOfInitialRecognition",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement estimated reimbursable service costs.",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCosts",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs for new research plan"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, License Fee",
        "label": "Collaborative Arrangement, License Fee",
        "terseLabel": "License fee"
       }
      }
     },
     "localname": "CollaborativeArrangementLicenseFee",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "label": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "terseLabel": "Maximum milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePaymentReceivable",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "label": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "terseLabel": "Maximum number of product targets replaced"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumNumberOfProductTargetsToReplace",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Milestones Achieved",
        "label": "Collaborative Arrangement, Number Of Milestones Achieved",
        "terseLabel": "Collaborative arrangement, number of milestones achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfMilestonesAchieved",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets",
        "label": "Collaborative Arrangement, Number Of Product Targets",
        "terseLabel": "Number of product targets"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargets",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargetsSelected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets Selected",
        "label": "Collaborative Arrangement, Number Of Product Targets Selected",
        "terseLabel": "Number of product targets selected"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargetsSelected",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementResearchServiceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Research Service Fees",
        "label": "Collaborative Arrangement, Research Service Fees",
        "terseLabel": "Research service fees"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchServiceFees",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "label": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "terseLabel": "Standstill restriction, ownership threshold percentage ownership percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction Period",
        "label": "Collaborative Arrangement, Standstill Restriction Period",
        "terseLabel": "Standstill restriction period"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionPeriod",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction price.",
        "label": "Collaborative Arrangement Transaction Price",
        "terseLabel": "Collaborative arrangement transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPrice",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment",
        "label": "Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Receive Payment",
        "terseLabel": "Maximum amount of achieved milestones to receive payment"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent development and sales based milestone payments to be received.",
        "label": "Contingent Development And Sales Based Milestone Payments To Be Received",
        "terseLabel": "Contingent development - and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer contract liability milestone payment eligible to receive.",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "terseLabel": "Development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Including US Government-Sponsored Enterprises Classified as Cash and Cash Equivalents",
        "label": "Debt Securities, Available-for-sale, Including US Government-Sponsored Enterprises Classified as Cash and Cash Equivalents",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ExtendedResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended Research Term Of Agreement",
        "label": "Extended Research Term Of Agreement",
        "terseLabel": "Extended research term of agreement"
       }
      }
     },
     "localname": "ExtendedResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_GainLossOnFreeShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on free shares.",
        "label": "Gain (Loss) On Free Shares",
        "negatedLabel": "Loss on free shares"
       }
      }
     },
     "localname": "GainLossOnFreeShares",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in long-term portion of lease liabilities.",
        "label": "Increase Decrease In Long Term Portion Of Lease Liabilities",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLongTermPortionOfLeaseLiabilities",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_InitialResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial research term of agreement.",
        "label": "Initial Research Term Of Agreement",
        "terseLabel": "Initial research term of agreement"
       }
      }
     },
     "localname": "InitialResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_KitePharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kite Pharma Inc.",
        "label": "Kite Pharma Inc [Member]",
        "terseLabel": "Kite Pharma, Inc."
       }
      }
     },
     "localname": "KitePharmaIncMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments received.",
        "label": "Milestone Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneRevenueReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone\u200b revenue receivable.",
        "label": "Milestone Revenue Receivable",
        "terseLabel": "Milestone revenue receivable"
       }
      }
     },
     "localname": "MilestoneRevenueReceivable",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NovartisInstitutesForBioMedicalResearchIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Institutes For BioMedical Research Inc.",
        "label": "Novartis Institutes For BioMedical Research Inc. [Member]",
        "terseLabel": "Novartis Institutes for BioMedical Research, Inc."
       }
      }
     },
     "localname": "NovartisInstitutesForBioMedicalResearchIncMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of clinical or regulatory milestones included in transaction price.",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "terseLabel": "Number of milestones included in transaction price"
       }
      }
     },
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfOptionsToExtendInitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Options To Extend Initial Research Term",
        "label": "Number Of Options To Extend Initial Research Term",
        "terseLabel": "Number of options to extend initial research term"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendInitialResearchTerm",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfResearchProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of research program.",
        "label": "Number Of Research Program",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "NumberOfResearchProgram",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other products.",
        "label": "Other Products [Member]",
        "terseLabel": "Other products"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerC9ORF72Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer C9ORF72",
        "label": "Pfizer C9ORF72 [Member]",
        "terseLabel": "Pfizer C9ORF72"
       }
      }
     },
     "localname": "PfizerC9ORF72Member",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer Inc."
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerSB525Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer SB-525 [Member]",
        "label": "Pfizer SB-525 [Member]",
        "terseLabel": "Pfizer SB-525"
       }
      }
     },
     "localname": "PfizerSB525Member",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PreApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-approval Milestone",
        "label": "Pre-approval Milestone [Member]",
        "terseLabel": "Pre-approval milestone"
       }
      }
     },
     "localname": "PreApprovalMilestoneMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services [Member]",
        "terseLabel": "Research services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk",
        "label": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SBFiveTwoFiveAndOtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "S B Five Two Five And Other Products",
        "label": "S B Five Two Five And Other Products [Member]",
        "terseLabel": "S B Five Two Five And Other Products"
       }
      }
     },
     "localname": "SBFiveTwoFiveAndOtherProductsMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Excess Consideration Received on Transaction",
        "label": "Sale of Stock, Excess Consideration Received on Transaction",
        "terseLabel": "Excess consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockExcessConsiderationReceivedOnTransaction",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based Milestone",
        "label": "Sales-based Milestone [Member]",
        "terseLabel": "Sales-based milestone"
       }
      }
     },
     "localname": "SalesBasedMilestoneMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi.",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi S.A.",
        "verboseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues",
        "label": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_SeparateUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separate upfront fee.",
        "label": "Separate Upfront Fee",
        "terseLabel": "Separate upfront fee"
       }
      }
     },
     "localname": "SeparateUpfrontFee",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_StockOfferingProgramMaximumValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Offering Program, Maximum Value",
        "label": "Stock Offering Program, Maximum Value",
        "terseLabel": "Stock offering program, maximum value"
       }
      }
     },
     "localname": "StockOfferingProgramMaximumValue",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock purchase agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.sangamo.com/20220331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r37",
      "r39",
      "r88",
      "r89",
      "r210",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r209",
      "r216",
      "r258",
      "r259",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r409",
      "r411",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r145",
      "r245",
      "r247",
      "r375",
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r145",
      "r245",
      "r247",
      "r375",
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r209",
      "r216",
      "r249",
      "r258",
      "r259",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r409",
      "r411",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r209",
      "r216",
      "r249",
      "r258",
      "r259",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r409",
      "r411",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r38",
      "r39",
      "r88",
      "r89",
      "r210",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28",
      "r341"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r17",
      "r148",
      "r149"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r30"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r44",
      "r46",
      "r47",
      "r397",
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r47",
      "r53",
      "r54",
      "r55",
      "r91",
      "r92",
      "r93",
      "r302",
      "r412",
      "r413",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r269",
      "r270",
      "r271",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r260",
      "r261",
      "r274",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r230",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Recognized portion of equity issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r261",
      "r266",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options and RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r164",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r85",
      "r134",
      "r137",
      "r143",
      "r174",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r297",
      "r303",
      "r325",
      "r339",
      "r341",
      "r379",
      "r395"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r36",
      "r85",
      "r174",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r297",
      "r303",
      "r325",
      "r339",
      "r341"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities and free shares asset"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r155",
      "r181"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": 2.0,
       "parentTag": "sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": 1.0,
       "parentTag": "sgmo_DebtSecuritiesAvailableForSaleIncludingUSGovernmentSponsoredEnterprisesClassifiedAsCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r151",
      "r156",
      "r181",
      "r381"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total marketable securities",
        "verboseLabel": "Available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r153",
      "r181"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r153",
      "r181"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in unpaid liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r26",
      "r77"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Cash equivalents, Estimated Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r77",
      "r82"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r327"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r288",
      "r289",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper securities",
        "verboseLabel": "Commercial paper securities"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r33",
      "r196",
      "r382",
      "r401"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r341"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r59",
      "r386",
      "r405"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Sangamo Therapeutics, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r51",
      "r58",
      "r295",
      "r296",
      "r307",
      "r385",
      "r404"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r51",
      "r57",
      "r294",
      "r307",
      "r384",
      "r403"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r123",
      "r124",
      "r147",
      "r322",
      "r323",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r123",
      "r124",
      "r147",
      "r322",
      "r323",
      "r419",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r123",
      "r124",
      "r147",
      "r322",
      "r323",
      "r419",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r123",
      "r124",
      "r147",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r322",
      "r324",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r123",
      "r124",
      "r147",
      "r322",
      "r323",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r233",
      "r235",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Portion of contract asset recognized"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r233",
      "r234",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r233",
      "r234",
      "r246"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r233",
      "r234",
      "r246"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r250",
      "r257",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r157",
      "r181",
      "r184",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss related to marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously Recorded",
        "terseLabel": "Allowance for credit loss related to marketable securities, not previously recorded"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r75",
      "r132"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r60",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r104",
      "r106",
      "r108",
      "r109",
      "r110",
      "r114",
      "r115",
      "r311",
      "r312",
      "r387",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r60",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r106",
      "r108",
      "r109",
      "r110",
      "r114",
      "r115",
      "r311",
      "r312",
      "r387",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "BASIC AND DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r103",
      "r117",
      "r175",
      "r230",
      "r231",
      "r269",
      "r270",
      "r271",
      "r284",
      "r285",
      "r310",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r412",
      "r413",
      "r414",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r211",
      "r213",
      "r214",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r314",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r313",
      "r314",
      "r316",
      "r317",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r211",
      "r250",
      "r251",
      "r256",
      "r257",
      "r314",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r211",
      "r213",
      "r214",
      "r250",
      "r251",
      "r256",
      "r257",
      "r314",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r211",
      "r213",
      "r214",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r314",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r211",
      "r213",
      "r214",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r318",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r187",
      "r188",
      "r212",
      "r228",
      "r309",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r189",
      "r190",
      "r341",
      "r378"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r63"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r102",
      "r103",
      "r133",
      "r283",
      "r286",
      "r287",
      "r407"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r74",
      "r373"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair value of investments available-for-sale"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r376",
      "r392",
      "r420",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "CASH EQUIVALENTS AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit established as a deposit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r85",
      "r138",
      "r174",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r298",
      "r303",
      "r304",
      "r325",
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r85",
      "r174",
      "r325",
      "r341",
      "r380",
      "r399"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r85",
      "r174",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r298",
      "r303",
      "r304",
      "r325",
      "r339",
      "r340",
      "r341"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Recognition of upfront fee"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r48",
      "r50",
      "r55",
      "r56",
      "r76",
      "r85",
      "r94",
      "r96",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r107",
      "r134",
      "r136",
      "r139",
      "r142",
      "r144",
      "r174",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r312",
      "r325",
      "r383",
      "r402"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Sangamo Therapeutics, Inc. stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r55",
      "r102",
      "r103",
      "r300",
      "r306"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r231",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r136",
      "r139",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r90",
      "r129",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r40",
      "r45",
      "r326",
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Net pension gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r41",
      "r44"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on marketable securities, net of tax",
        "verboseLabel": "Net unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings",
        "terseLabel": "Other impairment charges related to marketable securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Purchase of additional Sangamo France shares"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r341"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from at-the-market offering, net of offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r68",
      "r268"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and restricted stock units"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r65",
      "r152"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r65",
      "r152"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.",
        "label": "Proceeds from Sale of Held-to-maturity Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r48",
      "r50",
      "r55",
      "r70",
      "r85",
      "r94",
      "r102",
      "r103",
      "r134",
      "r136",
      "r139",
      "r142",
      "r144",
      "r174",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r294",
      "r299",
      "r301",
      "r306",
      "r307",
      "r312",
      "r325",
      "r388"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r193",
      "r341",
      "r393",
      "r400"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r278",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Revenues under agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r277",
      "r374",
      "r425"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r8",
      "r14",
      "r77",
      "r82",
      "r421"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r8",
      "r14",
      "r82",
      "r421"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r231",
      "r272",
      "r341",
      "r398",
      "r415",
      "r417"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r103",
      "r175",
      "r269",
      "r270",
      "r271",
      "r284",
      "r285",
      "r310",
      "r412",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r130",
      "r131",
      "r135",
      "r140",
      "r141",
      "r145",
      "r146",
      "r147",
      "r244",
      "r245",
      "r375"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r123",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from contract with customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r160",
      "r163",
      "r166",
      "r167",
      "r168",
      "r169",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Revenues Recognized under Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r261",
      "r265",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r261",
      "r265",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r11",
      "r82",
      "r377",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r263",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r34",
      "r53",
      "r54",
      "r55",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r103",
      "r117",
      "r175",
      "r230",
      "r231",
      "r269",
      "r270",
      "r271",
      "r284",
      "r285",
      "r310",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r412",
      "r413",
      "r414",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r117",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs (in shares)",
        "verboseLabel": "Issuance of common stock in connection with at-the-market offering, net of offering expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with at-the-market offering, net of offering expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r231",
      "r262",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r21",
      "r22",
      "r85",
      "r150",
      "r174",
      "r325",
      "r341"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r54",
      "r85",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r174",
      "r175",
      "r231",
      "r269",
      "r270",
      "r271",
      "r284",
      "r285",
      "r292",
      "r293",
      "r305",
      "r310",
      "r325",
      "r328",
      "r329",
      "r334",
      "r413",
      "r414",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r171",
      "r172",
      "r173",
      "r212",
      "r228",
      "r309",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r250",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored entity debt securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r87",
      "r250",
      "r257",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury bills"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r126",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r105",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r104",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r426": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r427": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r428": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r429": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r431": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r432": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r433": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r434": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r435": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r436": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r437": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r438": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r439": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.18)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001628280-22-012629-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-012629-xbrl.zip
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MEVR0A:_1;0$QO"A0PL):BI0%L$3FP$]G4GD1O*+&2C:N,+[84%HHPW.%Z\7
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MX$FI6(.3@N^0_GF0EQ0:K0!S#^HZ%<(*J0 *8TQA:95"GCK*HN4$U\+!7A#
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M06,=-=,T:J05J"+K@@[<85H3N#Q+VGGA$:=!T  ^+*?($N$$9D[0:(VW50*
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M-HKA\7$H!C/WKC=@XD(>>@[ZD_7@[JQ(^TCS <SLJ+$7SOKYH-'O-=Z B]'
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MJ6DRK-NI"",Y[W= .7_L]2^JRD[#7O4YSXJ/\+(AF$1YPLDT_[(T(!NQVG<
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MSU!Y>N73J>44<4RK4?T41)R/D,*GU/-L!9"'=1QFG+;)NO=$@,Y[Z#=;=+/
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MR3Z&SK4-65US[:>IFKEVH7?<3][*E9\K[73UQ\ITN_IS$<+':_<6)S=-W0"
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MO[XZ_=#=(>E*T(>]=_BH>W;:N>S$PQ["5;CV&%UV+@_(X9L_6!28"<)!!XR
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M>CU@]7HS)\V14 1':=/"92(PYARHR @P'8@Q(=I(U;?W )YZ)E3$7>;!DO-
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M&B$N1;(O;>I\*4O%4\P8;[W7R9E,MLM%*+FW8*-VP+3Q,?(06.Z]@!EM8_P
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MN>B->N-P'(9_]5R8:,RWP0T^]JM/J>1FV?NO377.5VU*,T%J3!@$G*O96:G
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M3K-8%[PT$H%/M@:&J ;%HX.(A R&,<PIW]JF;8'FR[*4#<UF8[T9!98*ZAN
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M6PHJUXQP&EO$,.<^Y+ ^F6\BW-#TX')R8-UV_^YQK I;-( MY@-A44:7])1
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M*^Q]:W'J-.]U'D-]*K$*;O703T=V5 $;YXC;DG2=>EG=\&J 0+U.561E#E"
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M\LOIW0Q;>74"SQO[J6UN?K3+4[JQH=<D(N0J"-4V>%HIN?P4=,>VIB\=T,?
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M@)A3F6@'4,XT)122<PPX."5:M4XY/ZH@@>?#T7&N^19+-,"EH,E38B7)1P[
M,0B5VNCJ!T5Q3-@71T"+\6EWS1'@*2<RT("()6 \&.Z1B9$A0:D'%N(Y,P:X
M!E -Q=KBJ2R'#AN59R*DY<XX'[(?(%GGI+"!2RRU#*D<.K16E!M4@Z5D)',.
M8<X% HLPQ_@$@K2E!KL8J#8;#\PMLMPJ65;1*>$P823D@ #C.#=4*BR]C#*2
MX@=HM4 W_0",4ZT2YPBPV".N<QU9[<" B-@2S%D @2^Z^2'+,]:)$4>QI2#)
MU I#@W:<D"!P-)85-T!K1;FAFPVSW!IL44H"Y^3T"6DM,8BR3I1$FKRUK=/-
MCRHBH*IJA_*88BC1 !<"D_!*6J58X(0'CDVR%'L5E=%@1]I0B$9[T>G5FA.
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MCALOIUA$N56B' R&'>"3=MYR4,4F15CZ9(V!+>%]\0*T69Z;7@!C0P3C+SL
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M1[A77B=./5>Y[)MT/I7CAA:CT^Z:$X#G[%0B L<0V0G@G4)6D81(=-I)*HW
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MK<[Z>1,VLS%0]E \-3]2=RG=V'S5NPILY8QU>9W!C(JC_!1TQ[:F+YW#478
M_-?%"P=6Y$$EN( \__K%WMM!/,]^#U"JU1C.V-#G4\8;E[NS^>#>_L%NA\TM
M^%,$MU'QCQ,'MK_FQ$H>E#&,1.%Y@+&GH(3^\()B2C'!!%4_L.S-.>V_>34
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M\$$A2O.E!BD",L9BI#TG5A/,5=IX[H,"$6V&B*NX*>X:(WX0[5"XQ&9"'N9
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M03,45&[1;^][<[_<]9!QKHULW<C6IRE;-^ZV^Y2F"UJVI=HR7EC"0,,F0H5
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M=@QY;#SM3U9L^3Z,L>/>Q;V.:K>M1L!!XPDJYF/0Z8!G-,9?!E&#3%3DVS6
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M< QH(OF1K=#IW^K'QWZ ]QPW*O,D*K]52MV>8&"W#B(._'0T[#PR&E;C6+(
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MW-ET= :\';T4:U=J41CA=_4P9SL<@]KX2USV%1-_8H?MRM.DW;PS7<W%J>'
M_;^WB"UZX641="A9$429<]!A,Y=9F2E%'9<R*OB4EDG!AP\+]:#YHKK_9C2T
MWKMQ,FZ;=0=1?S,S5OYD-@ ^$\Q8JTOG?5$2Y;4 .\!3HC4-A)F26U,RY@)_
M]J+(M^F:^DN@NW[<ZC.@>CCD&^8-/F;H[$R/I^-)U-6V075J17LZ7O%L\+-$
MGYA\,O+5J9F.QGZ6]K7V6%N2?;Y?'5>U(Q$N'B16;&EV>H8_W(9,32Z#8;(T
MBAM!\V! ]N1E&4(PF0"CH2;3@A>D^;":3!,T!JS%$(1(T^+_7U5]J.]5?3C
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M56DKUH$-IY,UM7 5[.#YJ)I,<(GA:&P2M#I!_IFTFB6!QVMF!^I6?8;U(T7
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M/7&--JK^=91PN7>D!1CDN9?$4"ZQ45)!2J<"85R F&3,V3)?J^JO[J;XT#;
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M,L/CWK/U<$R;O?_&O?]\)(T-03%*@,D8$1D0@ $V) '-KCQD65:"89/+[76
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M$=+L>ST8AJKW?GOGJ55\[@YZ_]2#!F)67-71K@/LV.F^?!/ V1DX8XV1Y:=
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MNJAP6DIR%J6[K4/)1)F%A9X&08W^_D..]Y%YME.2YVX%K-7U2$#'J\11S]1
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MOEE99ZM9LT0G!6R\+%O5N^R7X<XL<4"B.H#:>(2")B^L2J?E)1/;#3VR?LF
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MDLI$C/G(MM7QWH=_.>2COO0V@WT<3P)WU)5K];YKVZE:/SZ:NZ&2S&?3R"D
MT]EK<WY9@8^[Y!TW"#ZH4I&'[,,H?FX0I<&#;--4/!Q2:0]ET($R\/90!GLH
M@^?T$A\%97 O-$$/RB * Y[&61(EW T"%B1) A=F4>[YO/#B\5U0!L_%2WD%
M*K:Z$<BS=QY 0@/K"$#/ANGBZ^&Q_ZF.]-Y/_D@_6:&H]@RDC0O=BW'W0SUK
M"[UF'>Q7^]FM]HZ%2LQ*H!;>\4%%K1\5'-CW<#Y)Y, ]N?F#!SGFZUV;N45L
M!WGJVZD//R5!Q)+$8TY8)-_]Y'KWELOWZT?,RM!'Q6Q,DR(<>V&2\YP%D1\E
M7ACZ/DB4EQ9>P=V'2= >R>9)1<Q_<_E'[@<!YWY@%Y[GVD$\'MM)XH=8:N!$
M;NS%*98:1/>#EFR,.V@0"5/HC/+:^] =C11?%P%JZ*_;@#XUHX]$4(F"P W=
M-'+]. C&A9^,>9;FP3B,O31/QWOA?D["'8#^=&(.JQ5%MN,Y@1TP#JZSQYCM
MN0Y/.9QMCNM\]U.RE7 ;XC0@VV6A@$+:#& ',F0HE((I0 Q=MK(^14ENAL%2
MR$S<C)-BQD@'4$YF96ZCO%^!Q0!FQ?P2=L0]D"</>1,*HS::^:2=F,^&C/(H
M(#5'!#1#WU")S'XSATA(-LO!RMVB6QTM:Q@.^LE1?!P3-<I3A5,WASN4LBYA
M(X709N*@S:4TF]9+H< P0YX?V 3%PS3P$Y:ZS/<#AX^9R[PH#C+N%]BY'=_3
M:K^W%Q^Q4^X&#G/FALP+T]QFA5O8&$VQ4QYF=N(589['WCCQL9OI7G6'6:&/
M!OG8U&WYB<*RA_GX$NV7A.H=)F,7$3Z2,1RB7E'8L1^G-@/S)N9QX+K%<#'J
M8\!\?!9AVH-\/"W(QPV:8F&01 &#Y> ,0;:]U$XS[ %/_"@K6 [+^(D@'_O0
M5C^T9:+L[=%/'HA^,M14]\28*&$0Y+X;\FR<!ZP(63+V>)$F41&&7IZR![J7
M>TR4QSL'/YQ<_A%FL"X\RFQ_'( &\^/03O-Q9(>1,PYSA[E>'B-NYZ=#HCP8
M^"3UPG%:A#QU,S\(G"(-HS!UTRSQW"+/T^T#$WLP@B\E8=CV,W82GO+(MPN/
M)W; <D1'"1T['(^CV(N*+$3<QBW"O4/H*+WX&GI[K=^G^A<_"@KCT?367OJ^
ME/0YJ-_2.(B")+;](@:[+.*QS7+XU7$C/X$%CF./;>$\[K$D]E@2>RR)SX@E
MT3$Y=Q%,8H\A82S!0]B>GJ<\#Y>%W5_F90K?4Z$RH,HXYXNEB08A=4\K/S*R
M\+#2"2_GWAAL[]AW8_0-$GC#-/3=*'/ X!%DA9ZC.NN=O1'T_(P@[\WD#R=W
MG<P9)W;NL\(./#""8M=AMI\%.6=CEK&$/0AQP?5SG[M)FKE%$KAIP7+F,3?W
M@R)E:98[4BX2*1=.XCO[G/&7E(#49SQ*G-!.4L;L('9R&WTO.RIXP5(PA8MQ
M,6P&W^.4:7-1!0 VG%/42 -&S4J4NLNN- .I =N")$*#;N27( U.+W7\^+ S
M7>WY4-P9\ _SQ \CGKLLX"Z/F9-QSPO"E#EQ[+,]_L@7WP/^R:]_I&E>!*%?
MV%GF@!8LLM1.QH5GPX)Y##S[/'3#!VG!H/"#.,VB,&).$.=QPKR49RSE7A[&
MWAYOZ)FL>^%[A>LF8SN&A<).Q<1.O!#)K.(B9XD7C?WA),WGPIWI6\/6NJ]'
M:WAO=T,4?'>W@^AZG\& '@\:T">G%T=61+7CWH]W]?*Z8% D:1('+HN"?)PD
MODMTV?".13X.X\%=U=U(+\&'FU;-JN:GA6DVGHGPPR%"DYY?@1O^,SI'JC#C
M H;P\[3*WG_9+>.=',HM,WOSUYL_4?2//\!WWL.6\4\OIN7O?UZ&)W^^"7[_
M[1C^>^R#N ?]+?/[7WC_7^'Z(QC/&6R9+#S][;_+TY?OO3=_75W]_B?\]\\,
MMLA5\>;B\O8/CSGCC.<9Z$4OL(,D\NS88;$-"A.T8\:SF+-^DTOBAIF?N1&+
MHRQ(BSA-XP I/_,L&L?C<?(=E6PML!NM7O'O?CJ_.#W\I_WSY/SHI75X^N;M
MT<GYY.+X]*3?(OP)H8YA'M+[QOG3$\OC>7;%\]44I/%HMIA6MYQ+F/56"$TQ
MG4Q!"NFGT^),JY>WY'.3['[#DOK7'PF>KQE'XB>4SQ3<&C8N'#L)LMB+\S (
MO:PO>5\L!%:TK344>&RNJIM&YEOA5,_>VR(^DQG+CV6#(B+5BTN"49"+@C?X
MJ:FFU"B=6^=+^(\H%JP*ZU15X376]W1=M8*7R)N__Z"VE1R):BVM<U[;!$:R
M:/@/ZH<?\[)93-GM#^6<WHPN^E%N0-F/BCV8U[RFMF79:TI;4GPLVS.3Y #.
M78R@+&OX)U</ELV;!Q1<>;',US\;!P>!GVS\V#EPS<]@X/AZ__<[_SOU/?4*
M\XJ:+I_RFW>-K/=9Z&[]3EM/E>L<!.[FC^\>T!<9K+_5;5^0S-2;%D,V^O[@
M6"YI_T=9X7MOFJQ]U5M\P"__N-9TW=\>8F<\MCZ*[S/ '*&.T"1](TS2(S1)
M_T]:O_A)FZ7ZU/U2$_\4WWS 0*4F)#-YL;1(OUJX*C_NU#*C#=)9RH]]VV]J
MRMR'2'_*LO>7=;6:Y[8<89:!,5CTW]JB_WH'7MB= <0E6#LXJ\7G-U/H[34H
M*'JD1BG^%D+T9??VO<O0E^#[KMLHSGV)=JP!N1Y:U:>1ZBT7]F_]%7R\]S??
MFX!?GM6+/R3!Q?,X3OW"\<(H2'QLK')S-XORPG48\[U[0GBVWW?UI._&\V'7
M[DB8]MOE+?S==.^N?I]]F)[^>?GAQ(/OSOY=GEZ\#W_'>-PO)R5<"\^_FKWY
MY:P\^?/DSW]?_/=[=0T\:_5O[UUT^A+>9796_GMV'.)SP"4,?O?^&US#WX/3
M7WZ_^?<OQ]X;[V3Z9G96O"D=]_7%T?+-N?/7R5_P]U__B'PG]!W?L:.8%W8P
M9I'-DC"V7>;D('A^$L,B_A2,HO&FHI\GVSCJ4'C !MHKP+T"?$(%&.;CF,5A
MP>*T"#+/B>-QY ;QV!E[N3-VTGMR5WL%^ P4H-]3@'X01(A28(_#R+<#'N1V
MXK*QG49>'+/$&T>I@PK0"[U=48 /ML@+^M]N6N2_$&;[5/+?S,IYB46'F#;?
M09N\MQ ;O4KO88LY> +MM";.DRPKLC (QZF'') L\,=>-F;C-"KR6+*8[$W1
M9ZR);]=,4>:G3L%AQ9(DXW80N;&=."&S?==+\]P)PSA/OOO)'U$ XM,T\1T*
M[ZFLS?W6WG)KQV/&(^;Y$>=),(;C-X[R, "?).1ND(I.IKV1];RW=M_(8CQV
MN9N.;2_S/#OP>6BG09';49J"X9S$&;%8^2-O_,E&UB-N[<>,;'KAP?A9VU$7
M6Z59=]"F>APW7V9Q_05V.:PP)ZR69!\'>+0)^FK.L(\J@]F?8<_G##LY7#-/
MD]09<U@[>QPG"(+BA7;",68:!6"9N&X>,S!/QZ,H^63S]-%WUFZ$4O<Z=J]C
MM]>Q61*!0\#3P"^"@"4LC=RQ&X5NDA6YZT3)WD]X_CJV[R=X49X7W(WL?)QR
M.PB=U([C(+0=)\I<E[&$^Z1C0R_X:G0L>1DOJ&3PI_7BWK7FSP>7N8^?>9G[
M^/.4N9^C9W-536$QFZ/_K,KE[4FUY&WQ^[,I$[Y5/2#'-R>_G;R'[[U_<_$^
M./GS5]A!)U?_GOWJPJ[\@.6^)Q>PEWX[^M O$W[SY\3]W?L5QO3KA].+2P^>
M [OPU>S?+]_!KCSZZ_27(_?-7[^[OU^\*D[^S,(_$B_SPV0\MC/'85C&#ON.
M1[&=1EF<>BS*LVR-M6'LN[$3P<Y,_"3(?)]YL1-GXX0CR'/HC <+VO]Q^OKE
MT=FY1,6WCGY]=WSQ^]TE[8-5ZO<^?-M2>&_\14B)A_?#9&DOK[C]1B";GA8%
MIQZ9':89GJPN5\W2:(8?)AF>8R7VW)(O?HY8S?JE05:"V/E1H'G]-Z=)@3&^
M?GUH?8]RY#D_ZK_2[^Z/?Q=?QHYP"3H+3V!B<B5L;*4F5Y',"OBN];9,Y">C
M+POV6#Z=CF1W) )]( X!_I<M"3T#3@>N0!&H^[)!4T)CYO8Y(1"LM9J+H MV
M20D05XM=PKM?(F2',<I2@ \\'++:\2/?S1(W+ H69&$,9ZB;YB[+$C;.B\R5
M[<>Q:C^.[\04(S6J)/.MF+LW[$,Y6\W^A1@/.]%D_-F5[!LPK_[(P\ '$S6Q
MHS2+[&#L!38+L[&=LC#,N)_F"1HWH+WN!7=2&!/M;I <?GT!$XC-3("L(X1R
M.<_*!9MV<3XDF(>$%A&(,RCH1&TF);@%653WU,@;+^_OY!/#E^U\;E<3P)ZY
MHX%8/'X-A3UT(CC_"W"[P?R/F)-F>9KZ(8^9'Q?A0WN(2:B/FP:.-O$RHGV(
M_( &E"%]U&PGVE^XA_3SB_;%!/[V[L.;B]]O3U_"-9=_)*!DXL1Q['$T#NT@
M=7T[S=/<+D#MI+!:G'DN"/K(\8/1.%J/^!M:$Y5J1TLB&C9BD8/:!@,^IR\1
MHNP'@BV:WCX0SO^3!&D=L@./KM."Y.G0A$U2.-:G)G+L7E=N(5#!Z:]_9%$6
M,;#[[3R-P"T,<L>.BSRS>>%Z>> 4;LH\U)P'X_N R1ZF9\9AEGMYGD2IXX'K
MD3$^3@,7P='<R/,*]Z$]ZQ^C9YY?F_KG=U%TF_J;VY.+2T2D3L"*B6!EL6K+
M 14393;+O,@&)P;.TBQUG"($_W( 2UCJEAN.K 1X]&S1B-XYOKP]A>5=%);^
M9@K+[8,6XT@'+?:\EU]^+'O>R[Y ;PZE_=@1K+'7<\?M\9<+MQU?'+T1JLSR
M#L0/Z_]^,SF9_'+TYNCD0GH1Y];+X_/#=^?GQZ<GUN3D)?PS>?W[^?&Y=?K*
M>G5\,CDY/)Z\M@Y/3UX>7ZCOG!V=OWM]05\Y?7MT1L@%YSL6OD 7"7WY5=-(
M B 9;GC#YNQ2Q2:$H_6R_1Z&"29S-KU%S";8!J\4KPNUI),ZI^^<$=9<KPU=
M!C#(#&'E'+RZFF-AJ[S?2.-S"A0\ 88)YL(-JW-[6E7O\2AKVAYW P-OQAEA
M/<'SSKFP?KSQ1(4FX$]P#A)NWB0C?%,W\?T1P>+-Z"@4,'GZ4O=(77KT0:!Q
M&A<&YH6*&.B.8<KF_9'FXIZ6LW(IR8",[\EI4>?U356#!R!7A<$1C,XMS,U(
M3:/\*.531&Y=^[L*: Y\L)KF_3_JJ5_[X .&F=;^C 1#\WSMSS-VV__38@IB
MVO]CP_G[]3]>#8T,H5[UWUJY$-.#3&J20JF<(:BE)2F,YAAC0G@Q6L>J$=S=
M#7X,;P1&$HIS<V"=K[*KNQ:OQ^_T?E[=" E?S<7/==G FQC8ML2./BC) H-7
MX(UBY$W2M:]JBPFB)H'0")=W0#EK$YP7/JR0"B!?-<@BI:\0V***AQ4\Q;S$
M\(DF0R2&7H'+N\U3U"0)6%J8VFDI $N;N^?K />)\2H6"9L<C#D\B<&&"].
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M JV>D;59T\$J4S2@@$:J7444@(G##EY>_C8R[1F4$'E&&X>+-&I%>:)U!6\
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M>6GO6<5<M-S30FH*7QR'\=+M7$E^I7Y#.'Y?=%G3]S6?4]8A!3NPSN]AWND
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MEY#+&#50U4VS=6_5;]IU2^Z1Z=9[YE>C5T]I[S5(]!GI:7EY"J$0*@O.4"+
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M.2O;_'ZL_;"1ATX:I//F]>G):9J\?Z'AJ_*O+L83]HB,\9</_P=02P,$%
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M5T15(A:X)RD;%9WU6:4VM83WXWD&X4YMRE103)V5ZZJ,Y>T88 JKZTFO**+
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MS^'<8W72K4*[3<X.74V162'8QV&:-I7&T?3/RY[A_<"G?72^+J33>;5_6I[
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ME6U9;=4[-G".4[(4K)0D@K_>LNL-A,FUU@XJ!F81 6&($^V@*>>#41#.42F
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M<C;(M&A#DJ]Q]#A9W*J:;%XFLH$Q%QWT_W!9 _?7=#::8/[;C]/Q!=Y\D[B
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MX[QO8X?T^7+?X+G=RWN58'0 U7N>MQ3.]O.ZS3UUW^T]F;GG/.X!< HQ2:5
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MGR?ZUJ)9OZTVUBUV'I%6=T_KO. 9:.%WD+.(1H9@\MU;=;^W0+<A5+^^ZE$
MIU-SK?8BZ[I![7@2EPH SG@!)LC$+'G5BCNQUO<.Z!;[#;TYJ4>EFFZ=M4$5
M:[DE=J<<:V=M!,\< Q.#C(8'2D;:;'$]QP;H32C4GYL:R-?T6$NG3>#9V@*E
M* V*!E %*!G4[#8J)BC1-4T(MZ?]SYMP<D=N?[+]S\H9,B<B9"D15 @)HI0:
MDN(N6U9D+)VN8]CG_N>5B/!8__,J#ME9+VL7D'O?_[R2)]=J:EW'#3OCC,W,
MQ)(*Y%#O<+=20/0>R<.6EZ!L4*Y38/\M<&75_N?V5%G%^KU?+CPK)IE7(96L
MA9/!@ZWU>$I1_A"\#N!28/5V#)<B[[1/</M3GVK'\TI6'_5ALJ=5@'"KOME+
MY[V-'HH-E#)R4<@4,8/*12=1-!-W=4-W7WCPK#I^UHE2=D>!!JW7_91[=AG$
M]XZ?WK._=6G4I%-B'0X\V8Z?Z(7W]:ZJ& 7%'L5RRJM%HGDAHDU.H&ND6?&$
MB;R5CI_=\W@5UV^GXV=!LP<-<=%YZSPVPF1-/;( IBE>5J(>Z4<7(?*,HOAL
M&-NDK6=5/-_4+N^Z3'B\B:&I&[?8H',/I_.Z)!L,.*M5/<IGX*(JH- %LI/3
MP8D-Z+;PH=\YU9-#&BS!BR5"++<^>>U!9Y- .0JZ/4,&-+NCY(4I56*3)?6Y
MRD!MDKML[J(&Z@.KBHIT@?M=!JH'5V\HV+..GYZ #%2]]TPDXZ#$5%L#LP;'
M:-)V.N7LL_3L;O'.<Z+56C)06V75"N[9D0Q4L$RB3Q**G*EB60%.! 3NT&B+
M+,D4.P5&ST4&:B6?K2$#M8K!^XZ8OZX\NP9V%9M=OA]9&UML@F2KGD6@/#=*
M'Z$XE7PT4BC>;9^_P\/V-,)IXHN^Z]X?P7=]4/(XPL7QS7JLV<E!<1-WK<"%
M#6S=<%5Y *E/CJN8$P17^S483:1!*P06Z+50VGG7L>5AAVQ8=A3\1,BPBHG[
M)L$UEI,_1E>JSLB*,%*!E8JBJAP=Q. =I$1)/6,^)M/M=L'[G[W%,^)&YE_8
M<;>>[?J."&[@D%?P6G5')*$3Q?TF2E!*9?"Z$(F93!@=80O=NG47??IS=>>:
M]GN*@BWOR^"?.#X<IJTIMMQ]XM8E6QX<\AW-EIA]XI;21V.-D@:=B3QI9-+3
M#XS1JVJVW'WV$Q!M*;I@-%F"\,Z#LID83 D*H.>&:VU\R&WDI7<NVG(]1=2;
MQ@?#63(WNWW>"Q]#8!F8XXY,$BWXS#DDXY5,7):$W;K/ESWAFSHN6(\J7Y\6
M]&'IIU4VM4"P0[.@:&D14(S/% 861VL!&<H&7JQQDLENM\=\UVW9$C=W3X,G
MI-L26!05'DBR&,&FF"989L X:[3'J(OLN#NX;[HM:T^+6_)6W[HM!Q]I.O\8
MIGB0\\P_X>Q&4V3T\=)GUT-XB]-/HSS_A?L#$2JRXFE:T][4M\4%\$5JLJ!P
MZ(J.T7<L#ND1U;X1<6<>[5M-Y@&1&Z>*8=+X>AT#KS=R^BJRZ2EQ8]P7+0.]
M2:MENL]%4FAMVO1D[;;;V3>VN!()N2E0F5>QY%-O3 H4<(*6ME :[PENH.G4
M9FFY*4KICN18_=G[1IK&WNE;G.7N4CQOMB=4@I9:+C6"UK4V5.I,J(CQHK @
MF<Y2Q6ZWZBQ]Q+Y1HQ];-]1;V4C9JK@@8DX1''-5A-HG",7C[ R16>8%=M2"
MW6^%LCXFGJWYL4=EEGYTKKR)%KU5P"-EJ/70&KPB\"Y8S13W-I9NQ;%[JE"V
M-ONVZKD>]5Q6T\42VC@?J]2,3+5&O# (Z"-D#"A\YD)B1_'7YZU0UGOTM)$G
M>I1N>1#DE>GF0E>O$2>GHFBM%3I 82(HU *B#@:8Q!RT* 'E9I'W@H=^)TT_
M_EBP>]G#EOPLE7Q-)ERD3?3JSSI!#H8?#R83I/_ED_#GJ7'9>@P23-)5OS8A
M^%+/UVE.C#(4FC9;'6&M#':/N+<MERZ@X<;5V3V6#7HNN38AU?9!^D.5"#Y[
M1LFL%E:BXE&WZ3394^FI3:BZ([<_6>FI3,E.4$J F>4ZWEIZ#3D'[1(6$6PQ
MA7?A[CY+3ZU$A,>DIU9QR,YDA+J W'OIJ94\N9:>T#INV!EGC!-6N&3 >TZS
MME:4WKIZJNEL2I%I[G)Y+EQ957JJ/556L7[?-0N7-7'S>DJ%N6@;R6&E'AXY
M2^F'"!Y8"-FG["6R;J57MS_UJ4I/K63U41\FZ[NF^!+(\0LM])5*@ S6<D(C
M5:Y+GF,0!,M04DXH(CJ!W:K#[WWT,_7BNL9K\QJ^]$<?7EMQ5:YNI?"A!#!9
M6%"&QN=CJ37K*)(.T7K7;3MOP8<_4W>N;\ ^RW1HQ/-3C*/Q?'=GMI*XY(HL
M@FAE"85*55^>1@4BH*98E 5DG4H4.ZVRBQ#L<3R_L4/:$*1VRLX13>:O0!=0
MO<?O2^%L/U[?W%/WW=Z3F7N.SY>#\PR-D":"X8&#JK<E!R<D6&85D]D$SOJ+
MQ[?L^P?B[RVY?A7K]B[U^N+UX/?:DU;_(FBSN>T*ZGS=2LA%4=+2>U(K;A):
M"(PC6*NS8":AC++3PM_A8=L-!'KRR:BA0?L.TA?AT4)1IJ CV,1H$2NH(&2=
M0"MF-"JC4_"='/P<';JIP7JOZG\W&"*%E<?U(.6FF10E"\):&I\IOE8$,(B2
M"Y BL$ ,L]*43CY<_/G?O!M[,-O3DKB])4S)BHHT!@H]356MEB'3?&(ER(Q2
M26V#X]^EFI]:%K ["C201^M'@+#+(+Y+-?=^6KHNC9I(W*[#@2<KU9PM3S;4
M:JNZ1BE%,9ZW7H*VVD15E&6QS=UX3YC(6Y%JWCV/5W']SJ2:#X=3/#O#-+T(
M9Q1ST>(Y_?*P[F_VA:?( Y3HR;""%CF'7@ 3*@;&$C>R6ZK0#N,W552U+F/6
MDG1NZ^[MR#R_'V.Z/[+%^M6O!^,)V?[\G(+"03BK@L3W1JAC*;XD!1(#@K+6
M@U<:P0EN+::8 ^]V5?Q6X'[G]LY)T'2ROL%Y#V/DR"0M:L"M<J!0%G".!8B8
M<M:4%+O048>DVP/WFVH].:+W;OO;&+LP&[4/PAH!(:?95?8%@C(&R!*AQ&1"
MQFZWQ*_ZY/VF3]^NZ;,UOAZ 5Y/, F6NN?-5FB0JK>M^F@4G _T110R8M/6N
MTU6XW2JMKAZ[IUL^ZYN^SZ[X*Q!S&G:!T7]]Y@V [9_HKNF"NT[<P'Y]%U;>
MAN.4"(5X2<_FH(HKX%T5'*JB6K0X(?<]EDZV=N,#A[,]>W$%L_7LO;?AS\'Y
MQ?D<")/.A4 + BM5D5(%#]$Z18/)VGD535#]^>^K1V^Y!FM=XX_ZL-S27+5/
M]<WCDZ.7__'BX/C5SR^/WKY_]>[XX.3PZ-WQ=)1^>Q$FE*'?E@O[LWZ)ZPMO
MKO^PS34W>QKH';G-XJ,OW&;F=5:)EYB9*IYKFR//4?K3]1^[V=[P*_+'Z OB
M_&CR^%,8X[T''IS-/HB^JL'&3#?IGY2XXG@PHM^;3&_U*-GH,E=%0TB9$HI,
MV6>@C *X<9A0%PH\VW0L]CR0C2]!N7P2YL5 YBX\#0*#STH!8[)>Y,$,>*39
MPB!#'>LE5:I3R+KZW2>=\&T_\=DE'^_=E-*_#QM(?=[D ?W8[C(ED,(J7[P
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MFQ2LM8('\]RU%[?*@\>D%U?QQ\YD]+J W'OIQ94\N9:>WCINV!EGM(W.*%[
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MS<.^J.?/RU_%4RY6,QIRQ@024*:1FN_2(-?S70"Y1$E.$%&S9CI;;[Z7F5C
MW^Y:TRK]WT[YOUB,R/H$LZQ$N7Q9L>V<_#0_-M&J.5;/ROB7!7T2Y3-M;E (
M:/>E!N6?.N:#I01EJS,HM650SYT</&TP (4$M$(!_-G" !3UUY?K)\P;*,!S
M@P58:3 Z3YY7</S#+]OAF-C[-?]O_=;,QWMA;B38J LJHT!E/=B:#SY+4 ,
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M'3--HQ@3BU8QG2=/;JU3Z0;N?KX^7<#^#%99&HJ,1CH&A4.=0)U!FN-4UY/
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M0GC_4JZ73V(%V$Z.Z$HI;#$1NQPY T?FC<;#,R,U5@%M%MBQ:UO?4ZW/:].
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MOZS++[J,:M3&D"(:B R'D.6!/L3,*,1A'$,4(!*'/,[ST*J@08^LJ2T4*]U
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MI$[(SG @@E"F1@G9XZ@[->=J;[^V;$W>5-^Z JRQNMO8]4K]OC6\)CMMNDX
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M"1 =[CO(W4["D- H%S!)HQRBC 20Y@A!(;A,)0O"B!FY^X.D3XV#]Q*VI;8
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MF._MA;TE0 "-QY[7-S-C9^Q)D,P'@<W%5EZYY:AEG^/\^DOV(K6V%DF1[;[
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MZ!8,KE@"+4]-U-&0BV1<R]'M8GU,54<GBW9.C4=SD#6J/1I,\E%U'\WQZ*D
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M$411DL L\'*(9?7$%),XBOWI&UOFBP\%ODN!XZB4K2SWJW(U>ZY"("4#H.+
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MW8^NFL"UAIECV7D0+J?240D9NS&.O3,.&^JHPOQ>Q*/20X;)MFWQRVK%IWE
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M<KBG=U/8AASY<[?*S4YR612FU(NB%/*0>!#YE,,L\#%,TSSP?93&&5;RR Q
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MV!+-NJ#L56;6'N"8_.JN]%?QW;_\7?L;\45V[?Z7O_M_4$L#!!0    ( +B
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ME#"=2JM/KHAGEA,J=-!>V2!RG2/Q>;KZ/0CK :HK5;0#K(>R&BA(CGDE292
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MJQ\P=:/Y26TU]#V4[=UP\A7&G_8.Q_$3G 68#KB,#+1R)##T V26B3C%'%'
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M/YR/T^RJ;C$;KL $HJ0H#2W*G'$6 S'*@G5 C?!UHM"/T],OYOK#QZ1S934
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M7E#ZGB0.QW%T7AIMOE1D>=,#;&_V^"7W("2=I>::.+\H/%*B]%:F1!@PUKL
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MC46Q6!6]YPB]"NJ6K=5]S%? !=\;9"-99FK ':VK&IY;/"DZ5,8XX!\5C.!
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MA9'8FKZ7SO>!W2BE\]M@8.KM_NGRSR<JI5DE=\72C\JB*7OG-"((VQIM*Y$
M4TB09"%58W%"[%(?O^U\#A;'?5'T<D7OJ":=)XI7Z?"/Y K1UNS10?"V=8=W
M D(R%0RU9C8A6 QJ!Z@^.>C!5I2-A\?=C3.#F.%IMC<O?<S11K#%93"!@[ H
M2 #O0J1E%<;4-$H,T)^Q\1#(H':):'<WU S0MBTS7$MT5]D%J"DWJH5B(0A>
MN\'F4F+14=B1^F4</F/C5M#8D;%Q&SM-O=-V) U$+S3%K*'J%>&E5Q 4$LA
MSGH26>?4:9-]C8R-6]F[!V/C-LJ?$9[N]8*[C0N^KL5BG:\^0_:-# WY;)=T
M3%"#R3$YK8SL=@O98;!7PW;2ZW%D#(O,'&'KZ#;F($TJ&3!X#CP%+TRTAD @
M*\S8$$-Q0V!LTA>04<R[!79ZZ'IJ]-S._=-ORPVK/(FJG#;@M>'0H*0 "6.
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M0R7SBB_7.==*S0/0JE2Z DN]XF-J5.!.^.*,5B)L1UTY=DHH;A4-0,6$'[)
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M62##G@J#2=@M3>,RMN-(V!:#0;!?=4HYU)0B*B1%:H=I.2.6R1PT?&FP6M'
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M,2YH=&U02P$"% ,4    " "X@*54(A]-4^T/   WGP  $0
M@ &&K@$ <V=M;RTR,#(R,#,S,2YX<V102P$"% ,4    " "X@*54=4>:Y(T:
M   N  $ %0              @ &BO@$ <V=M;RTR,#(R,#,S,5]C86PN>&UL
M4$L! A0#%     @ N("E5&C@W=5/1@  .R # !4              ( !8MD!
M '-G;6\M,C R,C S,S%?9&5F+GAM;%!+ 0(4 Q0    ( +B I524>/?H')X
M &2$!@ 5              "  >0? @!S9VUO+3(P,C(P,S,Q7VQA8BYX;6Q0
M2P$"% ,4    " "X@*54%0[3:M]C  "ZC00 %0              @ $SO@(
M<V=M;RTR,#(R,#,S,5]P<F4N>&UL4$L! A0#%     @ N("E5%J69#\,"
M,B<  !<              ( !12(# '-G;6\M,C R,C S,S%X97@S,3$N:'1M
M4$L! A0#%     @ N("E5%INCXHD"   I2<  !<              ( !ABH#
M '-G;6\M,C R,C S,S%X97@S,3(N:'1M4$L! A0#%     @ N("E5-Z!QE%7
M!@  NAL  !<              ( !WS(# '-G;6\M,C R,C S,S%X97@S,C$N
9:'1M4$L%!@     )  D 60(  &LY P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
